data_6ytc_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6ytc _Structure_validation_residue.Date_analyzed 2020-07-03 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.513 -0.235 . . . . 52.25 112.513 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -158.0 122.26 4.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.347 . . . . 73.41 110.93 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.22 128.67 71.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.13 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -136.18 152.07 50.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 73.43 111.188 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.83 148.84 28.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 72.2 110.893 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.56 21.89 6.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.142 -0.481 . . . . 75.05 110.901 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.0 -58.58 2.2 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 75.14 111.17 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -119.14 -25.98 6.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.263 -0.426 . . . . 75.24 110.883 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.8 29.02 5.12 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 53.34 112.499 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -101.14 160.5 26.47 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.559 0.695 . . . . 74.15 110.888 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.73 145.46 57.39 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.688 2.259 . . . . 61.23 112.329 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 47.4 mm -83.07 115.63 25.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 75.31 111.171 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.3 mt -104.83 113.1 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.471 . . . . 73.4 111.191 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.51 32.66 6.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 73.4 112.5 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.06 128.14 36.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.858 0.361 . . . . 63.31 111.062 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.0 m -81.25 107.19 13.83 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.215 -0.448 . . . . 73.23 110.853 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.09 122.7 69.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.088 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.6 m -134.27 174.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 74.52 111.138 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 35.3 mp0 -91.17 166.14 13.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 74.12 110.92 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -65.43 -41.99 92.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 74.21 111.145 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.1 p -112.56 -22.16 10.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 64.03 111.083 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -101.32 65.65 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 72.13 111.086 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 87.5 m -77.34 -35.71 54.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 74.21 111.096 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.7 p -57.07 -31.6 65.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.23 111.169 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.41 1.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.3 110.929 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.36 152.37 49.64 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.781 -0.723 . . . . 74.25 112.499 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.6 t -135.56 168.46 19.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.74 0.305 . . . . 73.43 111.138 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.6 pt -116.55 167.72 9.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 75.01 111.134 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 23.0 p -89.74 150.61 22.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 71.25 111.174 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -95.22 -178.93 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 54.12 110.915 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -57.79 -30.44 65.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.48 . . . . 73.24 110.885 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -73.55 -19.39 60.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.152 -0.476 . . . . 73.22 110.892 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.7 28.26 12.83 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 120.736 -0.745 . . . . 75.31 112.458 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -136.58 166.07 24.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.914 0.388 . . . . 74.24 110.93 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 24.2 p90 -142.66 164.75 29.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 74.55 110.902 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -123.46 117.79 25.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 75.13 111.166 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.44 134.97 24.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.41 . . . . 72.41 110.903 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.2 t -107.02 121.85 45.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 73.42 110.846 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.92 133.26 24.84 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.565 0.698 . . . . 73.53 111.135 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -48.42 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.731 2.288 . . . . 75.02 112.353 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.77 149.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 71.24 111.167 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 70.8 m-80 -85.16 64.39 8.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 75.05 110.92 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -92.49 -179.56 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.42 110.812 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.71 156.08 19.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.075 -0.512 . . . . 72.33 111.17 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mt -115.24 124.9 52.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.275 -0.42 . . . . 71.23 110.888 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -95.64 122.43 38.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 74.32 110.885 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 2.2 mp -118.65 134.55 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 75.53 111.131 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 45.7 p -142.55 138.74 31.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 65.5 111.123 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -134.31 119.13 18.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 65.43 110.95 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.4 tt -51.49 112.46 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.132 -0.486 . . . . 74.23 111.175 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 133.98 -52.14 0.82 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.783 -0.723 . . . . 62.44 112.473 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -108.27 170.0 8.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.379 . . . . 73.11 110.919 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -62.81 158.24 53.87 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.553 0.692 . . . . 75.42 110.885 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.44 42.09 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.677 2.251 . . . . 74.4 112.334 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.72 138.5 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.155 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 34.6 p -131.37 139.52 49.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 61.3 111.166 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 26.5 m -146.69 147.05 18.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 74.32 111.153 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -66.04 157.1 31.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.982 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.99 125.9 29.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 74.21 111.168 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -156.79 166.49 33.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 63.13 111.106 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.23 -43.34 78.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.117 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.0 mt -140.48 112.11 4.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 72.31 111.11 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.49 128.83 64.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 75.01 111.131 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -102.71 133.55 47.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 74.11 110.877 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.5 t -122.29 148.89 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 75.42 111.1 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 13.2 mt -122.0 127.82 50.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 74.53 110.885 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.4 tp -88.19 121.58 30.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 75.25 110.866 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -90.39 144.42 25.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 73.42 110.921 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -58.24 141.33 51.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 75.12 110.897 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.7 t0 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 44.35 110.863 179.931 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.493 -0.243 . . . . 52.25 112.493 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -153.64 120.12 5.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 73.41 110.895 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.4 t -109.7 129.8 63.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 73.33 111.175 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.7 p -136.57 176.55 8.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.209 -0.45 . . . . 73.43 111.148 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.27 150.98 23.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.2 110.863 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.3 tmmt? -93.48 19.26 8.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 75.05 110.894 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.13 -58.72 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.244 -0.435 . . . . 75.14 111.146 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -120.17 -26.42 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 75.24 110.851 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.34 29.39 5.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.742 -0.742 . . . . 53.34 112.485 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.7 mm100 -100.35 160.24 27.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 74.15 110.911 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 137.67 36.14 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.715 2.277 . . . . 61.23 112.368 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 42.6 mm -87.15 125.33 40.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 75.31 111.177 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.4 mt -104.89 113.47 42.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.4 111.134 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.04 33.03 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.767 -0.73 . . . . 73.4 112.486 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.66 119.26 26.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.754 0.312 . . . . 63.31 111.073 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.23 107.53 5.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.23 110.859 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.0 t -109.99 106.5 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.102 -0.499 . . . . 75.44 111.121 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.4 m -114.97 140.76 34.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.132 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -85.79 133.52 33.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 74.12 110.857 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.6 p -54.51 -35.86 63.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 74.21 111.098 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.3 p -78.97 -22.09 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.267 -0.424 . . . . 64.03 111.133 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.51 110.69 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 72.13 111.079 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -86.51 -33.93 20.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 74.21 111.111 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 77.7 p -53.18 -29.59 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 74.23 111.154 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -94.26 31.19 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.3 110.885 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -73.25 141.18 29.65 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.801 -0.714 . . . . 74.25 112.46 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.41 168.9 9.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.737 0.303 . . . . 73.43 111.146 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.8 pt -124.13 148.59 28.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 75.01 111.119 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 9.9 p -73.93 150.74 40.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 71.25 111.174 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -99.79 -175.33 2.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 54.12 110.873 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -56.38 -31.47 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 73.24 110.886 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -76.78 -18.88 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.462 . . . . 73.22 110.905 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.25 28.84 10.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 75.31 112.518 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -135.99 159.88 40.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.822 0.344 . . . . 74.24 110.931 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -140.2 168.0 20.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 74.55 110.893 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 39.2 p -109.53 116.17 31.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 75.13 111.165 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.67 107.48 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 72.41 110.909 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 29.1 t -106.95 120.12 41.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 73.42 110.86 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.99 156.19 79.49 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.651 0.739 . . . . 73.53 111.109 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -48.02 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.7 2.267 . . . . 75.02 112.352 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 m -101.94 175.79 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 71.24 111.12 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -106.55 58.89 0.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 75.05 110.897 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.5 p -72.7 -170.2 0.66 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.493 . . . . 74.42 110.857 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.14 152.43 21.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 72.33 111.133 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.31 121.64 37.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 71.23 110.877 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 47.2 tttt -96.88 123.14 40.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 74.32 110.888 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.4 mp -116.56 132.23 66.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.446 . . . . 75.53 111.121 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.6 p -143.08 138.56 29.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 65.5 111.121 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -137.72 127.63 25.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.19 -0.459 . . . . 65.43 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 tp -51.63 119.98 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.489 . . . . 74.23 111.119 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.99 -51.12 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.775 -0.726 . . . . 62.44 112.479 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -108.61 170.12 8.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.933 0.397 . . . . 73.11 110.916 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -69.92 158.11 88.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.57 0.7 . . . . 75.42 110.914 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 164.56 34.12 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.681 2.254 . . . . 74.4 112.304 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.4 149.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.126 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.7 p -132.02 132.56 43.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 61.3 111.124 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.0 m -137.72 172.17 14.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.439 . . . . 74.32 111.16 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.38 156.82 18.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.901 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -93.18 130.07 38.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 74.21 111.045 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.55 -175.55 3.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 63.13 111.072 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.35 -49.53 66.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 73.13 111.097 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 43.9 mm -139.2 114.2 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 72.31 111.156 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.31 125.13 67.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 75.01 111.088 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -98.68 135.06 40.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.91 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.2 t -128.33 147.6 32.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 75.42 111.153 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -127.12 138.09 53.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.214 -0.448 . . . . 74.53 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -88.83 124.93 34.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 75.25 110.943 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -90.29 136.85 32.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 73.42 110.855 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -58.99 140.17 55.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.12 110.945 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 44.35 110.904 -179.987 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.498 -0.241 . . . . 52.25 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -118.39 128.19 54.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.915 0.388 . . . . 73.41 110.875 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 89.2 t -119.7 129.17 75.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 73.33 111.08 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.9 p -129.7 178.1 6.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.43 111.162 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 t -97.2 151.02 20.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.263 -0.426 . . . . 72.2 110.892 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -92.05 15.43 13.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 75.05 110.938 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.0 p -94.07 -59.07 2.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.238 -0.437 . . . . 75.14 111.117 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -120.44 -26.63 5.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 75.24 110.844 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.16 29.19 5.26 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.539 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -94.26 160.15 32.56 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.592 0.71 . . . . 74.15 110.913 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 139.5 40.7 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.703 2.269 . . . . 61.23 112.342 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 49.2 mm -83.97 113.56 23.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.104 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 22.6 mt -101.06 128.88 52.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 73.4 111.085 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.96 32.61 26.01 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.769 -0.729 . . . . 73.4 112.486 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.96 135.64 33.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.796 0.331 . . . . 63.31 111.093 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -85.6 107.2 17.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 73.23 110.804 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.9 p -118.33 122.39 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 75.44 111.107 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -134.61 151.83 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.149 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 -75.62 132.65 40.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 74.12 110.897 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.8 p -51.52 -34.93 38.39 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.091 -0.504 . . . . 74.21 111.153 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -96.68 -22.08 17.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 64.03 111.132 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -127.19 89.75 3.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.451 . . . . 72.13 111.104 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.8 p -86.79 -35.65 19.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 74.21 111.136 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 91.1 m -56.68 -31.0 64.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 74.23 111.146 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -93.13 30.74 1.58 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.19 -0.459 . . . . 74.3 110.865 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.52 147.01 50.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.782 -0.723 . . . . 74.25 112.517 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.6 t -135.49 168.94 18.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.787 0.327 . . . . 73.43 111.112 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.7 pt -110.98 158.15 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.01 111.116 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.2 p -80.34 150.68 29.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 71.25 111.143 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.37 176.3 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 54.12 110.893 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -56.95 -30.18 63.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 73.24 110.858 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -73.12 -19.05 61.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 73.22 110.914 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.62 28.26 17.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 75.31 112.462 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -131.95 165.43 23.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 74.24 110.878 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -148.51 168.04 23.76 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.851 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.9 t -128.99 120.11 25.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.079 -0.51 . . . . 75.13 111.134 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.84 111.14 13.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 72.41 110.894 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.9 m -93.38 111.91 23.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.145 -0.48 . . . . 73.42 110.817 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -128.35 156.1 77.39 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.57 0.7 . . . . 73.53 111.159 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.76 -48.19 0.77 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.67 2.247 . . . . 75.02 112.396 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.8 p -106.13 151.79 8.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 71.24 111.101 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -79.26 60.88 3.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 75.05 110.905 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -75.82 -170.4 1.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 74.42 110.825 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.86 157.52 17.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.105 -0.498 . . . . 72.33 111.122 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.8 mp -120.09 128.58 53.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 71.23 110.882 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -100.75 123.14 44.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 74.32 110.881 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.7 mp -120.55 134.22 64.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 75.53 111.102 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.1 p -145.76 140.07 26.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 65.5 111.148 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 14.9 t80 -135.6 121.39 19.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 65.43 110.963 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.8 tt -50.88 117.18 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.094 -0.503 . . . . 74.23 111.105 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.52 -50.76 0.88 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.752 -0.737 . . . . 62.44 112.439 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -109.68 169.98 8.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.969 0.414 . . . . 73.11 110.947 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -64.27 157.73 69.18 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.55 0.69 . . . . 75.42 110.868 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.66 162.26 42.72 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.707 2.272 . . . . 74.4 112.361 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 30.2 m -150.51 133.29 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.097 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 25.2 p -126.9 142.8 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.181 -0.463 . . . . 61.3 111.088 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -151.15 151.37 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 74.32 111.146 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt -73.98 157.32 36.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 70.32 110.898 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.12 134.18 46.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 74.21 111.11 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.68 161.79 20.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.437 . . . . 63.13 111.11 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.97 -40.36 60.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.13 111.066 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.0 mt -140.86 111.79 3.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 72.31 111.103 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 20.7 t -124.08 112.0 30.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 75.01 111.099 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -96.74 116.6 29.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.926 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 24.3 t -115.06 148.77 17.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 75.42 111.115 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -121.2 139.21 53.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 74.53 110.959 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -91.21 122.54 33.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 75.25 110.956 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -90.53 141.37 28.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.853 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -59.06 140.53 55.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 75.12 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.8 t0 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.154 -0.476 . . . . 44.35 110.87 179.968 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.487 -0.245 . . . . 52.25 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.75 127.51 40.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.87 0.367 . . . . 73.41 110.916 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.5 t -117.04 125.26 73.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 73.33 111.111 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -122.79 169.63 10.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 73.43 111.172 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.54 149.62 21.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 72.2 110.897 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -93.21 18.18 9.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.484 . . . . 75.05 110.882 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.21 -58.82 2.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 75.14 111.089 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -120.53 -25.97 5.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 75.24 110.91 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.97 29.13 5.03 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.672 -0.775 . . . . 53.34 112.509 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -98.29 154.13 37.76 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.62 0.724 . . . . 74.15 110.916 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 143.08 49.45 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.684 2.256 . . . . 61.23 112.334 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 47.3 mm -83.32 108.11 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 75.31 111.199 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.1 mt -101.46 126.57 55.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 73.4 111.078 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 42.11 7.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.748 -0.739 . . . . 73.4 112.47 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.89 162.39 13.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 63.31 111.096 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.2 m -105.62 107.53 18.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 73.23 110.859 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.4 t -110.43 106.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 75.44 111.085 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.9 m -124.64 138.01 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 74.52 111.101 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -72.02 173.53 8.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.861 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.2 p -76.35 -35.55 58.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 74.21 111.121 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 17.7 p -112.38 -22.14 11.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 64.03 111.104 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -117.2 77.2 1.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.24 -0.436 . . . . 72.13 111.05 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.6 p -86.72 -35.36 19.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.245 -0.434 . . . . 74.21 111.119 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 45.8 p -53.33 -30.2 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.23 111.159 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -94.76 31.3 1.85 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 74.3 110.907 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -59.38 136.1 50.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.74 -0.743 . . . . 74.25 112.485 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 5.0 m -111.15 157.87 19.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.758 0.313 . . . . 73.43 111.128 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -108.59 150.51 11.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.01 111.101 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 6.0 p -72.26 149.66 44.33 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.19 -0.459 . . . . 71.25 111.183 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -83.6 -175.44 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 54.12 110.859 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -58.88 -30.86 68.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 73.24 110.901 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.9 21.44 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 73.22 110.906 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.17 27.46 70.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.709 -0.757 . . . . 75.31 112.471 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -108.79 134.91 50.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.829 0.347 . . . . 74.24 110.89 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 18.5 p90 -133.54 167.93 19.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 74.55 110.856 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.29 121.42 12.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 75.13 111.162 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.5 mt -120.93 127.81 52.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.209 -0.451 . . . . 72.41 110.907 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -106.93 113.65 27.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 73.42 110.852 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -139.2 156.21 72.15 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.657 0.741 . . . . 73.53 111.138 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -48.35 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.651 2.234 . . . . 75.02 112.352 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.66 149.4 5.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 71.24 111.151 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -88.9 52.1 2.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 75.05 110.863 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.1 t -68.53 -169.78 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.992 0.425 . . . . 74.42 110.812 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.63 157.14 19.19 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.148 -0.478 . . . . 72.33 111.187 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 7.4 mp -125.39 125.01 42.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 71.23 110.874 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 43.1 tttt -102.64 126.89 49.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.194 -0.457 . . . . 74.32 110.912 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.9 mp -123.29 139.33 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 75.53 111.144 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 74.1 p -140.94 139.23 34.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 65.5 111.188 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -133.05 119.8 20.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.43 110.926 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.4 tp -51.42 116.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 74.23 111.141 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 130.35 -55.13 0.77 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 62.44 112.525 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -108.87 170.63 7.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.984 0.421 . . . . 73.11 110.915 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -62.01 157.72 49.54 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.555 0.693 . . . . 75.42 110.935 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 170.77 15.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.667 2.245 . . . . 74.4 112.367 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.6 p -151.49 140.92 15.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 74.11 111.135 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 p -131.95 135.35 46.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 61.3 111.183 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.8 m -152.17 149.24 13.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 74.32 111.2 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.3 mmtm -69.08 153.99 42.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.914 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.43 65.42 2.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 74.21 111.134 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -90.21 -175.1 4.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 63.13 111.045 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.3 -55.08 23.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 73.13 111.137 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 17.4 mm -128.76 137.14 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 72.31 111.076 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 5.7 p -145.7 119.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 75.01 111.111 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -120.24 109.52 15.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 74.11 110.855 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 17.2 t -124.59 149.1 28.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 75.42 111.19 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -103.39 145.73 29.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 74.53 110.945 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.6 tp -87.25 120.45 28.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 75.25 110.89 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -90.36 140.4 29.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 73.42 110.872 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -59.1 142.08 52.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 75.12 110.908 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.4 t70 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 44.35 110.866 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.459 -0.257 . . . . 52.25 112.459 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -144.15 127.52 16.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.41 110.842 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 t -115.57 116.5 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.33 111.091 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.4 p -129.95 153.72 48.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 73.43 111.152 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.88 150.98 30.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.873 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.4 tttp -94.01 20.16 8.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.194 -0.457 . . . . 75.05 110.849 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 35.1 p -94.04 -58.79 2.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 75.14 111.168 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -119.39 -26.39 5.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.209 -0.451 . . . . 75.24 110.94 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.5 5.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.856 -0.688 . . . . 53.34 112.495 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -97.95 160.4 28.54 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.586 0.707 . . . . 74.15 110.835 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 148.28 64.43 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.73 2.287 . . . . 61.23 112.318 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.4 mm -95.16 122.75 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.31 111.17 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.7 mt -107.4 116.28 50.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 73.4 111.136 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 99.41 33.26 5.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.744 -0.741 . . . . 73.4 112.499 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.57 129.41 36.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.805 0.336 . . . . 63.31 111.052 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 m -76.99 108.34 9.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 73.23 110.861 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.87 106.18 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 75.44 111.103 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.3 m -123.9 151.21 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.123 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -81.83 166.78 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 74.12 110.908 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.06 -41.99 98.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 74.21 111.136 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 33.6 p -112.44 -22.06 11.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.233 -0.44 . . . . 64.03 111.123 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -100.77 75.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 72.13 111.072 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.4 p -86.67 -35.61 19.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 74.21 111.173 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -60.6 -30.77 70.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.282 -0.417 . . . . 74.23 111.18 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -94.46 31.2 1.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 74.3 110.867 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.12 139.01 47.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.701 -0.761 . . . . 74.25 112.513 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -113.71 167.37 10.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.771 0.32 . . . . 73.43 111.168 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.9 pt -124.14 147.16 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 75.01 111.152 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 p -69.94 137.98 51.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 71.25 111.145 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.7 -179.52 7.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 54.12 110.856 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -57.0 -30.22 63.97 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.24 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -73.5 -18.75 61.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.85 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.08 28.21 14.13 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.738 -0.744 . . . . 75.31 112.529 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -134.2 168.35 19.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.856 0.36 . . . . 74.24 110.935 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -141.89 167.93 20.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.55 110.869 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 27.1 p -124.98 116.99 23.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.13 -0.486 . . . . 75.13 111.137 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 8.0 mp -136.58 120.79 17.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 72.41 110.915 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 26.7 m -106.94 112.05 24.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.092 -0.504 . . . . 73.42 110.886 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.95 156.16 69.49 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.661 0.743 . . . . 73.53 111.108 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -48.25 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.633 2.222 . . . . 75.02 112.338 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.6 p -110.51 152.11 12.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.118 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -80.63 58.49 3.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 75.05 110.942 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 94.9 p -72.84 -169.83 0.63 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 74.42 110.862 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.7 153.11 21.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 72.33 111.094 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mp -126.27 126.13 43.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 71.23 110.889 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -95.63 122.2 38.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 74.32 110.869 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -121.26 137.2 55.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.53 111.15 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.5 p -147.39 138.77 23.87 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.168 -0.469 . . . . 65.5 111.153 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -133.54 119.0 18.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 65.43 111.02 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.4 tp -51.02 117.58 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.176 -0.465 . . . . 74.23 111.185 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.68 -52.89 0.82 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.781 -0.723 . . . . 62.44 112.458 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -110.34 170.19 8.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.952 0.406 . . . . 73.11 110.945 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -60.5 157.63 35.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.589 0.709 . . . . 75.42 110.902 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 166.87 26.02 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.723 2.282 . . . . 74.4 112.283 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.5 m -151.24 126.35 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 74.11 111.112 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 21.8 p -125.06 132.81 53.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 61.3 111.109 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 m -152.09 157.34 5.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.199 -0.455 . . . . 74.32 111.079 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 39.6 mtpt -84.13 155.11 22.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 70.32 110.953 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.09 133.6 46.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 74.21 111.091 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.16 -179.67 8.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 63.13 111.101 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.73 -58.02 7.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 73.13 111.102 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 41.0 mm -142.36 111.65 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 72.31 111.104 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.76 122.3 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 75.01 111.167 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -119.78 115.33 23.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.888 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 18.7 t -113.16 126.9 70.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 75.42 111.109 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.34 140.59 32.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 74.53 110.894 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.5 tp -87.9 121.73 30.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 75.25 110.899 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -90.2 137.06 32.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.9 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -57.45 141.78 46.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 75.12 110.872 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.093 -0.503 . . . . 44.35 110.853 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.466 -0.254 . . . . 52.25 112.466 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -152.61 128.35 10.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.875 0.369 . . . . 73.41 110.859 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 94.2 t -117.99 131.8 69.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 73.33 111.112 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.9 p -138.12 172.88 12.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 73.43 111.088 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -92.74 156.25 17.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 72.2 110.922 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -93.57 16.38 13.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 75.05 110.876 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.1 p -94.05 -59.07 2.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 75.14 111.095 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -120.68 -26.24 5.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 75.24 110.91 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.63 29.12 5.14 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.747 -0.74 . . . . 53.34 112.503 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -95.02 153.93 39.74 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.606 0.717 . . . . 74.15 110.889 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 135.75 31.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.73 2.286 . . . . 61.23 112.296 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.6 mm -84.6 135.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 75.31 111.127 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.0 mt -114.29 125.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 73.4 111.104 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.86 33.83 10.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 73.4 112.492 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.17 162.67 18.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.72 0.295 . . . . 63.31 111.176 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.53 113.5 27.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.852 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -116.76 134.04 61.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 75.44 111.12 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.1 m -139.64 148.87 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 74.52 111.064 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -88.5 135.11 33.64 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 74.12 110.846 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.0 p -55.5 -32.64 63.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 74.21 111.159 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.6 p -71.87 -22.36 61.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.186 -0.461 . . . . 64.03 111.105 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -178.64 134.61 0.14 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 72.13 111.091 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.3 p -87.8 -19.29 27.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 74.21 111.241 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.0 p -52.16 -30.33 26.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.213 -0.449 . . . . 74.23 111.092 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.9 p-10 -93.2 31.24 1.5 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.917 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.69 135.51 38.4 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 74.25 112.483 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.5 m -124.38 161.45 25.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 73.43 111.164 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -107.71 145.67 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 75.01 111.133 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 p -70.07 149.51 47.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 71.25 111.155 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -87.14 -175.83 5.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.43 . . . . 54.12 110.871 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -57.11 -30.69 64.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 73.24 110.869 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -99.79 22.09 11.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 73.22 110.882 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.32 28.31 72.1 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 75.31 112.521 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 64.7 m-20 -110.75 128.84 55.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.874 0.369 . . . . 74.24 110.906 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -116.57 167.32 11.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 74.55 110.827 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.6 t -121.42 116.87 25.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 75.13 111.138 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 7.0 mp -141.15 116.75 10.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 72.41 110.9 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.3 m -106.81 108.16 19.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 73.42 110.887 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.4 m -124.69 156.08 68.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.579 0.704 . . . . 73.53 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -48.41 0.73 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.693 2.262 . . . . 75.02 112.351 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -103.67 152.0 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.182 -0.463 . . . . 71.24 111.103 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -84.94 68.36 10.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 75.05 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.0 t -80.57 -169.94 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 74.42 110.87 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.86 159.31 17.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.179 -0.464 . . . . 72.33 111.094 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 16.0 mt -124.0 135.21 53.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 71.23 110.902 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -105.7 129.86 53.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.915 179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 mt -123.7 134.67 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 75.53 111.097 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 25.2 p -149.78 139.48 21.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 65.5 111.134 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -138.22 125.88 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 65.43 110.879 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 tp -50.94 107.93 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 74.23 111.163 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.89 -47.04 0.91 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.785 -0.721 . . . . 62.44 112.524 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -112.47 170.89 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.382 . . . . 73.11 110.951 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.2 mttt -68.4 158.19 85.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.54 0.686 . . . . 75.42 110.935 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.67 160.3 50.26 Favored 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.696 2.264 . . . . 74.4 112.339 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.26 139.76 14.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 74.11 111.188 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.4 p -132.14 134.83 45.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 61.3 111.175 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.0 m -144.54 151.91 15.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 74.32 111.147 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.92 155.4 27.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 70.32 110.874 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -90.56 120.87 32.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 74.21 111.131 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -146.34 178.64 8.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 63.13 111.137 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.43 -44.22 68.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.13 111.096 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 56.2 mt -147.31 112.14 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.449 . . . . 72.31 111.059 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.61 128.42 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 75.01 111.172 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.9 m120 -95.91 137.56 34.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 74.11 110.892 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.2 t -124.51 148.98 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 75.42 111.192 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.58 125.74 40.84 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 74.53 110.873 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 2.4 tp -91.91 118.31 30.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 75.25 110.928 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -96.03 135.94 37.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 73.42 110.932 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -52.39 145.62 10.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.882 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 41.8 t0 . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.122 -0.49 . . . . 44.35 110.842 -179.961 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.465 -0.254 . . . . 52.25 112.465 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -131.53 126.43 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.913 0.387 . . . . 73.41 110.861 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.5 t -118.08 128.9 75.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 73.33 111.167 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.22 167.02 16.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.14 -0.482 . . . . 73.43 111.137 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.59 144.33 25.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 72.2 110.835 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.4 tttm -92.78 15.62 14.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.125 -0.488 . . . . 75.05 110.844 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -58.49 2.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 75.14 111.119 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -117.97 -26.81 6.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 75.24 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.23 29.13 5.26 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.701 -0.762 . . . . 53.34 112.463 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -98.34 160.12 28.95 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.58 0.705 . . . . 74.15 110.886 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 143.65 51.91 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.709 2.273 . . . . 61.23 112.375 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.3 mm -83.13 110.0 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 75.31 111.137 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.1 mt -103.45 126.94 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.446 . . . . 73.4 111.116 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.29 33.2 23.61 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 73.4 112.478 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.22 131.37 34.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 63.31 111.07 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.3 m -80.19 107.57 13.09 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.842 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 60.9 t -106.66 105.86 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.112 -0.495 . . . . 75.44 111.112 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 28.2 m -120.6 133.65 66.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 74.52 111.126 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -91.96 141.52 28.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.474 . . . . 74.12 110.915 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.9 p -55.43 -31.66 62.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.152 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.7 p -71.54 -21.38 61.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.215 -0.448 . . . . 64.03 111.193 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.52 111.49 0.79 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 72.13 111.049 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 m -85.46 -34.65 21.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 74.21 111.156 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 61.8 p -66.8 -26.44 66.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 74.23 111.179 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -93.51 31.22 1.57 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.903 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -74.99 150.26 40.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.77 -0.729 . . . . 74.25 112.473 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.6 t -117.81 168.76 10.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.738 0.304 . . . . 73.43 111.157 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.0 pt -111.68 171.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 75.01 111.139 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.8 p -99.35 150.62 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 71.25 111.155 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.33 179.93 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.435 . . . . 54.12 110.88 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -59.33 -30.7 68.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 73.24 110.852 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -73.81 -19.48 60.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.899 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.92 28.08 11.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.739 -0.743 . . . . 75.31 112.525 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -132.43 160.21 37.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.853 0.358 . . . . 74.24 110.932 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -138.37 166.08 25.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 74.55 110.881 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.8 t -126.0 119.15 26.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 75.13 111.178 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -146.15 134.3 21.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 72.41 110.932 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 p -106.89 122.63 46.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.485 . . . . 73.42 110.889 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.5 t -129.79 133.25 24.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.683 0.754 . . . . 73.53 111.093 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -48.51 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.664 2.242 . . . . 75.02 112.345 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 31.0 m -95.27 141.96 14.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.425 . . . . 71.24 111.162 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -79.39 59.05 2.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 75.05 110.83 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.4 t -80.07 -169.85 2.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 74.42 110.872 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 156.12 17.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 72.33 111.125 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.2 mp -129.05 132.22 47.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 71.23 110.903 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 22.8 tttp -106.76 123.25 47.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.245 -0.434 . . . . 74.32 110.909 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 34.8 mt -119.6 112.61 37.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 75.53 111.178 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.4 p -119.68 145.88 46.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.231 -0.44 . . . . 65.5 111.118 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -139.06 118.58 12.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 65.43 111.001 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.9 tt -51.0 107.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.133 -0.485 . . . . 74.23 111.103 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.86 -50.98 0.75 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.745 -0.74 . . . . 62.44 112.47 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -114.28 170.28 8.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.93 0.395 . . . . 73.11 110.92 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -58.22 158.2 14.7 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.42 110.932 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.8 167.79 23.48 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.627 2.218 . . . . 74.4 112.348 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.4 t -135.11 138.68 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 74.11 111.107 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.3 p -132.15 122.56 25.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.138 -0.483 . . . . 61.3 111.141 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.1 m -152.92 149.9 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 74.32 111.113 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -81.92 157.25 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.88 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.73 130.65 46.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.21 111.113 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.52 160.71 38.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 63.13 111.108 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.67 -52.37 48.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 73.13 111.113 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 69.7 mt -129.14 111.62 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 72.31 111.155 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.62 112.11 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 75.01 111.142 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -113.66 112.34 23.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.862 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.27 148.16 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 75.42 111.12 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.9 mp -105.08 144.86 31.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.491 . . . . 74.53 110.909 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.4 tp -87.83 122.23 31.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 75.25 110.961 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.8 mm-40 -90.17 140.9 29.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 73.42 110.945 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -58.45 141.23 52.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.904 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.1 -0.5 . . . . 44.35 110.905 179.964 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.439 -0.264 . . . . 52.25 112.439 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.69 119.94 5.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.887 0.375 . . . . 73.41 110.946 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -98.48 122.66 50.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 73.33 111.106 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.07 176.68 6.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 73.43 111.094 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.4 t -97.38 164.0 12.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 72.2 110.925 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.0 tmtt? -104.55 -11.11 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 75.05 110.869 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 55.8 p -77.94 -58.62 3.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.289 -0.414 . . . . 75.14 111.089 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -117.86 -26.38 6.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 75.24 110.854 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 100.99 29.39 6.47 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.734 -0.746 . . . . 53.34 112.495 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -85.05 159.4 57.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.531 0.681 . . . . 74.15 110.978 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 127.89 15.26 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 61.23 112.377 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 50.1 mm -77.37 120.41 27.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 75.31 111.16 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.7 mt -102.98 141.5 18.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 73.4 111.099 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.42 33.24 86.72 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.718 -0.753 . . . . 73.4 112.521 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -82.58 122.16 27.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 63.31 111.094 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -74.17 107.5 6.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 73.23 110.837 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 t -107.37 106.07 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.128 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.7 m -124.89 138.06 55.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 74.52 111.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -73.67 161.2 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 74.12 110.843 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 p -65.83 -41.82 91.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.466 . . . . 74.21 111.144 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 p -105.77 -22.18 13.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 64.03 111.08 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -116.18 68.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 72.13 111.165 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 96.5 m -81.53 -35.65 30.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 74.21 111.09 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 3.1 p -53.36 -32.17 48.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 74.23 111.139 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -94.95 31.16 1.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.916 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.95 138.95 37.79 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.811 -0.709 . . . . 74.25 112.517 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -117.22 168.72 10.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 73.43 111.155 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 pp -115.47 168.56 7.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.441 . . . . 75.01 111.093 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 70.3 p -101.29 150.76 22.66 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.168 -0.469 . . . . 71.25 111.129 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -90.88 -176.08 4.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.172 -0.467 . . . . 54.12 110.849 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.38 -30.73 68.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 73.24 110.854 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -73.87 -19.5 60.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 73.22 110.897 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.75 28.1 15.07 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.692 -0.766 . . . . 75.31 112.473 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -128.22 157.78 39.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.338 . . . . 74.24 110.906 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -143.67 167.45 22.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 74.55 110.874 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -123.05 121.69 36.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.477 . . . . 75.13 111.188 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.0 tt -144.01 125.68 15.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 72.41 110.96 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 45.0 t -101.72 114.92 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.262 -0.426 . . . . 73.42 110.842 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.3 t -120.6 133.29 24.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.579 0.704 . . . . 73.53 111.165 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -47.92 0.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.666 2.244 . . . . 75.02 112.343 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.6 m -96.9 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.157 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -111.64 62.38 0.62 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 75.05 110.891 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.6 t -86.88 -172.63 4.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 74.42 110.867 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.24 158.22 17.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.112 -0.495 . . . . 72.33 111.128 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 25.8 mt -128.32 143.13 50.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 71.23 110.947 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 7.1 ttpt -116.48 127.74 54.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 74.32 110.975 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 79.6 mt -120.01 137.97 52.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 75.53 111.055 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 39.0 p -148.28 138.59 22.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 65.5 111.183 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 15.6 t80 -136.01 126.85 27.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.233 -0.44 . . . . 65.43 110.903 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 13.3 tt -51.17 118.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.101 -0.5 . . . . 74.23 111.139 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.16 -51.27 0.85 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.857 -0.687 . . . . 62.44 112.536 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -108.1 170.21 8.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.98 0.419 . . . . 73.11 110.917 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.4 mmtm -68.9 158.19 86.86 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.567 0.698 . . . . 75.42 110.933 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 165.82 29.68 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.729 2.286 . . . . 74.4 112.377 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.66 147.94 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.083 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.9 p -132.1 139.83 48.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 61.3 111.148 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.1 m -150.83 171.57 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 74.32 111.076 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.06 157.21 18.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 70.32 110.868 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -86.08 134.08 33.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.21 111.099 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.65 179.87 6.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 63.13 111.124 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.34 -57.88 9.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 73.13 111.096 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -132.13 111.69 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 72.31 111.104 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.82 125.27 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 75.01 111.125 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -95.86 136.76 35.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.878 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.7 t -120.96 149.48 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 75.42 111.109 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 10.3 mt -125.45 124.15 40.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 74.53 110.885 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.4 tp -87.84 122.47 31.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 75.25 110.891 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -90.22 137.03 32.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.182 -0.463 . . . . 73.42 110.927 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -55.23 142.91 29.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 75.12 110.813 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.4 t70 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.087 -0.506 . . . . 44.35 110.845 179.948 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.519 -0.232 . . . . 52.25 112.519 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -127.73 119.95 26.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.891 0.377 . . . . 73.41 110.931 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.0 t -105.15 126.46 60.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.153 -0.476 . . . . 73.33 111.069 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.38 -178.7 4.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 73.43 111.094 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.74 163.72 13.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 72.2 110.881 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -103.64 -12.33 17.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.135 -0.484 . . . . 75.05 110.928 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -75.97 -58.72 3.11 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.197 -0.456 . . . . 75.14 111.17 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -119.44 -26.57 5.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 75.24 110.821 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.06 29.55 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.79 -0.719 . . . . 53.34 112.506 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -83.15 154.85 67.14 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.593 0.711 . . . . 74.15 110.934 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 128.71 16.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.737 2.291 . . . . 61.23 112.314 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 34.1 mm -75.03 101.7 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.31 111.128 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.2 mt -99.05 138.07 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 73.4 111.122 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 77.18 33.6 44.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 73.4 112.467 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.45 135.04 33.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 63.31 111.109 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.2 m -80.59 107.55 13.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 73.23 110.86 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.07 122.49 56.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 75.44 111.122 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -142.08 136.74 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 74.52 111.125 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -73.58 159.95 32.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.86 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 29.9 p -62.21 -41.98 98.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 74.21 111.164 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.0 p -108.22 -22.08 12.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 64.03 111.099 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.81 68.67 0.68 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 72.13 111.156 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.9 m -82.82 -35.37 26.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.466 . . . . 74.21 111.138 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.5 p -53.38 -31.18 43.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 74.23 111.06 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 -94.9 31.16 1.9 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 74.3 110.904 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.07 141.23 44.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.723 -0.751 . . . . 74.25 112.556 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.5 t -123.64 168.89 12.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 73.43 111.171 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.5 pt -107.63 156.76 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 75.01 111.141 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.1 p -81.65 150.63 27.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 71.25 111.113 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -82.39 173.34 12.12 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 54.12 110.837 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -59.46 -30.71 68.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 73.24 110.871 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -74.0 -19.38 60.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.102 -0.499 . . . . 73.22 110.886 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.97 28.15 10.32 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.463 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -128.92 152.68 48.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.93 0.395 . . . . 74.24 110.873 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -147.63 164.52 33.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.917 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -150.41 117.27 5.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 75.13 111.144 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.5 tt -115.93 109.77 18.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 72.41 110.947 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 89.7 p -68.9 108.41 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 73.42 110.856 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.3 p -130.78 133.21 24.54 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 73.53 111.138 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -43.26 2.74 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.66 2.24 . . . . 75.02 112.381 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 29.6 m -77.91 150.06 5.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 71.24 111.176 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -100.35 72.25 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 75.05 110.884 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 t -105.8 -170.95 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 74.42 110.827 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.13 155.35 17.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 72.33 111.167 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 10.4 mt -111.25 146.95 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 71.23 110.902 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.7 tttt -130.31 121.94 27.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 74.32 110.894 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 mp -119.27 144.01 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.144 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 37.7 p -138.36 138.67 38.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 65.5 111.165 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -131.83 115.21 15.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.282 -0.417 . . . . 65.43 110.977 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.3 tp -51.15 116.46 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 74.23 111.095 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.37 -53.42 0.81 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 62.44 112.475 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -110.47 170.53 8.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.925 0.393 . . . . 73.11 110.953 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -60.77 157.86 36.26 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.564 0.697 . . . . 75.42 110.874 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 172.81 12.02 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.661 2.241 . . . . 74.4 112.336 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.38 146.3 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 74.11 111.128 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.7 p -131.93 143.51 50.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 61.3 111.172 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.0 m -142.22 130.22 20.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.244 -0.435 . . . . 74.32 111.083 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 11.2 pttt -72.82 156.75 38.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 70.32 110.916 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.84 95.89 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.285 -0.416 . . . . 74.21 111.132 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -134.11 -173.22 3.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 63.13 111.094 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -88.04 -44.52 10.91 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 73.13 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.4 mt -138.09 126.17 30.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 72.31 111.112 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.71 126.93 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 75.01 111.159 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -119.92 125.53 48.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 74.11 110.902 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.2 t -137.15 149.07 25.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.449 . . . . 75.42 111.11 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.1 mp -105.02 143.54 33.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 74.53 110.907 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 2.1 tp -87.56 118.58 27.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.956 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -90.64 147.81 23.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -59.47 143.41 50.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.837 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 29.9 t70 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 44.35 110.827 -179.99 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.479 -0.249 . . . . 52.25 112.479 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.11 129.72 17.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.891 0.376 . . . . 73.41 110.826 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.3 t -123.02 133.37 69.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.091 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.6 p -130.03 172.55 11.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.141 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.16 153.2 21.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.828 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.1 tttm -92.55 16.24 12.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 75.05 110.904 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.02 -58.86 2.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 75.14 111.112 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -119.05 -26.66 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 75.24 110.847 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.45 29.25 5.14 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 53.34 112.525 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -97.87 159.78 30.07 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 74.15 110.917 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.64 146.61 61.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.724 2.282 . . . . 61.23 112.39 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.4 mm -96.68 117.43 41.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.074 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 29.9 mt -101.6 150.13 6.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 73.4 111.045 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.21 47.19 83.43 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.733 -0.746 . . . . 73.4 112.404 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.04 159.32 15.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.862 0.363 . . . . 63.31 111.044 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.2 m -105.92 107.25 18.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 73.23 110.837 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -112.66 129.82 67.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 75.44 111.113 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.0 m -145.98 146.31 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 74.52 111.17 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -80.75 174.33 11.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.888 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 43.5 p -68.95 -42.12 77.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 74.21 111.16 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.5 p -112.49 -22.22 10.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 64.03 111.159 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -104.89 76.44 1.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 72.13 111.112 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 p -86.53 -36.26 19.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 74.21 111.229 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.1 p -58.42 -28.44 65.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.115 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.42 1.75 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.229 -0.441 . . . . 74.3 110.857 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.51 143.11 47.99 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.766 -0.731 . . . . 74.25 112.533 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 m -117.87 160.55 21.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.725 0.298 . . . . 73.43 111.156 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.1 pt -116.41 149.31 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 75.01 111.088 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 15.9 p -69.87 150.64 46.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 71.25 111.202 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -84.15 -175.62 5.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 54.12 110.905 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -58.68 -30.65 67.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 73.24 110.882 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -99.4 21.99 11.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.884 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.4 28.18 71.95 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.669 -0.777 . . . . 75.31 112.533 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -110.44 131.34 55.14 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.835 0.35 . . . . 74.24 110.879 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -127.69 167.7 16.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 74.55 110.949 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.7 t -137.44 118.99 14.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 75.13 111.083 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -148.25 107.18 3.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 72.41 110.898 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.6 t -107.03 122.22 46.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 73.42 110.861 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -119.66 155.96 54.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.637 0.732 . . . . 73.53 111.048 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -48.39 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.644 2.229 . . . . 75.02 112.335 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.61 149.93 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 71.24 111.139 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -96.04 67.69 2.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 75.05 110.887 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.2 t -100.55 -169.29 1.7 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 74.42 110.89 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.45 163.06 16.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 72.33 111.148 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.92 131.75 46.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.253 -0.431 . . . . 71.23 110.91 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -101.0 126.2 47.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 74.32 110.901 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 2.5 mp -123.64 123.28 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 75.53 111.115 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 63.8 p -119.31 146.38 45.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 65.5 111.098 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.5 m-85 -129.14 154.62 46.55 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.185 -0.461 . . . . 65.43 110.947 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.7 tp -91.31 108.39 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.495 . . . . 74.23 111.133 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.95 -51.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.734 -0.746 . . . . 62.44 112.453 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -106.17 170.87 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.919 0.39 . . . . 73.11 110.958 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -67.31 146.67 98.88 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.598 0.713 . . . . 75.42 110.909 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 175.93 7.43 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.699 2.266 . . . . 74.4 112.317 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.1 m -149.82 142.76 17.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 74.11 111.155 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 13.9 p -122.17 131.98 54.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 61.3 111.158 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.2 m -152.91 156.51 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 74.32 111.202 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.79 154.27 27.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 70.32 110.893 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -63.95 107.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 74.21 111.066 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -130.83 159.3 37.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 63.13 111.107 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.64 -55.74 23.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 73.13 111.118 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 64.4 mt -126.01 131.49 71.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 72.31 111.092 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 23.7 t -143.06 123.53 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 75.01 111.148 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -119.86 109.43 15.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.848 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 26.6 t -125.18 148.87 29.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 75.42 111.169 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -103.72 144.44 31.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 74.53 110.938 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.6 tp -88.87 118.49 28.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 75.25 110.9 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.03 129.55 45.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.896 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 147.56 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.836 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 63.7 t0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 44.35 110.849 -179.995 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.531 -0.227 . . . . 52.25 112.531 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -157.96 119.82 3.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.895 0.378 . . . . 73.41 110.852 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 43.3 t -111.29 137.2 44.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 111.197 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.3 p -132.07 179.08 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 73.43 111.109 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -100.24 153.09 19.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 72.2 110.823 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 16.3 tttm -92.71 17.98 9.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.08 -0.509 . . . . 75.05 110.917 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 34.8 p -94.2 -58.68 2.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.271 -0.422 . . . . 75.14 111.217 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -120.15 -26.83 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.282 -0.417 . . . . 75.24 110.85 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.24 29.19 5.23 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.492 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -99.05 160.26 28.12 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.621 0.724 . . . . 74.15 110.911 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.62 143.33 51.13 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 61.23 112.393 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.6 mm -92.79 116.45 33.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.276 -0.42 . . . . 75.31 111.094 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 31.3 mt -98.42 150.18 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 73.4 111.107 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.05 48.25 72.97 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 73.4 112.449 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.04 158.27 15.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.799 0.333 . . . . 63.31 111.058 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.09 107.41 18.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 73.23 110.904 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.6 t -112.65 108.44 25.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.141 -0.482 . . . . 75.44 111.105 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -127.88 139.97 50.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 74.52 111.121 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -91.2 167.36 12.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 74.12 110.91 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 53.5 p -82.11 -33.75 29.59 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 74.21 111.13 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.2 p -79.42 -22.17 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 64.03 111.164 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.45 103.34 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 72.13 111.111 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -86.93 -35.44 18.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.194 -0.457 . . . . 74.21 111.155 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.2 p -53.99 -26.9 28.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.084 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -93.41 31.42 1.52 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 74.3 110.849 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -67.29 142.16 40.52 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 74.25 112.421 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.7 m -113.97 161.61 17.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.782 0.325 . . . . 73.43 111.108 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.6 pt -117.33 148.31 20.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.459 . . . . 75.01 111.156 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 19.1 p -71.33 150.69 44.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 71.25 111.108 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -86.59 -170.17 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 54.12 110.887 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -60.93 -30.65 70.34 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.152 -0.477 . . . . 73.24 110.974 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.67 17.88 12.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.485 . . . . 73.22 110.865 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.22 28.11 71.69 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.505 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -113.98 136.69 52.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 74.24 110.873 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -129.98 167.87 17.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.434 . . . . 74.55 110.925 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.1 t -123.36 117.44 25.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 75.13 111.166 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.62 124.44 14.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.41 110.915 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.8 t -106.98 108.07 19.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.848 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.1 m -139.95 152.57 68.09 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 73.53 111.113 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 170.61 16.09 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.705 2.27 . . . . 75.02 112.348 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.9 m -93.18 53.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.15 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -154.79 35.38 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 75.05 110.947 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.7 t -155.53 163.52 39.89 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.174 -0.466 . . . . 74.42 110.826 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 164.06 12.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 72.33 111.102 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 84.9 mt -130.45 117.19 19.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 71.23 110.937 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 37.3 tttt -102.27 123.55 46.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 74.32 110.868 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.3 mp -123.59 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.53 111.16 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.2 p -117.73 144.52 45.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 65.5 111.18 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -126.5 155.03 42.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 65.43 110.994 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.0 tt -92.36 107.86 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.114 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.84 -50.96 0.82 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.791 -0.719 . . . . 62.44 112.494 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -105.58 170.43 7.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 73.11 110.889 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -67.57 144.57 97.79 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.61 0.719 . . . . 75.42 110.87 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 176.99 6.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.605 2.203 . . . . 74.4 112.299 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.24 145.49 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 74.11 111.148 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 p -129.12 138.37 51.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 61.3 111.101 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 17.5 m -150.51 167.79 2.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.206 -0.452 . . . . 74.32 111.115 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -89.53 155.98 18.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.876 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -51.6 128.87 24.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 74.21 111.064 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -161.35 142.8 11.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 63.13 111.13 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.04 -49.32 66.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.085 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.3 mt -120.76 119.49 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.253 -0.43 . . . . 72.31 111.199 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.52 122.64 55.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 75.01 111.123 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -119.86 113.62 20.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 74.11 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.8 t -127.71 148.94 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 75.42 111.112 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 11.6 mt -106.44 145.29 31.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 74.53 110.932 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.1 tp -87.57 123.06 32.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.469 . . . . 75.25 110.903 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -102.06 133.3 47.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 73.42 110.882 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -51.91 139.54 21.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 75.12 110.927 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.879 -179.992 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.528 -0.229 . . . . 52.25 112.528 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -130.37 130.66 44.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 73.41 110.877 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.51 131.13 73.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 73.33 111.14 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.9 p -127.44 178.17 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.152 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 t -95.43 149.27 21.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.451 . . . . 72.2 110.828 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 33.8 tttm -90.05 12.26 18.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 75.05 110.909 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.4 p -93.61 -59.6 1.96 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.433 . . . . 75.14 111.182 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -118.69 -27.08 5.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 75.24 110.874 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.39 29.31 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.513 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -93.55 160.53 32.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.645 0.736 . . . . 74.15 110.918 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 138.21 37.18 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.606 2.204 . . . . 61.23 112.375 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 48.9 mm -85.64 120.07 35.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.259 -0.428 . . . . 75.31 111.105 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mt -105.93 140.97 22.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.161 -0.472 . . . . 73.4 111.101 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.41 50.41 21.25 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 73.4 112.452 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.06 159.0 15.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.771 0.32 . . . . 63.31 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.3 m -105.87 107.47 18.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 73.23 110.839 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.4 t -111.5 128.49 67.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.147 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.7 m -148.05 139.6 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.092 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -72.23 174.23 7.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.861 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.14 -35.21 49.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 74.21 111.146 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.5 p -112.4 -22.18 10.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 64.03 111.191 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -118.75 78.83 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.244 -0.435 . . . . 72.13 111.102 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.5 m -83.83 -39.21 20.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 74.21 111.11 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 p -53.59 -29.45 37.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 74.23 111.142 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -94.61 31.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.924 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -68.14 164.67 46.95 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.768 -0.729 . . . . 74.25 112.479 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -135.24 168.86 18.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.714 0.292 . . . . 73.43 111.178 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 13.9 pt -121.59 151.35 24.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.19 -0.459 . . . . 75.01 111.104 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 22.8 p -74.27 150.66 40.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.13 -0.487 . . . . 71.25 111.151 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -94.39 -178.1 4.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 54.12 110.885 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -56.92 -30.32 63.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 73.24 110.94 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -73.2 -18.72 61.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 73.22 110.853 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.43 28.19 20.38 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 75.31 112.471 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 23.7 p30 -133.93 163.53 29.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 74.24 110.906 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -144.86 167.76 21.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 74.55 110.887 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -135.72 122.84 21.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 75.13 111.105 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -138.01 118.68 14.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 72.41 110.893 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 t -93.08 115.31 27.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.817 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.66 155.98 44.22 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.646 0.736 . . . . 73.53 111.144 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -48.46 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.724 2.283 . . . . 75.02 112.337 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -111.97 -176.59 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.43 . . . . 71.24 111.104 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -106.04 64.99 0.68 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 75.05 110.885 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.9 t -92.52 -169.83 2.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 74.42 110.86 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.73 162.59 16.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 72.33 111.16 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 11.1 mt -134.39 133.15 40.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 71.23 110.98 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.6 ttpt -98.9 125.32 44.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.423 . . . . 74.32 110.876 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.7 mt -123.83 119.62 57.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 75.53 111.145 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 46.4 p -113.63 150.55 32.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 65.5 111.114 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -132.37 151.97 51.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 65.43 110.925 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -90.7 107.98 19.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 74.23 111.096 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.05 -51.19 0.8 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.752 -0.737 . . . . 62.44 112.551 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -104.4 170.5 7.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.931 0.396 . . . . 73.11 110.878 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -67.09 145.39 98.8 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.505 0.669 . . . . 75.42 110.889 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 175.2 8.46 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.686 2.258 . . . . 74.4 112.348 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.8 m -149.91 142.26 17.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 74.11 111.121 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.84 129.54 52.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 61.3 111.114 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.5 m -152.85 154.3 7.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 74.32 111.118 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -88.35 153.12 21.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 70.32 110.865 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -55.86 138.57 48.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 74.21 111.088 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -162.09 165.78 26.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 63.13 111.065 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.41 -56.76 16.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 73.13 111.139 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 61.7 mt -132.39 116.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 72.31 111.085 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.5 t -124.96 112.17 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 75.01 111.103 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -102.04 109.31 20.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 74.11 110.898 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.9 t -116.5 147.15 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.141 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.79 145.6 42.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 74.53 110.862 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.1 tp -93.62 121.3 34.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.222 -0.445 . . . . 75.25 110.921 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.13 137.14 45.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.276 -0.42 . . . . 73.42 110.925 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -51.08 137.34 21.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.481 . . . . 75.12 110.848 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 32.3 t0 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 44.35 110.873 179.988 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.464 -0.254 . . . . 52.25 112.464 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.28 126.36 40.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 73.41 110.945 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.6 t -110.84 125.13 68.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 73.33 111.15 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -128.59 177.15 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.166 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.21 161.38 14.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.802 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.9 tmtm? -101.59 -5.41 25.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.097 -0.502 . . . . 75.05 110.913 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 43.5 p -78.41 -58.58 3.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 75.14 111.177 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -118.36 -26.25 6.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 75.24 110.906 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.58 29.29 6.32 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.787 -0.72 . . . . 53.34 112.513 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -90.21 159.95 41.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.588 0.709 . . . . 74.15 110.959 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 139.24 39.6 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.702 2.268 . . . . 61.23 112.364 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.1 mm -91.3 101.56 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.241 -0.436 . . . . 75.31 111.102 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 3.2 mp -93.56 140.0 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 73.4 111.165 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.04 31.93 54.15 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.789 -0.72 . . . . 73.4 112.484 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.37 162.37 14.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.759 0.314 . . . . 63.31 111.088 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.7 m -105.79 107.29 18.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.471 . . . . 73.23 110.849 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.4 p -120.09 127.16 75.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 75.44 111.146 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.6 m -140.31 166.97 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 74.52 111.147 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -92.49 132.48 36.77 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 74.12 110.86 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 60.8 p -51.7 -35.03 41.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.121 -0.49 . . . . 74.21 111.124 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.6 p -95.37 -22.25 17.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 64.03 111.128 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -130.93 87.34 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.464 . . . . 72.13 111.104 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.2 p -86.81 -35.74 18.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 74.21 111.138 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.5 p -53.25 -30.56 38.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.139 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -93.96 31.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.417 . . . . 74.3 110.829 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.59 146.06 49.82 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.752 -0.737 . . . . 74.25 112.486 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.4 t -135.65 169.63 17.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.727 0.299 . . . . 73.43 111.178 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -107.9 157.55 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 75.01 111.149 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 p -76.22 150.97 36.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 71.25 111.099 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -79.49 -176.16 5.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 54.12 110.832 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -60.47 -30.62 69.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.208 -0.451 . . . . 73.24 110.838 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -99.44 20.87 12.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.197 -0.456 . . . . 73.22 110.882 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.28 27.98 71.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.781 -0.723 . . . . 75.31 112.392 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -107.04 143.43 35.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 74.24 110.955 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -144.57 161.79 38.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 74.55 110.872 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.6 t -151.34 128.36 11.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 75.13 111.211 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -130.63 159.8 36.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.41 110.846 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 6.1 m -95.52 108.23 20.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 73.42 110.798 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.9 t -133.35 133.19 22.53 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.611 0.72 . . . . 73.53 111.128 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 -48.39 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.747 2.298 . . . . 75.02 112.331 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 19.4 m -99.72 -173.83 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 71.24 111.116 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.5 m-20 -107.13 45.66 0.98 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 75.05 110.899 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -57.43 -179.55 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 74.42 110.89 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.7 m -87.69 159.72 18.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 72.33 111.137 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 6.7 mp -125.76 135.12 51.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 71.23 110.9 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.4 ttpt -106.86 120.84 43.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.32 110.92 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.8 mt -117.45 138.98 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 75.53 111.095 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.1 p -150.71 138.65 20.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 65.5 111.101 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -133.98 122.32 22.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 65.43 110.963 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 11.4 tt -51.57 115.08 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 74.23 111.159 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 131.23 -51.96 0.84 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.752 . . . . 62.44 112.467 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -107.98 170.18 8.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.9 0.381 . . . . 73.11 110.939 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -64.04 158.0 65.73 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.539 0.685 . . . . 75.42 110.914 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 164.26 35.15 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 74.4 112.357 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.8 m -150.83 141.08 16.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.197 -0.456 . . . . 74.11 111.133 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.9 p -130.25 140.1 50.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 61.3 111.041 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.6 m -147.55 148.0 16.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.097 -0.501 . . . . 74.32 111.093 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 6.9 mmmm -78.95 155.11 29.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 70.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -73.59 134.07 43.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 74.21 111.142 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.16 178.11 7.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.102 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.66 -57.32 9.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 73.13 111.13 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -143.78 111.77 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 72.31 111.084 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 12.2 p -118.84 141.82 36.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.127 -0.488 . . . . 75.01 111.136 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -115.89 134.98 54.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.4 t -122.83 149.18 26.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 75.42 111.143 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.34 133.37 54.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.176 -0.466 . . . . 74.53 110.934 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -90.54 121.49 32.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 75.25 110.928 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 50.3 mm-40 -92.38 145.29 24.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.155 -0.475 . . . . 73.42 110.862 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -58.45 140.4 53.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.17 -0.468 . . . . 75.12 110.929 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 44.35 110.851 -179.971 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.514 -0.235 . . . . 52.25 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -158.34 127.29 5.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.847 0.356 . . . . 73.41 110.929 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.94 130.59 72.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.33 111.105 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.5 p -128.5 163.71 24.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 73.43 111.103 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -84.73 148.96 26.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 72.2 110.88 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttp -92.43 17.53 9.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 75.05 110.851 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.95 -58.75 2.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.14 111.103 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -119.58 -26.68 5.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.24 110.892 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.35 5.12 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.736 -0.745 . . . . 53.34 112.409 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -97.44 159.95 29.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 74.15 110.939 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 141.62 45.65 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.663 2.242 . . . . 61.23 112.365 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 33.7 mm -86.04 115.22 26.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 75.31 111.065 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.4 mt -104.04 137.27 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.4 111.111 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 75.33 47.55 12.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.763 -0.732 . . . . 73.4 112.486 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.97 158.33 15.51 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.77 0.319 . . . . 63.31 111.135 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.9 m -105.99 107.21 18.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 73.23 110.875 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 95.4 t -110.91 110.39 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 75.44 111.111 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.8 m -123.53 146.05 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 74.52 111.106 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -90.24 156.7 18.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 74.12 110.836 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 51.9 p -73.03 -32.91 65.41 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.115 -0.493 . . . . 74.21 111.19 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.7 p -85.19 -22.2 28.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 64.03 111.17 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.76 104.74 1.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 72.13 111.047 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.4 p -86.75 -34.82 19.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 74.21 111.081 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.5 p -53.15 -29.68 32.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.251 -0.432 . . . . 74.23 111.188 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -94.29 31.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 74.3 110.892 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -72.86 164.37 54.86 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.718 -0.753 . . . . 74.25 112.492 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.8 t -130.96 169.08 16.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.712 0.291 . . . . 73.43 111.226 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 pp -115.99 164.55 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.255 -0.43 . . . . 75.01 111.141 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 14.1 p -89.28 150.66 22.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.205 -0.452 . . . . 71.25 111.15 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -91.37 -179.14 5.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.185 -0.461 . . . . 54.12 110.883 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -56.95 -30.64 64.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 73.24 110.968 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 46.0 m-20 -73.62 -18.46 61.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 73.22 110.865 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.97 28.1 21.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 75.31 112.506 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -127.23 165.38 19.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.812 0.339 . . . . 74.24 110.885 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -153.29 166.75 31.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 74.55 110.845 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.84 125.86 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 75.13 111.158 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -138.61 131.37 29.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 72.41 110.895 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 16.5 t -98.07 117.79 33.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.85 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.8 156.18 46.75 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.665 0.745 . . . . 73.53 111.104 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 -48.51 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.699 2.266 . . . . 75.02 112.376 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.9 m -113.14 -177.5 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.208 -0.451 . . . . 71.24 111.134 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -100.6 39.43 1.37 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 75.05 110.836 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.7 t -63.91 -169.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 74.42 110.866 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.65 161.43 17.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 72.33 111.132 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 12.7 mt -129.85 127.59 40.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.121 -0.491 . . . . 71.23 110.915 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -102.26 122.3 43.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 74.32 110.921 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.1 mt -123.63 118.94 55.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 75.53 111.086 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 55.0 p -113.34 146.86 38.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 65.5 111.168 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -126.28 155.15 42.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 65.43 110.892 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -91.65 107.76 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.072 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.88 -50.83 0.83 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.686 -0.769 . . . . 62.44 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -105.84 170.48 7.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.905 0.383 . . . . 73.11 110.952 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.8 mmtm -64.74 149.0 96.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.617 0.723 . . . . 75.42 110.882 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -179.15 2.73 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.722 2.281 . . . . 74.4 112.377 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 4.4 p -151.85 149.27 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.284 -0.416 . . . . 74.11 111.179 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.22 125.26 30.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 61.3 111.121 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.37 152.92 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 74.32 111.156 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -81.82 153.62 26.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 70.32 110.867 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -55.58 105.14 0.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 74.21 111.075 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.78 153.2 50.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.45 . . . . 63.13 111.129 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.09 -51.46 67.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 73.13 111.032 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 60.4 mt -120.03 115.48 47.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 72.31 111.199 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 20.1 t -126.63 106.61 15.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.222 -0.445 . . . . 75.01 111.197 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -114.26 109.43 18.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.11 110.898 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.6 t -129.04 148.38 33.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 75.42 111.13 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.6 mp -100.86 145.15 28.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 74.53 110.943 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.5 tp -87.72 120.93 29.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 75.25 110.947 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -96.14 127.25 41.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.903 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.52 143.16 25.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.877 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 44.35 110.904 179.981 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.477 -0.249 . . . . 52.25 112.477 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -132.43 127.79 36.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.841 0.353 . . . . 73.41 110.927 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.3 t -115.94 134.25 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 73.33 111.138 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.69 153.84 40.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 73.43 111.167 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.1 t -85.69 150.6 24.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 72.2 110.875 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 tttt -94.28 20.76 7.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 75.05 110.911 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.22 -58.69 2.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 75.14 111.098 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -120.05 -25.95 5.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 75.24 110.847 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.87 29.02 5.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 53.34 112.519 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -98.05 155.55 36.89 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 74.15 110.941 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.66 136.86 34.34 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.724 2.283 . . . . 61.23 112.351 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 50.0 mm -78.0 124.32 36.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 75.31 111.114 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.9 mt -110.18 119.35 59.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 73.4 111.095 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.68 33.4 8.47 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.774 -0.727 . . . . 73.4 112.528 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.54 132.21 35.18 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.722 0.296 . . . . 63.31 111.089 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.7 m -79.73 109.74 14.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 73.23 110.84 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -113.78 106.05 19.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.15 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.1 m -120.64 139.03 49.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.16 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -90.61 141.86 28.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 74.12 110.845 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.8 p -62.29 -31.6 72.22 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.074 -0.512 . . . . 74.21 111.166 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 64.8 p -71.71 -22.12 61.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 64.03 111.133 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.76 78.78 0.34 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 72.13 111.055 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 p -65.33 -35.62 81.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 74.21 111.184 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.7 m -54.09 -32.32 54.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.169 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.47 30.59 1.7 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 74.3 110.941 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.94 148.4 50.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.731 -0.747 . . . . 74.25 112.483 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -125.58 168.98 12.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.768 0.318 . . . . 73.43 111.181 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.0 pt -107.37 172.57 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 75.01 111.096 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 37.4 p -97.85 150.68 21.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.113 -0.494 . . . . 71.25 111.067 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -80.57 -175.99 5.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.483 . . . . 54.12 110.864 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -59.52 -30.74 68.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.274 -0.421 . . . . 73.24 110.869 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -100.04 22.77 10.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.16 -0.473 . . . . 73.22 110.886 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.94 28.15 72.32 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.76 . . . . 75.31 112.523 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -107.33 127.77 53.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 74.24 110.82 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -127.73 157.22 40.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.138 -0.483 . . . . 74.55 110.879 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.1 t -132.48 123.82 27.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.13 111.158 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.22 118.44 7.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 72.41 110.981 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.0 m -95.05 116.64 28.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 73.42 110.851 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -122.55 156.24 61.51 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.622 0.725 . . . . 73.53 111.155 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -35.88 11.83 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.667 2.245 . . . . 75.02 112.371 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.5 p -131.51 140.23 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 71.24 111.164 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -104.21 79.7 1.63 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 75.05 110.876 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.9 t -89.37 -76.96 0.4 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.861 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.64 159.99 40.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 72.33 111.147 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 15.6 mt -134.81 122.27 21.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 71.23 110.882 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -100.89 123.2 44.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 74.32 110.914 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.1 mt -121.12 138.4 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 75.53 111.149 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 47.2 p -148.82 138.66 22.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 65.5 111.11 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -133.98 122.8 23.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 65.43 110.927 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 7.2 tt -51.82 120.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 74.23 111.098 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.73 -50.94 0.85 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 62.44 112.521 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -109.23 169.97 8.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 73.11 110.932 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -64.54 157.33 73.51 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.52 0.676 . . . . 75.42 110.936 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.79 165.16 31.93 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.675 2.25 . . . . 74.4 112.311 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 32.1 m -150.55 138.25 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 74.11 111.154 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 p -131.76 140.85 49.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 61.3 111.171 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.0 m -145.92 175.66 2.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 74.32 111.11 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.41 149.9 25.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 70.32 110.9 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.43 118.37 18.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.181 -0.463 . . . . 74.21 111.137 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.97 -176.22 5.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 63.13 111.064 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -68.14 -57.66 5.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.153 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -126.69 114.26 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 72.31 111.139 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.87 127.45 58.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 75.01 111.136 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 36.0 m120 -100.35 127.59 46.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 74.11 110.897 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.7 148.88 21.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.254 -0.43 . . . . 75.42 111.093 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 15.3 mt -119.43 131.47 55.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.124 -0.489 . . . . 74.53 110.936 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -87.86 121.9 30.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 75.25 110.955 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -90.36 144.01 26.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 73.42 110.94 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -58.97 139.87 56.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.12 110.864 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 44.35 110.868 179.97 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.516 -0.234 . . . . 52.25 112.516 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.0 120.19 3.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.771 0.32 . . . . 73.41 110.928 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.1 t -105.93 131.64 54.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 73.33 111.126 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.9 p -129.37 159.26 36.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.43 111.126 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -84.34 156.95 21.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.2 110.858 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -93.96 20.09 8.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.079 -0.509 . . . . 75.05 110.966 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 60.1 p -94.52 -58.42 2.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 75.14 111.131 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -122.26 -26.36 4.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 75.24 110.915 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.64 29.27 5.08 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.753 -0.737 . . . . 53.34 112.539 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -98.99 159.69 29.6 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.552 0.692 . . . . 74.15 110.953 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.71 147.72 63.82 Favored 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.745 2.296 . . . . 61.23 112.399 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.5 mm -94.6 114.97 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 75.31 111.084 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 40.4 mt -100.22 138.6 24.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 73.4 111.159 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.27 46.64 12.23 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.659 -0.781 . . . . 73.4 112.522 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 157.82 15.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 63.31 111.043 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -106.01 107.14 17.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 73.23 110.855 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -112.15 122.58 66.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 75.44 111.132 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -138.91 151.95 23.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 74.52 111.177 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -84.31 174.28 10.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 74.12 110.912 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.13 -42.29 69.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 74.21 111.185 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.7 p -112.91 -22.16 10.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 64.03 111.143 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -110.26 76.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 72.13 111.2 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.2 p -86.95 -34.38 19.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 74.21 111.141 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.3 m -53.16 -30.48 37.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.434 . . . . 74.23 111.096 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -93.16 30.99 1.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 74.3 110.852 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.95 138.98 46.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.78 -0.724 . . . . 74.25 112.455 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.5 m -116.97 160.45 20.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 73.43 111.162 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -114.51 162.2 12.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 75.01 111.165 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.6 p -83.87 150.61 25.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 71.25 111.218 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -85.14 -175.89 5.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 54.12 110.91 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -58.99 -30.18 67.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.237 -0.438 . . . . 73.24 110.851 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.56 13.54 13.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 73.22 110.862 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 28.0 71.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.757 -0.735 . . . . 75.31 112.419 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -126.81 142.59 51.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.863 0.363 . . . . 74.24 110.917 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -132.39 168.01 18.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.469 . . . . 74.55 110.873 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.7 t -133.43 116.56 16.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 75.13 111.105 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -143.19 132.29 23.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 72.41 110.929 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 79.2 p -107.35 124.84 50.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 73.42 110.902 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.61 155.95 44.2 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.702 0.763 . . . . 73.53 111.111 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -48.5 0.71 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.665 2.243 . . . . 75.02 112.362 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.3 m -112.37 179.68 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 71.24 111.189 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 75.2 m-80 -100.31 36.88 1.77 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 75.05 110.862 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.3 t -61.98 -172.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.42 110.844 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.0 154.95 19.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.057 -0.52 . . . . 72.33 111.186 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 6.3 mp -127.41 130.96 50.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 71.23 110.91 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -99.82 121.25 41.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 74.32 110.917 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 2.4 mp -117.92 119.14 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.295 -0.411 . . . . 75.53 111.14 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 44.5 p -116.08 144.32 44.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.187 -0.46 . . . . 65.5 111.149 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -126.63 152.35 46.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 65.43 110.918 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.4 tt -89.71 107.73 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.109 -0.496 . . . . 74.23 111.142 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.5 -50.47 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.74 . . . . 62.44 112.49 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -103.62 170.69 7.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 73.11 110.925 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -67.95 145.17 97.71 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.58 0.705 . . . . 75.42 110.867 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 172.34 12.84 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.682 2.254 . . . . 74.4 112.382 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.5 m -150.08 143.66 17.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 74.11 111.128 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -122.49 134.76 54.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.246 -0.434 . . . . 61.3 111.168 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.1 m -152.94 158.82 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 74.32 111.127 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -82.47 157.28 23.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 70.32 110.882 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.18 138.14 49.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 74.21 111.113 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.72 -177.59 4.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 63.13 111.093 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.37 -58.0 7.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 73.13 111.085 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -124.25 137.71 56.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.2 -0.454 . . . . 72.31 111.149 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.1 p -143.61 120.92 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.142 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -119.98 110.55 16.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 74.11 110.831 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.2 t -116.37 146.32 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 75.42 111.128 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -102.14 135.33 43.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.185 -0.461 . . . . 74.53 110.932 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -87.53 120.87 29.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 75.25 110.919 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -95.69 142.9 27.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 73.42 110.905 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -55.02 141.25 34.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.12 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 13.0 t70 . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 116.264 -0.426 . . . . 44.35 110.946 179.951 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.529 -0.228 . . . . 52.25 112.529 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -152.74 119.95 5.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.36 . . . . 73.41 110.857 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.4 t -107.26 132.11 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 73.33 111.153 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -136.22 160.38 38.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 73.43 111.072 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.16 154.1 35.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 72.2 110.851 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.6 tttp -96.46 12.91 29.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 75.05 110.845 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 74.3 p -93.86 -58.72 2.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.261 -0.427 . . . . 75.14 111.144 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -119.04 -26.57 5.93 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.229 -0.442 . . . . 75.24 110.935 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.32 29.25 5.18 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.748 . . . . 53.34 112.445 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 47.0 mt-30 -90.45 160.46 39.26 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.598 0.713 . . . . 74.15 110.902 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 136.27 32.64 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.673 2.248 . . . . 61.23 112.368 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.4 mm -87.4 123.07 39.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.096 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.5 mt -107.92 128.23 63.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 73.4 111.118 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.53 32.87 14.68 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.686 -0.768 . . . . 73.4 112.501 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.42 127.76 36.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.792 0.329 . . . . 63.31 111.04 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -72.8 107.63 5.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 73.23 110.829 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.64 106.68 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.065 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.03 150.49 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 74.52 111.121 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -92.57 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 74.12 110.851 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.9 p -56.14 -34.85 66.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.066 -0.515 . . . . 74.21 111.204 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 66.5 p -98.16 -22.09 16.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.24 -0.436 . . . . 64.03 111.208 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -133.48 65.81 1.57 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 72.13 111.065 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 p -67.03 -35.32 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 74.21 111.17 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 88.8 m -64.1 -30.63 71.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 74.23 111.084 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -93.51 30.55 1.72 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.86 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -70.9 155.95 53.04 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.749 -0.739 . . . . 74.25 112.422 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -132.76 168.8 17.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.756 0.312 . . . . 73.43 111.199 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.89 150.83 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.44 . . . . 75.01 111.191 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 19.2 p -70.38 150.14 46.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 71.25 111.186 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -91.3 -179.23 5.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 54.12 110.821 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -58.25 -30.64 66.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 73.24 110.846 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -73.84 -19.48 60.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.853 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.03 28.16 12.42 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.689 -0.767 . . . . 75.31 112.501 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -137.68 164.59 28.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.859 0.361 . . . . 74.24 110.925 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 27.6 p90 -138.78 167.46 21.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 74.55 110.835 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -119.86 120.38 36.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.114 -0.493 . . . . 75.13 111.187 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.3 mt -148.11 108.18 4.06 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.265 -0.425 . . . . 72.41 110.899 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.4 t -82.4 108.08 15.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.851 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 6.7 m -139.98 106.77 6.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.653 0.74 . . . . 73.53 111.129 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -32.54 18.45 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.762 2.308 . . . . 75.02 112.365 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.4 m -55.57 -30.61 26.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 71.24 111.138 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 67.32 40.11 2.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 75.05 110.866 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.0 m -74.73 -176.01 2.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 74.42 110.91 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.95 150.05 24.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 72.33 111.186 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 6.1 mp -117.85 131.57 56.54 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.264 -0.425 . . . . 71.23 110.933 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -99.83 128.48 45.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 74.32 110.87 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 45.0 mt -123.79 124.93 70.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.233 -0.44 . . . . 75.53 111.097 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 71.8 p -140.88 143.33 34.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.104 -0.498 . . . . 65.5 111.131 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -139.29 121.02 15.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.216 -0.447 . . . . 65.43 110.856 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.1 tt -50.91 107.68 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.083 -0.508 . . . . 74.23 111.141 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 138.94 -43.86 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 62.44 112.46 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -114.94 170.96 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.981 0.42 . . . . 73.11 110.902 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mmtt -66.29 153.64 92.09 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.596 0.712 . . . . 75.42 110.905 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.77 157.68 59.54 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.711 2.274 . . . . 74.4 112.331 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.8 m -150.93 137.93 13.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 74.11 111.141 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 21.2 p -131.96 142.24 49.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 61.3 111.107 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.5 m -149.55 156.32 7.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 74.32 111.141 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.51 157.29 26.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 70.32 110.934 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.4 137.59 38.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.276 -0.42 . . . . 74.21 111.147 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.59 178.65 7.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.439 . . . . 63.13 111.112 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.71 -49.61 62.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 73.13 111.087 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -143.71 111.79 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 72.31 111.144 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.12 128.1 73.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 75.01 111.079 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.1 m120 -115.39 125.98 53.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 74.11 110.887 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.2 t -120.05 149.01 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.132 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.5 mp -121.35 120.46 35.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 74.53 110.968 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 3.4 tp -88.06 116.55 26.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 75.25 110.873 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 17.0 pm0 -95.9 146.47 24.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 73.42 110.82 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.58 143.89 33.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.131 -0.486 . . . . 75.12 110.932 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 44.35 110.862 179.995 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.433 -0.267 . . . . 52.25 112.433 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -156.83 125.76 5.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.829 0.347 . . . . 73.41 110.881 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.1 t -112.35 130.17 66.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 73.33 111.075 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 p -128.84 164.31 23.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 73.43 111.11 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -85.32 149.95 25.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 72.2 110.801 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.35 18.17 8.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.111 -0.495 . . . . 75.05 110.918 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.93 2.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 75.14 111.157 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -119.95 -26.77 5.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 75.24 110.88 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.11 29.39 5.19 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.773 -0.727 . . . . 53.34 112.507 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.2 mm100 -96.9 160.3 29.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.672 0.749 . . . . 74.15 110.918 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 138.54 38.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.649 2.233 . . . . 61.23 112.381 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 49.9 mm -83.79 123.09 38.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.133 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.3 mt -108.24 140.75 25.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 73.4 111.161 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.63 51.99 17.95 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.81 -0.71 . . . . 73.4 112.48 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.05 155.75 16.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.805 0.336 . . . . 63.31 111.078 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.5 m -106.14 107.42 18.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 73.23 110.843 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 94.8 t -113.31 116.8 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 75.44 111.158 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.2 m -138.65 144.01 30.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 74.52 111.049 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -78.94 173.65 12.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.12 110.866 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 66.1 p -75.41 -36.26 60.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 74.21 111.143 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 38.9 p -112.37 -22.08 11.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 64.03 111.111 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -114.97 75.56 0.94 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 72.13 111.073 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.1 m -84.36 -35.9 22.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 74.21 111.18 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -57.38 -28.93 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 74.23 111.128 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -94.54 31.23 1.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.91 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -69.67 149.28 47.97 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.799 -0.715 . . . . 74.25 112.48 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.2 t -123.1 169.12 11.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.716 0.293 . . . . 73.43 111.139 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.1 pt -124.42 156.64 32.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 75.01 111.148 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 35.6 p -81.79 149.05 28.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 71.25 111.115 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -91.62 -176.24 4.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.228 -0.442 . . . . 54.12 110.858 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.93 -30.62 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 73.24 110.892 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -73.8 -18.85 60.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 73.22 110.86 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.37 28.22 20.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.725 -0.75 . . . . 75.31 112.457 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.97 162.38 29.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.826 0.346 . . . . 74.24 110.901 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -146.02 164.14 33.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.921 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.7 t -128.5 116.28 19.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 75.13 111.14 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.5 107.46 3.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 72.41 110.877 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.6 m -68.82 107.93 3.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.83 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.2 t -139.97 133.41 15.31 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.62 0.724 . . . . 73.53 111.126 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 173.86 10.4 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.652 2.234 . . . . 75.02 112.384 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -95.48 31.99 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.178 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -92.19 -36.04 13.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 75.05 110.912 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 6.3 p -123.47 176.98 5.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.84 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.72 176.88 5.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 72.33 111.164 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 71.6 mt -131.17 126.78 36.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 71.23 110.951 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -102.44 122.04 43.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 74.32 110.865 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.2 mt -123.79 117.73 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 75.53 111.145 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 65.0 p -113.19 148.58 35.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 65.5 111.122 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -127.37 154.97 44.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 65.43 110.951 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -91.02 107.77 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 74.23 111.072 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 124.09 -51.23 0.82 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.707 -0.759 . . . . 62.44 112.429 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.93 170.66 7.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.995 0.426 . . . . 73.11 110.856 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 35.2 mttt -64.54 148.53 96.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.59 0.71 . . . . 75.42 110.878 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -178.75 2.51 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.268 . . . . 74.4 112.324 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 4.7 p -152.02 146.02 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 74.11 111.169 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.9 p -132.17 130.58 41.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 61.3 111.119 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.1 m -152.62 155.15 6.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.28 -0.418 . . . . 74.32 111.069 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.3 ptpt -74.68 152.46 39.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 70.32 110.892 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -58.26 120.74 9.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 74.21 111.098 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -148.49 150.76 33.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 63.13 111.089 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.81 -53.73 36.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.097 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.6 mp -117.17 133.28 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 72.31 111.204 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 5.4 p -146.39 118.05 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 75.01 111.145 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 32.9 m120 -120.11 109.46 15.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.473 . . . . 74.11 110.904 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -126.79 144.14 37.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 75.42 111.15 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.0 mp -96.92 145.19 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 74.53 111.008 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -87.77 121.49 30.25 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.281 -0.418 . . . . 75.25 110.931 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -98.71 136.11 39.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 73.42 110.888 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -55.05 140.46 37.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.88 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.0 t0 . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.861 -179.993 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.481 -0.248 . . . . 52.25 112.481 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -151.23 127.64 10.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 73.41 110.896 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.29 130.61 72.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 73.33 111.136 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.3 p -127.14 169.39 13.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 73.43 111.163 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.21 155.1 19.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.2 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -92.63 18.64 8.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 75.05 110.848 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.64 2.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 75.14 111.165 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -120.85 -26.42 5.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.3 -0.409 . . . . 75.24 110.832 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.79 29.05 5.12 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.491 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -100.63 154.19 37.31 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.566 0.698 . . . . 74.15 110.93 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 147.2 62.75 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.756 2.304 . . . . 61.23 112.335 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.5 mm -93.5 120.38 42.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 75.31 111.066 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.07 150.81 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 73.4 111.103 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.61 48.33 82.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 73.4 112.474 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.28 167.65 11.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 63.31 111.028 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.0 m -106.34 106.62 17.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.163 -0.471 . . . . 73.23 110.856 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.9 t -110.42 128.86 66.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 75.44 111.122 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.8 m -148.44 137.99 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 74.52 111.143 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -82.87 129.27 34.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 74.12 110.878 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.2 t -51.4 -33.21 29.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.21 111.168 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 42.1 p -89.45 -22.24 22.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 64.03 111.1 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -148.61 98.66 2.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 72.13 111.115 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 66.3 p -86.69 -32.83 20.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 74.21 111.189 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.3 m -52.78 -29.69 28.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.169 -0.469 . . . . 74.23 111.135 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -93.25 31.08 1.53 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.247 -0.433 . . . . 74.3 110.841 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -66.44 150.53 51.93 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.71 -0.757 . . . . 74.25 112.474 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.5 t -135.76 169.43 17.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 73.43 111.151 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 17.9 pt -113.16 152.08 14.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 75.01 111.146 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 10.0 p -69.98 150.72 46.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 71.25 111.119 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -81.26 -177.43 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 54.12 110.84 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -60.32 -30.61 69.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 73.24 110.867 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -97.42 20.38 11.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.22 110.867 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.27 27.94 71.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.719 -0.753 . . . . 75.31 112.474 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -108.5 139.38 43.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 74.24 110.919 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -133.49 168.13 19.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 74.55 110.928 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 25.6 p -145.1 117.69 8.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 75.13 111.092 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 7.4 mp -126.59 109.58 12.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 72.41 110.889 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -99.89 117.91 35.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.845 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.6 m -138.34 155.9 73.79 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 73.53 111.124 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 -48.34 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.634 2.223 . . . . 75.02 112.381 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.18 150.72 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 71.24 111.111 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -91.3 46.07 1.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 75.05 110.91 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 84.0 p -66.4 -169.83 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 74.42 110.819 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.64 160.74 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.503 . . . . 72.33 111.165 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 19.1 mt -121.15 117.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 71.23 110.931 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -97.82 114.58 26.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 74.32 110.867 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.0 mp -115.62 121.2 66.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 75.53 111.168 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 43.8 p -117.14 145.26 43.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 65.5 111.04 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 18.7 m-85 -125.81 155.29 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.481 . . . . 65.43 110.903 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -92.5 107.38 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.11 -0.496 . . . . 74.23 111.158 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.07 -46.16 1.1 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 62.44 112.467 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -111.82 170.89 7.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 73.11 110.828 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -63.6 150.75 89.74 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.568 0.699 . . . . 75.42 110.927 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 178.2 4.83 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.645 2.23 . . . . 74.4 112.371 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 3.7 p -152.03 147.9 14.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.088 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.6 p -132.14 130.82 41.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 61.3 111.174 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.5 m -141.66 145.97 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.263 -0.426 . . . . 74.32 111.125 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.97 157.18 37.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.965 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.18 98.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 74.21 111.155 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.15 178.2 6.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 63.13 111.071 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -86.36 -42.37 13.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.16 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -129.87 125.48 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.239 -0.437 . . . . 72.31 111.137 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.3 p -146.44 122.14 3.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 75.01 111.133 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -120.12 119.74 34.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 74.11 110.856 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.8 t -133.03 147.02 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 75.42 111.173 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 24.8 mt -98.17 135.19 40.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 74.53 110.912 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.4 tp -89.32 117.89 28.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 75.25 110.89 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -94.07 132.53 38.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.42 110.867 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -56.65 145.84 27.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.097 -0.501 . . . . 75.12 110.936 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 14.9 t70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 44.35 110.861 -179.941 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.464 -0.255 . . . . 52.25 112.464 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -158.13 119.85 3.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.843 0.354 . . . . 73.41 110.909 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 87.1 t -108.84 130.91 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 73.33 111.143 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.7 p -127.31 169.5 13.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.108 -0.497 . . . . 73.43 111.113 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -89.16 150.09 22.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.457 . . . . 72.2 110.832 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.9 tttm -90.83 15.0 12.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 75.05 110.882 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.74 -58.47 2.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 75.14 111.178 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -118.86 -26.66 5.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 75.24 110.828 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.28 29.29 6.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 53.34 112.503 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -96.93 160.16 29.81 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.533 0.682 . . . . 74.15 110.916 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 132.96 24.38 Favored 'Trans proline' 0 N--CA 1.465 -0.162 0 C-N-CA 122.664 2.242 . . . . 61.23 112.337 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 25.4 mm -77.67 118.11 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.164 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.8 mt -108.7 132.62 56.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 73.4 111.142 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.9 31.98 19.21 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.736 -0.745 . . . . 73.4 112.462 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.39 153.94 21.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.777 0.322 . . . . 63.31 111.114 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -106.86 107.04 17.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.429 . . . . 73.23 110.865 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.81 130.13 74.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 75.44 111.106 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.9 m -146.01 163.8 10.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 74.52 111.108 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -85.24 172.82 10.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 74.12 110.931 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.58 -42.03 65.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 74.21 111.162 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -112.55 -21.98 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.198 -0.455 . . . . 64.03 111.155 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.16 64.55 0.84 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 72.13 111.109 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 21.8 p -78.52 -35.24 46.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.224 -0.444 . . . . 74.21 111.176 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.1 p -53.23 -30.93 40.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.097 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -93.78 31.33 1.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.968 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.81 148.37 50.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.794 -0.717 . . . . 74.25 112.434 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.2 t -135.49 170.57 15.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.76 0.314 . . . . 73.43 111.194 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 11.6 pt -122.94 152.38 27.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 75.01 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.1 p -70.85 150.94 45.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.145 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -91.0 -177.02 4.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 54.12 110.896 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.2 -30.01 69.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 73.24 110.883 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -73.17 -18.52 61.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.46 28.04 20.74 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 75.31 112.452 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -129.65 166.88 18.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.887 0.375 . . . . 74.24 110.922 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -151.35 167.92 26.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 74.55 110.865 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.5 t -134.66 125.61 27.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 75.13 111.1 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -130.73 128.84 41.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 72.41 110.898 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.9 t -105.04 119.97 40.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 73.42 110.801 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.0 133.23 16.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.614 0.721 . . . . 73.53 111.157 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -48.35 0.73 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.725 2.283 . . . . 75.02 112.325 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.0 m -86.65 171.64 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.259 -0.428 . . . . 71.24 111.12 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -111.08 81.75 1.48 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 75.05 110.829 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.7 t -109.39 -169.41 1.47 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.924 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.54 161.93 17.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.461 . . . . 72.33 111.133 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -128.42 130.18 47.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 71.23 110.91 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -101.98 124.45 47.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 74.32 110.858 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.3 mt -123.64 119.57 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.448 . . . . 75.53 111.115 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 51.2 p -117.78 144.32 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 65.5 111.152 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -126.22 155.06 42.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.21 -0.45 . . . . 65.43 110.94 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -92.24 107.72 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 74.23 111.144 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 121.17 -51.1 0.8 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 62.44 112.513 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -101.5 170.75 8.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.897 0.379 . . . . 73.11 110.906 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 57.0 mttt -68.6 143.61 95.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.551 0.691 . . . . 75.42 110.963 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.73 174.22 9.8 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.713 2.275 . . . . 74.4 112.391 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.8 m -150.24 140.37 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 74.11 111.168 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -125.76 130.25 51.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 61.3 111.148 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.9 m -153.41 159.23 3.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.283 -0.417 . . . . 74.32 111.143 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -73.07 157.23 37.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.32 110.9 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.89 138.31 48.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 74.21 111.078 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -159.91 167.54 27.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 63.13 111.096 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.37 -57.14 13.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 73.13 111.064 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.5 135.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 72.31 111.143 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.1 p -146.48 120.72 2.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 75.01 111.185 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -120.01 109.81 15.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 74.11 110.848 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 36.7 t -123.65 135.18 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 75.42 111.148 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.5 pp -92.71 145.49 24.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 74.53 110.955 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -87.61 121.33 29.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 75.25 110.878 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 59.5 mt-10 -97.69 136.76 37.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.941 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -55.13 139.74 40.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 75.12 110.88 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 44.35 110.818 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.807 0.337 . . . . 72.11 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -96.66 118.58 6.06 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 45.31 112.532 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 61.1 t60 -73.9 117.01 15.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.788 0.328 . . . . 75.12 110.881 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 -103.38 135.01 45.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 64.44 110.89 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -84.95 142.85 29.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.445 . . . . 74.31 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 46.4 m80 -99.99 99.67 10.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 73.02 110.873 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -116.75 176.84 4.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 74.02 110.897 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -88.61 79.19 7.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 73.02 110.807 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 87.1 m -122.28 144.81 48.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 64.24 111.075 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.3 mttt -108.86 114.73 28.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 74.23 110.914 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.07 155.55 0.19 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 52.25 112.513 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -158.0 122.26 4.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.347 . . . . 73.41 110.93 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.22 128.67 71.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.13 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -136.18 152.07 50.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 73.43 111.188 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.83 148.84 28.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 72.2 110.893 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.56 21.89 6.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.142 -0.481 . . . . 75.05 110.901 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.0 -58.58 2.2 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 75.14 111.17 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -119.14 -25.98 6.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.263 -0.426 . . . . 75.24 110.883 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.8 29.02 5.12 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 53.34 112.499 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -101.14 160.5 26.47 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.559 0.695 . . . . 74.15 110.888 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.73 145.46 57.39 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.688 2.259 . . . . 61.23 112.329 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 47.4 mm -83.07 115.63 25.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 75.31 111.171 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.3 mt -104.83 113.1 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.471 . . . . 73.4 111.191 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.51 32.66 6.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 73.4 112.5 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.06 128.14 36.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.858 0.361 . . . . 63.31 111.062 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.0 m -81.25 107.19 13.83 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.215 -0.448 . . . . 73.23 110.853 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.09 122.7 69.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.088 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.6 m -134.27 174.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 74.52 111.138 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 35.3 mp0 -91.17 166.14 13.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 74.12 110.92 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -65.43 -41.99 92.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 74.21 111.145 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.1 p -112.56 -22.16 10.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 64.03 111.083 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -101.32 65.65 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 72.13 111.086 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 87.5 m -77.34 -35.71 54.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 74.21 111.096 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.7 p -57.07 -31.6 65.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.23 111.169 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.41 1.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.3 110.929 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.36 152.37 49.64 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.781 -0.723 . . . . 74.25 112.499 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.6 t -135.56 168.46 19.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.74 0.305 . . . . 73.43 111.138 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.6 pt -116.55 167.72 9.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 75.01 111.134 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 23.0 p -89.74 150.61 22.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 71.25 111.174 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -95.22 -178.93 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 54.12 110.915 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -57.79 -30.44 65.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.48 . . . . 73.24 110.885 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -73.55 -19.39 60.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.152 -0.476 . . . . 73.22 110.892 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.7 28.26 12.83 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 120.736 -0.745 . . . . 75.31 112.458 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -136.58 166.07 24.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.914 0.388 . . . . 74.24 110.93 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 24.2 p90 -142.66 164.75 29.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 74.55 110.902 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -123.46 117.79 25.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 75.13 111.166 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -144.44 134.97 24.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.41 . . . . 72.41 110.903 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 1.2 t -107.02 121.85 45.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 73.42 110.846 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.92 133.26 24.84 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.565 0.698 . . . . 73.53 111.135 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 -48.42 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.731 2.288 . . . . 75.02 112.353 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.77 149.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 71.24 111.167 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 70.8 m-80 -85.16 64.39 8.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 75.05 110.92 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -92.49 -179.56 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 74.42 110.812 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.71 156.08 19.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.075 -0.512 . . . . 72.33 111.17 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mt -115.24 124.9 52.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.275 -0.42 . . . . 71.23 110.888 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 28.8 tttt -95.64 122.43 38.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 74.32 110.885 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 2.2 mp -118.65 134.55 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 75.53 111.131 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 45.7 p -142.55 138.74 31.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 65.5 111.123 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -134.31 119.13 18.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 65.43 110.95 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.4 tt -51.49 112.46 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.132 -0.486 . . . . 74.23 111.175 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 133.98 -52.14 0.82 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.783 -0.723 . . . . 62.44 112.473 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -108.27 170.0 8.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.379 . . . . 73.11 110.919 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -62.81 158.24 53.87 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.553 0.692 . . . . 75.42 110.885 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.44 42.09 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.677 2.251 . . . . 74.4 112.334 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.72 138.5 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.155 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 34.6 p -131.37 139.52 49.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 61.3 111.166 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 26.5 m -146.69 147.05 18.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 74.32 111.153 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -66.04 157.1 31.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.982 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.99 125.9 29.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 74.21 111.168 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -156.79 166.49 33.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 63.13 111.106 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.23 -43.34 78.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.117 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.0 mt -140.48 112.11 4.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 72.31 111.11 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.7 p -130.49 128.83 64.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 75.01 111.131 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -102.71 133.55 47.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 74.11 110.877 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.5 t -122.29 148.89 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 75.42 111.1 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 13.2 mt -122.0 127.82 50.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 74.53 110.885 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.4 tp -88.19 121.58 30.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 75.25 110.866 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -90.39 144.42 25.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 73.42 110.921 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -58.24 141.33 51.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 75.12 110.897 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -103.95 147.84 26.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 44.35 110.863 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 13.8 p 49.93 38.65 16.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 74.43 111.047 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -147.81 120.28 8.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 74.23 110.941 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 11.2 ttm -99.78 103.83 15.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.34 110.861 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -129.79 110.4 19.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 75.24 111.128 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -92.02 127.97 37.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.858 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -109.14 66.8 0.64 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.882 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 13.4 p -129.25 147.59 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 55.31 111.13 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.7 p -157.2 144.24 10.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 74.02 111.092 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.5 p -158.5 134.45 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.01 111.14 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 32.2 p -120.21 -178.0 3.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 73.33 111.088 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.43 -134.33 3.19 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.741 -0.743 . . . . 61.42 112.485 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -58.97 148.64 29.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.901 0.382 . . . . 75.33 110.979 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 75.25 111.074 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 1.5 mpt? . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.8 0.333 . . . . 72.11 110.897 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -81.06 -82.75 0.79 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.741 -0.742 . . . . 45.31 112.497 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -114.56 -175.26 2.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 75.12 110.875 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -143.74 142.95 31.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 64.44 110.848 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 82.9 m-70 -139.71 154.89 47.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 74.31 110.86 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -59.46 -50.39 74.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 73.02 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -156.65 -176.57 6.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 74.02 110.869 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -128.21 62.09 1.44 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.221 -0.445 . . . . 73.02 110.837 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.7 t -81.8 167.02 19.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.44 . . . . 64.24 111.164 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mmtm -144.77 121.3 11.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.23 110.9 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.94 152.48 0.35 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 52.25 112.493 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -153.64 120.12 5.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 73.41 110.895 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.4 t -109.7 129.8 63.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 73.33 111.175 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.7 p -136.57 176.55 8.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.209 -0.45 . . . . 73.43 111.148 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.27 150.98 23.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.2 110.863 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.3 tmmt? -93.48 19.26 8.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 75.05 110.894 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.13 -58.72 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.244 -0.435 . . . . 75.14 111.146 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -120.17 -26.42 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 75.24 110.851 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.34 29.39 5.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.742 -0.742 . . . . 53.34 112.485 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.7 mm100 -100.35 160.24 27.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 74.15 110.911 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 137.67 36.14 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.715 2.277 . . . . 61.23 112.368 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 42.6 mm -87.15 125.33 40.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 75.31 111.177 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.4 mt -104.89 113.47 42.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.4 111.134 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.04 33.03 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.767 -0.73 . . . . 73.4 112.486 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.66 119.26 26.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.754 0.312 . . . . 63.31 111.073 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.23 107.53 5.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 73.23 110.859 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.0 t -109.99 106.5 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.102 -0.499 . . . . 75.44 111.121 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.4 m -114.97 140.76 34.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.132 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -85.79 133.52 33.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 74.12 110.857 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.6 p -54.51 -35.86 63.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 74.21 111.098 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.3 p -78.97 -22.09 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.267 -0.424 . . . . 64.03 111.133 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.51 110.69 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 72.13 111.079 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -86.51 -33.93 20.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 74.21 111.111 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 77.7 p -53.18 -29.59 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 74.23 111.154 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -94.26 31.19 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.3 110.885 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -73.25 141.18 29.65 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.801 -0.714 . . . . 74.25 112.46 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.41 168.9 9.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.737 0.303 . . . . 73.43 111.146 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.8 pt -124.13 148.59 28.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 75.01 111.119 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 9.9 p -73.93 150.74 40.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 71.25 111.174 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -99.79 -175.33 2.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 54.12 110.873 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -56.38 -31.47 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 73.24 110.886 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -76.78 -18.88 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.462 . . . . 73.22 110.905 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.25 28.84 10.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 75.31 112.518 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -135.99 159.88 40.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.822 0.344 . . . . 74.24 110.931 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -140.2 168.0 20.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 74.55 110.893 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 39.2 p -109.53 116.17 31.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 75.13 111.165 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.67 107.48 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 72.41 110.909 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 29.1 t -106.95 120.12 41.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 73.42 110.86 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.99 156.19 79.49 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.651 0.739 . . . . 73.53 111.109 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -48.02 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.7 2.267 . . . . 75.02 112.352 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 m -101.94 175.79 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 71.24 111.12 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -106.55 58.89 0.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 75.05 110.897 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.5 p -72.7 -170.2 0.66 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.493 . . . . 74.42 110.857 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.14 152.43 21.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 72.33 111.133 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.31 121.64 37.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 71.23 110.877 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 47.2 tttt -96.88 123.14 40.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 74.32 110.888 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.4 mp -116.56 132.23 66.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.446 . . . . 75.53 111.121 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.6 p -143.08 138.56 29.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 65.5 111.121 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -137.72 127.63 25.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.19 -0.459 . . . . 65.43 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 tp -51.63 119.98 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.489 . . . . 74.23 111.119 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.99 -51.12 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.775 -0.726 . . . . 62.44 112.479 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -108.61 170.12 8.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.933 0.397 . . . . 73.11 110.916 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -69.92 158.11 88.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.57 0.7 . . . . 75.42 110.914 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 164.56 34.12 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.681 2.254 . . . . 74.4 112.304 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.5 p -151.4 149.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.126 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.7 p -132.02 132.56 43.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 61.3 111.124 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.0 m -137.72 172.17 14.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.439 . . . . 74.32 111.16 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.38 156.82 18.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.901 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -93.18 130.07 38.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 74.21 111.045 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.55 -175.55 3.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 63.13 111.072 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.35 -49.53 66.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 73.13 111.097 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 43.9 mm -139.2 114.2 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 72.31 111.156 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.31 125.13 67.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 75.01 111.088 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -98.68 135.06 40.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.91 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.2 t -128.33 147.6 32.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 75.42 111.153 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -127.12 138.09 53.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.214 -0.448 . . . . 74.53 110.922 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -88.83 124.93 34.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 75.25 110.943 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -90.29 136.85 32.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 73.42 110.855 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -58.99 140.17 55.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.12 110.945 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -96.41 36.15 1.39 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 44.35 110.904 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 14.1 t -102.48 140.59 36.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.474 . . . . 74.43 111.165 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -143.92 117.49 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.23 110.931 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 9.8 mtp -108.09 79.66 1.29 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 74.34 110.85 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 16.7 m -79.11 58.65 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 75.24 111.103 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -57.99 158.72 6.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 62.52 110.86 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.6 mp0 -119.5 61.78 0.82 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 74.11 110.873 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -106.25 119.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 55.31 111.147 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.7 p -155.36 144.33 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 74.02 111.155 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.6 t -139.3 144.77 28.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.169 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 9.9 t -137.64 158.7 43.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 73.33 111.1 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 146.56 122.69 1.42 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.703 -0.761 . . . . 61.42 112.491 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -133.54 163.69 28.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.95 0.405 . . . . 75.33 110.947 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.5 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.121 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.0 mpt? . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.834 0.349 . . . . 72.11 110.867 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.93 -107.92 0.2 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.805 -0.712 . . . . 45.31 112.594 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 23.3 m80 56.56 50.09 13.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.832 0.349 . . . . 75.12 110.856 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -123.06 37.47 4.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 64.44 110.87 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -72.77 -36.21 67.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 74.31 110.884 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.3 p80 -71.62 139.9 49.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 73.02 110.877 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -73.37 -179.34 3.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 74.02 110.854 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -73.57 94.4 2.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 73.02 110.883 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.1 t -134.19 170.01 16.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.153 -0.476 . . . . 64.24 111.116 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.74 139.55 47.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.461 . . . . 74.23 110.936 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.49 96.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.653 -0.784 . . . . 52.25 112.498 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -118.39 128.19 54.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.915 0.388 . . . . 73.41 110.875 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 89.2 t -119.7 129.17 75.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 73.33 111.08 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.9 p -129.7 178.1 6.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.43 111.162 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 t -97.2 151.02 20.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.263 -0.426 . . . . 72.2 110.892 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.2 tmtt? -92.05 15.43 13.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 75.05 110.938 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.0 p -94.07 -59.07 2.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.238 -0.437 . . . . 75.14 111.117 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -120.44 -26.63 5.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 75.24 110.844 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.16 29.19 5.26 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.539 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -94.26 160.15 32.56 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.592 0.71 . . . . 74.15 110.913 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 139.5 40.7 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.703 2.269 . . . . 61.23 112.342 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 49.2 mm -83.97 113.56 23.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.104 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 22.6 mt -101.06 128.88 52.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 73.4 111.085 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.96 32.61 26.01 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.769 -0.729 . . . . 73.4 112.486 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.96 135.64 33.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.796 0.331 . . . . 63.31 111.093 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -85.6 107.2 17.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 73.23 110.804 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 2.9 p -118.33 122.39 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 75.44 111.107 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -134.61 151.83 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.149 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 -75.62 132.65 40.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 74.12 110.897 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.8 p -51.52 -34.93 38.39 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.091 -0.504 . . . . 74.21 111.153 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -96.68 -22.08 17.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 64.03 111.132 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -127.19 89.75 3.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.451 . . . . 72.13 111.104 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.8 p -86.79 -35.65 19.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 74.21 111.136 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 91.1 m -56.68 -31.0 64.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 74.23 111.146 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -93.13 30.74 1.58 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.19 -0.459 . . . . 74.3 110.865 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.52 147.01 50.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.782 -0.723 . . . . 74.25 112.517 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.6 t -135.49 168.94 18.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.787 0.327 . . . . 73.43 111.112 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.7 pt -110.98 158.15 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.01 111.116 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 39.2 p -80.34 150.68 29.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 71.25 111.143 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.37 176.3 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 54.12 110.893 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -56.95 -30.18 63.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 73.24 110.858 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -73.12 -19.05 61.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 73.22 110.914 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.62 28.26 17.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 75.31 112.462 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -131.95 165.43 23.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 74.24 110.878 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 26.7 p90 -148.51 168.04 23.76 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 74.55 110.851 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.9 t -128.99 120.11 25.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.079 -0.51 . . . . 75.13 111.134 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.84 111.14 13.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 72.41 110.894 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.9 m -93.38 111.91 23.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.145 -0.48 . . . . 73.42 110.817 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -128.35 156.1 77.39 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.57 0.7 . . . . 73.53 111.159 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.76 -48.19 0.77 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.67 2.247 . . . . 75.02 112.396 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.8 p -106.13 151.79 8.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 71.24 111.101 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -79.26 60.88 3.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 75.05 110.905 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -75.82 -170.4 1.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 74.42 110.825 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.86 157.52 17.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.105 -0.498 . . . . 72.33 111.122 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.8 mp -120.09 128.58 53.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 71.23 110.882 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 64.1 tttt -100.75 123.14 44.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 74.32 110.881 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.7 mp -120.55 134.22 64.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 75.53 111.102 179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.1 p -145.76 140.07 26.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 65.5 111.148 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 14.9 t80 -135.6 121.39 19.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 65.43 110.963 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 10.8 tt -50.88 117.18 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.094 -0.503 . . . . 74.23 111.105 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.52 -50.76 0.88 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.752 -0.737 . . . . 62.44 112.439 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -109.68 169.98 8.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.969 0.414 . . . . 73.11 110.947 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -64.27 157.73 69.18 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.55 0.69 . . . . 75.42 110.868 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.66 162.26 42.72 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.707 2.272 . . . . 74.4 112.361 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 30.2 m -150.51 133.29 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.097 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 25.2 p -126.9 142.8 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.181 -0.463 . . . . 61.3 111.088 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 30.3 m -151.15 151.37 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 74.32 111.146 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt -73.98 157.32 36.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 70.32 110.898 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.12 134.18 46.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 74.21 111.11 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.68 161.79 20.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.437 . . . . 63.13 111.11 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.97 -40.36 60.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.13 111.066 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.0 mt -140.86 111.79 3.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 72.31 111.103 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 20.7 t -124.08 112.0 30.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 75.01 111.099 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -96.74 116.6 29.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.926 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 24.3 t -115.06 148.77 17.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 75.42 111.115 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -121.2 139.21 53.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 74.53 110.959 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -91.21 122.54 33.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 75.25 110.956 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -90.53 141.37 28.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.853 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -59.06 140.53 55.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 75.12 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -120.88 83.07 2.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.154 -0.476 . . . . 44.35 110.87 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 24.7 p -90.97 165.37 13.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 74.43 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -54.94 173.31 0.09 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.933 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.2 ttm -55.76 171.24 0.23 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 74.34 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -107.15 -35.91 3.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 75.24 111.159 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -97.96 36.43 1.56 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 62.52 110.857 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -85.72 95.22 9.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 74.11 110.955 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.3 t -91.09 73.02 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.153 -0.476 . . . . 55.31 111.074 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.34 145.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 74.02 111.224 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -55.13 151.05 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 73.01 111.117 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -67.36 141.65 57.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 73.33 111.159 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.19 70.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.739 -0.743 . . . . 61.42 112.487 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 28.6 t80 -81.29 136.86 35.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.977 0.418 . . . . 75.33 110.873 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 75.25 111.138 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.5 ttm . . . . . 0 N--CA 1.458 -0.062 0 CA-C-O 120.799 0.333 . . . . 72.11 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -165.42 -170.4 30.31 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.709 -0.758 . . . . 45.31 112.493 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 5.4 t-160 -171.05 140.73 1.57 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.822 0.344 . . . . 75.12 110.886 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -137.13 169.11 18.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 64.44 110.852 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -113.55 -179.31 3.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 74.31 110.876 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -135.92 173.96 11.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 73.02 110.9 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 19.5 m80 -95.43 162.72 13.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.842 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -133.51 52.71 2.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.869 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.41 167.16 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 64.24 111.183 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.83 -173.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 74.23 110.881 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.46 126.74 24.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.778 -0.725 . . . . 52.25 112.487 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.75 127.51 40.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.87 0.367 . . . . 73.41 110.916 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 88.5 t -117.04 125.26 73.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 73.33 111.111 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -122.79 169.63 10.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 73.43 111.172 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.54 149.62 21.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 72.2 110.897 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -93.21 18.18 9.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.484 . . . . 75.05 110.882 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.21 -58.82 2.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 75.14 111.089 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -120.53 -25.97 5.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 75.24 110.91 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.97 29.13 5.03 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.672 -0.775 . . . . 53.34 112.509 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -98.29 154.13 37.76 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.62 0.724 . . . . 74.15 110.916 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 143.08 49.45 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.684 2.256 . . . . 61.23 112.334 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 47.3 mm -83.32 108.11 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 75.31 111.199 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.1 mt -101.46 126.57 55.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 73.4 111.078 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 42.11 7.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.748 -0.739 . . . . 73.4 112.47 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.89 162.39 13.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 63.31 111.096 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.2 m -105.62 107.53 18.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 73.23 110.859 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.4 t -110.43 106.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 75.44 111.085 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.9 m -124.64 138.01 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 74.52 111.101 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -72.02 173.53 8.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.861 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.2 p -76.35 -35.55 58.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 74.21 111.121 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 17.7 p -112.38 -22.14 11.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 64.03 111.104 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -117.2 77.2 1.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.24 -0.436 . . . . 72.13 111.05 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.6 p -86.72 -35.36 19.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.245 -0.434 . . . . 74.21 111.119 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 45.8 p -53.33 -30.2 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.23 111.159 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -94.76 31.3 1.85 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 74.3 110.907 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -59.38 136.1 50.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.74 -0.743 . . . . 74.25 112.485 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 5.0 m -111.15 157.87 19.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.758 0.313 . . . . 73.43 111.128 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -108.59 150.51 11.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 75.01 111.101 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 6.0 p -72.26 149.66 44.33 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.19 -0.459 . . . . 71.25 111.183 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -83.6 -175.44 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 54.12 110.859 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -58.88 -30.86 68.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 73.24 110.901 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.9 21.44 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 73.22 110.906 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.17 27.46 70.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.709 -0.757 . . . . 75.31 112.471 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -108.79 134.91 50.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.829 0.347 . . . . 74.24 110.89 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 18.5 p90 -133.54 167.93 19.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 74.55 110.856 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.29 121.42 12.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 75.13 111.162 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.5 mt -120.93 127.81 52.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.209 -0.451 . . . . 72.41 110.907 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -106.93 113.65 27.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 73.42 110.852 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -139.2 156.21 72.15 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.657 0.741 . . . . 73.53 111.138 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -48.35 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.651 2.234 . . . . 75.02 112.352 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.66 149.4 5.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 71.24 111.151 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -88.9 52.1 2.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 75.05 110.863 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.1 t -68.53 -169.78 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.992 0.425 . . . . 74.42 110.812 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.63 157.14 19.19 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.148 -0.478 . . . . 72.33 111.187 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 7.4 mp -125.39 125.01 42.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 71.23 110.874 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 43.1 tttt -102.64 126.89 49.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.194 -0.457 . . . . 74.32 110.912 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.9 mp -123.29 139.33 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 75.53 111.144 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 74.1 p -140.94 139.23 34.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 65.5 111.188 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -133.05 119.8 20.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.43 110.926 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.4 tp -51.42 116.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 74.23 111.141 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 130.35 -55.13 0.77 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 62.44 112.525 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -108.87 170.63 7.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.984 0.421 . . . . 73.11 110.915 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -62.01 157.72 49.54 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.555 0.693 . . . . 75.42 110.935 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 170.77 15.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.667 2.245 . . . . 74.4 112.367 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.6 p -151.49 140.92 15.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 74.11 111.135 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 11.4 p -131.95 135.35 46.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 61.3 111.183 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.8 m -152.17 149.24 13.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 74.32 111.2 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.3 mmtm -69.08 153.99 42.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.914 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.43 65.42 2.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 74.21 111.134 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -90.21 -175.1 4.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 63.13 111.045 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.3 -55.08 23.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 73.13 111.137 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 17.4 mm -128.76 137.14 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 72.31 111.076 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 5.7 p -145.7 119.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 75.01 111.111 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -120.24 109.52 15.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 74.11 110.855 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 17.2 t -124.59 149.1 28.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 75.42 111.19 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -103.39 145.73 29.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 74.53 110.945 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.6 tp -87.25 120.45 28.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 75.25 110.89 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -90.36 140.4 29.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 73.42 110.872 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -59.1 142.08 52.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 75.12 110.908 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -103.56 98.72 8.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 44.35 110.866 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.9 p -95.01 177.71 5.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.232 -0.44 . . . . 74.43 111.141 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -52.1 137.13 28.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 74.23 110.826 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -52.26 134.36 33.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.165 -0.471 . . . . 74.34 110.956 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.7 m -108.41 67.65 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.426 . . . . 75.24 111.035 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.0 p-10 -54.67 156.42 3.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.434 . . . . 62.52 110.847 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -120.22 74.02 1.02 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.895 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.1 p -135.98 136.58 49.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.162 -0.472 . . . . 55.31 111.079 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 36.1 t -132.12 146.3 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.178 -0.465 . . . . 74.02 111.17 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.5 m -90.47 -176.9 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 73.01 111.092 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.9 t -86.14 157.84 19.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.091 -0.504 . . . . 73.33 111.132 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -110.56 -47.4 0.8 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.739 . . . . 61.42 112.437 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -72.13 141.61 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 75.33 110.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 43.0 p . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.159 179.989 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.23 0.047 0 CA-C-O 120.841 0.353 . . . . 72.11 110.862 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 146.37 43.03 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.717 -0.754 . . . . 45.31 112.474 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 12.9 m-70 -56.21 166.53 0.8 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 75.12 110.828 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 21.7 p80 -123.14 145.06 48.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 64.44 110.84 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -148.79 -179.54 7.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.894 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -115.26 141.0 48.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.226 -0.443 . . . . 73.02 110.899 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 17.4 p80 -161.85 153.12 18.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 74.02 110.875 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -129.89 46.62 2.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.179 -0.464 . . . . 73.02 110.856 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 m -90.78 151.82 21.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 64.24 111.094 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -148.38 112.49 5.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 74.23 110.894 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.6 136.23 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.696 -0.764 . . . . 52.25 112.459 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -144.15 127.52 16.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.41 110.842 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 t -115.57 116.5 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.33 111.091 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.4 p -129.95 153.72 48.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 73.43 111.152 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -79.88 150.98 30.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.873 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 12.4 tttp -94.01 20.16 8.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.194 -0.457 . . . . 75.05 110.849 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 35.1 p -94.04 -58.79 2.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 75.14 111.168 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -119.39 -26.39 5.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.209 -0.451 . . . . 75.24 110.94 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.5 5.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.856 -0.688 . . . . 53.34 112.495 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -97.95 160.4 28.54 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.586 0.707 . . . . 74.15 110.835 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 148.28 64.43 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.73 2.287 . . . . 61.23 112.318 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.4 mm -95.16 122.75 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.31 111.17 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.7 mt -107.4 116.28 50.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 73.4 111.136 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 99.41 33.26 5.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.744 -0.741 . . . . 73.4 112.499 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.57 129.41 36.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.805 0.336 . . . . 63.31 111.052 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 m -76.99 108.34 9.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 73.23 110.861 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.87 106.18 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 75.44 111.103 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.3 m -123.9 151.21 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.123 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -81.83 166.78 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 74.12 110.908 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.06 -41.99 98.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 74.21 111.136 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 33.6 p -112.44 -22.06 11.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.233 -0.44 . . . . 64.03 111.123 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -100.77 75.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 72.13 111.072 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.4 p -86.67 -35.61 19.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 74.21 111.173 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -60.6 -30.77 70.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.282 -0.417 . . . . 74.23 111.18 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -94.46 31.2 1.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 74.3 110.867 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.12 139.01 47.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.701 -0.761 . . . . 74.25 112.513 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -113.71 167.37 10.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.771 0.32 . . . . 73.43 111.168 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 7.9 pt -124.14 147.16 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 75.01 111.152 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 34.4 p -69.94 137.98 51.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 71.25 111.145 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.7 -179.52 7.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 54.12 110.856 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -57.0 -30.22 63.97 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.24 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -73.5 -18.75 61.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.85 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.08 28.21 14.13 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.738 -0.744 . . . . 75.31 112.529 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -134.2 168.35 19.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.856 0.36 . . . . 74.24 110.935 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -141.89 167.93 20.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 74.55 110.869 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 27.1 p -124.98 116.99 23.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.13 -0.486 . . . . 75.13 111.137 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 8.0 mp -136.58 120.79 17.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 72.41 110.915 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 26.7 m -106.94 112.05 24.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.092 -0.504 . . . . 73.42 110.886 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.95 156.16 69.49 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.661 0.743 . . . . 73.53 111.108 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -48.25 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.633 2.222 . . . . 75.02 112.338 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.6 p -110.51 152.11 12.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.118 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -80.63 58.49 3.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 75.05 110.942 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 94.9 p -72.84 -169.83 0.63 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 74.42 110.862 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.7 153.11 21.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 72.33 111.094 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mp -126.27 126.13 43.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 71.23 110.889 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 12.1 ttpt -95.63 122.2 38.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 74.32 110.869 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -121.26 137.2 55.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 75.53 111.15 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.5 p -147.39 138.77 23.87 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.168 -0.469 . . . . 65.5 111.153 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -133.54 119.0 18.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 65.43 111.02 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.4 tp -51.02 117.58 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.176 -0.465 . . . . 74.23 111.185 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.68 -52.89 0.82 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.781 -0.723 . . . . 62.44 112.458 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -110.34 170.19 8.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.952 0.406 . . . . 73.11 110.945 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -60.5 157.63 35.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.589 0.709 . . . . 75.42 110.902 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 166.87 26.02 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.723 2.282 . . . . 74.4 112.283 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.5 m -151.24 126.35 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 74.11 111.112 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 21.8 p -125.06 132.81 53.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 61.3 111.109 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.8 m -152.09 157.34 5.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.199 -0.455 . . . . 74.32 111.079 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 39.6 mtpt -84.13 155.11 22.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 70.32 110.953 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.09 133.6 46.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 74.21 111.091 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.16 -179.67 8.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 63.13 111.101 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.73 -58.02 7.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 73.13 111.102 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 41.0 mm -142.36 111.65 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 72.31 111.104 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.76 122.3 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 75.01 111.167 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -119.78 115.33 23.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.888 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 18.7 t -113.16 126.9 70.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 75.42 111.109 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -83.34 140.59 32.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 74.53 110.894 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.5 tp -87.9 121.73 30.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 75.25 110.899 179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -90.2 137.06 32.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.9 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -57.45 141.78 46.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 75.12 110.872 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -85.73 144.36 27.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.093 -0.503 . . . . 44.35 110.853 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.0 t -175.15 152.22 1.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.156 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 30.0 tt0 -82.14 121.41 26.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 74.23 110.887 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.5 mmt -68.89 103.52 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 74.34 110.901 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.5 p -169.94 133.1 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.261 -0.427 . . . . 75.24 111.089 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -120.43 34.84 5.07 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.151 -0.477 . . . . 62.52 110.9 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -108.93 82.34 1.58 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 74.11 110.883 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.2 m -59.52 137.57 21.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.175 -0.466 . . . . 55.31 111.122 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.87 130.0 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.153 -0.476 . . . . 74.02 111.203 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.94 136.83 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 73.01 111.158 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 72.1 p -121.91 72.0 1.01 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 73.33 111.13 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.54 -126.38 8.43 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.849 -0.691 . . . . 61.42 112.457 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -172.46 155.47 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.983 0.42 . . . . 75.33 110.898 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.7 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 75.25 111.123 -179.941 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.725 0.297 . . . . 72.11 110.814 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 129.27 77.57 0.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.769 -0.729 . . . . 45.31 112.488 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -109.2 149.51 29.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 75.12 110.88 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 40.8 m170 -120.1 -179.2 3.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 64.44 110.865 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -125.93 126.13 43.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 74.31 110.818 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -167.65 169.93 11.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 73.02 110.844 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.4 t-80 -166.5 130.54 2.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.19 -0.459 . . . . 74.02 110.858 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 7.2 p80 -129.35 -47.79 1.19 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.265 -0.425 . . . . 73.02 110.801 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.7 t -126.81 165.16 19.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.189 -0.46 . . . . 64.24 111.14 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.5 pttp -129.43 152.66 48.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 74.23 110.929 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.12 145.26 0.51 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.719 -0.753 . . . . 52.25 112.466 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -152.61 128.35 10.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.875 0.369 . . . . 73.41 110.859 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 94.2 t -117.99 131.8 69.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 73.33 111.112 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.9 p -138.12 172.88 12.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 73.43 111.088 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -92.74 156.25 17.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 72.2 110.922 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -93.57 16.38 13.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 75.05 110.876 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.1 p -94.05 -59.07 2.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 75.14 111.095 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -120.68 -26.24 5.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 75.24 110.91 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.63 29.12 5.14 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.747 -0.74 . . . . 53.34 112.503 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -95.02 153.93 39.74 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.606 0.717 . . . . 74.15 110.889 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 135.75 31.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.73 2.286 . . . . 61.23 112.296 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.6 mm -84.6 135.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 75.31 111.127 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.0 mt -114.29 125.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 73.4 111.104 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.86 33.83 10.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 73.4 112.492 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.17 162.67 18.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.72 0.295 . . . . 63.31 111.176 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.53 113.5 27.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.852 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.6 t -116.76 134.04 61.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 75.44 111.12 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.1 m -139.64 148.87 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 74.52 111.064 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -88.5 135.11 33.64 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 74.12 110.846 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 21.0 p -55.5 -32.64 63.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 74.21 111.159 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.6 p -71.87 -22.36 61.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.186 -0.461 . . . . 64.03 111.105 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -178.64 134.61 0.14 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 72.13 111.091 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.3 p -87.8 -19.29 27.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 74.21 111.241 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.0 p -52.16 -30.33 26.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.213 -0.449 . . . . 74.23 111.092 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.9 p-10 -93.2 31.24 1.5 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.917 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.69 135.51 38.4 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 74.25 112.483 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.5 m -124.38 161.45 25.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 73.43 111.164 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -107.71 145.67 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 75.01 111.133 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 52.7 p -70.07 149.51 47.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 71.25 111.155 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -87.14 -175.83 5.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.43 . . . . 54.12 110.871 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -57.11 -30.69 64.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 73.24 110.869 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -99.79 22.09 11.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 73.22 110.882 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.32 28.31 72.1 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 75.31 112.521 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 64.7 m-20 -110.75 128.84 55.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.874 0.369 . . . . 74.24 110.906 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -116.57 167.32 11.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 74.55 110.827 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.6 t -121.42 116.87 25.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 75.13 111.138 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 7.0 mp -141.15 116.75 10.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 72.41 110.9 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.3 m -106.81 108.16 19.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 73.42 110.887 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.4 m -124.69 156.08 68.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.579 0.704 . . . . 73.53 111.128 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -48.41 0.73 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.693 2.262 . . . . 75.02 112.351 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -103.67 152.0 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.182 -0.463 . . . . 71.24 111.103 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -84.94 68.36 10.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 75.05 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.0 t -80.57 -169.94 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 74.42 110.87 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.86 159.31 17.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.179 -0.464 . . . . 72.33 111.094 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 16.0 mt -124.0 135.21 53.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 71.23 110.902 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -105.7 129.86 53.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.915 179.806 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 mt -123.7 134.67 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 75.53 111.097 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 25.2 p -149.78 139.48 21.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 65.5 111.134 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -138.22 125.88 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 65.43 110.879 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 tp -50.94 107.93 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 74.23 111.163 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.89 -47.04 0.91 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.785 -0.721 . . . . 62.44 112.524 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -112.47 170.89 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.382 . . . . 73.11 110.951 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.2 mttt -68.4 158.19 85.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.54 0.686 . . . . 75.42 110.935 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.67 160.3 50.26 Favored 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.696 2.264 . . . . 74.4 112.339 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 13.0 p -151.26 139.76 14.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 74.11 111.188 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.4 p -132.14 134.83 45.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 61.3 111.175 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.0 m -144.54 151.91 15.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 74.32 111.147 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.92 155.4 27.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 70.32 110.874 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -90.56 120.87 32.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 74.21 111.131 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -146.34 178.64 8.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 63.13 111.137 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.43 -44.22 68.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.13 111.096 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 56.2 mt -147.31 112.14 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.449 . . . . 72.31 111.059 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.61 128.42 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 75.01 111.172 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.9 m120 -95.91 137.56 34.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 74.11 110.892 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.2 t -124.51 148.98 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 75.42 111.192 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.58 125.74 40.84 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 74.53 110.873 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 2.4 tp -91.91 118.31 30.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 75.25 110.928 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -96.03 135.94 37.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 73.42 110.932 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -52.39 145.62 10.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.882 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -110.89 69.77 0.7 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.122 -0.49 . . . . 44.35 110.842 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -75.48 -38.5 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.43 111.126 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -82.51 60.15 5.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.23 110.949 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 50.0 mtp -67.89 131.25 45.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 74.34 110.866 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.3 p -171.63 133.78 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 75.24 111.111 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -74.26 153.87 39.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 62.52 110.879 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.39 67.68 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 74.11 110.938 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -117.61 96.1 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 55.31 111.136 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 p -54.63 145.89 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 74.02 111.127 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 47.6 t -66.74 130.82 32.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.053 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 37.2 p -101.28 140.16 35.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 73.33 111.135 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -83.03 62.83 4.58 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.726 -0.749 . . . . 61.42 112.538 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -135.41 144.38 46.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.005 0.431 . . . . 75.33 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 p . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 116.095 -0.502 . . . . 75.25 111.137 -179.975 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 32.1 mmt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.802 0.334 . . . . 72.11 110.955 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -132.86 148.92 19.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.766 -0.73 . . . . 45.31 112.572 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 18.3 m80 -129.39 133.08 47.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.829 0.347 . . . . 75.12 110.819 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -83.6 179.94 7.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 64.44 110.866 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 29.4 m80 -88.77 -177.46 5.53 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 74.31 110.85 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 10.2 t60 -137.01 164.81 27.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 73.02 110.835 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -104.29 151.84 22.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 74.02 110.866 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -90.16 119.99 30.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.253 -0.43 . . . . 73.02 110.876 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.2 t -126.43 171.15 11.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 64.24 111.119 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -96.18 -176.3 3.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 74.23 110.905 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.84 132.79 40.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 52.25 112.465 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -131.53 126.43 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.913 0.387 . . . . 73.41 110.861 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 30.5 t -118.08 128.9 75.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 73.33 111.167 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.22 167.02 16.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.14 -0.482 . . . . 73.43 111.137 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.59 144.33 25.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 72.2 110.835 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.4 tttm -92.78 15.62 14.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.125 -0.488 . . . . 75.05 110.844 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -58.49 2.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 75.14 111.119 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -117.97 -26.81 6.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 75.24 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.23 29.13 5.26 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.701 -0.762 . . . . 53.34 112.463 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -98.34 160.12 28.95 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.58 0.705 . . . . 74.15 110.886 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 143.65 51.91 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.709 2.273 . . . . 61.23 112.375 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.3 mm -83.13 110.0 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 75.31 111.137 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.1 mt -103.45 126.94 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.446 . . . . 73.4 111.116 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.29 33.2 23.61 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 73.4 112.478 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.22 131.37 34.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 63.31 111.07 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.3 m -80.19 107.57 13.09 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.842 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 60.9 t -106.66 105.86 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.112 -0.495 . . . . 75.44 111.112 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 28.2 m -120.6 133.65 66.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 74.52 111.126 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -91.96 141.52 28.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.474 . . . . 74.12 110.915 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.9 p -55.43 -31.66 62.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.152 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.7 p -71.54 -21.38 61.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.215 -0.448 . . . . 64.03 111.193 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.52 111.49 0.79 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 72.13 111.049 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 m -85.46 -34.65 21.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 74.21 111.156 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 61.8 p -66.8 -26.44 66.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 74.23 111.179 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -93.51 31.22 1.57 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.903 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -74.99 150.26 40.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.77 -0.729 . . . . 74.25 112.473 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.6 t -117.81 168.76 10.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.738 0.304 . . . . 73.43 111.157 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.0 pt -111.68 171.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 75.01 111.139 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 21.8 p -99.35 150.62 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 71.25 111.155 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.33 179.93 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.435 . . . . 54.12 110.88 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -59.33 -30.7 68.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 73.24 110.852 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -73.81 -19.48 60.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.899 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.92 28.08 11.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.739 -0.743 . . . . 75.31 112.525 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -132.43 160.21 37.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.853 0.358 . . . . 74.24 110.932 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 16.6 p90 -138.37 166.08 25.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 74.55 110.881 -179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.8 t -126.0 119.15 26.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 75.13 111.178 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -146.15 134.3 21.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 72.41 110.932 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 p -106.89 122.63 46.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.485 . . . . 73.42 110.889 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 61.5 t -129.79 133.25 24.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.683 0.754 . . . . 73.53 111.093 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -48.51 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.664 2.242 . . . . 75.02 112.345 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 31.0 m -95.27 141.96 14.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.425 . . . . 71.24 111.162 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -79.39 59.05 2.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 75.05 110.83 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.4 t -80.07 -169.85 2.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 74.42 110.872 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 156.12 17.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 72.33 111.125 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 2.2 mp -129.05 132.22 47.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 71.23 110.903 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 22.8 tttp -106.76 123.25 47.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.245 -0.434 . . . . 74.32 110.909 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 34.8 mt -119.6 112.61 37.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 75.53 111.178 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.4 p -119.68 145.88 46.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.231 -0.44 . . . . 65.5 111.118 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 13.7 t80 -139.06 118.58 12.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 65.43 111.001 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.9 tt -51.0 107.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.133 -0.485 . . . . 74.23 111.103 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.86 -50.98 0.75 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.745 -0.74 . . . . 62.44 112.47 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -114.28 170.28 8.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.93 0.395 . . . . 73.11 110.92 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -58.22 158.2 14.7 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.42 110.932 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.8 167.79 23.48 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.627 2.218 . . . . 74.4 112.348 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 96.4 t -135.11 138.68 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 74.11 111.107 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.3 p -132.15 122.56 25.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.138 -0.483 . . . . 61.3 111.141 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.1 m -152.92 149.9 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 74.32 111.113 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -81.92 157.25 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.88 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.73 130.65 46.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 74.21 111.113 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.52 160.71 38.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 63.13 111.108 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.67 -52.37 48.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 73.13 111.113 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 69.7 mt -129.14 111.62 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 72.31 111.155 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 21.8 t -113.62 112.11 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 75.01 111.142 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -113.66 112.34 23.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.862 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 39.4 t -129.27 148.16 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 75.42 111.12 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.9 mp -105.08 144.86 31.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.491 . . . . 74.53 110.909 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.4 tp -87.83 122.23 31.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 75.25 110.961 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.8 mm-40 -90.17 140.9 29.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 73.42 110.945 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -58.45 141.23 52.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.904 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -98.96 149.95 22.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.1 -0.5 . . . . 44.35 110.905 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 p -141.67 175.01 10.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 74.43 111.143 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 49.0 tt0 -109.0 90.29 3.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.884 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 4.9 ptt? -125.73 167.24 15.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 74.34 110.874 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 15.8 m -149.63 124.85 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 75.24 111.113 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.3 p30 -60.41 159.1 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 62.52 110.835 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.0 mm-40 -126.48 45.12 2.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 74.11 110.84 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.38 140.25 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 55.31 111.142 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.5 p -131.96 138.67 52.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 74.02 111.16 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 44.0 t -105.8 108.02 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 73.01 111.14 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 11.0 p -99.08 168.12 10.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 73.33 111.134 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -74.21 -159.85 6.68 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.708 -0.758 . . . . 61.42 112.417 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -153.29 161.47 42.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.98 0.419 . . . . 75.33 110.852 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 18.2 m . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.146 -0.479 . . . . 75.25 111.172 179.961 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 71.4 mtm . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.824 0.345 . . . . 72.11 110.956 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.82 140.73 6.48 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.794 -0.717 . . . . 45.31 112.553 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -97.3 150.95 20.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 75.12 110.88 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -165.32 173.33 11.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.197 -0.456 . . . . 64.44 110.855 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 2.1 p-80 -130.35 164.91 23.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 74.31 110.838 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -140.5 158.21 44.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 73.02 110.937 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -128.07 165.69 19.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 74.02 110.89 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -132.54 110.3 10.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.423 . . . . 73.02 110.844 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 88.3 m -123.32 143.59 49.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.146 -0.479 . . . . 64.24 111.177 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.0 tptt -66.34 91.37 0.17 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.287 -0.415 . . . . 74.23 110.899 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.5 147.72 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.767 -0.73 . . . . 52.25 112.439 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.69 119.94 5.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.887 0.375 . . . . 73.41 110.946 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.7 t -98.48 122.66 50.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 73.33 111.106 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.07 176.68 6.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 73.43 111.094 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.4 t -97.38 164.0 12.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 72.2 110.925 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.0 tmtt? -104.55 -11.11 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 75.05 110.869 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 55.8 p -77.94 -58.62 3.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.289 -0.414 . . . . 75.14 111.089 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -117.86 -26.38 6.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 75.24 110.854 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 100.99 29.39 6.47 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.734 -0.746 . . . . 53.34 112.495 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -85.05 159.4 57.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.531 0.681 . . . . 74.15 110.978 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 127.89 15.26 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 61.23 112.377 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 50.1 mm -77.37 120.41 27.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 75.31 111.16 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.7 mt -102.98 141.5 18.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 73.4 111.099 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.42 33.24 86.72 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.718 -0.753 . . . . 73.4 112.521 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -82.58 122.16 27.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 63.31 111.094 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -74.17 107.5 6.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 73.23 110.837 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 t -107.37 106.07 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.128 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.7 m -124.89 138.06 55.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 74.52 111.102 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 55.4 tt0 -73.67 161.2 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 74.12 110.843 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 p -65.83 -41.82 91.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.466 . . . . 74.21 111.144 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 p -105.77 -22.18 13.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 64.03 111.08 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -116.18 68.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 72.13 111.165 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 96.5 m -81.53 -35.65 30.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 74.21 111.09 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 3.1 p -53.36 -32.17 48.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 74.23 111.139 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -94.95 31.16 1.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.916 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.95 138.95 37.79 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.811 -0.709 . . . . 74.25 112.517 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -117.22 168.72 10.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 73.43 111.155 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 pp -115.47 168.56 7.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.441 . . . . 75.01 111.093 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 70.3 p -101.29 150.76 22.66 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.168 -0.469 . . . . 71.25 111.129 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -90.88 -176.08 4.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.172 -0.467 . . . . 54.12 110.849 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.38 -30.73 68.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 73.24 110.854 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -73.87 -19.5 60.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 73.22 110.897 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.75 28.1 15.07 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.692 -0.766 . . . . 75.31 112.473 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -128.22 157.78 39.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.338 . . . . 74.24 110.906 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 28.5 p90 -143.67 167.45 22.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 74.55 110.874 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -123.05 121.69 36.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.477 . . . . 75.13 111.188 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.0 tt -144.01 125.68 15.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 72.41 110.96 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 45.0 t -101.72 114.92 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.262 -0.426 . . . . 73.42 110.842 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.3 t -120.6 133.29 24.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.579 0.704 . . . . 73.53 111.165 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -47.92 0.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.666 2.244 . . . . 75.02 112.343 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.6 m -96.9 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.157 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -111.64 62.38 0.62 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 75.05 110.891 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.6 t -86.88 -172.63 4.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 74.42 110.867 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.24 158.22 17.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.112 -0.495 . . . . 72.33 111.128 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 25.8 mt -128.32 143.13 50.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 71.23 110.947 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 7.1 ttpt -116.48 127.74 54.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 74.32 110.975 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 79.6 mt -120.01 137.97 52.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 75.53 111.055 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 39.0 p -148.28 138.59 22.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 65.5 111.183 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 15.6 t80 -136.01 126.85 27.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.233 -0.44 . . . . 65.43 110.903 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 13.3 tt -51.17 118.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.101 -0.5 . . . . 74.23 111.139 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.16 -51.27 0.85 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.857 -0.687 . . . . 62.44 112.536 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -108.1 170.21 8.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.98 0.419 . . . . 73.11 110.917 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.4 mmtm -68.9 158.19 86.86 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.567 0.698 . . . . 75.42 110.933 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 165.82 29.68 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.729 2.286 . . . . 74.4 112.377 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.66 147.94 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.083 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.9 p -132.1 139.83 48.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 61.3 111.148 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.1 m -150.83 171.57 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 74.32 111.076 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.06 157.21 18.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 70.32 110.868 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -86.08 134.08 33.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 74.21 111.099 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.65 179.87 6.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 63.13 111.124 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -54.34 -57.88 9.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 73.13 111.096 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -132.13 111.69 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 72.31 111.104 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.82 125.27 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 75.01 111.125 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -95.86 136.76 35.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.878 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.7 t -120.96 149.48 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 75.42 111.109 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 10.3 mt -125.45 124.15 40.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 74.53 110.885 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.4 tp -87.84 122.47 31.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 75.25 110.891 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -90.22 137.03 32.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.182 -0.463 . . . . 73.42 110.927 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -55.23 142.91 29.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 75.12 110.813 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -111.55 43.01 1.59 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.087 -0.506 . . . . 44.35 110.845 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.4 p -101.59 45.74 0.96 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 74.43 111.081 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -143.09 134.65 26.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 74.23 110.882 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 6.3 ttm -81.18 128.47 33.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 74.34 110.884 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -166.59 131.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.253 -0.43 . . . . 75.24 111.057 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.02 134.54 56.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.142 -0.481 . . . . 62.52 110.968 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -129.14 74.98 1.62 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 74.11 110.891 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.0 m -59.01 144.03 12.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 55.31 111.11 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 59.9 t -99.2 126.99 52.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 74.02 111.221 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.7 p -109.61 141.37 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 73.01 111.135 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.3 t -104.45 167.71 9.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 73.33 111.129 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 176.43 -65.54 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.803 -0.713 . . . . 61.42 112.566 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -115.83 143.74 44.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.927 0.394 . . . . 75.33 110.91 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.5 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.08 -0.509 . . . . 75.25 111.132 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 28.2 ttm . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.855 0.359 . . . . 72.11 110.813 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 165.79 136.49 2.02 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.718 -0.753 . . . . 45.31 112.455 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 47.9 p-80 -156.18 152.6 28.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.825 0.345 . . . . 75.12 110.86 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -89.84 120.31 30.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.23 -0.441 . . . . 64.44 110.868 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 81.6 t60 -127.47 124.37 38.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 74.31 110.874 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 58.4 55.01 5.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 73.02 110.907 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -169.16 133.22 1.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 74.02 110.92 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -169.71 174.95 5.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 73.02 110.869 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 t -68.81 173.84 4.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 64.24 111.195 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 mmpt? -60.35 -171.64 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.23 -0.441 . . . . 74.23 110.921 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.89 134.71 35.48 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.752 -0.737 . . . . 52.25 112.519 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -127.73 119.95 26.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.891 0.377 . . . . 73.41 110.931 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 45.0 t -105.15 126.46 60.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.153 -0.476 . . . . 73.33 111.069 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.38 -178.7 4.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 73.43 111.094 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.74 163.72 13.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 72.2 110.881 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -103.64 -12.33 17.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.135 -0.484 . . . . 75.05 110.928 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -75.97 -58.72 3.11 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.197 -0.456 . . . . 75.14 111.17 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -119.44 -26.57 5.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 75.24 110.821 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.06 29.55 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.79 -0.719 . . . . 53.34 112.506 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -83.15 154.85 67.14 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.593 0.711 . . . . 74.15 110.934 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 128.71 16.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.737 2.291 . . . . 61.23 112.314 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 34.1 mm -75.03 101.7 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.31 111.128 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.2 mt -99.05 138.07 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 73.4 111.122 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 77.18 33.6 44.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 73.4 112.467 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.45 135.04 33.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 63.31 111.109 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.2 m -80.59 107.55 13.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 73.23 110.86 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 48.7 t -104.07 122.49 56.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 75.44 111.122 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -142.08 136.74 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 74.52 111.125 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -73.58 159.95 32.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.86 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 29.9 p -62.21 -41.98 98.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 74.21 111.164 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.0 p -108.22 -22.08 12.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 64.03 111.099 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.81 68.67 0.68 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 72.13 111.156 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 92.9 m -82.82 -35.37 26.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.466 . . . . 74.21 111.138 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.5 p -53.38 -31.18 43.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 74.23 111.06 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.8 m-20 -94.9 31.16 1.9 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 74.3 110.904 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.07 141.23 44.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.723 -0.751 . . . . 74.25 112.556 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.5 t -123.64 168.89 12.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 73.43 111.171 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.5 pt -107.63 156.76 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 75.01 111.141 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 33.1 p -81.65 150.63 27.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 71.25 111.113 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -82.39 173.34 12.12 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 54.12 110.837 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -59.46 -30.71 68.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 73.24 110.871 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -74.0 -19.38 60.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.102 -0.499 . . . . 73.22 110.886 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.97 28.15 10.32 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.463 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -128.92 152.68 48.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.93 0.395 . . . . 74.24 110.873 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 54.4 p90 -147.63 164.52 33.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.917 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -150.41 117.27 5.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 75.13 111.144 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.5 tt -115.93 109.77 18.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 72.41 110.947 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 89.7 p -68.9 108.41 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 73.42 110.856 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 7.3 p -130.78 133.21 24.54 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 73.53 111.138 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -43.26 2.74 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.66 2.24 . . . . 75.02 112.381 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 29.6 m -77.91 150.06 5.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 71.24 111.176 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -100.35 72.25 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 75.05 110.884 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 t -105.8 -170.95 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 74.42 110.827 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.13 155.35 17.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 72.33 111.167 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 10.4 mt -111.25 146.95 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 71.23 110.902 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.7 tttt -130.31 121.94 27.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 74.32 110.894 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 mp -119.27 144.01 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.144 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 37.7 p -138.36 138.67 38.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 65.5 111.165 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 7.4 t80 -131.83 115.21 15.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.282 -0.417 . . . . 65.43 110.977 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.3 tp -51.15 116.46 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 74.23 111.095 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.37 -53.42 0.81 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 62.44 112.475 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -110.47 170.53 8.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.925 0.393 . . . . 73.11 110.953 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -60.77 157.86 36.26 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.564 0.697 . . . . 75.42 110.874 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 172.81 12.02 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.661 2.241 . . . . 74.4 112.336 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 7.4 p -151.38 146.3 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 74.11 111.128 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.7 p -131.93 143.51 50.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 61.3 111.172 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 35.0 m -142.22 130.22 20.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.244 -0.435 . . . . 74.32 111.083 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 11.2 pttt -72.82 156.75 38.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 70.32 110.916 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.84 95.89 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.285 -0.416 . . . . 74.21 111.132 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -134.11 -173.22 3.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 63.13 111.094 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -88.04 -44.52 10.91 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 73.13 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.4 mt -138.09 126.17 30.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 72.31 111.112 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.2 p -139.71 126.93 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 75.01 111.159 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -119.92 125.53 48.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 74.11 110.902 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.2 t -137.15 149.07 25.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.449 . . . . 75.42 111.11 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.1 mp -105.02 143.54 33.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 74.53 110.907 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 2.1 tp -87.56 118.58 27.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.956 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -90.64 147.81 23.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -59.47 143.41 50.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.837 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -106.88 84.69 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 44.35 110.827 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.7 t -138.44 154.72 48.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 74.43 111.172 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 39.0 tp60 -66.5 115.45 6.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.251 -0.431 . . . . 74.23 110.953 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 21.7 mmt -57.44 170.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 74.34 110.842 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.2 m -128.32 111.22 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 75.24 111.099 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -126.82 36.05 4.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 62.52 110.83 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -85.88 90.88 8.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 74.11 110.827 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.56 113.45 29.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 55.31 111.204 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 46.3 t -134.19 145.41 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 74.02 111.119 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -74.3 151.84 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 73.01 111.174 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 5.2 t -161.8 159.51 27.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 73.33 111.177 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -108.96 147.88 16.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.685 -0.769 . . . . 61.42 112.427 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 15.6 t80 -100.54 142.5 31.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.901 0.381 . . . . 75.33 110.879 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 m . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 75.25 111.138 179.982 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.812 0.339 . . . . 72.11 110.908 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -142.51 -52.27 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.739 -0.743 . . . . 45.31 112.468 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -151.16 137.43 18.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.809 0.338 . . . . 75.12 110.854 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -86.96 130.17 34.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 64.44 110.932 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 14.9 t60 54.83 60.32 3.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 74.31 110.799 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.1 t-80 -139.65 133.45 30.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 73.02 110.886 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 24.1 p-80 -108.18 162.78 13.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 74.02 110.889 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -134.75 163.06 30.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 73.02 110.913 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.1 t -138.58 162.1 35.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.234 -0.439 . . . . 64.24 111.146 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.2 pttm -128.62 127.43 42.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 74.23 110.876 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.9 119.9 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.748 -0.739 . . . . 52.25 112.479 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.11 129.72 17.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.891 0.376 . . . . 73.41 110.826 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 95.3 t -123.02 133.37 69.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.091 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.6 p -130.03 172.55 11.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.141 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.16 153.2 21.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.828 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 17.1 tttm -92.55 16.24 12.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 75.05 110.904 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.02 -58.86 2.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 75.14 111.112 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -119.05 -26.66 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 75.24 110.847 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.45 29.25 5.14 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 53.34 112.525 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -97.87 159.78 30.07 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 74.15 110.917 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.64 146.61 61.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.724 2.282 . . . . 61.23 112.39 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 28.4 mm -96.68 117.43 41.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.074 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 29.9 mt -101.6 150.13 6.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 73.4 111.045 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.21 47.19 83.43 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.733 -0.746 . . . . 73.4 112.404 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.04 159.32 15.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.862 0.363 . . . . 63.31 111.044 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.2 m -105.92 107.25 18.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 73.23 110.837 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -112.66 129.82 67.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 75.44 111.113 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.0 m -145.98 146.31 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 74.52 111.17 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -80.75 174.33 11.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.888 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 43.5 p -68.95 -42.12 77.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 74.21 111.16 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.5 p -112.49 -22.22 10.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 64.03 111.159 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -104.89 76.44 1.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 72.13 111.112 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 p -86.53 -36.26 19.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 74.21 111.229 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.1 p -58.42 -28.44 65.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.115 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.42 1.75 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.229 -0.441 . . . . 74.3 110.857 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.51 143.11 47.99 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.766 -0.731 . . . . 74.25 112.533 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 m -117.87 160.55 21.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.725 0.298 . . . . 73.43 111.156 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.1 pt -116.41 149.31 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 75.01 111.088 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 15.9 p -69.87 150.64 46.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 71.25 111.202 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -84.15 -175.62 5.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 54.12 110.905 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -58.68 -30.65 67.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 73.24 110.882 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -99.4 21.99 11.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.884 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.4 28.18 71.95 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.669 -0.777 . . . . 75.31 112.533 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -110.44 131.34 55.14 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.835 0.35 . . . . 74.24 110.879 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 20.2 p90 -127.69 167.7 16.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 74.55 110.949 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.7 t -137.44 118.99 14.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 75.13 111.083 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -148.25 107.18 3.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 72.41 110.898 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.6 t -107.03 122.22 46.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 73.42 110.861 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -119.66 155.96 54.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.637 0.732 . . . . 73.53 111.048 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -48.39 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.644 2.229 . . . . 75.02 112.335 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.61 149.93 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 71.24 111.139 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -96.04 67.69 2.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 75.05 110.887 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.2 t -100.55 -169.29 1.7 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 74.42 110.89 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.45 163.06 16.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 72.33 111.148 -179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.92 131.75 46.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.253 -0.431 . . . . 71.23 110.91 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -101.0 126.2 47.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 74.32 110.901 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 2.5 mp -123.64 123.28 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 75.53 111.115 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 63.8 p -119.31 146.38 45.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 65.5 111.098 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.5 m-85 -129.14 154.62 46.55 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.185 -0.461 . . . . 65.43 110.947 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.7 tp -91.31 108.39 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.495 . . . . 74.23 111.133 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.95 -51.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.734 -0.746 . . . . 62.44 112.453 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -106.17 170.87 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.919 0.39 . . . . 73.11 110.958 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -67.31 146.67 98.88 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.598 0.713 . . . . 75.42 110.909 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 175.93 7.43 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.699 2.266 . . . . 74.4 112.317 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.1 m -149.82 142.76 17.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 74.11 111.155 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 13.9 p -122.17 131.98 54.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 61.3 111.158 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.2 m -152.91 156.51 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 74.32 111.202 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.79 154.27 27.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 70.32 110.893 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -63.95 107.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 74.21 111.066 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -130.83 159.3 37.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 63.13 111.107 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.64 -55.74 23.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 73.13 111.118 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 64.4 mt -126.01 131.49 71.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 72.31 111.092 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 23.7 t -143.06 123.53 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 75.01 111.148 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -119.86 109.43 15.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.848 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 26.6 t -125.18 148.87 29.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 75.42 111.169 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -103.72 144.44 31.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 74.53 110.938 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.6 tp -88.87 118.49 28.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 75.25 110.9 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.03 129.55 45.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.896 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 147.56 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.836 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 63.7 t0 -111.71 119.82 39.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 44.35 110.849 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 17.7 p -106.92 139.49 41.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 74.43 111.146 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -70.22 152.22 44.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 2.1 tpp -123.95 106.88 10.78 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 74.34 110.901 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.8 t -106.79 56.46 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 75.24 111.067 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 42.1 m-20 -103.0 123.2 46.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 62.52 110.869 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -132.79 76.07 1.66 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 74.11 110.856 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.1 p -146.19 150.79 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 55.31 111.099 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.9 p -64.63 139.5 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 74.02 111.089 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.4 m -127.42 43.74 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.201 -0.454 . . . . 73.01 111.135 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 3.5 t -162.54 139.74 8.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 73.33 111.147 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.11 175.41 17.73 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.729 -0.748 . . . . 61.42 112.492 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 63.7 t80 -126.23 151.89 46.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 75.33 110.936 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 73.9 p . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 75.25 111.157 -180.0 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 6.6 mmt . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.788 0.327 . . . . 72.11 110.884 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 162.22 -147.74 14.19 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.739 -0.743 . . . . 45.31 112.473 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 4.1 t-160 -117.8 109.83 17.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.887 0.375 . . . . 75.12 110.878 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 15.5 p80 -108.74 36.49 2.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.151 -0.477 . . . . 64.44 110.901 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 16.2 t60 -91.35 71.62 6.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 74.31 110.881 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 35.1 t60 -106.59 83.58 1.88 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.256 -0.429 . . . . 73.02 110.83 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 26.6 t60 -169.21 111.78 0.51 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 74.02 110.931 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -124.28 147.42 48.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.433 . . . . 73.02 110.864 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.6 m -59.43 137.04 58.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 64.24 111.152 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -75.29 101.61 4.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.222 -0.444 . . . . 74.23 110.935 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 85.98 115.38 0.87 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 52.25 112.531 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -157.96 119.82 3.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.895 0.378 . . . . 73.41 110.852 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 43.3 t -111.29 137.2 44.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 111.197 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.3 p -132.07 179.08 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 73.43 111.109 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -100.24 153.09 19.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 72.2 110.823 -179.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 16.3 tttm -92.71 17.98 9.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.08 -0.509 . . . . 75.05 110.917 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 34.8 p -94.2 -58.68 2.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.271 -0.422 . . . . 75.14 111.217 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -120.15 -26.83 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.282 -0.417 . . . . 75.24 110.85 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.24 29.19 5.23 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.492 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -99.05 160.26 28.12 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.621 0.724 . . . . 74.15 110.911 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.62 143.33 51.13 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 61.23 112.393 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.6 mm -92.79 116.45 33.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.276 -0.42 . . . . 75.31 111.094 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 31.3 mt -98.42 150.18 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 73.4 111.107 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.05 48.25 72.97 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 73.4 112.449 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.04 158.27 15.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.799 0.333 . . . . 63.31 111.058 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.09 107.41 18.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 73.23 110.904 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.6 t -112.65 108.44 25.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.141 -0.482 . . . . 75.44 111.105 180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -127.88 139.97 50.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 74.52 111.121 179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -91.2 167.36 12.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 74.12 110.91 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 53.5 p -82.11 -33.75 29.59 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 74.21 111.13 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.2 p -79.42 -22.17 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 64.03 111.164 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.45 103.34 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 72.13 111.111 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 99.1 m -86.93 -35.44 18.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.194 -0.457 . . . . 74.21 111.155 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.2 p -53.99 -26.9 28.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.084 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -93.41 31.42 1.52 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 74.3 110.849 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -67.29 142.16 40.52 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 74.25 112.421 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.7 m -113.97 161.61 17.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.782 0.325 . . . . 73.43 111.108 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.6 pt -117.33 148.31 20.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.459 . . . . 75.01 111.156 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 19.1 p -71.33 150.69 44.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 71.25 111.108 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -86.59 -170.17 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 54.12 110.887 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -60.93 -30.65 70.34 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.152 -0.477 . . . . 73.24 110.974 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.67 17.88 12.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.485 . . . . 73.22 110.865 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.22 28.11 71.69 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.505 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -113.98 136.69 52.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 74.24 110.873 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 28.8 p90 -129.98 167.87 17.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.434 . . . . 74.55 110.925 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.1 t -123.36 117.44 25.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 75.13 111.166 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -143.62 124.44 14.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.41 110.915 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.8 t -106.98 108.07 19.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.848 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.1 m -139.95 152.57 68.09 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 73.53 111.113 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 170.61 16.09 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.705 2.27 . . . . 75.02 112.348 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.9 m -93.18 53.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.15 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -154.79 35.38 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 75.05 110.947 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.7 t -155.53 163.52 39.89 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.174 -0.466 . . . . 74.42 110.826 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 164.06 12.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 72.33 111.102 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 84.9 mt -130.45 117.19 19.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 71.23 110.937 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 37.3 tttt -102.27 123.55 46.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 74.32 110.868 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 3.3 mp -123.59 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 75.53 111.16 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.2 p -117.73 144.52 45.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 65.5 111.18 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 20.6 m-85 -126.5 155.03 42.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 65.43 110.994 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.0 tt -92.36 107.86 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.114 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.84 -50.96 0.82 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.791 -0.719 . . . . 62.44 112.494 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -105.58 170.43 7.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 73.11 110.889 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -67.57 144.57 97.79 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.61 0.719 . . . . 75.42 110.87 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 176.99 6.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.605 2.203 . . . . 74.4 112.299 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.24 145.49 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 74.11 111.148 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.9 p -129.12 138.37 51.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 61.3 111.101 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 17.5 m -150.51 167.79 2.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.206 -0.452 . . . . 74.32 111.115 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -89.53 155.98 18.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.876 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -51.6 128.87 24.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 74.21 111.064 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -161.35 142.8 11.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 63.13 111.13 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.04 -49.32 66.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.085 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.3 mt -120.76 119.49 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.253 -0.43 . . . . 72.31 111.199 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.52 122.64 55.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 75.01 111.123 179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -119.86 113.62 20.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 74.11 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.8 t -127.71 148.94 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 75.42 111.112 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 11.6 mt -106.44 145.29 31.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 74.53 110.932 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.1 tp -87.57 123.06 32.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.469 . . . . 75.25 110.903 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -102.06 133.3 47.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 73.42 110.882 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -51.91 139.54 21.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 75.12 110.927 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -95.49 135.95 36.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.879 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.12 -41.17 1.62 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 74.43 111.092 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -53.92 122.55 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 74.23 110.942 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.6 ttm -124.71 169.74 11.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 74.34 110.901 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 m -147.55 -170.75 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.24 111.084 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -70.19 177.03 3.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 62.52 110.881 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 58.31 45.95 16.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 74.11 110.856 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.5 t -68.08 114.59 5.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 55.31 111.089 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 71.2 t -52.69 -63.14 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.137 -0.483 . . . . 74.02 111.131 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.0 t -99.13 112.43 31.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 73.01 111.105 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.65 151.71 26.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 73.33 111.177 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -155.26 -97.03 0.13 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 61.42 112.519 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -121.76 158.06 29.64 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.931 0.396 . . . . 75.33 110.983 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 75.25 111.211 179.957 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.8 tpp . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.803 0.335 . . . . 72.11 110.852 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 130.94 159.4 9.58 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 45.31 112.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 20.6 t60 -167.9 157.96 10.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.8 0.333 . . . . 75.12 110.858 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -153.02 176.36 11.96 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 64.44 110.896 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 15.7 p80 -138.08 158.75 43.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 74.31 110.902 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -129.26 52.13 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 73.02 110.86 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 70.6 m-70 -104.73 155.81 18.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 74.02 110.856 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 31.1 p-80 -122.6 114.42 20.6 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 73.02 110.893 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -115.19 171.5 7.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 64.24 111.101 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -116.0 -171.91 2.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.861 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.1 126.07 29.26 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 52.25 112.528 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -130.37 130.66 44.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 73.41 110.877 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.51 131.13 73.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 73.33 111.14 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.9 p -127.44 178.17 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.152 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 t -95.43 149.27 21.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.451 . . . . 72.2 110.828 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 33.8 tttm -90.05 12.26 18.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 75.05 110.909 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.4 p -93.61 -59.6 1.96 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.433 . . . . 75.14 111.182 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -118.69 -27.08 5.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 75.24 110.874 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.39 29.31 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.513 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -93.55 160.53 32.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.645 0.736 . . . . 74.15 110.918 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 138.21 37.18 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.606 2.204 . . . . 61.23 112.375 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 48.9 mm -85.64 120.07 35.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.259 -0.428 . . . . 75.31 111.105 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mt -105.93 140.97 22.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.161 -0.472 . . . . 73.4 111.101 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.41 50.41 21.25 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 73.4 112.452 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.06 159.0 15.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.771 0.32 . . . . 63.31 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.3 m -105.87 107.47 18.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 73.23 110.839 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.4 t -111.5 128.49 67.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.147 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.7 m -148.05 139.6 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.092 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -72.23 174.23 7.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.861 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.14 -35.21 49.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 74.21 111.146 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.5 p -112.4 -22.18 10.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 64.03 111.191 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -118.75 78.83 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.244 -0.435 . . . . 72.13 111.102 179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 97.5 m -83.83 -39.21 20.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 74.21 111.11 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 p -53.59 -29.45 37.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 74.23 111.142 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -94.61 31.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.924 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -68.14 164.67 46.95 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.768 -0.729 . . . . 74.25 112.479 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -135.24 168.86 18.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.714 0.292 . . . . 73.43 111.178 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 13.9 pt -121.59 151.35 24.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.19 -0.459 . . . . 75.01 111.104 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 22.8 p -74.27 150.66 40.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.13 -0.487 . . . . 71.25 111.151 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -94.39 -178.1 4.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 54.12 110.885 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -56.92 -30.32 63.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 73.24 110.94 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -73.2 -18.72 61.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 73.22 110.853 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.43 28.19 20.38 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 75.31 112.471 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 23.7 p30 -133.93 163.53 29.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 74.24 110.906 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -144.86 167.76 21.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 74.55 110.887 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -135.72 122.84 21.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 75.13 111.105 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -138.01 118.68 14.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 72.41 110.893 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 t -93.08 115.31 27.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.817 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.66 155.98 44.22 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.646 0.736 . . . . 73.53 111.144 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -48.46 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.724 2.283 . . . . 75.02 112.337 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -111.97 -176.59 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.43 . . . . 71.24 111.104 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -106.04 64.99 0.68 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 75.05 110.885 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.9 t -92.52 -169.83 2.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 74.42 110.86 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.73 162.59 16.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 72.33 111.16 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 11.1 mt -134.39 133.15 40.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 71.23 110.98 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 9.6 ttpt -98.9 125.32 44.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.423 . . . . 74.32 110.876 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.7 mt -123.83 119.62 57.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 75.53 111.145 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 46.4 p -113.63 150.55 32.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 65.5 111.114 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 23.1 m-85 -132.37 151.97 51.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 65.43 110.925 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -90.7 107.98 19.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 74.23 111.096 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.05 -51.19 0.8 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.752 -0.737 . . . . 62.44 112.551 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -104.4 170.5 7.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.931 0.396 . . . . 73.11 110.878 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -67.09 145.39 98.8 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.505 0.669 . . . . 75.42 110.889 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 175.2 8.46 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.686 2.258 . . . . 74.4 112.348 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.8 m -149.91 142.26 17.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 74.11 111.121 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.84 129.54 52.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 61.3 111.114 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.5 m -152.85 154.3 7.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 74.32 111.118 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -88.35 153.12 21.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 70.32 110.865 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -55.86 138.57 48.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 74.21 111.088 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -162.09 165.78 26.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 63.13 111.065 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.41 -56.76 16.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 73.13 111.139 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 61.7 mt -132.39 116.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 72.31 111.085 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.5 t -124.96 112.17 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 75.01 111.103 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -102.04 109.31 20.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 74.11 110.898 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.9 t -116.5 147.15 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.141 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.79 145.6 42.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 74.53 110.862 180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.1 tp -93.62 121.3 34.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.222 -0.445 . . . . 75.25 110.921 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.13 137.14 45.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.276 -0.42 . . . . 73.42 110.925 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -51.08 137.34 21.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.481 . . . . 75.12 110.848 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -105.63 -35.07 7.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 44.35 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -56.09 143.31 33.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 74.43 111.111 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.5 mt-30 -125.76 60.28 1.27 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 74.23 110.913 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.03 109.28 2.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 74.34 110.861 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.6 t -143.39 120.96 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.202 -0.454 . . . . 75.24 111.078 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -70.31 131.72 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 62.52 110.823 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 81.0 mt-10 -124.53 89.09 3.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.152 -0.477 . . . . 74.11 110.892 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.17 128.16 45.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 55.31 111.101 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -59.07 169.32 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 74.02 111.138 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.2 p -175.18 142.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 73.01 111.095 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.54 -47.74 2.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.158 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -175.84 -176.75 44.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 61.42 112.478 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -158.64 146.56 18.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.972 0.415 . . . . 75.33 110.948 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 66.0 p . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 75.25 111.15 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.1 mpp? . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.831 0.348 . . . . 72.11 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 154.8 -54.05 0.43 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.731 -0.747 . . . . 45.31 112.559 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 52.28 47.21 25.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.933 0.397 . . . . 75.12 110.859 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 26.0 p80 -81.12 155.82 26.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.169 -0.468 . . . . 64.44 110.896 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 11.3 t60 -52.25 156.18 1.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 74.31 110.838 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -79.17 -59.56 2.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 73.02 110.836 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 6.0 t60 56.2 50.94 12.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.238 -0.437 . . . . 74.02 110.83 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.2 m170 -93.2 87.37 5.65 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 73.02 110.865 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.9 m -106.48 143.43 34.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 64.24 111.128 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.9 mtmt -72.41 110.59 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 74.23 110.843 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.4 103.17 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.799 -0.715 . . . . 52.25 112.464 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.28 126.36 40.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 73.41 110.945 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.6 t -110.84 125.13 68.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 73.33 111.15 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -128.59 177.15 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.166 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.21 161.38 14.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.802 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.9 tmtm? -101.59 -5.41 25.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.097 -0.502 . . . . 75.05 110.913 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 43.5 p -78.41 -58.58 3.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 75.14 111.177 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -118.36 -26.25 6.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 75.24 110.906 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.58 29.29 6.32 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.787 -0.72 . . . . 53.34 112.513 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -90.21 159.95 41.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.588 0.709 . . . . 74.15 110.959 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 139.24 39.6 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.702 2.268 . . . . 61.23 112.364 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.1 mm -91.3 101.56 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.241 -0.436 . . . . 75.31 111.102 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 3.2 mp -93.56 140.0 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 73.4 111.165 179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.04 31.93 54.15 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.789 -0.72 . . . . 73.4 112.484 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.37 162.37 14.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.759 0.314 . . . . 63.31 111.088 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.7 m -105.79 107.29 18.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.471 . . . . 73.23 110.849 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.4 p -120.09 127.16 75.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 75.44 111.146 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.6 m -140.31 166.97 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 74.52 111.147 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 62.6 tt0 -92.49 132.48 36.77 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 74.12 110.86 -179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 60.8 p -51.7 -35.03 41.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.121 -0.49 . . . . 74.21 111.124 -179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.6 p -95.37 -22.25 17.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 64.03 111.128 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -130.93 87.34 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.464 . . . . 72.13 111.104 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.2 p -86.81 -35.74 18.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 74.21 111.138 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.5 p -53.25 -30.56 38.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.139 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -93.96 31.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.417 . . . . 74.3 110.829 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.59 146.06 49.82 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.752 -0.737 . . . . 74.25 112.486 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 10.4 t -135.65 169.63 17.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.727 0.299 . . . . 73.43 111.178 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -107.9 157.55 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 75.01 111.149 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.0 p -76.22 150.97 36.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 71.25 111.099 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -79.49 -176.16 5.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 54.12 110.832 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -60.47 -30.62 69.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.208 -0.451 . . . . 73.24 110.838 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -99.44 20.87 12.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.197 -0.456 . . . . 73.22 110.882 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.28 27.98 71.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.781 -0.723 . . . . 75.31 112.392 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -107.04 143.43 35.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 74.24 110.955 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -144.57 161.79 38.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 74.55 110.872 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.6 t -151.34 128.36 11.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 75.13 111.211 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -130.63 159.8 36.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.41 110.846 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 6.1 m -95.52 108.23 20.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 73.42 110.798 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.9 t -133.35 133.19 22.53 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.611 0.72 . . . . 73.53 111.128 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 -48.39 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.747 2.298 . . . . 75.02 112.331 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 19.4 m -99.72 -173.83 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 71.24 111.116 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.5 m-20 -107.13 45.66 0.98 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 75.05 110.899 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -57.43 -179.55 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 74.42 110.89 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 1.7 m -87.69 159.72 18.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 72.33 111.137 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 6.7 mp -125.76 135.12 51.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 71.23 110.9 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.4 ttpt -106.86 120.84 43.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.32 110.92 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.8 mt -117.45 138.98 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 75.53 111.095 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.1 p -150.71 138.65 20.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 65.5 111.101 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 13.4 t80 -133.98 122.32 22.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 65.43 110.963 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 11.4 tt -51.57 115.08 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 74.23 111.159 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 131.23 -51.96 0.84 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.752 . . . . 62.44 112.467 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -107.98 170.18 8.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.9 0.381 . . . . 73.11 110.939 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -64.04 158.0 65.73 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.539 0.685 . . . . 75.42 110.914 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 164.26 35.15 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 74.4 112.357 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 27.8 m -150.83 141.08 16.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.197 -0.456 . . . . 74.11 111.133 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.9 p -130.25 140.1 50.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 61.3 111.041 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.6 m -147.55 148.0 16.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.097 -0.501 . . . . 74.32 111.093 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 6.9 mmmm -78.95 155.11 29.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 70.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -73.59 134.07 43.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 74.21 111.142 179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.16 178.11 7.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.102 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.66 -57.32 9.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 73.13 111.13 179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -143.78 111.77 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 72.31 111.084 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 12.2 p -118.84 141.82 36.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.127 -0.488 . . . . 75.01 111.136 179.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -115.89 134.98 54.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.4 t -122.83 149.18 26.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 75.42 111.143 179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.34 133.37 54.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.176 -0.466 . . . . 74.53 110.934 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -90.54 121.49 32.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 75.25 110.928 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 50.3 mm-40 -92.38 145.29 24.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.155 -0.475 . . . . 73.42 110.862 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -58.45 140.4 53.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.17 -0.468 . . . . 75.12 110.929 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -91.03 136.42 33.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 44.35 110.851 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -159.69 153.55 23.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 74.43 111.171 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.8 mm-40 -73.68 168.64 18.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.277 -0.42 . . . . 74.23 110.882 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 35.3 mtt -76.25 165.16 25.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 74.34 110.895 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 67.3 t -58.99 -65.49 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 75.24 111.151 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -65.19 -179.65 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 62.52 110.892 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -124.05 44.55 2.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 74.11 110.823 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -104.94 69.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 55.31 111.118 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.8 t -131.78 120.66 45.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 74.02 111.102 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 46.8 t 54.4 80.38 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.01 111.143 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.2 t -99.16 162.18 13.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.131 -0.486 . . . . 73.33 111.117 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.6 -136.15 12.58 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.723 -0.751 . . . . 61.42 112.499 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 19.7 t80 -142.27 128.45 19.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.918 0.39 . . . . 75.33 110.949 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 72.1 p . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 75.25 111.195 179.993 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.4 ttt . . . . . 0 CA--C 1.526 0.043 0 CA-C-O 120.834 0.349 . . . . 72.11 110.864 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.51 -117.06 0.49 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.682 -0.771 . . . . 45.31 112.474 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 21.2 m170 56.63 63.23 2.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.851 0.358 . . . . 75.12 110.922 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.7 m-70 -127.12 140.09 52.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 64.44 110.86 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -64.48 169.23 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 74.31 110.874 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.8 m80 -141.61 110.01 5.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 73.02 110.88 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -109.9 108.86 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 74.02 110.845 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.5 m80 -92.01 71.46 5.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.189 -0.459 . . . . 73.02 110.966 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.3 m -67.36 141.89 56.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 64.24 111.169 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -108.03 93.98 4.82 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 74.23 110.88 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 73.68 127.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.752 -0.737 . . . . 52.25 112.514 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -158.34 127.29 5.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.847 0.356 . . . . 73.41 110.929 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 83.0 t -117.94 130.59 72.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.33 111.105 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.5 p -128.5 163.71 24.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 73.43 111.103 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -84.73 148.96 26.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 72.2 110.88 -179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttp -92.43 17.53 9.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 75.05 110.851 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.95 -58.75 2.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.14 111.103 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -119.58 -26.68 5.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.24 110.892 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.35 5.12 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.736 -0.745 . . . . 53.34 112.409 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -97.44 159.95 29.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 74.15 110.939 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.78 141.62 45.65 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.663 2.242 . . . . 61.23 112.365 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 33.7 mm -86.04 115.22 26.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 75.31 111.065 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.4 mt -104.04 137.27 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 73.4 111.111 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 75.33 47.55 12.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.763 -0.732 . . . . 73.4 112.486 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.97 158.33 15.51 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.77 0.319 . . . . 63.31 111.135 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.9 m -105.99 107.21 18.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 73.23 110.875 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 95.4 t -110.91 110.39 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 75.44 111.111 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.8 m -123.53 146.05 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 74.52 111.106 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -90.24 156.7 18.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 74.12 110.836 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 51.9 p -73.03 -32.91 65.41 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.115 -0.493 . . . . 74.21 111.19 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.7 p -85.19 -22.2 28.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 64.03 111.17 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.76 104.74 1.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 72.13 111.047 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.4 p -86.75 -34.82 19.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 74.21 111.081 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.5 p -53.15 -29.68 32.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.251 -0.432 . . . . 74.23 111.188 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -94.29 31.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 74.3 110.892 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -72.86 164.37 54.86 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.718 -0.753 . . . . 74.25 112.492 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.8 t -130.96 169.08 16.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.712 0.291 . . . . 73.43 111.226 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 pp -115.99 164.55 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.255 -0.43 . . . . 75.01 111.141 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 14.1 p -89.28 150.66 22.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.205 -0.452 . . . . 71.25 111.15 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -91.37 -179.14 5.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.185 -0.461 . . . . 54.12 110.883 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -56.95 -30.64 64.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 73.24 110.968 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 46.0 m-20 -73.62 -18.46 61.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 73.22 110.865 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.97 28.1 21.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 75.31 112.506 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -127.23 165.38 19.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.812 0.339 . . . . 74.24 110.885 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -153.29 166.75 31.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 74.55 110.845 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.84 125.86 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 75.13 111.158 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -138.61 131.37 29.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 72.41 110.895 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 16.5 t -98.07 117.79 33.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.85 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.8 156.18 46.75 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.665 0.745 . . . . 73.53 111.104 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 -48.51 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.699 2.266 . . . . 75.02 112.376 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.9 m -113.14 -177.5 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.208 -0.451 . . . . 71.24 111.134 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -100.6 39.43 1.37 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 75.05 110.836 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.7 t -63.91 -169.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 74.42 110.866 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.65 161.43 17.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 72.33 111.132 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 12.7 mt -129.85 127.59 40.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.121 -0.491 . . . . 71.23 110.915 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -102.26 122.3 43.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 74.32 110.921 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.1 mt -123.63 118.94 55.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 75.53 111.086 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 55.0 p -113.34 146.86 38.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 65.5 111.168 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 19.0 m-85 -126.28 155.15 42.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 65.43 110.892 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -91.65 107.76 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.072 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.88 -50.83 0.83 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.686 -0.769 . . . . 62.44 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -105.84 170.48 7.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.905 0.383 . . . . 73.11 110.952 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.8 mmtm -64.74 149.0 96.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.617 0.723 . . . . 75.42 110.882 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -179.15 2.73 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.722 2.281 . . . . 74.4 112.377 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 4.4 p -151.85 149.27 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.284 -0.416 . . . . 74.11 111.179 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.22 125.26 30.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 61.3 111.121 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 18.2 m -147.37 152.92 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 74.32 111.156 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -81.82 153.62 26.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 70.32 110.867 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -55.58 105.14 0.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 74.21 111.075 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.78 153.2 50.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.45 . . . . 63.13 111.129 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.09 -51.46 67.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 73.13 111.032 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 60.4 mt -120.03 115.48 47.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 72.31 111.199 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 20.1 t -126.63 106.61 15.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.222 -0.445 . . . . 75.01 111.197 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -114.26 109.43 18.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.11 110.898 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.6 t -129.04 148.38 33.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 75.42 111.13 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.6 mp -100.86 145.15 28.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 74.53 110.943 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.5 tp -87.72 120.93 29.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 75.25 110.947 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -96.14 127.25 41.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.903 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.52 143.16 25.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.877 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -104.94 156.99 17.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 44.35 110.904 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.8 t -158.97 144.97 16.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 74.43 111.197 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -75.59 95.7 3.4 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.223 -0.444 . . . . 74.23 110.888 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 4.6 ttp -104.0 121.05 42.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 74.34 110.889 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.4 t -116.71 -54.79 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.263 -0.426 . . . . 75.24 111.167 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -102.96 37.02 2.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 62.52 110.854 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 39.46 41.71 0.75 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 74.11 110.96 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 57.5 t -70.59 85.28 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.101 -0.499 . . . . 55.31 111.155 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.9 p -105.55 136.18 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 74.02 111.11 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.4 m -57.77 -178.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 73.01 111.168 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.45 111.6 22.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 73.33 111.195 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -173.72 -43.23 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.768 -0.73 . . . . 61.42 112.501 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 58.1 t80 -165.16 146.7 7.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.994 0.426 . . . . 75.33 110.931 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 75.25 111.107 -179.953 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 11.9 mtt . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.788 0.328 . . . . 72.11 110.882 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.33 148.32 13.38 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.715 -0.755 . . . . 45.31 112.542 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -146.27 168.7 20.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.853 0.358 . . . . 75.12 110.803 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -124.3 123.67 40.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 64.44 110.86 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 30.5 m170 -120.6 38.96 3.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 74.31 110.854 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.3 t-80 -80.36 -45.02 18.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 73.02 110.889 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -127.24 68.53 1.28 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 74.02 110.833 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 25.7 t60 -103.84 57.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.163 -0.471 . . . . 73.02 110.858 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -106.26 149.47 26.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 64.24 111.192 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 65.4 mttt -65.0 134.36 53.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.44 . . . . 74.23 110.866 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.02 114.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.72 -0.753 . . . . 52.25 112.477 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -132.43 127.79 36.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.841 0.353 . . . . 73.41 110.927 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.3 t -115.94 134.25 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 73.33 111.138 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.69 153.84 40.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 73.43 111.167 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.1 t -85.69 150.6 24.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 72.2 110.875 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 tttt -94.28 20.76 7.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 75.05 110.911 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.22 -58.69 2.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 75.14 111.098 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -120.05 -25.95 5.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 75.24 110.847 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.87 29.02 5.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 53.34 112.519 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -98.05 155.55 36.89 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 74.15 110.941 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.66 136.86 34.34 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.724 2.283 . . . . 61.23 112.351 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 50.0 mm -78.0 124.32 36.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 75.31 111.114 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.9 mt -110.18 119.35 59.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 73.4 111.095 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.68 33.4 8.47 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.774 -0.727 . . . . 73.4 112.528 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.54 132.21 35.18 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.722 0.296 . . . . 63.31 111.089 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.7 m -79.73 109.74 14.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 73.23 110.84 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -113.78 106.05 19.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.15 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.1 m -120.64 139.03 49.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.16 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -90.61 141.86 28.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 74.12 110.845 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.8 p -62.29 -31.6 72.22 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.074 -0.512 . . . . 74.21 111.166 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 64.8 p -71.71 -22.12 61.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 64.03 111.133 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.76 78.78 0.34 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 72.13 111.055 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 p -65.33 -35.62 81.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 74.21 111.184 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.7 m -54.09 -32.32 54.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.169 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 35.6 t30 -93.47 30.59 1.7 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 74.3 110.941 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -62.94 148.4 50.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.731 -0.747 . . . . 74.25 112.483 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -125.58 168.98 12.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.768 0.318 . . . . 73.43 111.181 -179.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.0 pt -107.37 172.57 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 75.01 111.096 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 37.4 p -97.85 150.68 21.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.113 -0.494 . . . . 71.25 111.067 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -80.57 -175.99 5.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.483 . . . . 54.12 110.864 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -59.52 -30.74 68.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.274 -0.421 . . . . 73.24 110.869 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -100.04 22.77 10.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.16 -0.473 . . . . 73.22 110.886 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.94 28.15 72.32 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.76 . . . . 75.31 112.523 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -107.33 127.77 53.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 74.24 110.82 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -127.73 157.22 40.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.138 -0.483 . . . . 74.55 110.879 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.1 t -132.48 123.82 27.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 75.13 111.158 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.22 118.44 7.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 72.41 110.981 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.0 m -95.05 116.64 28.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 73.42 110.851 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -122.55 156.24 61.51 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.622 0.725 . . . . 73.53 111.155 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -35.88 11.83 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.667 2.245 . . . . 75.02 112.371 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.5 p -131.51 140.23 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 71.24 111.164 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -104.21 79.7 1.63 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 75.05 110.876 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.9 t -89.37 -76.96 0.4 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 74.42 110.861 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.64 159.99 40.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 72.33 111.147 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 15.6 mt -134.81 122.27 21.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 71.23 110.882 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 71.0 tttt -100.89 123.2 44.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 74.32 110.914 179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.1 mt -121.12 138.4 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 75.53 111.149 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 47.2 p -148.82 138.66 22.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 65.5 111.11 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 12.6 t80 -133.98 122.8 23.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 65.43 110.927 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 7.2 tt -51.82 120.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 74.23 111.098 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.73 -50.94 0.85 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 62.44 112.521 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -109.23 169.97 8.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 73.11 110.932 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -64.54 157.33 73.51 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.52 0.676 . . . . 75.42 110.936 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.79 165.16 31.93 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.675 2.25 . . . . 74.4 112.311 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 32.1 m -150.55 138.25 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 74.11 111.154 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 5.1 p -131.76 140.85 49.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 61.3 111.171 -179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.0 m -145.92 175.66 2.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 74.32 111.11 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.41 149.9 25.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 70.32 110.9 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.43 118.37 18.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.181 -0.463 . . . . 74.21 111.137 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.97 -176.22 5.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 63.13 111.064 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -68.14 -57.66 5.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.153 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -126.69 114.26 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 72.31 111.139 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.87 127.45 58.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 75.01 111.136 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 36.0 m120 -100.35 127.59 46.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 74.11 110.897 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.7 148.88 21.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.254 -0.43 . . . . 75.42 111.093 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 15.3 mt -119.43 131.47 55.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.124 -0.489 . . . . 74.53 110.936 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -87.86 121.9 30.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 75.25 110.955 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -90.36 144.01 26.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 73.42 110.94 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -58.97 139.87 56.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.12 110.864 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -91.23 -34.29 15.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 44.35 110.868 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.0 t -103.76 66.68 0.86 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 74.43 111.131 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -119.92 -48.83 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 74.23 110.893 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 8.3 tpp -76.77 116.98 17.94 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.416 . . . . 74.34 110.821 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.25 108.53 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 75.24 111.186 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -115.84 174.24 6.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 62.52 110.903 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -118.54 65.89 0.77 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.857 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.88 130.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 55.31 111.077 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.28 98.53 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 74.02 111.113 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.0 m -113.38 169.61 4.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 73.01 111.141 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.0 t -82.01 141.42 33.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 73.33 111.137 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.93 148.38 50.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.767 -0.73 . . . . 61.42 112.445 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -82.25 132.49 35.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.93 0.395 . . . . 75.33 110.942 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 75.25 111.157 -179.988 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 48.5 mtm . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.832 0.349 . . . . 72.11 110.904 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -134.95 103.65 0.48 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.732 -0.747 . . . . 45.31 112.443 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -136.62 128.31 28.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.84 0.352 . . . . 75.12 110.868 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 2.5 p-80 -71.4 169.5 15.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 64.44 110.907 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -121.8 92.97 3.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.287 -0.415 . . . . 74.31 110.866 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -129.33 147.19 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 73.02 110.804 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 31.8 p80 -126.06 164.06 21.69 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 74.02 110.904 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 22.6 t60 -122.75 -64.56 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 73.02 110.875 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.7 m -104.57 121.62 43.89 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.143 -0.481 . . . . 64.24 111.176 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -101.29 92.24 4.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.272 -0.422 . . . . 74.23 110.891 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 86.06 117.17 0.95 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.762 -0.732 . . . . 52.25 112.516 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.0 120.19 3.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.771 0.32 . . . . 73.41 110.928 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 39.1 t -105.93 131.64 54.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 73.33 111.126 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.9 p -129.37 159.26 36.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.43 111.126 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -84.34 156.95 21.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.2 110.858 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -93.96 20.09 8.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.079 -0.509 . . . . 75.05 110.966 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 60.1 p -94.52 -58.42 2.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 75.14 111.131 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -122.26 -26.36 4.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 75.24 110.915 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.64 29.27 5.08 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.753 -0.737 . . . . 53.34 112.539 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -98.99 159.69 29.6 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.552 0.692 . . . . 74.15 110.953 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.71 147.72 63.82 Favored 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.745 2.296 . . . . 61.23 112.399 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.5 mm -94.6 114.97 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 75.31 111.084 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 40.4 mt -100.22 138.6 24.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 73.4 111.159 179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.27 46.64 12.23 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.659 -0.781 . . . . 73.4 112.522 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 157.82 15.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 63.31 111.043 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -106.01 107.14 17.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 73.23 110.855 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -112.15 122.58 66.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 75.44 111.132 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -138.91 151.95 23.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 74.52 111.177 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -84.31 174.28 10.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 74.12 110.912 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.13 -42.29 69.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 74.21 111.185 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.7 p -112.91 -22.16 10.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 64.03 111.143 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -110.26 76.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 72.13 111.2 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.2 p -86.95 -34.38 19.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 74.21 111.141 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.3 m -53.16 -30.48 37.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.434 . . . . 74.23 111.096 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -93.16 30.99 1.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 74.3 110.852 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.95 138.98 46.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.78 -0.724 . . . . 74.25 112.455 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.5 m -116.97 160.45 20.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 73.43 111.162 -179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -114.51 162.2 12.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 75.01 111.165 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 5.6 p -83.87 150.61 25.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 71.25 111.218 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -85.14 -175.89 5.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 54.12 110.91 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -58.99 -30.18 67.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.237 -0.438 . . . . 73.24 110.851 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.56 13.54 13.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 73.22 110.862 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 28.0 71.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.757 -0.735 . . . . 75.31 112.419 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -126.81 142.59 51.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.863 0.363 . . . . 74.24 110.917 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 30.9 p90 -132.39 168.01 18.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.469 . . . . 74.55 110.873 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.7 t -133.43 116.56 16.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 75.13 111.105 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.2 tm? -143.19 132.29 23.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 72.41 110.929 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 79.2 p -107.35 124.84 50.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 73.42 110.902 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.61 155.95 44.2 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.702 0.763 . . . . 73.53 111.111 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -48.5 0.71 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.665 2.243 . . . . 75.02 112.362 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.3 m -112.37 179.68 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 71.24 111.189 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 75.2 m-80 -100.31 36.88 1.77 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 75.05 110.862 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.3 t -61.98 -172.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.42 110.844 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.0 154.95 19.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.057 -0.52 . . . . 72.33 111.186 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 6.3 mp -127.41 130.96 50.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 71.23 110.91 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -99.82 121.25 41.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 74.32 110.917 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 2.4 mp -117.92 119.14 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.295 -0.411 . . . . 75.53 111.14 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 44.5 p -116.08 144.32 44.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.187 -0.46 . . . . 65.5 111.149 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -126.63 152.35 46.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 65.43 110.918 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.4 tt -89.71 107.73 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.109 -0.496 . . . . 74.23 111.142 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.5 -50.47 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.74 . . . . 62.44 112.49 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 12.8 m-85 -103.62 170.69 7.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 73.11 110.925 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -67.95 145.17 97.71 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.58 0.705 . . . . 75.42 110.867 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 172.34 12.84 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.682 2.254 . . . . 74.4 112.382 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.5 m -150.08 143.66 17.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 74.11 111.128 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -122.49 134.76 54.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.246 -0.434 . . . . 61.3 111.168 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.1 m -152.94 158.82 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 74.32 111.127 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -82.47 157.28 23.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 70.32 110.882 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.18 138.14 49.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 74.21 111.113 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.72 -177.59 4.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 63.13 111.093 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.37 -58.0 7.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 73.13 111.085 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -124.25 137.71 56.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.2 -0.454 . . . . 72.31 111.149 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.1 p -143.61 120.92 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 75.01 111.142 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -119.98 110.55 16.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 74.11 110.831 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.2 t -116.37 146.32 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 75.42 111.128 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -102.14 135.33 43.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.185 -0.461 . . . . 74.53 110.932 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -87.53 120.87 29.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 75.25 110.919 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -95.69 142.9 27.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 73.42 110.905 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -55.02 141.25 34.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.12 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -124.44 120.2 31.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.264 -0.426 . . . . 44.35 110.946 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -134.65 141.06 46.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 74.43 111.164 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -106.67 152.75 23.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 74.23 110.89 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -113.29 85.2 2.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 74.34 110.876 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -175.36 134.37 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.237 -0.438 . . . . 75.24 111.113 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -55.31 131.81 46.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 62.52 110.855 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -106.75 86.21 2.29 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.926 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.9 m -59.67 157.22 2.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 55.31 111.152 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.2 p -52.92 135.74 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 74.02 111.129 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.4 m -111.87 175.94 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 73.01 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.5 p -64.02 -179.54 0.43 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.445 . . . . 73.33 111.165 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -79.88 151.03 33.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.774 -0.727 . . . . 61.42 112.489 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -90.8 156.11 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 75.33 110.966 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 p . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 75.25 111.151 -179.937 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.0 mmt . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.852 0.358 . . . . 72.11 110.886 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -88.52 -166.91 42.74 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.745 -0.74 . . . . 45.31 112.496 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 36.3 m170 -118.45 -44.22 2.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.837 0.351 . . . . 75.12 110.855 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -70.34 169.16 14.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 64.44 110.786 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 60.8 m170 -110.36 112.29 24.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 74.31 110.874 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -72.73 122.2 21.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.206 -0.452 . . . . 73.02 110.888 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -115.32 -42.22 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.02 110.877 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -62.42 156.56 22.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.267 -0.424 . . . . 73.02 110.849 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.1 m -94.42 154.02 17.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.205 -0.452 . . . . 64.24 111.179 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.34 133.65 51.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 74.23 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.53 124.79 0.86 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.705 -0.759 . . . . 52.25 112.529 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -152.74 119.95 5.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.36 . . . . 73.41 110.857 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 22.4 t -107.26 132.11 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 73.33 111.153 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -136.22 160.38 38.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 73.43 111.072 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.16 154.1 35.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 72.2 110.851 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.6 tttp -96.46 12.91 29.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 75.05 110.845 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 74.3 p -93.86 -58.72 2.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.261 -0.427 . . . . 75.14 111.144 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -119.04 -26.57 5.93 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.229 -0.442 . . . . 75.24 110.935 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.32 29.25 5.18 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.748 . . . . 53.34 112.445 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 47.0 mt-30 -90.45 160.46 39.26 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.598 0.713 . . . . 74.15 110.902 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 136.27 32.64 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.673 2.248 . . . . 61.23 112.368 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.4 mm -87.4 123.07 39.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.096 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.5 mt -107.92 128.23 63.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 73.4 111.118 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.53 32.87 14.68 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.686 -0.768 . . . . 73.4 112.501 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.42 127.76 36.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.792 0.329 . . . . 63.31 111.04 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -72.8 107.63 5.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 73.23 110.829 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -111.64 106.68 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.065 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.03 150.49 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 74.52 111.121 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -92.57 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 74.12 110.851 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.9 p -56.14 -34.85 66.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.066 -0.515 . . . . 74.21 111.204 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 66.5 p -98.16 -22.09 16.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.24 -0.436 . . . . 64.03 111.208 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -133.48 65.81 1.57 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 72.13 111.065 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 p -67.03 -35.32 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 74.21 111.17 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 88.8 m -64.1 -30.63 71.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 74.23 111.084 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -93.51 30.55 1.72 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.86 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -70.9 155.95 53.04 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.749 -0.739 . . . . 74.25 112.422 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -132.76 168.8 17.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.756 0.312 . . . . 73.43 111.199 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.89 150.83 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.44 . . . . 75.01 111.191 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 19.2 p -70.38 150.14 46.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 71.25 111.186 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -91.3 -179.23 5.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 54.12 110.821 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -58.25 -30.64 66.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 73.24 110.846 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -73.84 -19.48 60.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.853 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.03 28.16 12.42 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.689 -0.767 . . . . 75.31 112.501 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -137.68 164.59 28.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.859 0.361 . . . . 74.24 110.925 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 27.6 p90 -138.78 167.46 21.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 74.55 110.835 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -119.86 120.38 36.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.114 -0.493 . . . . 75.13 111.187 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.3 mt -148.11 108.18 4.06 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.265 -0.425 . . . . 72.41 110.899 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.4 t -82.4 108.08 15.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.851 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 6.7 m -139.98 106.77 6.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.653 0.74 . . . . 73.53 111.129 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -32.54 18.45 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.762 2.308 . . . . 75.02 112.365 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.4 m -55.57 -30.61 26.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 71.24 111.138 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 67.32 40.11 2.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 75.05 110.866 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.0 m -74.73 -176.01 2.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 74.42 110.91 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.95 150.05 24.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 72.33 111.186 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 6.1 mp -117.85 131.57 56.54 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.264 -0.425 . . . . 71.23 110.933 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -99.83 128.48 45.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 74.32 110.87 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 45.0 mt -123.79 124.93 70.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.233 -0.44 . . . . 75.53 111.097 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 71.8 p -140.88 143.33 34.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.104 -0.498 . . . . 65.5 111.131 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 9.3 t80 -139.29 121.02 15.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.216 -0.447 . . . . 65.43 110.856 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.1 tt -50.91 107.68 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.083 -0.508 . . . . 74.23 111.141 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 138.94 -43.86 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 62.44 112.46 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -114.94 170.96 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.981 0.42 . . . . 73.11 110.902 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mmtt -66.29 153.64 92.09 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.596 0.712 . . . . 75.42 110.905 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.77 157.68 59.54 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.711 2.274 . . . . 74.4 112.331 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.8 m -150.93 137.93 13.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 74.11 111.141 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 21.2 p -131.96 142.24 49.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 61.3 111.107 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 15.5 m -149.55 156.32 7.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 74.32 111.141 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.51 157.29 26.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 70.32 110.934 179.892 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -77.4 137.59 38.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.276 -0.42 . . . . 74.21 111.147 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.59 178.65 7.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.439 . . . . 63.13 111.112 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.71 -49.61 62.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 73.13 111.087 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 5.4 mp -143.71 111.79 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 72.31 111.144 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.12 128.1 73.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 75.01 111.079 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.1 m120 -115.39 125.98 53.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 74.11 110.887 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.2 t -120.05 149.01 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.132 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.5 mp -121.35 120.46 35.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 74.53 110.968 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 3.4 tp -88.06 116.55 26.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 75.25 110.873 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 17.0 pm0 -95.9 146.47 24.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 73.42 110.82 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.58 143.89 33.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.131 -0.486 . . . . 75.12 110.932 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -97.7 -34.44 10.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 44.35 110.862 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.3 p -139.56 169.01 18.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 74.43 111.168 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 2.3 pp0? -133.39 158.56 42.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 74.23 110.916 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -145.73 148.11 32.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.286 -0.416 . . . . 74.34 110.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.4 t -99.84 -44.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.259 -0.428 . . . . 75.24 111.117 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -127.47 172.4 10.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.101 -0.499 . . . . 62.52 110.933 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.52 82.4 6.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 74.11 110.86 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 68.9 t -89.29 117.37 32.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 55.31 111.147 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.5 p -80.03 138.02 20.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.02 111.085 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 41.7 t -138.97 121.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.117 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -64.05 128.26 35.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.141 -0.481 . . . . 73.33 111.128 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 132.27 119.87 2.1 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.782 -0.723 . . . . 61.42 112.54 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -142.7 164.1 31.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.95 0.405 . . . . 75.33 110.86 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.051 -0.522 . . . . 75.25 111.136 -179.97 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.1 mmt . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.845 0.355 . . . . 72.11 110.855 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 131.07 141.99 4.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 45.31 112.465 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -144.29 150.16 37.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.854 0.359 . . . . 75.12 110.901 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -144.75 144.04 30.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.265 -0.425 . . . . 64.44 110.921 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 3.3 m80 -74.99 163.38 27.68 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.882 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -66.18 172.34 3.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.253 -0.43 . . . . 73.02 110.901 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -99.83 109.16 21.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 74.02 110.872 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.0 t-80 -139.32 -55.18 0.58 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 73.02 110.835 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 3.5 m -106.13 127.81 53.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 64.24 111.121 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -74.43 102.25 4.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.87 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.38 105.4 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.769 -0.729 . . . . 52.25 112.433 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -156.83 125.76 5.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.829 0.347 . . . . 73.41 110.881 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 93.1 t -112.35 130.17 66.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 73.33 111.075 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 p -128.84 164.31 23.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 73.43 111.11 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -85.32 149.95 25.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 72.2 110.801 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.35 18.17 8.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.111 -0.495 . . . . 75.05 110.918 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.93 2.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 75.14 111.157 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -119.95 -26.77 5.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 75.24 110.88 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.11 29.39 5.19 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.773 -0.727 . . . . 53.34 112.507 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.2 mm100 -96.9 160.3 29.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.672 0.749 . . . . 74.15 110.918 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 138.54 38.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.649 2.233 . . . . 61.23 112.381 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 49.9 mm -83.79 123.09 38.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.133 179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.3 mt -108.24 140.75 25.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 73.4 111.161 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.63 51.99 17.95 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.81 -0.71 . . . . 73.4 112.48 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.05 155.75 16.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.805 0.336 . . . . 63.31 111.078 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.5 m -106.14 107.42 18.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 73.23 110.843 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 94.8 t -113.31 116.8 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 75.44 111.158 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 13.2 m -138.65 144.01 30.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 74.52 111.049 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -78.94 173.65 12.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.12 110.866 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 66.1 p -75.41 -36.26 60.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 74.21 111.143 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 38.9 p -112.37 -22.08 11.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 64.03 111.111 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -114.97 75.56 0.94 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 72.13 111.073 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.1 m -84.36 -35.9 22.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 74.21 111.18 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -57.38 -28.93 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 74.23 111.128 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -94.54 31.23 1.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.91 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -69.67 149.28 47.97 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.799 -0.715 . . . . 74.25 112.48 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.2 t -123.1 169.12 11.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.716 0.293 . . . . 73.43 111.139 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.1 pt -124.42 156.64 32.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 75.01 111.148 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 35.6 p -81.79 149.05 28.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 71.25 111.115 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -91.62 -176.24 4.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.228 -0.442 . . . . 54.12 110.858 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.93 -30.62 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 73.24 110.892 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -73.8 -18.85 60.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 73.22 110.86 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.37 28.22 20.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.725 -0.75 . . . . 75.31 112.457 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.97 162.38 29.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.826 0.346 . . . . 74.24 110.901 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 28.2 p90 -146.02 164.14 33.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 74.55 110.921 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.7 t -128.5 116.28 19.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 75.13 111.14 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -148.5 107.46 3.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 72.41 110.877 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.6 m -68.82 107.93 3.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.83 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.2 t -139.97 133.41 15.31 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.62 0.724 . . . . 73.53 111.126 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 173.86 10.4 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.652 2.234 . . . . 75.02 112.384 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.8 p -95.48 31.99 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.178 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -92.19 -36.04 13.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 75.05 110.912 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 6.3 p -123.47 176.98 5.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 74.42 110.84 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -97.72 176.88 5.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 72.33 111.164 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 71.6 mt -131.17 126.78 36.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 71.23 110.951 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -102.44 122.04 43.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 74.32 110.865 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 61.2 mt -123.79 117.73 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 75.53 111.145 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 65.0 p -113.19 148.58 35.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 65.5 111.122 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -127.37 154.97 44.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 65.43 110.951 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -91.02 107.77 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 74.23 111.072 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 124.09 -51.23 0.82 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.707 -0.759 . . . . 62.44 112.429 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.93 170.66 7.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.995 0.426 . . . . 73.11 110.856 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 35.2 mttt -64.54 148.53 96.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.59 0.71 . . . . 75.42 110.878 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -178.75 2.51 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.268 . . . . 74.4 112.324 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 4.7 p -152.02 146.02 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 74.11 111.169 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.9 p -132.17 130.58 41.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 61.3 111.119 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 8.1 m -152.62 155.15 6.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.28 -0.418 . . . . 74.32 111.069 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.3 ptpt -74.68 152.46 39.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 70.32 110.892 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -58.26 120.74 9.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 74.21 111.098 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -148.49 150.76 33.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 63.13 111.089 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.81 -53.73 36.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.097 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.6 mp -117.17 133.28 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 72.31 111.204 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 5.4 p -146.39 118.05 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 75.01 111.145 179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 32.9 m120 -120.11 109.46 15.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.473 . . . . 74.11 110.904 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -126.79 144.14 37.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 75.42 111.15 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.0 mp -96.92 145.19 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 74.53 111.008 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.3 tp -87.77 121.49 30.25 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.281 -0.418 . . . . 75.25 110.931 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -98.71 136.11 39.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 73.42 110.888 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -55.05 140.46 37.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.88 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -106.4 86.84 2.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.861 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.0 p -127.02 -178.6 4.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.237 -0.438 . . . . 74.43 111.144 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -54.91 121.05 7.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 74.23 110.904 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 77.3 mmm -118.8 176.6 5.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 74.34 110.904 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.4 t -140.04 113.69 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 75.24 111.108 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -97.14 170.05 9.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.135 -0.484 . . . . 62.52 110.887 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 53.52 53.17 11.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 74.11 110.862 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 57.8 t -92.69 140.13 16.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 55.31 111.153 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.7 138.11 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 74.02 111.134 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.38 141.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 73.01 111.103 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.0 t -106.56 150.77 25.82 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.134 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -142.58 -104.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.705 -0.759 . . . . 61.42 112.497 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -93.32 150.74 20.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.918 0.39 . . . . 75.33 110.943 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 75.25 111.165 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 16.6 ptm . . . . . 0 N--CA 1.458 -0.042 0 CA-C-O 120.844 0.354 . . . . 72.11 110.866 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 160.18 161.27 11.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 45.31 112.508 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 12.4 t60 -152.05 121.45 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.833 0.349 . . . . 75.12 110.843 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -105.53 167.34 9.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 64.44 110.879 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -117.37 137.92 52.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 74.31 110.849 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.5 p80 -58.32 154.23 13.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 73.02 110.841 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 34.2 p-80 -120.1 140.67 50.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 74.02 110.917 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.2 t-160 -118.43 61.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.196 -0.456 . . . . 73.02 110.845 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -87.68 149.49 24.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 64.24 111.061 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -152.35 -176.07 5.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 74.23 110.879 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.17 127.29 32.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 52.25 112.481 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -151.23 127.64 10.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 73.41 110.896 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 90.7 t -118.29 130.61 72.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 73.33 111.136 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 20.3 p -127.14 169.39 13.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 73.43 111.163 -179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.21 155.1 19.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.2 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -92.63 18.64 8.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 75.05 110.848 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.64 2.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 75.14 111.165 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -120.85 -26.42 5.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.3 -0.409 . . . . 75.24 110.832 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.79 29.05 5.12 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.491 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -100.63 154.19 37.31 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.566 0.698 . . . . 74.15 110.93 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.7 147.2 62.75 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.756 2.304 . . . . 61.23 112.335 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 15.5 mm -93.5 120.38 42.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 75.31 111.066 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.07 150.81 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 73.4 111.103 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.61 48.33 82.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 73.4 112.474 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -95.28 167.65 11.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 63.31 111.028 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.0 m -106.34 106.62 17.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.163 -0.471 . . . . 73.23 110.856 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.9 t -110.42 128.86 66.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 75.44 111.122 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.8 m -148.44 137.99 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 74.52 111.143 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 15.7 tt0 -82.87 129.27 34.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 74.12 110.878 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.2 t -51.4 -33.21 29.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.21 111.168 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 42.1 p -89.45 -22.24 22.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 64.03 111.1 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -148.61 98.66 2.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 72.13 111.115 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 66.3 p -86.69 -32.83 20.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 74.21 111.189 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.3 m -52.78 -29.69 28.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.169 -0.469 . . . . 74.23 111.135 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -93.25 31.08 1.53 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.247 -0.433 . . . . 74.3 110.841 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -66.44 150.53 51.93 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.71 -0.757 . . . . 74.25 112.474 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.5 t -135.76 169.43 17.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 73.43 111.151 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 17.9 pt -113.16 152.08 14.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 75.01 111.146 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 10.0 p -69.98 150.72 46.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 71.25 111.119 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -81.26 -177.43 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 54.12 110.84 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -60.32 -30.61 69.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 73.24 110.867 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -97.42 20.38 11.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.22 110.867 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.27 27.94 71.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.719 -0.753 . . . . 75.31 112.474 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -108.5 139.38 43.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 74.24 110.919 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 13.2 p90 -133.49 168.13 19.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 74.55 110.928 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 25.6 p -145.1 117.69 8.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 75.13 111.092 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 7.4 mp -126.59 109.58 12.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 72.41 110.889 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -99.89 117.91 35.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.845 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.6 m -138.34 155.9 73.79 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 73.53 111.124 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 -48.34 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.634 2.223 . . . . 75.02 112.381 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.18 150.72 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 71.24 111.111 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -91.3 46.07 1.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 75.05 110.91 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 84.0 p -66.4 -169.83 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 74.42 110.819 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.64 160.74 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.503 . . . . 72.33 111.165 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 19.1 mt -121.15 117.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 71.23 110.931 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -97.82 114.58 26.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 74.32 110.867 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 4.0 mp -115.62 121.2 66.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 75.53 111.168 179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 43.8 p -117.14 145.26 43.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 65.5 111.04 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 18.7 m-85 -125.81 155.29 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.481 . . . . 65.43 110.903 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -92.5 107.38 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.11 -0.496 . . . . 74.23 111.158 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.07 -46.16 1.1 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 62.44 112.467 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -111.82 170.89 7.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 73.11 110.828 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -63.6 150.75 89.74 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.568 0.699 . . . . 75.42 110.927 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 178.2 4.83 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.645 2.23 . . . . 74.4 112.371 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 3.7 p -152.03 147.9 14.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.088 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.6 p -132.14 130.82 41.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 61.3 111.174 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 19.5 m -141.66 145.97 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.263 -0.426 . . . . 74.32 111.125 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.97 157.18 37.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.965 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.18 98.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 74.21 111.155 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.15 178.2 6.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 63.13 111.071 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -86.36 -42.37 13.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.16 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -129.87 125.48 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.239 -0.437 . . . . 72.31 111.137 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.3 p -146.44 122.14 3.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 75.01 111.133 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -120.12 119.74 34.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 74.11 110.856 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.8 t -133.03 147.02 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 75.42 111.173 179.879 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 24.8 mt -98.17 135.19 40.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 74.53 110.912 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.4 tp -89.32 117.89 28.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 75.25 110.89 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -94.07 132.53 38.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.42 110.867 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -56.65 145.84 27.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.097 -0.501 . . . . 75.12 110.936 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -111.88 97.87 6.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 44.35 110.861 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.0 p -107.06 100.65 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 74.43 111.129 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -66.37 117.05 8.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.409 . . . . 74.23 110.979 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 20.2 mtt -52.39 128.94 27.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 74.34 110.83 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.5 m -113.86 67.62 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 75.24 111.113 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -70.57 164.39 24.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 62.52 110.815 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -153.98 43.74 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 74.11 110.962 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 70.4 t 50.78 87.33 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 55.31 111.166 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.8 p -163.55 143.36 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 74.02 111.163 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.6 m -77.32 146.85 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.125 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 151.49 47.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 73.33 111.124 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -110.13 148.1 17.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.717 . . . . 61.42 112.489 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 53.6 t80 -91.59 144.87 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.931 0.396 . . . . 75.33 110.924 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 23.3 p . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 75.25 111.172 179.99 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.0 ptp . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.828 0.346 . . . . 72.11 110.877 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -140.92 163.4 26.62 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.784 -0.722 . . . . 45.31 112.547 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 43.9 p-80 -118.02 164.73 14.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 75.12 110.837 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -154.69 162.22 41.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 64.44 110.841 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -69.75 140.42 53.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 74.31 110.855 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -89.09 -63.09 1.34 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 73.02 110.864 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -92.7 161.58 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 74.02 110.913 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.8 m170 -115.45 154.06 29.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.414 . . . . 73.02 110.793 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -96.48 145.28 25.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.135 -0.484 . . . . 64.24 111.175 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -72.41 102.22 3.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 74.23 110.91 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.84 117.72 0.38 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.691 -0.766 . . . . 52.25 112.464 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -158.13 119.85 3.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.843 0.354 . . . . 73.41 110.909 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 87.1 t -108.84 130.91 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 73.33 111.143 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.7 p -127.31 169.5 13.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.108 -0.497 . . . . 73.43 111.113 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -89.16 150.09 22.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.457 . . . . 72.2 110.832 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 14.9 tttm -90.83 15.0 12.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 75.05 110.882 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.74 -58.47 2.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 75.14 111.178 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -118.86 -26.66 5.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 75.24 110.828 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.28 29.29 6.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 53.34 112.503 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -96.93 160.16 29.81 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.533 0.682 . . . . 74.15 110.916 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 132.96 24.38 Favored 'Trans proline' 0 N--CA 1.465 -0.162 0 C-N-CA 122.664 2.242 . . . . 61.23 112.337 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 25.4 mm -77.67 118.11 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.164 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.8 mt -108.7 132.62 56.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 73.4 111.142 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.9 31.98 19.21 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.736 -0.745 . . . . 73.4 112.462 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.39 153.94 21.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.777 0.322 . . . . 63.31 111.114 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -106.86 107.04 17.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.429 . . . . 73.23 110.865 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.81 130.13 74.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 75.44 111.106 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.9 m -146.01 163.8 10.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 74.52 111.108 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -85.24 172.82 10.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 74.12 110.931 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.58 -42.03 65.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 74.21 111.162 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -112.55 -21.98 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.198 -0.455 . . . . 64.03 111.155 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.16 64.55 0.84 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 72.13 111.109 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 21.8 p -78.52 -35.24 46.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.224 -0.444 . . . . 74.21 111.176 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.1 p -53.23 -30.93 40.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.097 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -93.78 31.33 1.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.968 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -63.81 148.37 50.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.794 -0.717 . . . . 74.25 112.434 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 13.2 t -135.49 170.57 15.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.76 0.314 . . . . 73.43 111.194 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 11.6 pt -122.94 152.38 27.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 75.01 111.119 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 18.1 p -70.85 150.94 45.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.145 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -91.0 -177.02 4.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 54.12 110.896 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.2 -30.01 69.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 73.24 110.883 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -73.17 -18.52 61.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.46 28.04 20.74 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 75.31 112.452 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -129.65 166.88 18.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.887 0.375 . . . . 74.24 110.922 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -151.35 167.92 26.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 74.55 110.865 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.5 t -134.66 125.61 27.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 75.13 111.1 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -130.73 128.84 41.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 72.41 110.898 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.9 t -105.04 119.97 40.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 73.42 110.801 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 58.0 t -139.0 133.23 16.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.614 0.721 . . . . 73.53 111.157 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -48.35 0.73 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.725 2.283 . . . . 75.02 112.325 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.0 m -86.65 171.64 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.259 -0.428 . . . . 71.24 111.12 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -111.08 81.75 1.48 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 75.05 110.829 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.7 t -109.39 -169.41 1.47 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.924 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.54 161.93 17.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.461 . . . . 72.33 111.133 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -128.42 130.18 47.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 71.23 110.91 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -101.98 124.45 47.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 74.32 110.858 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.3 mt -123.64 119.57 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.448 . . . . 75.53 111.115 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 51.2 p -117.78 144.32 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 65.5 111.152 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -126.22 155.06 42.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.21 -0.45 . . . . 65.43 110.94 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 9.2 tt -92.24 107.72 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 74.23 111.144 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 121.17 -51.1 0.8 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 62.44 112.513 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -101.5 170.75 8.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.897 0.379 . . . . 73.11 110.906 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 57.0 mttt -68.6 143.61 95.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.551 0.691 . . . . 75.42 110.963 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.73 174.22 9.8 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.713 2.275 . . . . 74.4 112.391 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.8 m -150.24 140.37 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 74.11 111.168 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -125.76 130.25 51.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 61.3 111.148 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.9 m -153.41 159.23 3.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.283 -0.417 . . . . 74.32 111.143 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -73.07 157.23 37.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.32 110.9 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -71.89 138.31 48.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 74.21 111.078 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -159.91 167.54 27.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 63.13 111.096 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.37 -57.14 13.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 73.13 111.064 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.5 135.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 72.31 111.143 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.1 p -146.48 120.72 2.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 75.01 111.185 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -120.01 109.81 15.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 74.11 110.848 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 36.7 t -123.65 135.18 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 75.42 111.148 179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.5 pp -92.71 145.49 24.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 74.53 110.955 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 1.2 tp -87.61 121.33 29.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 75.25 110.878 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 59.5 mt-10 -97.69 136.76 37.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.941 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -55.13 139.74 40.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 75.12 110.88 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -107.75 127.91 54.11 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 44.35 110.818 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 69.9 p -137.61 172.26 13.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.105 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 -90.2 47.89 1.5 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 74.23 110.962 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 1.8 mpt? 58.4 52.27 7.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 74.34 110.894 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.6 m -133.23 69.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.238 -0.437 . . . . 75.24 111.144 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -108.58 163.37 13.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 62.52 110.936 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -103.09 68.66 0.99 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 74.11 110.895 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -66.24 145.1 14.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 55.31 111.124 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.0 p -54.88 131.99 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 74.02 111.152 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 39.2 t -80.56 111.17 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.287 -0.415 . . . . 73.01 111.179 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 70.9 p -87.81 -39.58 14.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 73.33 111.202 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.77 -102.6 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.745 -0.74 . . . . 61.42 112.481 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.19 134.48 48.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.008 0.432 . . . . 75.33 110.884 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 p . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.122 -0.49 . . . . 75.25 111.157 -179.976 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.513 -0.235 . . . . 42.34 112.513 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -158.0 122.26 4.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.347 . . . . 73.41 110.93 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 19' ' ' ILE . 21.8 t -114.22 128.67 71.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.13 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.464 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -136.18 152.07 50.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 73.43 111.188 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.83 148.84 28.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 72.2 110.893 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.56 21.89 6.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.142 -0.481 . . . . 60.22 110.901 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.407 HG21 ' OH ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -94.0 -58.58 2.2 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 75.14 111.17 179.964 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -119.14 -25.98 6.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.263 -0.426 . . . . 72.52 110.883 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.8 29.02 5.12 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 53.34 112.499 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -101.14 160.5 26.47 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.559 0.695 . . . . 74.15 110.888 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.464 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.6 Cg_endo -69.73 145.46 57.39 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.688 2.259 . . . . 61.23 112.329 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.728 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 47.4 mm -83.07 115.63 25.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 75.31 111.171 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.3 mt -104.83 113.1 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.471 . . . . 42.2 111.191 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.51 32.66 6.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.5 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.728 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -91.06 128.14 36.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.858 0.361 . . . . 63.11 111.062 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.0 m -81.25 107.19 13.83 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.215 -0.448 . . . . 52.44 110.853 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.709 HG23 HG13 ' A' ' 54' ' ' ILE . 3.0 p -120.09 122.7 69.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.088 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.757 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.6 m -134.27 174.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 74.52 111.138 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 35.3 mp0 -91.17 166.14 13.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 74.12 110.92 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -65.43 -41.99 92.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.145 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.1 p -112.56 -22.16 10.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 64.03 111.083 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.601 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -101.32 65.65 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 63.21 111.086 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 87.5 m -77.34 -35.71 54.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 73.01 111.096 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.7 p -57.07 -31.6 65.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.23 111.169 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.664 ' O ' HD21 ' A' ' 44' ' ' LEU . 1.7 m-20 -94.45 31.41 1.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.3 110.929 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.757 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.36 152.37 49.64 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.781 -0.723 . . . . 61.22 112.499 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.593 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -135.56 168.46 19.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.74 0.305 . . . . 73.43 111.138 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.6 pt -116.55 167.72 9.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 72.12 111.134 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.499 HG22 ' HD2' ' A' ' 42' ' ' PHE . 23.0 p -89.74 150.61 22.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 55.34 111.174 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -95.22 -178.93 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 34.54 110.915 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -57.79 -30.44 65.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.48 . . . . 72.12 110.885 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -73.55 -19.39 60.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.152 -0.476 . . . . 73.22 110.892 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.7 28.26 12.83 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 120.736 -0.745 . . . . 75.31 112.458 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -136.58 166.07 24.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.914 0.388 . . . . 71.23 110.93 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.548 ' CZ ' HG21 ' A' ' 24' ' ' VAL . 24.2 p90 -142.66 164.75 29.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 71.21 110.902 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -123.46 117.79 25.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.166 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.664 HD21 ' O ' ' A' ' 32' ' ' ASN . 0.3 OUTLIER -144.44 134.97 24.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.41 . . . . 72.23 110.903 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.582 ' N ' HD13 ' A' ' 44' ' ' LEU . 1.2 t -107.02 121.85 45.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 73.42 110.846 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.5 t -126.92 133.26 24.84 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.565 0.698 . . . . 71.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.0 Cg_endo -69.69 -48.42 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.731 2.288 . . . . 60.01 112.353 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.77 149.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 71.24 111.167 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 70.8 m-80 -85.16 64.39 8.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 63.41 110.92 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -92.49 -179.56 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 64.13 110.812 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.71 156.08 19.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.075 -0.512 . . . . 72.33 111.17 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mt -115.24 124.9 52.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.275 -0.42 . . . . 62.04 110.888 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.584 ' HA ' HG22 ' A' ' 63' ' ' THR . 28.8 tttt -95.64 122.43 38.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 74.21 110.885 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.709 HG13 HG23 ' A' ' 24' ' ' VAL . 2.2 mp -118.65 134.55 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 73.4 111.131 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 45.7 p -142.55 138.74 31.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 62.11 111.123 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -134.31 119.13 18.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 65.43 110.95 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -51.49 112.46 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.132 -0.486 . . . . 74.23 111.175 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 133.98 -52.14 0.82 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.783 -0.723 . . . . 45.03 112.473 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.407 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.1 m-85 -108.27 170.0 8.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.379 . . . . 61.23 110.919 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -62.81 158.24 53.87 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.553 0.692 . . . . 75.3 110.885 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.44 42.09 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.677 2.251 . . . . 71.32 112.334 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.1 m -150.72 138.5 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.155 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 53' ' ' LYS . 34.6 p -131.37 139.52 49.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 60.11 111.166 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.701 HG11 HG22 ' A' ' 72' ' ' VAL . 26.5 m -146.69 147.05 18.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 74.21 111.153 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -66.04 157.1 31.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.982 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.99 125.9 29.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 72.41 111.168 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -156.79 166.49 33.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 63.13 111.106 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.23 -43.34 78.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.117 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.0 mt -140.48 112.11 4.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 72.31 111.11 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.514 HG21 ' HB ' ' A' ' 64' ' ' VAL . 7.7 p -130.49 128.83 64.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.131 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -102.71 133.55 47.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 74.11 110.877 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.701 HG22 HG11 ' A' ' 64' ' ' VAL . 21.5 t -122.29 148.89 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 61.34 111.1 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 13.2 mt -122.0 127.82 50.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 72.02 110.885 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.653 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.4 tp -88.19 121.58 30.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 65.54 110.866 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -90.39 144.42 25.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 73.42 110.921 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -58.24 141.33 51.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 75.12 110.897 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.7 t0 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 44.35 110.863 179.931 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.493 -0.243 . . . . 42.34 112.493 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.2 t30 -153.64 120.12 5.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 73.41 110.895 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.73 ' HB ' HG21 ' A' ' 36' ' ' THR . 22.4 t -109.7 129.8 63.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 73.33 111.175 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.55 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.7 p -136.57 176.55 8.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.209 -0.45 . . . . 73.43 111.148 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.601 ' OG ' HD11 ' A' ' 19' ' ' ILE . 0.3 OUTLIER -103.27 150.98 23.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.2 110.863 -179.846 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.564 ' HG3' HD12 ' A' ' 73' ' ' LEU . 1.3 tmmt? -93.48 19.26 8.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 60.22 110.894 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.13 -58.72 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.244 -0.435 . . . . 75.14 111.146 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -120.17 -26.42 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 72.52 110.851 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.34 29.39 5.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.742 -0.742 . . . . 53.34 112.485 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.7 mm100 -100.35 160.24 27.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 74.15 110.911 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.55 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.9 Cg_endo -69.72 137.67 36.14 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.715 2.277 . . . . 61.23 112.368 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.601 HD11 ' OG ' ' A' ' 12' ' ' SER . 42.6 mm -87.15 125.33 40.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 75.31 111.177 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.4 mt -104.89 113.47 42.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 42.2 111.134 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.04 33.03 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.486 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.66 119.26 26.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.754 0.312 . . . . 63.11 111.073 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.23 107.53 5.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 52.44 110.859 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.622 HG13 HG13 ' A' ' 54' ' ' ILE . 57.0 t -109.99 106.5 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.102 -0.499 . . . . 75.44 111.121 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.4 m -114.97 140.76 34.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.132 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.502 ' CD ' HG11 ' A' ' 46' ' ' VAL . 18.8 tt0 -85.79 133.52 33.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 74.12 110.857 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.6 p -54.51 -35.86 63.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 52.43 111.098 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.3 p -78.97 -22.09 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.267 -0.424 . . . . 64.03 111.133 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.51 110.69 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 63.21 111.079 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -86.51 -33.93 20.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.111 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 77.7 p -53.18 -29.59 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 74.23 111.154 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -94.26 31.19 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.3 110.885 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -73.25 141.18 29.65 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.801 -0.714 . . . . 61.22 112.46 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.423 HG21 ' O ' ' A' ' 43' ' ' THR . 0.2 OUTLIER -113.41 168.9 9.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.737 0.303 . . . . 73.43 111.146 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.405 ' H ' HG22 ' A' ' 34' ' ' THR . 4.8 pt -124.13 148.59 28.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 72.12 111.119 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.73 HG21 ' HB ' ' A' ' 10' ' ' VAL . 9.9 p -73.93 150.74 40.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 55.34 111.174 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -99.79 -175.33 2.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 34.54 110.873 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -56.38 -31.47 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.886 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -76.78 -18.88 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.462 . . . . 73.22 110.905 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.25 28.84 10.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 75.31 112.518 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -135.99 159.88 40.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.822 0.344 . . . . 71.23 110.931 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.494 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 30.9 p90 -140.2 168.0 20.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 71.21 110.893 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.423 ' O ' HG21 ' A' ' 34' ' ' THR . 39.2 p -109.53 116.17 31.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 72.34 111.165 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.67 107.48 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 72.23 110.909 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 29.1 t -106.95 120.12 41.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 73.42 110.86 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.502 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.2 m -129.99 156.19 79.49 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.651 0.739 . . . . 71.43 111.109 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -48.02 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.7 2.267 . . . . 60.01 112.352 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 m -101.94 175.79 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 71.24 111.12 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -106.55 58.89 0.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.897 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.5 p -72.7 -170.2 0.66 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.493 . . . . 64.13 110.857 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.471 ' C ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -89.14 152.43 21.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 72.33 111.133 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.847 HD13 ' HB2' ' A' ' 66' ' ' ALA . 10.0 mp -122.31 121.64 37.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 62.04 110.877 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 47.2 tttt -96.88 123.14 40.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.888 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.622 HG13 HG13 ' A' ' 24' ' ' VAL . 5.4 mp -116.56 132.23 66.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.446 . . . . 73.4 111.121 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.6 p -143.08 138.56 29.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 62.11 111.121 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.824 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -137.72 127.63 25.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.19 -0.459 . . . . 65.43 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.42 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.6 tp -51.63 119.98 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.489 . . . . 74.23 111.119 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.99 -51.12 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.775 -0.726 . . . . 45.03 112.479 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -108.61 170.12 8.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.933 0.397 . . . . 61.23 110.916 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -69.92 158.11 88.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.57 0.7 . . . . 75.3 110.914 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 164.56 34.12 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.681 2.254 . . . . 71.32 112.304 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.466 HG11 ' CG1' ' A' ' 72' ' ' VAL . 14.5 p -151.4 149.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.126 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.7 p -132.02 132.56 43.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.124 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.749 HG11 HG22 ' A' ' 72' ' ' VAL . 31.0 m -137.72 172.17 14.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.439 . . . . 74.21 111.16 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.38 156.82 18.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.901 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.847 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -93.18 130.07 38.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 72.41 111.045 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.55 -175.55 3.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 63.13 111.072 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.512 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -53.35 -49.53 66.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 73.13 111.097 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 68' ' ' ALA . 43.9 mm -139.2 114.2 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 72.31 111.156 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.31 125.13 67.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 74.42 111.088 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -98.68 135.06 40.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.91 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.749 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -128.33 147.6 32.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 61.34 111.153 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.564 HD12 ' HG3' ' A' ' 13' ' ' LYS . 1.2 pt? -127.12 138.09 53.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.214 -0.448 . . . . 72.02 110.922 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.824 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.2 tp -88.83 124.93 34.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 65.54 110.943 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -90.29 136.85 32.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 73.42 110.855 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -58.99 140.17 55.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.12 110.945 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 44.35 110.904 -179.987 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.498 -0.241 . . . . 42.34 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -118.39 128.19 54.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.915 0.388 . . . . 73.41 110.875 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.477 HG22 ' HB ' ' A' ' 72' ' ' VAL . 89.2 t -119.7 129.17 75.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 73.33 111.08 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.45 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.9 p -129.7 178.1 6.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.43 111.162 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 t -97.2 151.02 20.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.263 -0.426 . . . . 72.2 110.892 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.428 ' HG3' HD12 ' A' ' 73' ' ' LEU . 7.2 tmtt? -92.05 15.43 13.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 60.22 110.938 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.0 p -94.07 -59.07 2.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.238 -0.437 . . . . 75.14 111.117 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -120.44 -26.63 5.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 72.52 110.844 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.16 29.19 5.26 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.539 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -94.26 160.15 32.56 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.592 0.71 . . . . 74.15 110.913 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.45 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.2 Cg_endo -69.67 139.5 40.7 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.703 2.269 . . . . 61.23 112.342 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.641 HG22 ' HB2' ' A' ' 22' ' ' ALA . 49.2 mm -83.97 113.56 23.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.104 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 22.6 mt -101.06 128.88 52.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 42.2 111.085 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.96 32.61 26.01 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.769 -0.729 . . . . 62.52 112.486 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.641 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -90.96 135.64 33.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.796 0.331 . . . . 63.11 111.093 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -85.6 107.2 17.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 52.44 110.804 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.722 HG23 HG13 ' A' ' 54' ' ' ILE . 2.9 p -118.33 122.39 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 75.44 111.107 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.726 HG12 ' HA3' ' A' ' 33' ' ' GLY . 16.2 m -134.61 151.83 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.149 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.528 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 13.8 tp10 -75.62 132.65 40.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 74.12 110.897 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.8 p -51.52 -34.93 38.39 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.091 -0.504 . . . . 52.43 111.153 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -96.68 -22.08 17.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 64.03 111.132 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.528 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -127.19 89.75 3.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.451 . . . . 63.21 111.104 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.8 p -86.79 -35.65 19.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.136 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 91.1 m -56.68 -31.0 64.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 74.23 111.146 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -93.13 30.74 1.58 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.19 -0.459 . . . . 74.3 110.865 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.726 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.52 147.01 50.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.782 -0.723 . . . . 61.22 112.517 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.616 HG22 HD11 ' A' ' 44' ' ' LEU . 13.6 t -135.49 168.94 18.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.787 0.327 . . . . 73.43 111.112 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.7 pt -110.98 158.15 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.116 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.506 HG22 ' HD2' ' A' ' 42' ' ' PHE . 39.2 p -80.34 150.68 29.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 55.34 111.143 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.37 176.3 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 34.54 110.893 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -56.95 -30.18 63.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 72.12 110.858 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -73.12 -19.05 61.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 73.22 110.914 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.62 28.26 17.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 75.31 112.462 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -131.95 165.43 23.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 71.23 110.878 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.619 ' CE1' HG21 ' A' ' 24' ' ' VAL . 26.7 p90 -148.51 168.04 23.76 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 71.21 110.851 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 43' ' ' THR . 4.9 t -128.99 120.11 25.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.079 -0.51 . . . . 72.34 111.134 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 34' ' ' THR . 0.2 OUTLIER -127.84 111.14 13.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 72.23 110.894 179.92 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.9 m -93.38 111.91 23.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.145 -0.48 . . . . 73.42 110.817 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -128.35 156.1 77.39 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.57 0.7 . . . . 71.43 111.159 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.76 -48.19 0.77 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.67 2.247 . . . . 60.01 112.396 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.8 p -106.13 151.79 8.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 71.24 111.101 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -79.26 60.88 3.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 63.41 110.905 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -75.82 -170.4 1.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 64.13 110.825 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.86 157.52 17.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.105 -0.498 . . . . 72.33 111.122 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.474 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 2.8 mp -120.09 128.58 53.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 62.04 110.882 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.524 ' HA ' HG22 ' A' ' 63' ' ' THR . 64.1 tttt -100.75 123.14 44.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.881 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.722 HG13 HG23 ' A' ' 24' ' ' VAL . 3.7 mp -120.55 134.22 64.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 73.4 111.102 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.1 p -145.76 140.07 26.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 62.11 111.148 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.688 ' HB3' HD21 ' A' ' 74' ' ' LEU . 14.9 t80 -135.6 121.39 19.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 65.43 110.963 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.431 HG23 ' O ' ' A' ' 57' ' ' ILE . 10.8 tt -50.88 117.18 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.094 -0.503 . . . . 74.23 111.105 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.52 -50.76 0.88 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.439 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -109.68 169.98 8.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.969 0.414 . . . . 61.23 110.947 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -64.27 157.73 69.18 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.55 0.69 . . . . 75.3 110.868 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.66 162.26 42.72 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.707 2.272 . . . . 71.32 112.361 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.559 HG23 ' HB ' ' A' ' 54' ' ' ILE . 30.2 m -150.51 133.29 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.097 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.524 HG22 ' HA ' ' A' ' 53' ' ' LYS . 25.2 p -126.9 142.8 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.181 -0.463 . . . . 60.11 111.088 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.829 HG11 HG22 ' A' ' 72' ' ' VAL . 30.3 m -151.15 151.37 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 74.21 111.146 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt -73.98 157.32 36.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 70.32 110.898 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.474 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -71.12 134.18 46.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 72.41 111.11 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.476 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -164.68 161.79 20.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.437 . . . . 63.13 111.11 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.97 -40.36 60.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.13 111.066 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.0 mt -140.86 111.79 3.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 72.31 111.103 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.514 HG11 ' CG2' ' A' ' 64' ' ' VAL . 20.7 t -124.08 112.0 30.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 74.42 111.099 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -96.74 116.6 29.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.926 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.829 HG22 HG11 ' A' ' 64' ' ' VAL . 24.3 t -115.06 148.77 17.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 61.34 111.115 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.428 HD12 ' HG3' ' A' ' 13' ' ' LYS . 0.6 OUTLIER -121.2 139.21 53.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 72.02 110.959 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.688 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -91.21 122.54 33.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 65.54 110.956 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -90.53 141.37 28.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.853 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -59.06 140.53 55.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 75.12 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.8 t0 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.154 -0.476 . . . . 44.35 110.87 179.968 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.487 -0.245 . . . . 42.34 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -129.75 127.51 40.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.87 0.367 . . . . 73.41 110.916 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.447 HG23 ' HE2' ' A' ' 42' ' ' PHE . 88.5 t -117.04 125.26 73.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 73.33 111.111 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.2 p -122.79 169.63 10.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 73.43 111.172 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.54 149.62 21.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 72.2 110.897 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -93.21 18.18 9.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.484 . . . . 60.22 110.882 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.21 -58.82 2.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 75.14 111.089 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -120.53 -25.97 5.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 72.52 110.91 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.97 29.13 5.03 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.672 -0.775 . . . . 53.34 112.509 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -98.29 154.13 37.76 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.62 0.724 . . . . 74.15 110.916 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.82 143.08 49.45 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.684 2.256 . . . . 61.23 112.334 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.448 ' CD1' HD22 ' A' ' 74' ' ' LEU . 47.3 mm -83.32 108.11 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 75.31 111.199 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.1 mt -101.46 126.57 55.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 42.2 111.078 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 42.11 7.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.748 -0.739 . . . . 62.52 112.47 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -94.89 162.39 13.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 63.11 111.096 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.2 m -105.62 107.53 18.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 52.44 110.859 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.728 HG13 HG13 ' A' ' 54' ' ' ILE . 43.4 t -110.43 106.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 75.44 111.085 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.9 m -124.64 138.01 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 74.52 111.101 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.512 ' CD ' HG11 ' A' ' 46' ' ' VAL . 10.6 mt-10 -72.02 173.53 8.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.861 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.2 p -76.35 -35.55 58.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.121 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 17.7 p -112.38 -22.14 11.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 64.03 111.104 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -117.2 77.2 1.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.24 -0.436 . . . . 63.21 111.05 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.6 p -86.72 -35.36 19.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.245 -0.434 . . . . 73.01 111.119 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 45.8 p -53.33 -30.2 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.23 111.159 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -94.76 31.3 1.85 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 74.3 110.907 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -59.38 136.1 50.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.485 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 5.0 m -111.15 157.87 19.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.758 0.313 . . . . 73.43 111.128 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -108.59 150.51 11.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 72.12 111.101 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.622 HG22 ' HD2' ' A' ' 42' ' ' PHE . 6.0 p -72.26 149.66 44.33 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.183 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -83.6 -175.44 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 34.54 110.859 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -58.88 -30.86 68.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 72.12 110.901 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.9 21.44 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 73.22 110.906 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.17 27.46 70.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.709 -0.757 . . . . 75.31 112.471 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -108.79 134.91 50.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.829 0.347 . . . . 71.23 110.89 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.622 ' HD2' HG22 ' A' ' 36' ' ' THR . 18.5 p90 -133.54 167.93 19.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 71.21 110.856 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.29 121.42 12.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.162 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.5 mt -120.93 127.81 52.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.209 -0.451 . . . . 72.23 110.907 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -106.93 113.65 27.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 73.42 110.852 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.512 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.3 m -139.2 156.21 72.15 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.657 0.741 . . . . 71.43 111.138 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -48.35 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.651 2.234 . . . . 60.01 112.352 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.66 149.4 5.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 71.24 111.151 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -88.9 52.1 2.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 63.41 110.863 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.1 t -68.53 -169.78 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.992 0.425 . . . . 64.13 110.812 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.554 ' O ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -87.63 157.14 19.19 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.148 -0.478 . . . . 72.33 111.187 -179.955 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 66' ' ' ALA . 7.4 mp -125.39 125.01 42.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 62.04 110.874 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.434 ' HA ' HG22 ' A' ' 63' ' ' THR . 43.1 tttt -102.64 126.89 49.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.194 -0.457 . . . . 74.21 110.912 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.728 HG13 HG13 ' A' ' 24' ' ' VAL . 3.9 mp -123.29 139.33 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 73.4 111.144 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 74.1 p -140.94 139.23 34.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 62.11 111.188 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.471 ' HB3' HD21 ' A' ' 74' ' ' LEU . 17.4 t80 -133.05 119.8 20.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.43 110.926 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.42 116.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 74.23 111.141 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 130.35 -55.13 0.77 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 45.03 112.525 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -108.87 170.63 7.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.984 0.421 . . . . 61.23 110.915 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -62.01 157.72 49.54 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.555 0.693 . . . . 75.3 110.935 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 170.77 15.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.667 2.245 . . . . 71.32 112.367 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.66 ' CG2' HG11 ' A' ' 72' ' ' VAL . 14.6 p -151.49 140.92 15.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 74.11 111.135 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 53' ' ' LYS . 11.4 p -131.95 135.35 46.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 60.11 111.183 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.503 HG11 HG21 ' A' ' 72' ' ' VAL . 6.8 m -152.17 149.24 13.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 74.21 111.2 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.3 mmtm -69.08 153.99 42.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.914 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.654 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -77.43 65.42 2.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 72.41 111.134 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -90.21 -175.1 4.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 63.13 111.045 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.736 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -64.3 -55.08 23.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 73.13 111.137 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.736 HD13 ' O ' ' A' ' 68' ' ' ALA . 17.4 mm -128.76 137.14 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 72.31 111.076 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.5 HG21 HG21 ' A' ' 64' ' ' VAL . 5.7 p -145.7 119.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 74.42 111.111 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 -120.24 109.52 15.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 74.11 110.855 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.66 HG11 ' CG2' ' A' ' 62' ' ' VAL . 17.2 t -124.59 149.1 28.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 61.34 111.19 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -103.39 145.73 29.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.02 110.945 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.471 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.6 tp -87.25 120.45 28.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 65.54 110.89 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -90.36 140.4 29.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 73.42 110.872 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -59.1 142.08 52.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 75.12 110.908 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.4 t70 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 44.35 110.866 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.459 -0.257 . . . . 42.34 112.459 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -144.15 127.52 16.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.41 110.842 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 t -115.57 116.5 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.33 111.091 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.515 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.4 p -129.95 153.72 48.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 73.43 111.152 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -79.88 150.98 30.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.873 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.565 ' HA ' HD12 ' A' ' 73' ' ' LEU . 12.4 tttp -94.01 20.16 8.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.194 -0.457 . . . . 60.22 110.849 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 35.1 p -94.04 -58.79 2.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 75.14 111.168 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -119.39 -26.39 5.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.209 -0.451 . . . . 72.52 110.94 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.5 5.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.856 -0.688 . . . . 53.34 112.495 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -97.95 160.4 28.54 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.586 0.707 . . . . 74.15 110.835 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.515 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.8 148.28 64.43 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.73 2.287 . . . . 61.23 112.318 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.411 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.4 mm -95.16 122.75 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.31 111.17 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.7 mt -107.4 116.28 50.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 42.2 111.136 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 99.41 33.26 5.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.499 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -89.57 129.41 36.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.805 0.336 . . . . 63.11 111.052 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 m -76.99 108.34 9.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 52.44 110.861 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.791 HG21 ' CD2' ' A' ' 42' ' ' PHE . 68.7 t -114.87 106.18 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 75.44 111.103 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 33' ' ' GLY . 18.3 m -123.9 151.21 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.123 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.685 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 4.0 mm-40 -81.83 166.78 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 74.12 110.908 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.06 -41.99 98.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 52.43 111.136 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 33.6 p -112.44 -22.06 11.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.233 -0.44 . . . . 64.03 111.123 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.685 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -100.77 75.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 63.21 111.072 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.4 p -86.67 -35.61 19.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 73.01 111.173 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -60.6 -30.77 70.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.282 -0.417 . . . . 74.23 111.18 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -94.46 31.2 1.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 74.3 110.867 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.425 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -61.12 139.01 47.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.701 -0.761 . . . . 61.22 112.513 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.484 ' HB ' HD11 ' A' ' 44' ' ' LEU . 0.3 OUTLIER -113.71 167.37 10.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.771 0.32 . . . . 73.43 111.168 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' H ' HG22 ' A' ' 34' ' ' THR . 7.9 pt -124.14 147.16 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 72.12 111.152 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 34.4 p -69.94 137.98 51.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 55.34 111.145 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.7 -179.52 7.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 34.54 110.856 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -57.0 -30.22 63.97 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 72.12 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -73.5 -18.75 61.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.85 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.08 28.21 14.13 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.738 -0.744 . . . . 75.31 112.529 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -134.2 168.35 19.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.856 0.36 . . . . 71.23 110.935 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.791 ' CD2' HG21 ' A' ' 24' ' ' VAL . 3.1 p90 -141.89 167.93 20.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 71.21 110.869 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 27.1 p -124.98 116.99 23.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.13 -0.486 . . . . 72.34 111.137 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 8.0 mp -136.58 120.79 17.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 72.23 110.915 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 26.7 m -106.94 112.05 24.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.092 -0.504 . . . . 73.42 110.886 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.95 156.16 69.49 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.661 0.743 . . . . 71.43 111.108 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -48.25 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.633 2.222 . . . . 60.01 112.338 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.6 p -110.51 152.11 12.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.118 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -80.63 58.49 3.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 63.41 110.942 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 94.9 p -72.84 -169.83 0.63 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 64.13 110.862 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.452 HG23 ' HG2' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -87.7 153.11 21.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 72.33 111.094 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.795 HD11 ' HB2' ' A' ' 66' ' ' ALA . 5.9 mp -126.27 126.13 43.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 62.04 110.889 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.652 ' HA ' HG22 ' A' ' 63' ' ' THR . 12.1 ttpt -95.63 122.2 38.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.869 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.74 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.8 mt -121.26 137.2 55.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 73.4 111.15 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.5 p -147.39 138.77 23.87 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.153 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -133.54 119.0 18.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 65.43 111.02 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.02 117.58 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.176 -0.465 . . . . 74.23 111.185 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.68 -52.89 0.82 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.781 -0.723 . . . . 45.03 112.458 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -110.34 170.19 8.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.952 0.406 . . . . 61.23 110.945 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -60.5 157.63 35.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.589 0.709 . . . . 75.3 110.902 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 166.87 26.02 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.723 2.282 . . . . 71.32 112.283 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.5 m -151.24 126.35 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 74.11 111.112 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.652 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.8 p -125.06 132.81 53.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.109 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.479 HG11 ' CG2' ' A' ' 72' ' ' VAL . 14.8 m -152.09 157.34 5.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.079 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.452 ' HG2' HG23 ' A' ' 51' ' ' THR . 39.6 mtpt -84.13 155.11 22.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 70.32 110.953 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.795 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.09 133.6 46.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 72.41 111.091 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.16 -179.67 8.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 63.13 111.101 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.73 -58.02 7.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 73.13 111.102 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 68' ' ' ALA . 41.0 mm -142.36 111.65 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 72.31 111.104 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.76 122.3 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 74.42 111.167 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -119.78 115.33 23.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.888 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.718 HG11 ' HB ' ' A' ' 62' ' ' VAL . 18.7 t -113.16 126.9 70.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 61.34 111.109 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.565 HD12 ' HA ' ' A' ' 13' ' ' LYS . 0.7 OUTLIER -83.34 140.59 32.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.894 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.402 HD12 ' HA ' ' A' ' 74' ' ' LEU . 1.5 tp -87.9 121.73 30.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.899 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -90.2 137.06 32.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.9 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -57.45 141.78 46.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 75.12 110.872 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.093 -0.503 . . . . 44.35 110.853 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.466 -0.254 . . . . 42.34 112.466 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -152.61 128.35 10.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.875 0.369 . . . . 73.41 110.859 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.666 HG22 HD13 ' A' ' 54' ' ' ILE . 94.2 t -117.99 131.8 69.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 73.33 111.112 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.565 HG22 ' HA ' ' A' ' 18' ' ' PRO . 16.9 p -138.12 172.88 12.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 73.43 111.088 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.417 ' HB2' HD11 ' A' ' 19' ' ' ILE . 1.2 t -92.74 156.25 17.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 72.2 110.922 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -93.57 16.38 13.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 60.22 110.876 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.1 p -94.05 -59.07 2.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 75.14 111.095 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -120.68 -26.24 5.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.52 110.91 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.63 29.12 5.14 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.747 -0.74 . . . . 53.34 112.503 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -95.02 153.93 39.74 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.606 0.717 . . . . 74.15 110.889 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.565 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.7 135.75 31.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.73 2.286 . . . . 61.23 112.296 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.417 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -84.6 135.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 75.31 111.127 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.0 mt -114.29 125.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 42.2 111.104 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.86 33.83 10.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 62.52 112.492 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -86.17 162.67 18.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.72 0.295 . . . . 63.11 111.176 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.53 113.5 27.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 52.44 110.852 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.705 HG21 ' CD2' ' A' ' 42' ' ' PHE . 44.6 t -116.76 134.04 61.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 75.44 111.12 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.1 m -139.64 148.87 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 74.52 111.064 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.664 ' HG3' HG11 ' A' ' 46' ' ' VAL . 1.7 tm-20 -88.5 135.11 33.64 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 74.12 110.846 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.411 HG21 ' HB ' ' A' ' 51' ' ' THR . 21.0 p -55.5 -32.64 63.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 52.43 111.159 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.6 p -71.87 -22.36 61.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.186 -0.461 . . . . 64.03 111.105 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -178.64 134.61 0.14 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 63.21 111.091 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.3 p -87.8 -19.29 27.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.241 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.0 p -52.16 -30.33 26.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.213 -0.449 . . . . 74.23 111.092 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.9 p-10 -93.2 31.24 1.5 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.917 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.69 135.51 38.4 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 61.22 112.483 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.58 ' HB ' HD11 ' A' ' 44' ' ' LEU . 2.5 m -124.38 161.45 25.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 73.43 111.164 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -107.71 145.67 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 72.12 111.133 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 52.7 p -70.07 149.51 47.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 55.34 111.155 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -87.14 -175.83 5.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.43 . . . . 34.54 110.871 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -57.11 -30.69 64.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 72.12 110.869 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -99.79 22.09 11.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 73.22 110.882 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.32 28.31 72.1 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 75.31 112.521 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 64.7 m-20 -110.75 128.84 55.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.874 0.369 . . . . 71.23 110.906 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.705 ' CD2' HG21 ' A' ' 24' ' ' VAL . 1.6 p90 -116.57 167.32 11.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.827 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 2.6 t -121.42 116.87 25.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 72.34 111.138 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 7.0 mp -141.15 116.75 10.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 72.23 110.9 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.3 m -106.81 108.16 19.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 73.42 110.887 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.664 HG11 ' HG3' ' A' ' 26' ' ' GLU . 3.4 m -124.69 156.08 68.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.579 0.704 . . . . 71.43 111.128 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -48.41 0.73 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.693 2.262 . . . . 60.01 112.351 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -103.67 152.0 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.182 -0.463 . . . . 71.24 111.103 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -84.94 68.36 10.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 63.41 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.0 t -80.57 -169.94 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 64.13 110.87 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.411 ' HB ' HG21 ' A' ' 27' ' ' THR . 0.6 OUTLIER -88.86 159.31 17.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.179 -0.464 . . . . 72.33 111.094 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.436 ' CD2' HD22 ' A' ' 44' ' ' LEU . 16.0 mt -124.0 135.21 53.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.902 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.601 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.3 OUTLIER -105.7 129.86 53.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 74.21 110.915 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 10' ' ' VAL . 17.6 mt -123.7 134.67 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.097 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 25.2 p -149.78 139.48 21.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 62.11 111.134 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.499 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -138.22 125.88 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 65.43 110.879 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 57' ' ' ILE . 3.7 tp -50.94 107.93 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 74.23 111.163 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.89 -47.04 0.91 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.785 -0.721 . . . . 45.03 112.524 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -112.47 170.89 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.382 . . . . 61.23 110.951 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.2 mttt -68.4 158.19 85.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.54 0.686 . . . . 75.3 110.935 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.67 160.3 50.26 Favored 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.696 2.264 . . . . 71.32 112.339 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.472 HG13 ' HB ' ' A' ' 54' ' ' ILE . 13.0 p -151.26 139.76 14.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 74.11 111.188 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.601 HG22 ' HA ' ' A' ' 53' ' ' LYS . 1.4 p -132.14 134.83 45.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 60.11 111.175 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.408 HG21 HG22 ' A' ' 72' ' ' VAL . 25.0 m -144.54 151.91 15.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 74.21 111.147 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.92 155.4 27.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 70.32 110.874 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -90.56 120.87 32.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 72.41 111.131 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -146.34 178.64 8.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 63.13 111.137 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.43 -44.22 68.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.13 111.096 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 56.2 mt -147.31 112.14 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.449 . . . . 72.31 111.059 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.61 128.42 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.172 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -95.91 137.56 34.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 74.11 110.892 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.466 HG21 ' CD1' ' A' ' 54' ' ' ILE . 21.2 t -124.51 148.98 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 61.34 111.192 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.58 125.74 40.84 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 72.02 110.873 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.499 HD21 ' HB3' ' A' ' 56' ' ' TYR . 2.4 tp -91.91 118.31 30.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 65.54 110.928 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -96.03 135.94 37.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 73.42 110.932 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -52.39 145.62 10.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.882 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 41.8 t0 . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.122 -0.49 . . . . 44.35 110.842 -179.961 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.465 -0.254 . . . . 42.34 112.465 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -131.53 126.43 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.913 0.387 . . . . 73.41 110.861 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.58 HG12 HG13 ' A' ' 19' ' ' ILE . 30.5 t -118.08 128.9 75.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 73.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.22 167.02 16.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.14 -0.482 . . . . 73.43 111.137 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.59 144.33 25.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 72.2 110.835 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.4 tttm -92.78 15.62 14.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.125 -0.488 . . . . 60.22 110.844 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -58.49 2.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 75.14 111.119 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -117.97 -26.81 6.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.23 29.13 5.26 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.701 -0.762 . . . . 53.34 112.463 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -98.34 160.12 28.95 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.58 0.705 . . . . 74.15 110.886 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 143.65 51.91 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.709 2.273 . . . . 61.23 112.375 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.701 HD12 HD22 ' A' ' 74' ' ' LEU . 51.3 mm -83.13 110.0 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 75.31 111.137 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.1 mt -103.45 126.94 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.446 . . . . 42.2 111.116 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.29 33.2 23.61 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 62.52 112.478 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.697 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -87.22 131.37 34.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 63.11 111.07 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.3 m -80.19 107.57 13.09 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.129 -0.487 . . . . 52.44 110.842 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.841 HG22 HG23 ' A' ' 54' ' ' ILE . 60.9 t -106.66 105.86 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.112 -0.495 . . . . 75.44 111.112 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 28.2 m -120.6 133.65 66.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 74.52 111.126 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -91.96 141.52 28.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.474 . . . . 74.12 110.915 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.9 p -55.43 -31.66 62.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 52.43 111.152 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.7 p -71.54 -21.38 61.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.215 -0.448 . . . . 64.03 111.193 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.52 111.49 0.79 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 63.21 111.049 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 m -85.46 -34.65 21.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 73.01 111.156 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 61.8 p -66.8 -26.44 66.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 74.23 111.179 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -93.51 31.22 1.57 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.903 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -74.99 150.26 40.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.77 -0.729 . . . . 61.22 112.473 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.473 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -117.81 168.76 10.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.738 0.304 . . . . 73.43 111.157 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.0 pt -111.68 171.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 72.12 111.139 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.59 HG22 ' HD2' ' A' ' 42' ' ' PHE . 21.8 p -99.35 150.62 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 55.34 111.155 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.33 179.93 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.435 . . . . 34.54 110.88 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -59.33 -30.7 68.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.852 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -73.81 -19.48 60.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.899 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.92 28.08 11.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.739 -0.743 . . . . 75.31 112.525 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -132.43 160.21 37.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.853 0.358 . . . . 71.23 110.932 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.59 ' HD2' HG22 ' A' ' 36' ' ' THR . 16.6 p90 -138.37 166.08 25.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.881 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.8 t -126.0 119.15 26.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 72.34 111.178 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.596 HD13 ' N ' ' A' ' 45' ' ' SER . 0.3 OUTLIER -146.15 134.3 21.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 72.23 110.932 179.985 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.596 ' N ' HD13 ' A' ' 44' ' ' LEU . 38.5 p -106.89 122.63 46.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.485 . . . . 73.42 110.889 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 61.5 t -129.79 133.25 24.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.683 0.754 . . . . 71.43 111.093 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.5 Cg_endo -69.72 -48.51 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.664 2.242 . . . . 60.01 112.345 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 31.0 m -95.27 141.96 14.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.425 . . . . 71.24 111.162 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -79.39 59.05 2.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 63.41 110.83 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.4 t -80.07 -169.85 2.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 64.13 110.872 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 156.12 17.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 72.33 111.125 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.687 HD11 ' HB2' ' A' ' 66' ' ' ALA . 2.2 mp -129.05 132.22 47.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 62.04 110.903 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 22.8 tttp -106.76 123.25 47.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.245 -0.434 . . . . 74.21 110.909 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.841 HG23 HG22 ' A' ' 24' ' ' VAL . 34.8 mt -119.6 112.61 37.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 73.4 111.178 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.4 p -119.68 145.88 46.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.231 -0.44 . . . . 62.11 111.118 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.417 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -139.06 118.58 12.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 65.43 111.001 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.457 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.9 tt -51.0 107.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.133 -0.485 . . . . 74.23 111.103 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.86 -50.98 0.75 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.47 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -114.28 170.28 8.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.93 0.395 . . . . 61.23 110.92 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -58.22 158.2 14.7 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.3 110.932 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.8 167.79 23.48 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.627 2.218 . . . . 71.32 112.348 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.739 HG13 HG11 ' A' ' 72' ' ' VAL . 96.4 t -135.11 138.68 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 74.11 111.107 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.3 p -132.15 122.56 25.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.138 -0.483 . . . . 60.11 111.141 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 70' ' ' VAL . 6.1 m -152.92 149.9 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.113 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -81.92 157.25 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.88 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.687 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -61.73 130.65 46.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 72.41 111.113 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.52 160.71 38.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 63.13 111.108 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.67 -52.37 48.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 73.13 111.113 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 69.7 mt -129.14 111.62 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 72.31 111.155 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 64' ' ' VAL . 21.8 t -113.62 112.11 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.142 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 -113.66 112.34 23.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.862 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.739 HG11 HG13 ' A' ' 62' ' ' VAL . 39.4 t -129.27 148.16 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 61.34 111.12 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.9 mp -105.08 144.86 31.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.491 . . . . 72.02 110.909 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.701 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.83 122.23 31.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.961 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.8 mm-40 -90.17 140.9 29.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 73.42 110.945 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -58.45 141.23 52.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.904 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.1 -0.5 . . . . 44.35 110.905 179.964 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.439 -0.264 . . . . 42.34 112.439 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.69 119.94 5.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.887 0.375 . . . . 73.41 110.946 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.655 HG12 HG13 ' A' ' 19' ' ' ILE . 21.7 t -98.48 122.66 50.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 73.33 111.106 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.07 176.68 6.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 73.43 111.094 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.4 t -97.38 164.0 12.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 72.2 110.925 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.0 tmtt? -104.55 -11.11 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 60.22 110.869 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 55.8 p -77.94 -58.62 3.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.289 -0.414 . . . . 75.14 111.089 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -117.86 -26.38 6.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 72.52 110.854 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 100.99 29.39 6.47 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.734 -0.746 . . . . 53.34 112.495 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -85.05 159.4 57.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.531 0.681 . . . . 74.15 110.978 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 127.89 15.26 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 61.23 112.377 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.756 HD12 HD22 ' A' ' 74' ' ' LEU . 50.1 mm -77.37 120.41 27.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 75.31 111.16 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.7 mt -102.98 141.5 18.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.099 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.42 33.24 86.72 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.718 -0.753 . . . . 62.52 112.521 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.698 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -82.58 122.16 27.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 63.11 111.094 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -74.17 107.5 6.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 52.44 110.837 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.668 HG13 HG12 ' A' ' 54' ' ' ILE . 24.2 t -107.37 106.07 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.128 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.669 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.7 m -124.89 138.06 55.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 74.52 111.102 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.697 ' HA ' HD23 ' A' ' 52' ' ' LEU . 55.4 tt0 -73.67 161.2 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 74.12 110.843 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 p -65.83 -41.82 91.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.466 . . . . 52.43 111.144 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 p -105.77 -22.18 13.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 64.03 111.08 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -116.18 68.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 63.21 111.165 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' HB ' ' A' ' 25' ' ' VAL . 96.5 m -81.53 -35.65 30.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.09 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 3.1 p -53.36 -32.17 48.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 74.23 111.139 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -94.95 31.16 1.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.916 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -65.95 138.95 37.79 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.811 -0.709 . . . . 61.22 112.517 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -117.22 168.72 10.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 73.43 111.155 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 pp -115.47 168.56 7.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.441 . . . . 72.12 111.093 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.605 HG22 ' HD2' ' A' ' 42' ' ' PHE . 70.3 p -101.29 150.76 22.66 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.168 -0.469 . . . . 55.34 111.129 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -90.88 -176.08 4.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.172 -0.467 . . . . 34.54 110.849 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.38 -30.73 68.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 72.12 110.854 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -73.87 -19.5 60.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 73.22 110.897 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.75 28.1 15.07 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.692 -0.766 . . . . 75.31 112.473 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -128.22 157.78 39.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.338 . . . . 71.23 110.906 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.605 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.5 p90 -143.67 167.45 22.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.874 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -123.05 121.69 36.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.477 . . . . 72.34 111.188 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.585 HD22 HG23 ' A' ' 46' ' ' VAL . 2.0 tt -144.01 125.68 15.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.96 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.502 ' N ' HD23 ' A' ' 44' ' ' LEU . 45.0 t -101.72 114.92 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.262 -0.426 . . . . 73.42 110.842 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.585 HG23 HD22 ' A' ' 44' ' ' LEU . 58.3 t -120.6 133.29 24.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.579 0.704 . . . . 71.43 111.165 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.43 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -47.92 0.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.666 2.244 . . . . 60.01 112.343 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.6 m -96.9 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.157 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -111.64 62.38 0.62 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 63.41 110.891 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.6 t -86.88 -172.63 4.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 64.13 110.867 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.24 158.22 17.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.112 -0.495 . . . . 72.33 111.128 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.697 HD23 ' HA ' ' A' ' 26' ' ' GLU . 25.8 mt -128.32 143.13 50.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 62.04 110.947 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 7.1 ttpt -116.48 127.74 54.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 74.21 110.975 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.668 HG12 HG13 ' A' ' 24' ' ' VAL . 79.6 mt -120.01 137.97 52.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 73.4 111.055 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 39.0 p -148.28 138.59 22.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 62.11 111.183 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.75 ' HB3' HD21 ' A' ' 74' ' ' LEU . 15.6 t80 -136.01 126.85 27.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.233 -0.44 . . . . 65.43 110.903 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.434 HG23 ' O ' ' A' ' 57' ' ' ILE . 13.3 tt -51.17 118.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.101 -0.5 . . . . 74.23 111.139 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.16 -51.27 0.85 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.857 -0.687 . . . . 45.03 112.536 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -108.1 170.21 8.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.98 0.419 . . . . 61.23 110.917 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.4 mmtm -68.9 158.19 86.86 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.567 0.698 . . . . 75.3 110.933 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 165.82 29.68 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.729 2.286 . . . . 71.32 112.377 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.565 HG11 ' CG1' ' A' ' 72' ' ' VAL . 11.1 p -151.66 147.94 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.083 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.9 p -132.1 139.83 48.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 60.11 111.148 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.1 m -150.83 171.57 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 74.21 111.076 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.06 157.21 18.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 70.32 110.868 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -86.08 134.08 33.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 72.41 111.099 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.65 179.87 6.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 63.13 111.124 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.497 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -54.34 -57.88 9.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 73.13 111.096 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.497 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -132.13 111.69 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 72.31 111.104 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.82 125.27 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.125 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -95.86 136.76 35.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.878 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.565 ' CG1' HG11 ' A' ' 62' ' ' VAL . 21.7 t -120.96 149.48 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 61.34 111.109 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 10.3 mt -125.45 124.15 40.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.885 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.756 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.84 122.47 31.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 65.54 110.891 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -90.22 137.03 32.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.182 -0.463 . . . . 73.42 110.927 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -55.23 142.91 29.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 75.12 110.813 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.4 t70 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.087 -0.506 . . . . 44.35 110.845 179.948 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.519 -0.232 . . . . 42.34 112.519 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -127.73 119.95 26.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.891 0.377 . . . . 73.41 110.931 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.591 HG12 HG13 ' A' ' 19' ' ' ILE . 45.0 t -105.15 126.46 60.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.153 -0.476 . . . . 73.33 111.069 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.499 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.0 OUTLIER -124.38 -178.7 4.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 73.43 111.094 179.988 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.74 163.72 13.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 72.2 110.881 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -103.64 -12.33 17.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.135 -0.484 . . . . 60.22 110.928 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -75.97 -58.72 3.11 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.197 -0.456 . . . . 75.14 111.17 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -119.44 -26.57 5.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 72.52 110.821 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.06 29.55 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.79 -0.719 . . . . 53.34 112.506 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.499 ' C ' HG22 ' A' ' 11' ' ' THR . 4.9 pt20 -83.15 154.85 67.14 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.593 0.711 . . . . 74.15 110.934 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 128.71 16.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.737 2.291 . . . . 61.23 112.314 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.721 HD12 HD22 ' A' ' 74' ' ' LEU . 34.1 mm -75.03 101.7 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.31 111.128 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.2 mt -99.05 138.07 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 42.2 111.122 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 77.18 33.6 44.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 62.52 112.467 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.559 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -89.45 135.04 33.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 63.11 111.109 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.2 m -80.59 107.55 13.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 52.44 110.86 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.724 HG22 HG12 ' A' ' 54' ' ' ILE . 48.7 t -104.07 122.49 56.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 75.44 111.122 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.667 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.0 m -142.08 136.74 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 74.52 111.125 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -73.58 159.95 32.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.86 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 29.9 p -62.21 -41.98 98.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.164 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.0 p -108.22 -22.08 12.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 64.03 111.099 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.81 68.67 0.68 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 63.21 111.156 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' HB ' ' A' ' 25' ' ' VAL . 92.9 m -82.82 -35.37 26.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.138 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.5 p -53.38 -31.18 43.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 74.23 111.06 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.468 ' O ' HD11 ' A' ' 44' ' ' LEU . 1.8 m-20 -94.9 31.16 1.9 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 74.3 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.07 141.23 44.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.723 -0.751 . . . . 61.22 112.556 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.5 t -123.64 168.89 12.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 73.43 111.171 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.5 pt -107.63 156.76 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.141 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.593 HG22 ' HD2' ' A' ' 42' ' ' PHE . 33.1 p -81.65 150.63 27.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.113 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -82.39 173.34 12.12 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.837 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -59.46 -30.71 68.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 72.12 110.871 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -74.0 -19.38 60.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.102 -0.499 . . . . 73.22 110.886 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.97 28.15 10.32 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.463 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -128.92 152.68 48.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.93 0.395 . . . . 71.23 110.873 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.593 ' HD2' HG22 ' A' ' 36' ' ' THR . 54.4 p90 -147.63 164.52 33.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 71.21 110.917 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -150.41 117.27 5.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 72.34 111.144 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 32' ' ' ASN . 1.5 tt -115.93 109.77 18.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 72.23 110.947 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 89.7 p -68.9 108.41 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 73.42 110.856 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.433 HG23 ' HD2' ' A' ' 47' ' ' PRO . 7.3 p -130.78 133.21 24.54 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 71.43 111.138 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.433 ' HD2' HG23 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -43.26 2.74 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.66 2.24 . . . . 60.01 112.381 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 29.6 m -77.91 150.06 5.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 71.24 111.176 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -100.35 72.25 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 63.41 110.884 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 t -105.8 -170.95 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 64.13 110.827 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.13 155.35 17.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 72.33 111.167 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.618 HD12 HG23 ' A' ' 64' ' ' VAL . 10.4 mt -111.25 146.95 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 62.04 110.902 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.7 tttt -130.31 121.94 27.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.894 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.724 HG12 HG22 ' A' ' 24' ' ' VAL . 5.3 mp -119.27 144.01 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 73.4 111.144 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 37.7 p -138.36 138.67 38.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 62.11 111.165 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.459 ' HB3' HD21 ' A' ' 74' ' ' LEU . 7.4 t80 -131.83 115.21 15.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.282 -0.417 . . . . 65.43 110.977 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.445 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.3 tp -51.15 116.46 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 74.23 111.095 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.37 -53.42 0.81 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 45.03 112.475 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -110.47 170.53 8.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.925 0.393 . . . . 61.23 110.953 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -60.77 157.86 36.26 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.564 0.697 . . . . 75.3 110.874 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 172.81 12.02 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.661 2.241 . . . . 71.32 112.336 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 HG11 ' A' ' 72' ' ' VAL . 7.4 p -151.38 146.3 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 74.11 111.128 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.7 p -131.93 143.51 50.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 60.11 111.172 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.618 HG23 HD12 ' A' ' 52' ' ' LEU . 35.0 m -142.22 130.22 20.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.083 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 11.2 pttt -72.82 156.75 38.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 70.32 110.916 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.84 95.89 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.285 -0.416 . . . . 72.41 111.132 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -134.11 -173.22 3.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 63.13 111.094 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -88.04 -44.52 10.91 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 73.13 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.4 mt -138.09 126.17 30.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 72.31 111.112 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 64' ' ' VAL . 7.2 p -139.71 126.93 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 74.42 111.159 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 -119.92 125.53 48.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 74.11 110.902 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 62' ' ' VAL . 20.2 t -137.15 149.07 25.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.449 . . . . 61.34 111.11 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.1 mp -105.02 143.54 33.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 72.02 110.907 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.721 HD22 HD12 ' A' ' 19' ' ' ILE . 2.1 tp -87.56 118.58 27.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 65.54 110.956 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -90.64 147.81 23.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -59.47 143.41 50.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.837 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 29.9 t70 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 44.35 110.827 -179.99 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.479 -0.249 . . . . 42.34 112.479 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -146.11 129.72 17.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.891 0.376 . . . . 73.41 110.826 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.633 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 95.3 t -123.02 133.37 69.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.091 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 18' ' ' PRO . 17.6 p -130.03 172.55 11.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.141 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.16 153.2 21.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.828 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.436 ' HG3' HD22 ' A' ' 73' ' ' LEU . 17.1 tttm -92.55 16.24 12.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 60.22 110.904 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.02 -58.86 2.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 75.14 111.112 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -119.05 -26.66 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 72.52 110.847 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.45 29.25 5.14 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 53.34 112.525 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -97.87 159.78 30.07 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 74.15 110.917 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.617 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.64 146.61 61.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.724 2.282 . . . . 61.23 112.39 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.507 HG21 ' CD2' ' A' ' 56' ' ' TYR . 28.4 mm -96.68 117.43 41.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.074 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 29.9 mt -101.6 150.13 6.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 42.2 111.045 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.21 47.19 83.43 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.733 -0.746 . . . . 62.52 112.404 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.435 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 159.32 15.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.862 0.363 . . . . 63.11 111.044 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.2 m -105.92 107.25 18.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.44 110.837 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.773 HG22 HG23 ' A' ' 54' ' ' ILE . 12.3 t -112.66 129.82 67.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 75.44 111.113 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.0 m -145.98 146.31 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 74.52 111.17 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -80.75 174.33 11.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.888 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.562 HG23 ' O ' ' A' ' 51' ' ' THR . 43.5 p -68.95 -42.12 77.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 52.43 111.16 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.5 p -112.49 -22.22 10.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 64.03 111.159 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -104.89 76.44 1.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 63.21 111.112 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 p -86.53 -36.26 19.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.229 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.1 p -58.42 -28.44 65.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.115 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.42 1.75 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.229 -0.441 . . . . 74.3 110.857 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.51 143.11 47.99 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.766 -0.731 . . . . 61.22 112.533 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 m -117.87 160.55 21.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.725 0.298 . . . . 73.43 111.156 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.435 HG22 ' O ' ' A' ' 22' ' ' ALA . 8.1 pt -116.41 149.31 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.088 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.576 HG22 ' HD2' ' A' ' 42' ' ' PHE . 15.9 p -69.87 150.64 46.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 55.34 111.202 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -84.15 -175.62 5.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 34.54 110.905 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -58.68 -30.65 67.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 72.12 110.882 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -99.4 21.99 11.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.884 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.4 28.18 71.95 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.669 -0.777 . . . . 75.31 112.533 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -110.44 131.34 55.14 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.835 0.35 . . . . 71.23 110.879 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.576 ' HD2' HG22 ' A' ' 36' ' ' THR . 20.2 p90 -127.69 167.7 16.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 71.21 110.949 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 43' ' ' THR . 4.7 t -137.44 118.99 14.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 72.34 111.083 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.483 HD13 HD21 ' A' ' 52' ' ' LEU . 0.7 OUTLIER -148.25 107.18 3.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 72.23 110.898 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.6 t -107.03 122.22 46.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 73.42 110.861 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -119.66 155.96 54.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.637 0.732 . . . . 71.43 111.048 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -48.39 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.644 2.229 . . . . 60.01 112.335 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.61 149.93 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 71.24 111.139 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -96.04 67.69 2.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 63.41 110.887 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.2 t -100.55 -169.29 1.7 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 64.13 110.89 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 27' ' ' THR . 0.2 OUTLIER -87.45 163.06 16.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 72.33 111.148 -179.918 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.606 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 0.2 OUTLIER -129.92 131.75 46.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.253 -0.431 . . . . 62.04 110.91 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -101.0 126.2 47.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.901 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 24' ' ' VAL . 2.5 mp -123.64 123.28 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 73.4 111.115 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 63.8 p -119.31 146.38 45.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 62.11 111.098 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.792 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.5 m-85 -129.14 154.62 46.55 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.185 -0.461 . . . . 65.43 110.947 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 57' ' ' ILE . 4.7 tp -91.31 108.39 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.495 . . . . 74.23 111.133 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.95 -51.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.734 -0.746 . . . . 45.03 112.453 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -106.17 170.87 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.919 0.39 . . . . 61.23 110.958 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -67.31 146.67 98.88 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.598 0.713 . . . . 75.3 110.909 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 175.93 7.43 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.699 2.266 . . . . 71.32 112.317 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.547 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.1 m -149.82 142.76 17.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 74.11 111.155 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 13.9 p -122.17 131.98 54.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 60.11 111.158 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.2 m -152.91 156.51 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.202 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.79 154.27 27.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 70.32 110.893 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.606 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -63.95 107.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 72.41 111.066 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -130.83 159.3 37.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 63.13 111.107 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.64 -55.74 23.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 73.13 111.118 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 64.4 mt -126.01 131.49 71.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 72.31 111.092 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 23.7 t -143.06 123.53 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 74.42 111.148 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -119.86 109.43 15.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.848 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 26.6 t -125.18 148.87 29.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 61.34 111.169 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.436 HD22 ' HG3' ' A' ' 13' ' ' LYS . 4.6 mp -103.72 144.44 31.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 72.02 110.938 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.792 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.6 tp -88.87 118.49 28.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 65.54 110.9 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.03 129.55 45.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.896 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 147.56 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.836 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 63.7 t0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 44.35 110.849 -179.995 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.531 -0.227 . . . . 42.34 112.531 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -157.96 119.82 3.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.895 0.378 . . . . 73.41 110.852 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.663 HG11 ' OH ' ' A' ' 56' ' ' TYR . 43.3 t -111.29 137.2 44.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 111.197 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.642 HG22 ' HA ' ' A' ' 18' ' ' PRO . 11.3 p -132.07 179.08 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 73.43 111.109 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.608 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -100.24 153.09 19.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 72.2 110.823 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 16.3 tttm -92.71 17.98 9.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.08 -0.509 . . . . 60.22 110.917 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.608 HG21 ' OH ' ' A' ' 59' ' ' TYR . 34.8 p -94.2 -58.68 2.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.271 -0.422 . . . . 75.14 111.217 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -120.15 -26.83 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.282 -0.417 . . . . 72.52 110.85 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.24 29.19 5.23 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.492 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -99.05 160.26 28.12 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.621 0.724 . . . . 74.15 110.911 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.642 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.62 143.33 51.13 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 61.23 112.393 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.608 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -92.79 116.45 33.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.276 -0.42 . . . . 75.31 111.094 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 31.3 mt -98.42 150.18 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 42.2 111.107 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.05 48.25 72.97 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 62.52 112.449 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 158.27 15.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.799 0.333 . . . . 63.11 111.058 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.09 107.41 18.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 52.44 110.904 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.526 HG22 HG23 ' A' ' 54' ' ' ILE . 20.6 t -112.65 108.44 25.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.141 -0.482 . . . . 75.44 111.105 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.718 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.2 m -127.88 139.97 50.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 74.52 111.121 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.567 ' OE1' HD11 ' A' ' 44' ' ' LEU . 2.3 mp0 -91.2 167.36 12.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 74.12 110.91 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 53.5 p -82.11 -33.75 29.59 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 52.43 111.13 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.552 HG23 ' OG ' ' A' ' 50' ' ' SER . 20.2 p -79.42 -22.17 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 64.03 111.164 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.45 103.34 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 63.21 111.111 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.718 HG23 ' HB ' ' A' ' 25' ' ' VAL . 99.1 m -86.93 -35.44 18.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.194 -0.457 . . . . 73.01 111.155 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.2 p -53.99 -26.9 28.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.084 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -93.41 31.42 1.52 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 74.3 110.849 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -67.29 142.16 40.52 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 61.22 112.421 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.7 m -113.97 161.61 17.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.782 0.325 . . . . 73.43 111.108 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 14.6 pt -117.33 148.31 20.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.459 . . . . 72.12 111.156 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.581 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.1 p -71.33 150.69 44.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 55.34 111.108 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -86.59 -170.17 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 34.54 110.887 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -60.93 -30.65 70.34 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.152 -0.477 . . . . 72.12 110.974 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.67 17.88 12.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.485 . . . . 73.22 110.865 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.22 28.11 71.69 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.505 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -113.98 136.69 52.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 71.23 110.873 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.581 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.8 p90 -129.98 167.87 17.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.434 . . . . 71.21 110.925 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.1 t -123.36 117.44 25.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.166 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.567 HD11 ' OE1' ' A' ' 26' ' ' GLU . 0.5 OUTLIER -143.62 124.44 14.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.23 110.915 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.8 t -106.98 108.07 19.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.848 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 44' ' ' LEU . 19.1 m -139.95 152.57 68.09 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 71.43 111.113 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 170.61 16.09 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.705 2.27 . . . . 60.01 112.348 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.9 m -93.18 53.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.15 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -154.79 35.38 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 63.41 110.947 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.552 ' OG ' HG23 ' A' ' 28' ' ' THR . 7.7 t -155.53 163.52 39.89 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.174 -0.466 . . . . 64.13 110.826 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 164.06 12.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 72.33 111.102 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 84.9 mt -130.45 117.19 19.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 62.04 110.937 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.544 ' HA ' HG22 ' A' ' 63' ' ' THR . 37.3 tttt -102.27 123.55 46.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 74.21 110.868 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.526 HG23 HG22 ' A' ' 24' ' ' VAL . 3.3 mp -123.59 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 73.4 111.16 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.2 p -117.73 144.52 45.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 62.11 111.18 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.817 ' CD1' HD11 ' A' ' 74' ' ' LEU . 20.6 m-85 -126.5 155.03 42.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 65.43 110.994 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.0 tt -92.36 107.86 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.114 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.84 -50.96 0.82 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.791 -0.719 . . . . 45.03 112.494 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.608 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.8 m-85 -105.58 170.43 7.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 61.23 110.889 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -67.57 144.57 97.79 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.61 0.719 . . . . 75.3 110.87 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 176.99 6.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.605 2.203 . . . . 71.32 112.299 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.584 HG22 ' HE1' ' A' ' 56' ' ' TYR . 15.3 m -149.24 145.49 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 74.11 111.148 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 53' ' ' LYS . 4.9 p -129.12 138.37 51.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 60.11 111.101 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 70' ' ' VAL . 17.5 m -150.51 167.79 2.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.206 -0.452 . . . . 74.21 111.115 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -89.53 155.98 18.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.876 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -51.6 128.87 24.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 72.41 111.064 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -161.35 142.8 11.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 63.13 111.13 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.04 -49.32 66.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.085 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.3 mt -120.76 119.49 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.253 -0.43 . . . . 72.31 111.199 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 64' ' ' VAL . 6.7 p -129.52 122.64 55.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.42 111.123 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -119.86 113.62 20.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 74.11 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.8 t -127.71 148.94 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 61.34 111.112 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 11.6 mt -106.44 145.29 31.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.932 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.817 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -87.57 123.06 32.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.903 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -102.06 133.3 47.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 73.42 110.882 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -51.91 139.54 21.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 75.12 110.927 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.879 -179.992 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.528 -0.229 . . . . 42.34 112.528 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -130.37 130.66 44.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 73.41 110.877 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.62 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.6 t -123.51 131.13 73.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 73.33 111.14 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.9 p -127.44 178.17 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.152 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 t -95.43 149.27 21.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.451 . . . . 72.2 110.828 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.405 ' HG3' HD13 ' A' ' 73' ' ' LEU . 33.8 tttm -90.05 12.26 18.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 60.22 110.909 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.443 HG21 ' OH ' ' A' ' 59' ' ' TYR . 41.4 p -93.61 -59.6 1.96 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.433 . . . . 75.14 111.182 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -118.69 -27.08 5.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 72.52 110.874 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.39 29.31 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.513 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -93.55 160.53 32.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.645 0.736 . . . . 74.15 110.918 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 138.21 37.18 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.606 2.204 . . . . 61.23 112.375 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 48.9 mm -85.64 120.07 35.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.259 -0.428 . . . . 75.31 111.105 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mt -105.93 140.97 22.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.161 -0.472 . . . . 42.2 111.101 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.41 50.41 21.25 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.452 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.545 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.06 159.0 15.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.771 0.32 . . . . 63.11 111.109 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.3 m -105.87 107.47 18.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 52.44 110.839 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.635 HG22 HG23 ' A' ' 54' ' ' ILE . 17.4 t -111.5 128.49 67.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.147 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.681 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.7 m -148.05 139.6 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.092 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.495 ' CD ' ' HB3' ' A' ' 29' ' ' ALA . 33.8 mt-10 -72.23 174.23 7.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.861 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.14 -35.21 49.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 52.43 111.146 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.5 p -112.4 -22.18 10.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 64.03 111.191 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.495 ' HB3' ' CD ' ' A' ' 26' ' ' GLU . . . -118.75 78.83 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.244 -0.435 . . . . 63.21 111.102 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.681 HG23 ' HB ' ' A' ' 25' ' ' VAL . 97.5 m -83.83 -39.21 20.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.01 111.11 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 p -53.59 -29.45 37.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 74.23 111.142 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -94.61 31.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.924 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -68.14 164.67 46.95 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.768 -0.729 . . . . 61.22 112.479 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -135.24 168.86 18.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.714 0.292 . . . . 73.43 111.178 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.545 HG22 ' O ' ' A' ' 22' ' ' ALA . 13.9 pt -121.59 151.35 24.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.19 -0.459 . . . . 72.12 111.104 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.547 HG22 ' HD2' ' A' ' 42' ' ' PHE . 22.8 p -74.27 150.66 40.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.13 -0.487 . . . . 55.34 111.151 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -94.39 -178.1 4.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 34.54 110.885 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -56.92 -30.32 63.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 72.12 110.94 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -73.2 -18.72 61.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 73.22 110.853 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.43 28.19 20.38 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 75.31 112.471 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 23.7 p30 -133.93 163.53 29.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 71.23 110.906 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.547 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.4 p90 -144.86 167.76 21.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.887 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -135.72 122.84 21.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.105 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -138.01 118.68 14.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.893 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 t -93.08 115.31 27.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.817 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.66 155.98 44.22 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.646 0.736 . . . . 71.43 111.144 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -48.46 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.724 2.283 . . . . 60.01 112.337 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -111.97 -176.59 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.43 . . . . 71.24 111.104 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -106.04 64.99 0.68 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 63.41 110.885 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.9 t -92.52 -169.83 2.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 64.13 110.86 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.73 162.59 16.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 72.33 111.16 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.547 HD11 ' HB2' ' A' ' 66' ' ' ALA . 11.1 mt -134.39 133.15 40.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 62.04 110.98 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.421 ' HA ' HG23 ' A' ' 63' ' ' THR . 9.6 ttpt -98.9 125.32 44.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.423 . . . . 74.21 110.876 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.635 HG23 HG22 ' A' ' 24' ' ' VAL . 8.7 mt -123.83 119.62 57.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 73.4 111.145 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 46.4 p -113.63 150.55 32.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.114 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.806 ' CD1' HD11 ' A' ' 74' ' ' LEU . 23.1 m-85 -132.37 151.97 51.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 65.43 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -90.7 107.98 19.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 74.23 111.096 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.05 -51.19 0.8 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.551 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.443 ' OH ' HG21 ' A' ' 14' ' ' THR . 8.8 m-85 -104.4 170.5 7.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.931 0.396 . . . . 61.23 110.878 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -67.09 145.39 98.8 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.505 0.669 . . . . 75.3 110.889 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 175.2 8.46 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.686 2.258 . . . . 71.32 112.348 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.579 HG21 HG11 ' A' ' 72' ' ' VAL . 16.8 m -149.91 142.26 17.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 74.11 111.121 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HA ' ' A' ' 53' ' ' LYS . 0.3 OUTLIER -121.84 129.54 52.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 60.11 111.114 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.5 m -152.85 154.3 7.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 74.21 111.118 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -88.35 153.12 21.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 70.32 110.865 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.547 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -55.86 138.57 48.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 72.41 111.088 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.479 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . . . -162.09 165.78 26.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 63.13 111.065 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.41 -56.76 16.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 73.13 111.139 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 61.7 mt -132.39 116.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 72.31 111.085 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.479 ' CG2' ' HB3' ' A' ' 67' ' ' ALA . 19.5 t -124.96 112.17 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 74.42 111.103 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 -102.04 109.31 20.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 74.11 110.898 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.579 HG11 HG21 ' A' ' 62' ' ' VAL . 21.9 t -116.5 147.15 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 61.34 111.141 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.405 HD13 ' HG3' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -115.79 145.6 42.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.862 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.806 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -93.62 121.3 34.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.222 -0.445 . . . . 65.54 110.921 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.13 137.14 45.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.276 -0.42 . . . . 73.42 110.925 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -51.08 137.34 21.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.481 . . . . 75.12 110.848 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 32.3 t0 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 44.35 110.873 179.988 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.464 -0.254 . . . . 42.34 112.464 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -128.28 126.36 40.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 73.41 110.945 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.628 HG23 ' HE2' ' A' ' 42' ' ' PHE . 90.6 t -110.84 125.13 68.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 73.33 111.15 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -128.59 177.15 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.166 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.21 161.38 14.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.802 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.9 tmtm? -101.59 -5.41 25.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.097 -0.502 . . . . 60.22 110.913 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 43.5 p -78.41 -58.58 3.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 75.14 111.177 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -118.36 -26.25 6.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 72.52 110.906 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.58 29.29 6.32 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.787 -0.72 . . . . 53.34 112.513 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -90.21 159.95 41.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.588 0.709 . . . . 74.15 110.959 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 139.24 39.6 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.702 2.268 . . . . 61.23 112.364 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.65 HG22 ' HB2' ' A' ' 22' ' ' ALA . 44.1 mm -91.3 101.56 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.241 -0.436 . . . . 75.31 111.102 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.418 ' H ' HD12 ' A' ' 20' ' ' ILE . 3.2 mp -93.56 140.0 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 42.2 111.165 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.04 31.93 54.15 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.789 -0.72 . . . . 62.52 112.484 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.65 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -91.37 162.37 14.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.759 0.314 . . . . 63.11 111.088 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.7 m -105.79 107.29 18.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.471 . . . . 52.44 110.849 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.4 p -120.09 127.16 75.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 75.44 111.146 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.696 HG12 ' HA3' ' A' ' 33' ' ' GLY . 14.6 m -140.31 166.97 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 74.52 111.147 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.422 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 62.6 tt0 -92.49 132.48 36.77 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 74.12 110.86 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.44 HG21 ' HB ' ' A' ' 51' ' ' THR . 60.8 p -51.7 -35.03 41.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.121 -0.49 . . . . 52.43 111.124 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.6 p -95.37 -22.25 17.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 64.03 111.128 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.422 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -130.93 87.34 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.464 . . . . 63.21 111.104 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.2 p -86.81 -35.74 18.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 73.01 111.138 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.5 p -53.25 -30.56 38.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.139 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -93.96 31.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.417 . . . . 74.3 110.829 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.696 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.59 146.06 49.82 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.752 -0.737 . . . . 61.22 112.486 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.642 ' CG2' HD21 ' A' ' 44' ' ' LEU . 10.4 t -135.65 169.63 17.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.727 0.299 . . . . 73.43 111.178 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -107.9 157.55 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 72.12 111.149 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.411 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.0 p -76.22 150.97 36.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.099 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -79.49 -176.16 5.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 34.54 110.832 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -60.47 -30.62 69.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.208 -0.451 . . . . 72.12 110.838 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -99.44 20.87 12.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.197 -0.456 . . . . 73.22 110.882 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.28 27.98 71.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.781 -0.723 . . . . 75.31 112.392 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -107.04 143.43 35.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 71.23 110.955 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.628 ' HE2' HG23 ' A' ' 10' ' ' VAL . 24.1 p90 -144.57 161.79 38.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.21 110.872 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.558 ' C ' HD22 ' A' ' 44' ' ' LEU . 4.6 t -151.34 128.36 11.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 72.34 111.211 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.642 HD21 ' CG2' ' A' ' 34' ' ' THR . 3.0 mm? -130.63 159.8 36.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.23 110.846 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 6.1 m -95.52 108.23 20.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 73.42 110.798 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.434 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.9 t -133.35 133.19 22.53 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.611 0.72 . . . . 71.43 111.128 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.434 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.2 Cg_endo -69.74 -48.39 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.747 2.298 . . . . 60.01 112.331 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.451 HG23 ' H ' ' A' ' 50' ' ' SER . 19.4 m -99.72 -173.83 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 71.24 111.116 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.5 m-20 -107.13 45.66 0.98 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.899 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.451 ' H ' HG23 ' A' ' 48' ' ' VAL . 1.8 m -57.43 -179.55 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 64.13 110.89 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.44 ' HB ' HG21 ' A' ' 27' ' ' THR . 1.7 m -87.69 159.72 18.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 72.33 111.137 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.829 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.7 mp -125.76 135.12 51.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 62.04 110.9 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.4 ttpt -106.86 120.84 43.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.21 110.92 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.678 ' HB ' HG23 ' A' ' 62' ' ' VAL . 5.8 mt -117.45 138.98 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 73.4 111.095 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.1 p -150.71 138.65 20.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.11 111.101 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.684 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.4 t80 -133.98 122.32 22.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 65.43 110.963 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.435 HG23 ' O ' ' A' ' 57' ' ' ILE . 11.4 tt -51.57 115.08 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 74.23 111.159 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 131.23 -51.96 0.84 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.752 . . . . 45.03 112.467 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -107.98 170.18 8.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.9 0.381 . . . . 61.23 110.939 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -64.04 158.0 65.73 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.539 0.685 . . . . 75.3 110.914 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 164.26 35.15 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 71.32 112.357 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.678 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.8 m -150.83 141.08 16.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.197 -0.456 . . . . 74.11 111.133 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.9 p -130.25 140.1 50.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 60.11 111.041 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.912 HG11 HG22 ' A' ' 72' ' ' VAL . 8.6 m -147.55 148.0 16.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.097 -0.501 . . . . 74.21 111.093 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 6.9 mmmm -78.95 155.11 29.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 70.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.829 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -73.59 134.07 43.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 72.41 111.142 179.814 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.16 178.11 7.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.102 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.553 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.66 -57.32 9.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 73.13 111.13 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.553 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.78 111.77 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 72.31 111.084 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.493 HG21 ' HB ' ' A' ' 64' ' ' VAL . 12.2 p -118.84 141.82 36.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.127 -0.488 . . . . 74.42 111.136 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -115.89 134.98 54.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.912 HG22 HG11 ' A' ' 64' ' ' VAL . 22.4 t -122.83 149.18 26.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 61.34 111.143 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.34 133.37 54.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.176 -0.466 . . . . 72.02 110.934 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -90.54 121.49 32.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 65.54 110.928 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 50.3 mm-40 -92.38 145.29 24.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.155 -0.475 . . . . 73.42 110.862 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -58.45 140.4 53.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.17 -0.468 . . . . 75.12 110.929 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 44.35 110.851 -179.971 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.514 -0.235 . . . . 42.34 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -158.34 127.29 5.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.847 0.356 . . . . 73.41 110.929 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.656 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 83.0 t -117.94 130.59 72.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.33 111.105 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.5 p -128.5 163.71 24.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 73.43 111.103 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.451 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.2 t -84.73 148.96 26.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 72.2 110.88 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttp -92.43 17.53 9.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 60.22 110.851 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.95 -58.75 2.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.14 111.103 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -119.58 -26.68 5.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 72.52 110.892 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.35 5.12 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.736 -0.745 . . . . 53.34 112.409 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -97.44 159.95 29.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 74.15 110.939 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.78 141.62 45.65 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.663 2.242 . . . . 61.23 112.365 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.626 HG21 ' CD2' ' A' ' 56' ' ' TYR . 33.7 mm -86.04 115.22 26.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 75.31 111.065 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.4 mt -104.04 137.27 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 42.2 111.111 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 75.33 47.55 12.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.486 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.97 158.33 15.51 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.77 0.319 . . . . 63.11 111.135 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.9 m -105.99 107.21 18.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 52.44 110.875 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.658 HG13 HG12 ' A' ' 54' ' ' ILE . 95.4 t -110.91 110.39 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 75.44 111.111 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.8 m -123.53 146.05 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 74.52 111.106 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.646 ' OE1' HD22 ' A' ' 52' ' ' LEU . 1.9 mm-40 -90.24 156.7 18.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 74.12 110.836 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 51.9 p -73.03 -32.91 65.41 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.115 -0.493 . . . . 52.43 111.19 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.7 p -85.19 -22.2 28.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 64.03 111.17 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.76 104.74 1.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 63.21 111.047 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.4 p -86.75 -34.82 19.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 73.01 111.081 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.5 p -53.15 -29.68 32.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.251 -0.432 . . . . 74.23 111.188 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -94.29 31.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 74.3 110.892 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -72.86 164.37 54.86 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.718 -0.753 . . . . 61.22 112.492 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.8 t -130.96 169.08 16.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.712 0.291 . . . . 73.43 111.226 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 pp -115.99 164.55 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.255 -0.43 . . . . 72.12 111.141 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.522 HG22 ' HD2' ' A' ' 42' ' ' PHE . 14.1 p -89.28 150.66 22.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.205 -0.452 . . . . 55.34 111.15 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -91.37 -179.14 5.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.185 -0.461 . . . . 34.54 110.883 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -56.95 -30.64 64.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 72.12 110.968 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 46.0 m-20 -73.62 -18.46 61.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 73.22 110.865 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.97 28.1 21.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 75.31 112.506 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -127.23 165.38 19.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.812 0.339 . . . . 71.23 110.885 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.522 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.5 p90 -153.29 166.75 31.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 71.21 110.845 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.84 125.86 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 72.34 111.158 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.614 HD13 ' CD ' ' A' ' 26' ' ' GLU . 1.0 OUTLIER -138.61 131.37 29.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 72.23 110.895 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.469 ' N ' HD23 ' A' ' 44' ' ' LEU . 16.5 t -98.07 117.79 33.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.85 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.8 156.18 46.75 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.665 0.745 . . . . 71.43 111.104 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 -48.51 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.699 2.266 . . . . 60.01 112.376 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.9 m -113.14 -177.5 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.208 -0.451 . . . . 71.24 111.134 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -100.6 39.43 1.37 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 63.41 110.836 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.7 t -63.91 -169.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 64.13 110.866 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.691 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.0 OUTLIER -87.65 161.43 17.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 72.33 111.132 -179.987 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.691 HD23 ' O ' ' A' ' 51' ' ' THR . 12.7 mt -129.85 127.59 40.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.121 -0.491 . . . . 62.04 110.915 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -102.26 122.3 43.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 74.21 110.921 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.658 HG12 HG13 ' A' ' 24' ' ' VAL . 58.1 mt -123.63 118.94 55.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.086 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 55.0 p -113.34 146.86 38.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 62.11 111.168 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.838 ' CD1' HD11 ' A' ' 74' ' ' LEU . 19.0 m-85 -126.28 155.15 42.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 65.43 110.892 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.65 107.76 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.072 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.88 -50.83 0.83 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.686 -0.769 . . . . 45.03 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -105.84 170.48 7.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.905 0.383 . . . . 61.23 110.952 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.8 mmtm -64.74 149.0 96.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.617 0.723 . . . . 75.3 110.882 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -179.15 2.73 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.722 2.281 . . . . 71.32 112.377 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.88 HG21 HG11 ' A' ' 72' ' ' VAL . 4.4 p -151.85 149.27 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.284 -0.416 . . . . 74.11 111.179 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.22 125.26 30.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.121 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.762 HG21 HG11 ' A' ' 70' ' ' VAL . 18.2 m -147.37 152.92 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.156 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -81.82 153.62 26.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 70.32 110.867 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.436 ' HA ' HD11 ' A' ' 52' ' ' LEU . . . -55.58 105.14 0.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.075 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ALA . . . . . 0.453 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -131.78 153.2 50.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.45 . . . . 63.13 111.129 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.09 -51.46 67.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 73.13 111.032 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 60.4 mt -120.03 115.48 47.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 72.31 111.199 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.762 HG11 HG21 ' A' ' 64' ' ' VAL . 20.1 t -126.63 106.61 15.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.222 -0.445 . . . . 74.42 111.197 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -114.26 109.43 18.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.11 110.898 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.88 HG11 HG21 ' A' ' 62' ' ' VAL . 21.6 t -129.04 148.38 33.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 61.34 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.6 mp -100.86 145.15 28.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 72.02 110.943 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.838 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.5 tp -87.72 120.93 29.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 65.54 110.947 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -96.14 127.25 41.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.903 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.52 143.16 25.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.877 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 44.35 110.904 179.981 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.477 -0.249 . . . . 42.34 112.477 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -132.43 127.79 36.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.841 0.353 . . . . 73.41 110.927 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.537 HG12 HG13 ' A' ' 19' ' ' ILE . 21.3 t -115.94 134.25 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 73.33 111.138 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.413 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -146.69 153.84 40.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 73.43 111.167 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.1 t -85.69 150.6 24.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 72.2 110.875 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 tttt -94.28 20.76 7.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 60.22 110.911 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.22 -58.69 2.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 75.14 111.098 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -120.05 -25.95 5.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 72.52 110.847 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.87 29.02 5.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 53.34 112.519 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -98.05 155.55 36.89 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 74.15 110.941 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.413 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.66 136.86 34.34 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.724 2.283 . . . . 61.23 112.351 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.548 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 50.0 mm -78.0 124.32 36.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 75.31 111.114 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.9 mt -110.18 119.35 59.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 42.2 111.095 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.68 33.4 8.47 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.774 -0.727 . . . . 62.52 112.528 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -89.54 132.21 35.18 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.722 0.296 . . . . 63.11 111.089 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.7 m -79.73 109.74 14.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.84 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.577 HG13 HG12 ' A' ' 54' ' ' ILE . 98.3 t -113.78 106.05 19.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.15 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.778 HG12 ' HA3' ' A' ' 33' ' ' GLY . 20.1 m -120.64 139.03 49.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.16 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.447 ' OE1' HD13 ' A' ' 44' ' ' LEU . 1.5 pm0 -90.61 141.86 28.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 74.12 110.845 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.8 p -62.29 -31.6 72.22 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.074 -0.512 . . . . 52.43 111.166 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.717 HG21 HG13 ' A' ' 48' ' ' VAL . 64.8 p -71.71 -22.12 61.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 64.03 111.133 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.76 78.78 0.34 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 63.21 111.055 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 p -65.33 -35.62 81.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 73.01 111.184 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.7 m -54.09 -32.32 54.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.169 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.482 ' O ' HD11 ' A' ' 44' ' ' LEU . 35.6 t30 -93.47 30.59 1.7 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 74.3 110.941 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.778 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.94 148.4 50.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.731 -0.747 . . . . 61.22 112.483 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.628 HG22 HD12 ' A' ' 44' ' ' LEU . 14.6 t -125.58 168.98 12.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.768 0.318 . . . . 73.43 111.181 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.0 pt -107.37 172.57 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 72.12 111.096 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.444 HG22 ' CD2' ' A' ' 42' ' ' PHE . 37.4 p -97.85 150.68 21.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.113 -0.494 . . . . 55.34 111.067 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -80.57 -175.99 5.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.483 . . . . 34.54 110.864 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -59.52 -30.74 68.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.274 -0.421 . . . . 72.12 110.869 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -100.04 22.77 10.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.16 -0.473 . . . . 73.22 110.886 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.94 28.15 72.32 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.76 . . . . 75.31 112.523 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -107.33 127.77 53.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.23 110.82 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.444 ' CD2' HG22 ' A' ' 36' ' ' THR . 25.9 p90 -127.73 157.22 40.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.879 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.1 t -132.48 123.82 27.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 72.34 111.158 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.628 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.22 118.44 7.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 72.23 110.981 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.0 m -95.05 116.64 28.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 73.42 110.851 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -122.55 156.24 61.51 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.622 0.725 . . . . 71.43 111.155 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -35.88 11.83 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.667 2.245 . . . . 60.01 112.371 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.717 HG13 HG21 ' A' ' 28' ' ' THR . 14.5 p -131.51 140.23 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 71.24 111.164 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -104.21 79.7 1.63 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 63.41 110.876 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.9 t -89.37 -76.96 0.4 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 64.13 110.861 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.64 159.99 40.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 72.33 111.147 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 66' ' ' ALA . 15.6 mt -134.81 122.27 21.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 62.04 110.882 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HA ' HG22 ' A' ' 63' ' ' THR . 71.0 tttt -100.89 123.2 44.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.914 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.601 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.1 mt -121.12 138.4 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 73.4 111.149 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 47.2 p -148.82 138.66 22.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 62.11 111.11 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.667 ' HB3' HD21 ' A' ' 74' ' ' LEU . 12.6 t80 -133.98 122.8 23.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 65.43 110.927 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.419 HG23 ' O ' ' A' ' 57' ' ' ILE . 7.2 tt -51.82 120.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 74.23 111.098 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.73 -50.94 0.85 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 45.03 112.521 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -109.23 169.97 8.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 61.23 110.932 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -64.54 157.33 73.51 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.52 0.676 . . . . 75.3 110.936 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.79 165.16 31.93 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.675 2.25 . . . . 71.32 112.311 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.601 HG23 ' HB ' ' A' ' 54' ' ' ILE . 32.1 m -150.55 138.25 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 74.11 111.154 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 53' ' ' LYS . 5.1 p -131.76 140.85 49.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 60.11 111.171 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.0 m -145.92 175.66 2.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 74.21 111.11 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.41 149.9 25.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 70.32 110.9 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.615 ' HA ' HD12 ' A' ' 52' ' ' LEU . . . -75.43 118.37 18.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.181 -0.463 . . . . 72.41 111.137 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.97 -176.22 5.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 63.13 111.064 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.503 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -68.14 -57.66 5.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.153 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.503 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -126.69 114.26 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 72.31 111.139 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.87 127.45 58.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 74.42 111.136 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 71.4 m-80 -100.35 127.59 46.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 74.11 110.897 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.565 HG11 HG21 ' A' ' 62' ' ' VAL . 21.4 t -118.7 148.88 21.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.254 -0.43 . . . . 61.34 111.093 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 15.3 mt -119.43 131.47 55.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.124 -0.489 . . . . 72.02 110.936 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.667 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -87.86 121.9 30.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.955 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -90.36 144.01 26.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 73.42 110.94 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -58.97 139.87 56.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.12 110.864 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 44.35 110.868 179.97 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.516 -0.234 . . . . 42.34 112.516 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.0 120.19 3.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.771 0.32 . . . . 73.41 110.928 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.1 t -105.93 131.64 54.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 73.33 111.126 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.9 p -129.37 159.26 36.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.43 111.126 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -84.34 156.95 21.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.2 110.858 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -93.96 20.09 8.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.079 -0.509 . . . . 60.22 110.966 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.58 HG21 ' OH ' ' A' ' 59' ' ' TYR . 60.1 p -94.52 -58.42 2.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 75.14 111.131 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -122.26 -26.36 4.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 72.52 110.915 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.64 29.27 5.08 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.753 -0.737 . . . . 53.34 112.539 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -98.99 159.69 29.6 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.552 0.692 . . . . 74.15 110.953 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.71 147.72 63.82 Favored 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.745 2.296 . . . . 61.23 112.399 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.515 HG21 ' CD2' ' A' ' 56' ' ' TYR . 26.5 mm -94.6 114.97 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 75.31 111.084 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.472 HD13 ' CD2' ' A' ' 38' ' ' PHE . 40.4 mt -100.22 138.6 24.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 42.2 111.159 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.27 46.64 12.23 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.659 -0.781 . . . . 62.52 112.522 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.461 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -94.87 157.82 15.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 63.11 111.043 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -106.01 107.14 17.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 52.44 110.855 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.785 HG22 HG23 ' A' ' 54' ' ' ILE . 13.3 t -112.15 122.58 66.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 75.44 111.132 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -138.91 151.95 23.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 74.52 111.177 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.402 ' OE1' HG11 ' A' ' 46' ' ' VAL . 2.4 mm-40 -84.31 174.28 10.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 74.12 110.912 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.13 -42.29 69.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 52.43 111.185 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.7 p -112.91 -22.16 10.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 64.03 111.143 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -110.26 76.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 63.21 111.2 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.2 p -86.95 -34.38 19.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 73.01 111.141 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.3 m -53.16 -30.48 37.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.434 . . . . 74.23 111.096 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -93.16 30.99 1.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 74.3 110.852 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.95 138.98 46.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.78 -0.724 . . . . 61.22 112.455 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.535 ' OG1' HD23 ' A' ' 44' ' ' LEU . 3.5 m -116.97 160.45 20.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 73.43 111.162 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.461 HG22 ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.51 162.2 12.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 72.12 111.165 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.455 HG22 ' HD2' ' A' ' 42' ' ' PHE . 5.6 p -83.87 150.61 25.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 55.34 111.218 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -85.14 -175.89 5.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 34.54 110.91 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CD2' HD13 ' A' ' 20' ' ' ILE . 8.2 t80 -58.99 -30.18 67.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.237 -0.438 . . . . 72.12 110.851 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.56 13.54 13.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 73.22 110.862 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 28.0 71.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.757 -0.735 . . . . 75.31 112.419 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -126.81 142.59 51.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.863 0.363 . . . . 71.23 110.917 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.455 ' HD2' HG22 ' A' ' 36' ' ' THR . 30.9 p90 -132.39 168.01 18.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.469 . . . . 71.21 110.873 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.7 t -133.43 116.56 16.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 72.34 111.105 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.657 HD13 ' N ' ' A' ' 45' ' ' SER . 1.2 tm? -143.19 132.29 23.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 72.23 110.929 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' SER . . . . . 0.657 ' N ' HD13 ' A' ' 44' ' ' LEU . 79.2 p -107.35 124.84 50.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 73.42 110.902 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.402 HG11 ' OE1' ' A' ' 26' ' ' GLU . 3.5 m -113.61 155.95 44.2 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.702 0.763 . . . . 71.43 111.111 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -48.5 0.71 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.665 2.243 . . . . 60.01 112.362 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.3 m -112.37 179.68 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 71.24 111.189 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 75.2 m-80 -100.31 36.88 1.77 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 63.41 110.862 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.3 t -61.98 -172.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 64.13 110.844 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.0 154.95 19.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.057 -0.52 . . . . 72.33 111.186 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.723 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.3 mp -127.41 130.96 50.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 62.04 110.91 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -99.82 121.25 41.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 74.21 110.917 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.785 HG23 HG22 ' A' ' 24' ' ' VAL . 2.4 mp -117.92 119.14 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.295 -0.411 . . . . 73.4 111.14 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 44.5 p -116.08 144.32 44.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.187 -0.46 . . . . 62.11 111.149 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.8 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.3 m-85 -126.63 152.35 46.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 65.43 110.918 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.493 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -89.71 107.73 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.109 -0.496 . . . . 74.23 111.142 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.5 -50.47 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.49 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.58 ' OH ' HG21 ' A' ' 14' ' ' THR . 12.8 m-85 -103.62 170.69 7.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 61.23 110.925 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -67.95 145.17 97.71 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.58 0.705 . . . . 75.3 110.867 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 172.34 12.84 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.682 2.254 . . . . 71.32 112.382 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.539 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.5 m -150.08 143.66 17.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 74.11 111.128 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -122.49 134.76 54.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.246 -0.434 . . . . 60.11 111.168 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 70' ' ' VAL . 6.1 m -152.94 158.82 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 74.21 111.127 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -82.47 157.28 23.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 70.32 110.882 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.723 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.18 138.14 49.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 72.41 111.113 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.72 -177.59 4.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 63.13 111.093 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.37 -58.0 7.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 73.13 111.085 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -124.25 137.71 56.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.2 -0.454 . . . . 72.31 111.149 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 64' ' ' VAL . 6.1 p -143.61 120.92 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 74.42 111.142 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -119.98 110.55 16.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 74.11 110.831 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.446 HG11 HG21 ' A' ' 62' ' ' VAL . 22.2 t -116.37 146.32 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 61.34 111.128 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -102.14 135.33 43.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.185 -0.461 . . . . 72.02 110.932 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.8 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.53 120.87 29.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 65.54 110.919 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -95.69 142.9 27.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 73.42 110.905 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -55.02 141.25 34.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.12 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 13.0 t70 . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 116.264 -0.426 . . . . 44.35 110.946 179.951 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.529 -0.228 . . . . 42.34 112.529 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -152.74 119.95 5.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.36 . . . . 73.41 110.857 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.638 ' CG2' HD13 ' A' ' 54' ' ' ILE . 22.4 t -107.26 132.11 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 73.33 111.153 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.407 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.9 OUTLIER -136.22 160.38 38.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 73.43 111.072 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.16 154.1 35.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 72.2 110.851 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.6 tttp -96.46 12.91 29.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 60.22 110.845 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 74.3 p -93.86 -58.72 2.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.261 -0.427 . . . . 75.14 111.144 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -119.04 -26.57 5.93 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.229 -0.442 . . . . 72.52 110.935 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.32 29.25 5.18 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.748 . . . . 53.34 112.445 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLN . . . . . 0.407 ' C ' HG22 ' A' ' 11' ' ' THR . 47.0 mt-30 -90.45 160.46 39.26 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.598 0.713 . . . . 74.15 110.902 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 136.27 32.64 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.673 2.248 . . . . 61.23 112.368 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.4 mm -87.4 123.07 39.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.096 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.5 mt -107.92 128.23 63.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 42.2 111.118 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.53 32.87 14.68 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.686 -0.768 . . . . 62.52 112.501 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.42 127.76 36.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.792 0.329 . . . . 63.11 111.04 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -72.8 107.63 5.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.829 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.548 HG22 HG12 ' A' ' 54' ' ' ILE . 21.8 t -111.64 106.68 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.065 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.03 150.49 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 74.52 111.121 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.514 ' O ' HG23 ' A' ' 30' ' ' THR . 2.4 mp0 -92.57 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 74.12 110.851 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.9 p -56.14 -34.85 66.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.066 -0.515 . . . . 52.43 111.204 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 66.5 p -98.16 -22.09 16.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.24 -0.436 . . . . 64.03 111.208 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -133.48 65.81 1.57 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 63.21 111.065 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 26' ' ' GLU . 1.2 p -67.03 -35.32 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 73.01 111.17 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 88.8 m -64.1 -30.63 71.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 74.23 111.084 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -93.51 30.55 1.72 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.86 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -70.9 155.95 53.04 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.749 -0.739 . . . . 61.22 112.422 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -132.76 168.8 17.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.756 0.312 . . . . 73.43 111.199 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.89 150.83 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.191 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.2 p -70.38 150.14 46.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.186 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -91.3 -179.23 5.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 34.54 110.821 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -58.25 -30.64 66.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 72.12 110.846 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -73.84 -19.48 60.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.853 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.03 28.16 12.42 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.689 -0.767 . . . . 75.31 112.501 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -137.68 164.59 28.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.859 0.361 . . . . 71.23 110.925 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.524 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 27.6 p90 -138.78 167.46 21.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 71.21 110.835 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 43' ' ' THR . 5.0 t -119.86 120.38 36.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.114 -0.493 . . . . 72.34 111.187 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.3 mt -148.11 108.18 4.06 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.265 -0.425 . . . . 72.23 110.899 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.4 t -82.4 108.08 15.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.851 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.414 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.7 m -139.98 106.77 6.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.653 0.74 . . . . 71.43 111.129 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -32.54 18.45 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.762 2.308 . . . . 60.01 112.365 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.4 m -55.57 -30.61 26.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 71.24 111.138 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 67.32 40.11 2.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 63.41 110.866 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.0 m -74.73 -176.01 2.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 64.13 110.91 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.725 HG23 ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -86.95 150.05 24.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 72.33 111.186 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.1 mp -117.85 131.57 56.54 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.264 -0.425 . . . . 62.04 110.933 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LYS . . . . . 0.805 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.2 OUTLIER -99.83 128.48 45.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 74.21 110.87 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.638 HD13 ' CG2' ' A' ' 10' ' ' VAL . 45.0 mt -123.79 124.93 70.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.233 -0.44 . . . . 73.4 111.097 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' THR . . . . . 0.584 HG23 ' HD3' ' A' ' 53' ' ' LYS . 71.8 p -140.88 143.33 34.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.104 -0.498 . . . . 62.11 111.131 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.423 ' HB3' HD21 ' A' ' 74' ' ' LEU . 9.3 t80 -139.29 121.02 15.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.216 -0.447 . . . . 65.43 110.856 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.452 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.1 tt -50.91 107.68 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.083 -0.508 . . . . 74.23 111.141 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 138.94 -43.86 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 45.03 112.46 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -114.94 170.96 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.981 0.42 . . . . 61.23 110.902 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mmtt -66.29 153.64 92.09 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.596 0.712 . . . . 75.3 110.905 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.77 157.68 59.54 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.711 2.274 . . . . 71.32 112.331 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.529 ' CG2' HG11 ' A' ' 72' ' ' VAL . 26.8 m -150.93 137.93 13.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 74.11 111.141 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.805 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.2 p -131.96 142.24 49.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 60.11 111.107 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.605 HG11 HG22 ' A' ' 72' ' ' VAL . 15.5 m -149.55 156.32 7.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 74.21 111.141 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.725 ' HG3' HG23 ' A' ' 51' ' ' THR . 0.1 OUTLIER -80.51 157.29 26.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 70.32 110.934 179.892 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.861 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -77.4 137.59 38.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.276 -0.42 . . . . 72.41 111.147 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.59 178.65 7.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.439 . . . . 63.13 111.112 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.569 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.71 -49.61 62.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 73.13 111.087 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.71 111.79 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 72.31 111.144 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.12 128.1 73.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.079 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -115.39 125.98 53.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 74.11 110.887 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.605 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -120.05 149.01 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 61.34 111.132 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.5 mp -121.35 120.46 35.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 72.02 110.968 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.423 HD21 ' HB3' ' A' ' 56' ' ' TYR . 3.4 tp -88.06 116.55 26.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 65.54 110.873 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 17.0 pm0 -95.9 146.47 24.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 73.42 110.82 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.58 143.89 33.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.131 -0.486 . . . . 75.12 110.932 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 44.35 110.862 179.995 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.433 -0.267 . . . . 42.34 112.433 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -156.83 125.76 5.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.829 0.347 . . . . 73.41 110.881 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.654 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 93.1 t -112.35 130.17 66.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 73.33 111.075 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.511 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.0 p -128.84 164.31 23.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 73.43 111.11 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -85.32 149.95 25.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 72.2 110.801 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.35 18.17 8.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.111 -0.495 . . . . 60.22 110.918 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.93 2.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 75.14 111.157 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -119.95 -26.77 5.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 72.52 110.88 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.11 29.39 5.19 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.773 -0.727 . . . . 53.34 112.507 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.2 mm100 -96.9 160.3 29.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.672 0.749 . . . . 74.15 110.918 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.511 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.73 138.54 38.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.649 2.233 . . . . 61.23 112.381 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 49.9 mm -83.79 123.09 38.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.133 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.3 mt -108.24 140.75 25.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.161 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.63 51.99 17.95 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.81 -0.71 . . . . 62.52 112.48 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.595 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.05 155.75 16.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.805 0.336 . . . . 63.11 111.078 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.5 m -106.14 107.42 18.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 52.44 110.843 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.63 HG13 HG12 ' A' ' 54' ' ' ILE . 94.8 t -113.31 116.8 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 75.44 111.158 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 30' ' ' THR . 13.2 m -138.65 144.01 30.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 74.52 111.049 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HG3' HD22 ' A' ' 52' ' ' LEU . 1.7 mp0 -78.94 173.65 12.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.12 110.866 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 66.1 p -75.41 -36.26 60.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 52.43 111.143 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 38.9 p -112.37 -22.08 11.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 64.03 111.111 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB3' ' OE2' ' A' ' 26' ' ' GLU . . . -114.97 75.56 0.94 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 63.21 111.073 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.674 HG23 ' HB ' ' A' ' 25' ' ' VAL . 15.1 m -84.36 -35.9 22.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 73.01 111.18 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -57.38 -28.93 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 74.23 111.128 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -94.54 31.23 1.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.91 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -69.67 149.28 47.97 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.799 -0.715 . . . . 61.22 112.48 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.648 HG22 HD12 ' A' ' 44' ' ' LEU . 13.2 t -123.1 169.12 11.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.716 0.293 . . . . 73.43 111.139 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.595 HG22 ' O ' ' A' ' 22' ' ' ALA . 12.1 pt -124.42 156.64 32.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.148 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.57 HG22 ' HD2' ' A' ' 42' ' ' PHE . 35.6 p -81.79 149.05 28.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 55.34 111.115 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -91.62 -176.24 4.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.228 -0.442 . . . . 34.54 110.858 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.93 -30.62 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 72.12 110.892 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -73.8 -18.85 60.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 73.22 110.86 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.37 28.22 20.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.725 -0.75 . . . . 75.31 112.457 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.97 162.38 29.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.826 0.346 . . . . 71.23 110.901 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.57 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.2 p90 -146.02 164.14 33.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 71.21 110.921 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.7 t -128.5 116.28 19.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 72.34 111.14 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.648 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.5 107.46 3.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 72.23 110.877 179.917 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.6 m -68.82 107.93 3.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.83 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.773 HG11 HD21 ' A' ' 52' ' ' LEU . 58.2 t -139.97 133.41 15.31 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.62 0.724 . . . . 71.43 111.126 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.498 ' O ' ' HB3' ' A' ' 66' ' ' ALA . 53.9 Cg_endo -69.81 173.86 10.4 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.652 2.234 . . . . 60.01 112.384 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 48' ' ' VAL . 9.8 p -95.48 31.99 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.178 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -92.19 -36.04 13.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 63.41 110.912 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 6.3 p -123.47 176.98 5.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 64.13 110.84 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.509 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -97.72 176.88 5.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 72.33 111.164 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.773 HD21 HG11 ' A' ' 46' ' ' VAL . 71.6 mt -131.17 126.78 36.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 62.04 110.951 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -102.44 122.04 43.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 74.21 110.865 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.63 HG12 HG13 ' A' ' 24' ' ' VAL . 61.2 mt -123.79 117.73 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 73.4 111.145 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 65.0 p -113.19 148.58 35.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 62.11 111.122 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 21.9 m-85 -127.37 154.97 44.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 65.43 110.951 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.02 107.77 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 74.23 111.072 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 124.09 -51.23 0.82 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.707 -0.759 . . . . 45.03 112.429 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.93 170.66 7.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.995 0.426 . . . . 61.23 110.856 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 35.2 mttt -64.54 148.53 96.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.59 0.71 . . . . 75.3 110.878 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -178.75 2.51 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.268 . . . . 71.32 112.324 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.128 HG21 HG11 ' A' ' 72' ' ' VAL . 4.7 p -152.02 146.02 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 74.11 111.169 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.9 p -132.17 130.58 41.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 60.11 111.119 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 70' ' ' VAL . 8.1 m -152.62 155.15 6.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.28 -0.418 . . . . 74.21 111.069 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.3 ptpt -74.68 152.46 39.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 70.32 110.892 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 47' ' ' PRO . . . -58.26 120.74 9.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 72.41 111.098 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -148.49 150.76 33.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 63.13 111.089 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.81 -53.73 36.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.097 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.6 mp -117.17 133.28 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 72.31 111.204 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 64' ' ' VAL . 5.4 p -146.39 118.05 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.145 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -120.11 109.46 15.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.473 . . . . 74.11 110.904 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 1.128 HG11 HG21 ' A' ' 62' ' ' VAL . 22.0 t -126.79 144.14 37.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 61.34 111.15 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.0 mp -96.92 145.19 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 72.02 111.008 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.3 tp -87.77 121.49 30.25 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.281 -0.418 . . . . 65.54 110.931 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -98.71 136.11 39.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 73.42 110.888 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -55.05 140.46 37.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.88 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.0 t0 . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.861 -179.993 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.481 -0.248 . . . . 42.34 112.481 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -151.23 127.64 10.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 73.41 110.896 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' OH ' ' A' ' 56' ' ' TYR . 90.7 t -118.29 130.61 72.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 73.33 111.136 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.602 HG22 ' HA ' ' A' ' 18' ' ' PRO . 20.3 p -127.14 169.39 13.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 73.43 111.163 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.21 155.1 19.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.2 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -92.63 18.64 8.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 60.22 110.848 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.64 2.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 75.14 111.165 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -120.85 -26.42 5.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.3 -0.409 . . . . 72.52 110.832 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.79 29.05 5.12 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.491 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -100.63 154.19 37.31 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.566 0.698 . . . . 74.15 110.93 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.602 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.8 Cg_endo -69.7 147.2 62.75 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.756 2.304 . . . . 61.23 112.335 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.486 HG21 ' CD2' ' A' ' 56' ' ' TYR . 15.5 mm -93.5 120.38 42.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 75.31 111.066 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.07 150.81 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 42.2 111.103 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.61 48.33 82.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.474 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.28 167.65 11.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 63.11 111.028 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.0 m -106.34 106.62 17.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.163 -0.471 . . . . 52.44 110.856 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.697 HG13 HG13 ' A' ' 54' ' ' ILE . 5.9 t -110.42 128.86 66.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 75.44 111.122 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.8 m -148.44 137.99 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 74.52 111.143 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.674 ' OE2' HG11 ' A' ' 46' ' ' VAL . 15.7 tt0 -82.87 129.27 34.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 74.12 110.878 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.44 HG22 ' O ' ' A' ' 51' ' ' THR . 1.2 t -51.4 -33.21 29.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.168 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 42.1 p -89.45 -22.24 22.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 64.03 111.1 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -148.61 98.66 2.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 63.21 111.115 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 66.3 p -86.69 -32.83 20.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 73.01 111.189 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.3 m -52.78 -29.69 28.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.169 -0.469 . . . . 74.23 111.135 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -93.25 31.08 1.53 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.247 -0.433 . . . . 74.3 110.841 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -66.44 150.53 51.93 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.71 -0.757 . . . . 61.22 112.474 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.526 ' CG2' HD11 ' A' ' 44' ' ' LEU . 13.5 t -135.76 169.43 17.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 73.43 111.151 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.45 HG22 ' O ' ' A' ' 22' ' ' ALA . 17.9 pt -113.16 152.08 14.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 72.12 111.146 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 42' ' ' PHE . 10.0 p -69.98 150.72 46.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 55.34 111.119 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -81.26 -177.43 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.84 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -60.32 -30.61 69.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 72.12 110.867 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -97.42 20.38 11.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.22 110.867 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.27 27.94 71.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.719 -0.753 . . . . 75.31 112.474 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -108.5 139.38 43.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 71.23 110.919 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.472 ' HE2' HG23 ' A' ' 10' ' ' VAL . 13.2 p90 -133.49 168.13 19.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 71.21 110.928 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.508 ' C ' HD12 ' A' ' 44' ' ' LEU . 25.6 p -145.1 117.69 8.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 72.34 111.092 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.577 HD22 HD22 ' A' ' 52' ' ' LEU . 7.4 mp -126.59 109.58 12.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 72.23 110.889 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -99.89 117.91 35.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.845 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.674 HG11 ' OE2' ' A' ' 26' ' ' GLU . 3.6 m -138.34 155.9 73.79 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 71.43 111.124 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 -48.34 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.634 2.223 . . . . 60.01 112.381 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.18 150.72 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 71.24 111.111 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -91.3 46.07 1.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 63.41 110.91 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 84.0 p -66.4 -169.83 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 64.13 110.819 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.44 ' O ' HG22 ' A' ' 27' ' ' THR . 0.2 OUTLIER -94.64 160.74 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.503 . . . . 72.33 111.165 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.667 HD23 ' HG3' ' A' ' 26' ' ' GLU . 19.1 mt -121.15 117.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.931 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -97.82 114.58 26.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.867 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.697 HG13 HG13 ' A' ' 24' ' ' VAL . 4.0 mp -115.62 121.2 66.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 73.4 111.168 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 43.8 p -117.14 145.26 43.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 62.11 111.04 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.544 ' OH ' HG21 ' A' ' 10' ' ' VAL . 18.7 m-85 -125.81 155.29 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.481 . . . . 65.43 110.903 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.498 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.5 107.38 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.11 -0.496 . . . . 74.23 111.158 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.07 -46.16 1.1 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 45.03 112.467 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -111.82 170.89 7.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 61.23 110.828 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -63.6 150.75 89.74 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.568 0.699 . . . . 75.3 110.927 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 178.2 4.83 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.645 2.23 . . . . 71.32 112.371 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.666 HG21 HG11 ' A' ' 72' ' ' VAL . 3.7 p -152.03 147.9 14.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.088 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.6 p -132.14 130.82 41.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.174 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.65 HG11 HG21 ' A' ' 70' ' ' VAL . 19.5 m -141.66 145.97 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.263 -0.426 . . . . 74.21 111.125 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.97 157.18 37.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.965 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.18 98.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 72.41 111.155 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.15 178.2 6.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 63.13 111.071 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -86.36 -42.37 13.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.16 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -129.87 125.48 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.239 -0.437 . . . . 72.31 111.137 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.65 HG21 HG11 ' A' ' 64' ' ' VAL . 6.3 p -146.44 122.14 3.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 74.42 111.133 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -120.12 119.74 34.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 74.11 110.856 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.666 HG11 HG21 ' A' ' 62' ' ' VAL . 27.8 t -133.03 147.02 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 61.34 111.173 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 24.8 mt -98.17 135.19 40.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 72.02 110.912 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' A' ' 56' ' ' TYR . 4.4 tp -89.32 117.89 28.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 65.54 110.89 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -94.07 132.53 38.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.42 110.867 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -56.65 145.84 27.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.097 -0.501 . . . . 75.12 110.936 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 14.9 t70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 44.35 110.861 -179.941 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.464 -0.255 . . . . 42.34 112.464 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -158.13 119.85 3.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.843 0.354 . . . . 73.41 110.909 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.643 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 87.1 t -108.84 130.91 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 73.33 111.143 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 18' ' ' PRO . 3.7 p -127.31 169.5 13.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.108 -0.497 . . . . 73.43 111.113 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.512 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.4 t -89.16 150.09 22.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.457 . . . . 72.2 110.832 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . 0.5 ' CG ' HD13 ' A' ' 73' ' ' LEU . 14.9 tttm -90.83 15.0 12.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 60.22 110.882 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.74 -58.47 2.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 75.14 111.178 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -118.86 -26.66 5.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 72.52 110.828 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.28 29.29 6.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 53.34 112.503 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -96.93 160.16 29.81 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.533 0.682 . . . . 74.15 110.916 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.78 132.96 24.38 Favored 'Trans proline' 0 N--CA 1.465 -0.162 0 C-N-CA 122.664 2.242 . . . . 61.23 112.337 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.551 HG21 ' CD2' ' A' ' 56' ' ' TYR . 25.4 mm -77.67 118.11 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.164 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.493 HD13 ' CD2' ' A' ' 38' ' ' PHE . 23.8 mt -108.7 132.62 56.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 42.2 111.142 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.9 31.98 19.21 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.736 -0.745 . . . . 62.52 112.462 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -86.39 153.94 21.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.777 0.322 . . . . 63.11 111.114 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -106.86 107.04 17.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.429 . . . . 52.44 110.865 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.763 HG23 HG12 ' A' ' 54' ' ' ILE . 4.1 p -118.81 130.13 74.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 75.44 111.106 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.524 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.9 m -146.01 163.8 10.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 74.52 111.108 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLU . . . . . 0.685 ' OE1' HG21 ' A' ' 46' ' ' VAL . 4.1 mm-40 -85.24 172.82 10.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 74.12 110.931 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.58 -42.03 65.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 52.43 111.162 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -112.55 -21.98 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.198 -0.455 . . . . 64.03 111.155 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.16 64.55 0.84 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 63.21 111.109 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 21.8 p -78.52 -35.24 46.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.224 -0.444 . . . . 73.01 111.176 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.1 p -53.23 -30.93 40.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.097 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -93.78 31.33 1.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.968 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.81 148.37 50.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.794 -0.717 . . . . 61.22 112.434 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . 0.582 HG22 HD11 ' A' ' 44' ' ' LEU . 13.2 t -135.49 170.57 15.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.76 0.314 . . . . 73.43 111.194 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 11.6 pt -122.94 152.38 27.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 72.12 111.119 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.549 HG22 ' HD2' ' A' ' 42' ' ' PHE . 18.1 p -70.85 150.94 45.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 55.34 111.145 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -91.0 -177.02 4.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 34.54 110.896 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.493 ' CD2' HD13 ' A' ' 20' ' ' ILE . 0.4 OUTLIER -60.2 -30.01 69.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 72.12 110.883 -179.876 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -73.17 -18.52 61.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.46 28.04 20.74 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 75.31 112.452 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -129.65 166.88 18.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.887 0.375 . . . . 71.23 110.922 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PHE . . . . . 0.549 ' HD2' HG22 ' A' ' 36' ' ' THR . 26.8 p90 -151.35 167.92 26.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 71.21 110.865 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.5 t -134.66 125.61 27.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 72.34 111.1 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.697 HD22 HD21 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -130.73 128.84 41.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 72.23 110.898 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.9 t -105.04 119.97 40.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 73.42 110.801 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.685 HG21 ' OE1' ' A' ' 26' ' ' GLU . 58.0 t -139.0 133.23 16.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.614 0.721 . . . . 71.43 111.157 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.6 Cg_endo -69.77 -48.35 0.73 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.725 2.283 . . . . 60.01 112.325 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.0 m -86.65 171.64 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.259 -0.428 . . . . 71.24 111.12 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -111.08 81.75 1.48 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 63.41 110.829 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.7 t -109.39 -169.41 1.47 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.185 -0.461 . . . . 64.13 110.924 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.54 161.93 17.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.461 . . . . 72.33 111.133 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' LEU . . . . . 0.697 HD21 HD22 ' A' ' 44' ' ' LEU . 0.4 OUTLIER -128.42 130.18 47.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 62.04 110.91 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -101.98 124.45 47.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.858 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.763 HG12 HG23 ' A' ' 24' ' ' VAL . 10.3 mt -123.64 119.57 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.448 . . . . 73.4 111.115 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 51.2 p -117.78 144.32 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 62.11 111.152 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 25.0 m-85 -126.22 155.06 42.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.21 -0.45 . . . . 65.43 110.94 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.492 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.24 107.72 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 74.23 111.144 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 121.17 -51.1 0.8 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 45.03 112.513 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -101.5 170.75 8.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.897 0.379 . . . . 61.23 110.906 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 57.0 mttt -68.6 143.61 95.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.551 0.691 . . . . 75.3 110.963 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.73 174.22 9.8 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.713 2.275 . . . . 71.32 112.391 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.555 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.8 m -150.24 140.37 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 74.11 111.168 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -125.76 130.25 51.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 60.11 111.148 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.9 m -153.41 159.23 3.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.283 -0.417 . . . . 74.21 111.143 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -73.07 157.23 37.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.32 110.9 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.691 ' HB2' HD12 ' A' ' 52' ' ' LEU . . . -71.89 138.31 48.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 72.41 111.078 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -159.91 167.54 27.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 63.13 111.096 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.37 -57.14 13.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 73.13 111.064 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.5 135.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 72.31 111.143 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.1 p -146.48 120.72 2.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 74.42 111.185 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -120.01 109.81 15.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 74.11 110.848 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 10' ' ' VAL . 36.7 t -123.65 135.18 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 61.34 111.148 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.5 HD13 ' CG ' ' A' ' 13' ' ' LYS . 4.5 pp -92.71 145.49 24.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 72.02 110.955 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.61 121.33 29.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 65.54 110.878 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 59.5 mt-10 -97.69 136.76 37.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.941 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -55.13 139.74 40.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 75.12 110.88 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 44.35 110.818 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.807 0.337 . . . . 72.11 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -96.66 118.58 6.06 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 33.14 112.532 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 61.1 t60 -73.9 117.01 15.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.788 0.328 . . . . 75.12 110.881 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 -103.38 135.01 45.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 62.11 110.89 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -84.95 142.85 29.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.445 . . . . 72.04 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 46.4 m80 -99.99 99.67 10.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 71.31 110.873 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -116.75 176.84 4.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 74.02 110.897 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -88.61 79.19 7.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 73.02 110.807 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 87.1 m -122.28 144.81 48.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 51.53 111.075 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.3 mttt -108.86 114.73 28.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 74.23 110.914 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.07 155.55 0.19 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 42.34 112.513 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 17.6 t30 -158.0 122.26 4.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.347 . . . . 73.41 110.93 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 19' ' ' ILE . 21.8 t -114.22 128.67 71.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.13 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.464 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -136.18 152.07 50.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 73.43 111.188 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.83 148.84 28.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 72.2 110.893 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.56 21.89 6.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.142 -0.481 . . . . 60.22 110.901 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.407 HG21 ' OH ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -94.0 -58.58 2.2 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 75.14 111.17 179.964 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -119.14 -25.98 6.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.263 -0.426 . . . . 72.52 110.883 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.8 29.02 5.12 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 53.34 112.499 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -101.14 160.5 26.47 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.559 0.695 . . . . 74.15 110.888 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.464 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.6 Cg_endo -69.73 145.46 57.39 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.688 2.259 . . . . 61.23 112.329 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.728 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 47.4 mm -83.07 115.63 25.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 75.31 111.171 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.3 mt -104.83 113.1 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.471 . . . . 42.2 111.191 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.51 32.66 6.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.5 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.728 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -91.06 128.14 36.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.858 0.361 . . . . 63.11 111.062 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.0 m -81.25 107.19 13.83 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.215 -0.448 . . . . 52.44 110.853 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.709 HG23 HG13 ' A' ' 54' ' ' ILE . 3.0 p -120.09 122.7 69.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.088 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.757 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.6 m -134.27 174.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 74.52 111.138 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 35.3 mp0 -91.17 166.14 13.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 74.12 110.92 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -65.43 -41.99 92.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.145 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.1 p -112.56 -22.16 10.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 64.03 111.083 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.601 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -101.32 65.65 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 63.21 111.086 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 87.5 m -77.34 -35.71 54.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 73.01 111.096 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.7 p -57.07 -31.6 65.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.23 111.169 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.664 ' O ' HD21 ' A' ' 44' ' ' LEU . 1.7 m-20 -94.45 31.41 1.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.3 110.929 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.757 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.36 152.37 49.64 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.781 -0.723 . . . . 61.22 112.499 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.593 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -135.56 168.46 19.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.74 0.305 . . . . 73.43 111.138 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.6 pt -116.55 167.72 9.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 72.12 111.134 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.499 HG22 ' HD2' ' A' ' 42' ' ' PHE . 23.0 p -89.74 150.61 22.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 55.34 111.174 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -95.22 -178.93 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 34.54 110.915 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -57.79 -30.44 65.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.48 . . . . 72.12 110.885 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -73.55 -19.39 60.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.152 -0.476 . . . . 73.22 110.892 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.7 28.26 12.83 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 120.736 -0.745 . . . . 75.31 112.458 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -136.58 166.07 24.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.914 0.388 . . . . 71.23 110.93 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.548 ' CZ ' HG21 ' A' ' 24' ' ' VAL . 24.2 p90 -142.66 164.75 29.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 71.21 110.902 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -123.46 117.79 25.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.166 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.664 HD21 ' O ' ' A' ' 32' ' ' ASN . 0.3 OUTLIER -144.44 134.97 24.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.41 . . . . 72.23 110.903 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.582 ' N ' HD13 ' A' ' 44' ' ' LEU . 1.2 t -107.02 121.85 45.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 73.42 110.846 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.5 t -126.92 133.26 24.84 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.565 0.698 . . . . 71.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.0 Cg_endo -69.69 -48.42 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.731 2.288 . . . . 60.01 112.353 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.77 149.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 71.24 111.167 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 70.8 m-80 -85.16 64.39 8.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 63.41 110.92 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -92.49 -179.56 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 64.13 110.812 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.71 156.08 19.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.075 -0.512 . . . . 72.33 111.17 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mt -115.24 124.9 52.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.275 -0.42 . . . . 62.04 110.888 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.584 ' HA ' HG22 ' A' ' 63' ' ' THR . 28.8 tttt -95.64 122.43 38.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 74.21 110.885 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.709 HG13 HG23 ' A' ' 24' ' ' VAL . 2.2 mp -118.65 134.55 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 73.4 111.131 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 45.7 p -142.55 138.74 31.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 62.11 111.123 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -134.31 119.13 18.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 65.43 110.95 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -51.49 112.46 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.132 -0.486 . . . . 74.23 111.175 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 133.98 -52.14 0.82 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.783 -0.723 . . . . 45.03 112.473 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.407 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.1 m-85 -108.27 170.0 8.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.379 . . . . 61.23 110.919 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -62.81 158.24 53.87 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.553 0.692 . . . . 75.3 110.885 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.44 42.09 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.677 2.251 . . . . 71.32 112.334 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.1 m -150.72 138.5 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.155 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 53' ' ' LYS . 34.6 p -131.37 139.52 49.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 60.11 111.166 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.701 HG11 HG22 ' A' ' 72' ' ' VAL . 26.5 m -146.69 147.05 18.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 74.21 111.153 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -66.04 157.1 31.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.982 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.99 125.9 29.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 72.41 111.168 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -156.79 166.49 33.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 63.13 111.106 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.23 -43.34 78.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.117 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.0 mt -140.48 112.11 4.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 72.31 111.11 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.514 HG21 ' HB ' ' A' ' 64' ' ' VAL . 7.7 p -130.49 128.83 64.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.131 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -102.71 133.55 47.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 74.11 110.877 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.701 HG22 HG11 ' A' ' 64' ' ' VAL . 21.5 t -122.29 148.89 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 61.34 111.1 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 13.2 mt -122.0 127.82 50.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 72.02 110.885 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.653 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.4 tp -88.19 121.58 30.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 65.54 110.866 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -90.39 144.42 25.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 73.42 110.921 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -58.24 141.33 51.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 75.12 110.897 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -103.95 147.84 26.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 44.35 110.863 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 13.8 p 49.93 38.65 16.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 74.43 111.047 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -147.81 120.28 8.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 74.23 110.941 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 11.2 ttm -99.78 103.83 15.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.23 110.861 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -129.79 110.4 19.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 72.15 111.128 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -92.02 127.97 37.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.858 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -109.14 66.8 0.64 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 64.43 110.882 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 13.4 p -129.25 147.59 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 53.25 111.13 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.7 p -157.2 144.24 10.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 62.05 111.092 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.5 p -158.5 134.45 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.01 111.14 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 32.2 p -120.21 -178.0 3.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 65.24 111.088 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.43 -134.33 3.19 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.741 -0.743 . . . . 61.42 112.485 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -58.97 148.64 29.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.901 0.382 . . . . 75.33 110.979 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 73.03 111.074 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 1.5 mpt? . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.8 0.333 . . . . 72.11 110.897 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -81.06 -82.75 0.79 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.741 -0.742 . . . . 33.14 112.497 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -114.56 -175.26 2.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 75.12 110.875 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -143.74 142.95 31.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 62.11 110.848 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 82.9 m-70 -139.71 154.89 47.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 72.04 110.86 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -59.46 -50.39 74.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 71.31 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -156.65 -176.57 6.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 74.02 110.869 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -128.21 62.09 1.44 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.221 -0.445 . . . . 73.02 110.837 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.7 t -81.8 167.02 19.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.44 . . . . 51.53 111.164 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mmtm -144.77 121.3 11.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.23 110.9 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.94 152.48 0.35 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 42.34 112.493 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.2 t30 -153.64 120.12 5.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 73.41 110.895 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.73 ' HB ' HG21 ' A' ' 36' ' ' THR . 22.4 t -109.7 129.8 63.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 73.33 111.175 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.55 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.7 p -136.57 176.55 8.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.209 -0.45 . . . . 73.43 111.148 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.601 ' OG ' HD11 ' A' ' 19' ' ' ILE . 0.3 OUTLIER -103.27 150.98 23.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.2 110.863 -179.846 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.564 ' HG3' HD12 ' A' ' 73' ' ' LEU . 1.3 tmmt? -93.48 19.26 8.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 60.22 110.894 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.13 -58.72 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.244 -0.435 . . . . 75.14 111.146 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -120.17 -26.42 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 72.52 110.851 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.34 29.39 5.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.742 -0.742 . . . . 53.34 112.485 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.7 mm100 -100.35 160.24 27.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 74.15 110.911 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.55 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.9 Cg_endo -69.72 137.67 36.14 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.715 2.277 . . . . 61.23 112.368 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.601 HD11 ' OG ' ' A' ' 12' ' ' SER . 42.6 mm -87.15 125.33 40.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 75.31 111.177 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.4 mt -104.89 113.47 42.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 42.2 111.134 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.04 33.03 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.486 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.66 119.26 26.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.754 0.312 . . . . 63.11 111.073 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.23 107.53 5.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 52.44 110.859 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.622 HG13 HG13 ' A' ' 54' ' ' ILE . 57.0 t -109.99 106.5 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.102 -0.499 . . . . 75.44 111.121 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.4 m -114.97 140.76 34.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.132 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.502 ' CD ' HG11 ' A' ' 46' ' ' VAL . 18.8 tt0 -85.79 133.52 33.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 74.12 110.857 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.6 p -54.51 -35.86 63.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 52.43 111.098 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.3 p -78.97 -22.09 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.267 -0.424 . . . . 64.03 111.133 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.51 110.69 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 63.21 111.079 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -86.51 -33.93 20.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.111 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 77.7 p -53.18 -29.59 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 74.23 111.154 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -94.26 31.19 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.3 110.885 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -73.25 141.18 29.65 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.801 -0.714 . . . . 61.22 112.46 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.423 HG21 ' O ' ' A' ' 43' ' ' THR . 0.2 OUTLIER -113.41 168.9 9.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.737 0.303 . . . . 73.43 111.146 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.405 ' H ' HG22 ' A' ' 34' ' ' THR . 4.8 pt -124.13 148.59 28.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 72.12 111.119 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.73 HG21 ' HB ' ' A' ' 10' ' ' VAL . 9.9 p -73.93 150.74 40.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 55.34 111.174 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -99.79 -175.33 2.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 34.54 110.873 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -56.38 -31.47 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.886 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -76.78 -18.88 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.462 . . . . 73.22 110.905 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.25 28.84 10.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 75.31 112.518 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -135.99 159.88 40.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.822 0.344 . . . . 71.23 110.931 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.494 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 30.9 p90 -140.2 168.0 20.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 71.21 110.893 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.423 ' O ' HG21 ' A' ' 34' ' ' THR . 39.2 p -109.53 116.17 31.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 72.34 111.165 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.67 107.48 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 72.23 110.909 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 29.1 t -106.95 120.12 41.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 73.42 110.86 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.502 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.2 m -129.99 156.19 79.49 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.651 0.739 . . . . 71.43 111.109 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -48.02 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.7 2.267 . . . . 60.01 112.352 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 m -101.94 175.79 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 71.24 111.12 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -106.55 58.89 0.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.897 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.5 p -72.7 -170.2 0.66 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.493 . . . . 64.13 110.857 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.471 ' C ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -89.14 152.43 21.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 72.33 111.133 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.847 HD13 ' HB2' ' A' ' 66' ' ' ALA . 10.0 mp -122.31 121.64 37.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 62.04 110.877 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 47.2 tttt -96.88 123.14 40.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.888 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.622 HG13 HG13 ' A' ' 24' ' ' VAL . 5.4 mp -116.56 132.23 66.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.446 . . . . 73.4 111.121 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.6 p -143.08 138.56 29.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 62.11 111.121 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.824 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -137.72 127.63 25.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.19 -0.459 . . . . 65.43 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.42 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.6 tp -51.63 119.98 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.489 . . . . 74.23 111.119 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.99 -51.12 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.775 -0.726 . . . . 45.03 112.479 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -108.61 170.12 8.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.933 0.397 . . . . 61.23 110.916 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -69.92 158.11 88.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.57 0.7 . . . . 75.3 110.914 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 164.56 34.12 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.681 2.254 . . . . 71.32 112.304 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.466 HG11 ' CG1' ' A' ' 72' ' ' VAL . 14.5 p -151.4 149.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.126 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.7 p -132.02 132.56 43.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.124 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.749 HG11 HG22 ' A' ' 72' ' ' VAL . 31.0 m -137.72 172.17 14.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.439 . . . . 74.21 111.16 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.38 156.82 18.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.901 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.847 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -93.18 130.07 38.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 72.41 111.045 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.55 -175.55 3.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 63.13 111.072 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.512 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -53.35 -49.53 66.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 73.13 111.097 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 68' ' ' ALA . 43.9 mm -139.2 114.2 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 72.31 111.156 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.31 125.13 67.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 74.42 111.088 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -98.68 135.06 40.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.91 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.749 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -128.33 147.6 32.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 61.34 111.153 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.564 HD12 ' HG3' ' A' ' 13' ' ' LYS . 1.2 pt? -127.12 138.09 53.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.214 -0.448 . . . . 72.02 110.922 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.824 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.2 tp -88.83 124.93 34.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 65.54 110.943 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -90.29 136.85 32.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 73.42 110.855 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -58.99 140.17 55.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.12 110.945 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -96.41 36.15 1.39 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 44.35 110.904 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 14.1 t -102.48 140.59 36.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.474 . . . . 74.43 111.165 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -143.92 117.49 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.23 110.931 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 9.8 mtp -108.09 79.66 1.29 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 74.23 110.85 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 16.7 m -79.11 58.65 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 72.15 111.103 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -57.99 158.72 6.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 62.52 110.86 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.6 mp0 -119.5 61.78 0.82 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 64.43 110.873 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -106.25 119.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 53.25 111.147 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.7 p -155.36 144.33 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 62.05 111.155 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.6 t -139.3 144.77 28.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.169 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 9.9 t -137.64 158.7 43.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 65.24 111.1 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 146.56 122.69 1.42 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.703 -0.761 . . . . 61.42 112.491 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -133.54 163.69 28.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.95 0.405 . . . . 75.33 110.947 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.5 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.142 -0.481 . . . . 73.03 111.121 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.0 mpt? . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.834 0.349 . . . . 72.11 110.867 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.93 -107.92 0.2 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.805 -0.712 . . . . 33.14 112.594 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 23.3 m80 56.56 50.09 13.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.832 0.349 . . . . 75.12 110.856 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -123.06 37.47 4.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 62.11 110.87 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -72.77 -36.21 67.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 72.04 110.884 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.3 p80 -71.62 139.9 49.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 71.31 110.877 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -73.37 -179.34 3.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 74.02 110.854 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -73.57 94.4 2.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 73.02 110.883 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.499 HG21 HD22 ' A' ' 41' ' ' ASN . 15.1 t -134.19 170.01 16.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.153 -0.476 . . . . 51.53 111.116 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.74 139.55 47.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.461 . . . . 74.23 110.936 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.49 96.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.653 -0.784 . . . . 42.34 112.498 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -118.39 128.19 54.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.915 0.388 . . . . 73.41 110.875 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.477 HG22 ' HB ' ' A' ' 72' ' ' VAL . 89.2 t -119.7 129.17 75.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 73.33 111.08 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.45 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.9 p -129.7 178.1 6.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.43 111.162 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 t -97.2 151.02 20.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.263 -0.426 . . . . 72.2 110.892 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.428 ' HG3' HD12 ' A' ' 73' ' ' LEU . 7.2 tmtt? -92.05 15.43 13.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 60.22 110.938 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.0 p -94.07 -59.07 2.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.238 -0.437 . . . . 75.14 111.117 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -120.44 -26.63 5.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 72.52 110.844 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.16 29.19 5.26 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.539 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -94.26 160.15 32.56 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.592 0.71 . . . . 74.15 110.913 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.2 Cg_endo -69.67 139.5 40.7 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.703 2.269 . . . . 61.23 112.342 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.641 HG22 ' HB2' ' A' ' 22' ' ' ALA . 49.2 mm -83.97 113.56 23.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.104 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 22.6 mt -101.06 128.88 52.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 42.2 111.085 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.96 32.61 26.01 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.769 -0.729 . . . . 62.52 112.486 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.641 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -90.96 135.64 33.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.796 0.331 . . . . 63.11 111.093 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -85.6 107.2 17.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 52.44 110.804 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.722 HG23 HG13 ' A' ' 54' ' ' ILE . 2.9 p -118.33 122.39 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 75.44 111.107 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.726 HG12 ' HA3' ' A' ' 33' ' ' GLY . 16.2 m -134.61 151.83 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.149 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.528 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 13.8 tp10 -75.62 132.65 40.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 74.12 110.897 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.8 p -51.52 -34.93 38.39 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.091 -0.504 . . . . 52.43 111.153 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -96.68 -22.08 17.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 64.03 111.132 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.528 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -127.19 89.75 3.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.451 . . . . 63.21 111.104 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.8 p -86.79 -35.65 19.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.136 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 91.1 m -56.68 -31.0 64.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 74.23 111.146 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -93.13 30.74 1.58 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.19 -0.459 . . . . 74.3 110.865 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.726 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.52 147.01 50.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.782 -0.723 . . . . 61.22 112.517 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.616 HG22 HD11 ' A' ' 44' ' ' LEU . 13.6 t -135.49 168.94 18.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.787 0.327 . . . . 73.43 111.112 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.7 pt -110.98 158.15 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.116 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.506 HG22 ' HD2' ' A' ' 42' ' ' PHE . 39.2 p -80.34 150.68 29.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 55.34 111.143 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.37 176.3 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 34.54 110.893 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -56.95 -30.18 63.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 72.12 110.858 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -73.12 -19.05 61.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 73.22 110.914 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.62 28.26 17.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 75.31 112.462 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.499 HD22 HG21 ' A' ' 6' ' ' THR . 26.4 p30 -131.95 165.43 23.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 71.23 110.878 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.619 ' CE1' HG21 ' A' ' 24' ' ' VAL . 26.7 p90 -148.51 168.04 23.76 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 71.21 110.851 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 43' ' ' THR . 4.9 t -128.99 120.11 25.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.079 -0.51 . . . . 72.34 111.134 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 34' ' ' THR . 0.2 OUTLIER -127.84 111.14 13.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 72.23 110.894 179.92 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.9 m -93.38 111.91 23.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.145 -0.48 . . . . 73.42 110.817 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -128.35 156.1 77.39 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.57 0.7 . . . . 71.43 111.159 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.76 -48.19 0.77 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.67 2.247 . . . . 60.01 112.396 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.8 p -106.13 151.79 8.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 71.24 111.101 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -79.26 60.88 3.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 63.41 110.905 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -75.82 -170.4 1.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 64.13 110.825 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.86 157.52 17.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.105 -0.498 . . . . 72.33 111.122 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.474 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 2.8 mp -120.09 128.58 53.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 62.04 110.882 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.524 ' HA ' HG22 ' A' ' 63' ' ' THR . 64.1 tttt -100.75 123.14 44.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.881 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.722 HG13 HG23 ' A' ' 24' ' ' VAL . 3.7 mp -120.55 134.22 64.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 73.4 111.102 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.1 p -145.76 140.07 26.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 62.11 111.148 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.688 ' HB3' HD21 ' A' ' 74' ' ' LEU . 14.9 t80 -135.6 121.39 19.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 65.43 110.963 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.431 HG23 ' O ' ' A' ' 57' ' ' ILE . 10.8 tt -50.88 117.18 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.094 -0.503 . . . . 74.23 111.105 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.52 -50.76 0.88 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.439 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -109.68 169.98 8.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.969 0.414 . . . . 61.23 110.947 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -64.27 157.73 69.18 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.55 0.69 . . . . 75.3 110.868 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.66 162.26 42.72 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.707 2.272 . . . . 71.32 112.361 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.559 HG23 ' HB ' ' A' ' 54' ' ' ILE . 30.2 m -150.51 133.29 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.097 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.524 HG22 ' HA ' ' A' ' 53' ' ' LYS . 25.2 p -126.9 142.8 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.181 -0.463 . . . . 60.11 111.088 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.829 HG11 HG22 ' A' ' 72' ' ' VAL . 30.3 m -151.15 151.37 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 74.21 111.146 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt -73.98 157.32 36.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 70.32 110.898 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.474 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -71.12 134.18 46.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 72.41 111.11 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.476 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -164.68 161.79 20.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.437 . . . . 63.13 111.11 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.97 -40.36 60.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.13 111.066 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.0 mt -140.86 111.79 3.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 72.31 111.103 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.514 HG11 ' CG2' ' A' ' 64' ' ' VAL . 20.7 t -124.08 112.0 30.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 74.42 111.099 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 69.8 m-20 -96.74 116.6 29.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.926 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.829 HG22 HG11 ' A' ' 64' ' ' VAL . 24.3 t -115.06 148.77 17.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 61.34 111.115 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.428 HD12 ' HG3' ' A' ' 13' ' ' LYS . 0.6 OUTLIER -121.2 139.21 53.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 72.02 110.959 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.688 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -91.21 122.54 33.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 65.54 110.956 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -90.53 141.37 28.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.853 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -59.06 140.53 55.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 75.12 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -120.88 83.07 2.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.154 -0.476 . . . . 44.35 110.87 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 24.7 p -90.97 165.37 13.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 74.43 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -54.94 173.31 0.09 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.933 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.2 ttm -55.76 171.24 0.23 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 74.23 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -107.15 -35.91 3.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 72.15 111.159 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -97.96 36.43 1.56 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 62.52 110.857 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -85.72 95.22 9.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 64.43 110.955 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.3 t -91.09 73.02 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.153 -0.476 . . . . 53.25 111.074 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.34 145.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 62.05 111.224 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -55.13 151.05 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 73.01 111.117 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -67.36 141.65 57.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 65.24 111.159 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.19 70.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.739 -0.743 . . . . 61.42 112.487 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 28.6 t80 -81.29 136.86 35.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.977 0.418 . . . . 75.33 110.873 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 73.03 111.138 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.5 ttm . . . . . 0 N--CA 1.458 -0.062 0 CA-C-O 120.799 0.333 . . . . 72.11 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -165.42 -170.4 30.31 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.709 -0.758 . . . . 33.14 112.493 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 5.4 t-160 -171.05 140.73 1.57 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.822 0.344 . . . . 75.12 110.886 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -137.13 169.11 18.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 62.11 110.852 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -113.55 -179.31 3.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 72.04 110.876 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -135.92 173.96 11.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 71.31 110.9 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 19.5 m80 -95.43 162.72 13.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.842 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -133.51 52.71 2.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.869 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.715 ' O ' HD12 ' A' ' 69' ' ' ILE . 0.2 OUTLIER -93.41 167.16 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 51.53 111.183 -179.977 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.83 -173.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 74.23 110.881 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.46 126.74 24.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.778 -0.725 . . . . 42.34 112.487 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -129.75 127.51 40.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.87 0.367 . . . . 73.41 110.916 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.447 HG23 ' HE2' ' A' ' 42' ' ' PHE . 88.5 t -117.04 125.26 73.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 73.33 111.111 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.2 p -122.79 169.63 10.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 73.43 111.172 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.54 149.62 21.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 72.2 110.897 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -93.21 18.18 9.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.484 . . . . 60.22 110.882 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.21 -58.82 2.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 75.14 111.089 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -120.53 -25.97 5.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 72.52 110.91 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.97 29.13 5.03 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.672 -0.775 . . . . 53.34 112.509 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -98.29 154.13 37.76 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.62 0.724 . . . . 74.15 110.916 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.82 143.08 49.45 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.684 2.256 . . . . 61.23 112.334 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.448 ' CD1' HD22 ' A' ' 74' ' ' LEU . 47.3 mm -83.32 108.11 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 75.31 111.199 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.1 mt -101.46 126.57 55.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 42.2 111.078 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 42.11 7.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.748 -0.739 . . . . 62.52 112.47 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -94.89 162.39 13.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 63.11 111.096 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.2 m -105.62 107.53 18.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 52.44 110.859 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.728 HG13 HG13 ' A' ' 54' ' ' ILE . 43.4 t -110.43 106.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 75.44 111.085 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.9 m -124.64 138.01 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 74.52 111.101 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.512 ' CD ' HG11 ' A' ' 46' ' ' VAL . 10.6 mt-10 -72.02 173.53 8.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.861 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.2 p -76.35 -35.55 58.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.121 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 17.7 p -112.38 -22.14 11.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 64.03 111.104 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -117.2 77.2 1.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.24 -0.436 . . . . 63.21 111.05 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.6 p -86.72 -35.36 19.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.245 -0.434 . . . . 73.01 111.119 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 45.8 p -53.33 -30.2 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.23 111.159 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -94.76 31.3 1.85 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 74.3 110.907 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -59.38 136.1 50.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.485 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 5.0 m -111.15 157.87 19.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.758 0.313 . . . . 73.43 111.128 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -108.59 150.51 11.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 72.12 111.101 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.622 HG22 ' HD2' ' A' ' 42' ' ' PHE . 6.0 p -72.26 149.66 44.33 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.183 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -83.6 -175.44 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 34.54 110.859 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -58.88 -30.86 68.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 72.12 110.901 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.9 21.44 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 73.22 110.906 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.17 27.46 70.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.709 -0.757 . . . . 75.31 112.471 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -108.79 134.91 50.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.829 0.347 . . . . 71.23 110.89 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.622 ' HD2' HG22 ' A' ' 36' ' ' THR . 18.5 p90 -133.54 167.93 19.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 71.21 110.856 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.29 121.42 12.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.162 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.5 mt -120.93 127.81 52.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.209 -0.451 . . . . 72.23 110.907 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -106.93 113.65 27.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 73.42 110.852 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.512 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.3 m -139.2 156.21 72.15 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.657 0.741 . . . . 71.43 111.138 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -48.35 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.651 2.234 . . . . 60.01 112.352 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.66 149.4 5.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 71.24 111.151 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -88.9 52.1 2.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 63.41 110.863 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.1 t -68.53 -169.78 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.992 0.425 . . . . 64.13 110.812 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.554 ' O ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -87.63 157.14 19.19 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.148 -0.478 . . . . 72.33 111.187 -179.955 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 66' ' ' ALA . 7.4 mp -125.39 125.01 42.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 62.04 110.874 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.434 ' HA ' HG22 ' A' ' 63' ' ' THR . 43.1 tttt -102.64 126.89 49.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.194 -0.457 . . . . 74.21 110.912 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.728 HG13 HG13 ' A' ' 24' ' ' VAL . 3.9 mp -123.29 139.33 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 73.4 111.144 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 74.1 p -140.94 139.23 34.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 62.11 111.188 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.471 ' HB3' HD21 ' A' ' 74' ' ' LEU . 17.4 t80 -133.05 119.8 20.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.43 110.926 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.42 116.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 74.23 111.141 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 130.35 -55.13 0.77 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 45.03 112.525 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -108.87 170.63 7.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.984 0.421 . . . . 61.23 110.915 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -62.01 157.72 49.54 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.555 0.693 . . . . 75.3 110.935 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 170.77 15.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.667 2.245 . . . . 71.32 112.367 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.66 ' CG2' HG11 ' A' ' 72' ' ' VAL . 14.6 p -151.49 140.92 15.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 74.11 111.135 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 53' ' ' LYS . 11.4 p -131.95 135.35 46.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 60.11 111.183 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.503 HG11 HG21 ' A' ' 72' ' ' VAL . 6.8 m -152.17 149.24 13.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 74.21 111.2 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.3 mmtm -69.08 153.99 42.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.914 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.654 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -77.43 65.42 2.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 72.41 111.134 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -90.21 -175.1 4.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 63.13 111.045 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.736 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -64.3 -55.08 23.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 73.13 111.137 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.736 HD13 ' O ' ' A' ' 68' ' ' ALA . 17.4 mm -128.76 137.14 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 72.31 111.076 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.5 HG21 HG21 ' A' ' 64' ' ' VAL . 5.7 p -145.7 119.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 74.42 111.111 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 73.3 m-80 -120.24 109.52 15.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 74.11 110.855 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.66 HG11 ' CG2' ' A' ' 62' ' ' VAL . 17.2 t -124.59 149.1 28.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 61.34 111.19 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -103.39 145.73 29.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.02 110.945 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.471 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.6 tp -87.25 120.45 28.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 65.54 110.89 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -90.36 140.4 29.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 73.42 110.872 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -59.1 142.08 52.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 75.12 110.908 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -103.56 98.72 8.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 44.35 110.866 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.9 p -95.01 177.71 5.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.232 -0.44 . . . . 74.43 111.141 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -52.1 137.13 28.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 74.23 110.826 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -52.26 134.36 33.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.165 -0.471 . . . . 74.23 110.956 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.7 m -108.41 67.65 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.426 . . . . 72.15 111.035 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.0 p-10 -54.67 156.42 3.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.434 . . . . 62.52 110.847 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -120.22 74.02 1.02 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 64.43 110.895 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.1 p -135.98 136.58 49.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.162 -0.472 . . . . 53.25 111.079 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 36.1 t -132.12 146.3 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.178 -0.465 . . . . 62.05 111.17 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.5 m -90.47 -176.9 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 73.01 111.092 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.9 t -86.14 157.84 19.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.091 -0.504 . . . . 65.24 111.132 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -110.56 -47.4 0.8 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.739 . . . . 61.42 112.437 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -72.13 141.61 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 75.33 110.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 43.0 p . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 73.03 111.159 179.989 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.23 0.047 0 CA-C-O 120.841 0.353 . . . . 72.11 110.862 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 146.37 43.03 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.717 -0.754 . . . . 33.14 112.474 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 12.9 m-70 -56.21 166.53 0.8 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 75.12 110.828 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 21.7 p80 -123.14 145.06 48.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 62.11 110.84 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -148.79 -179.54 7.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 72.04 110.894 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -115.26 141.0 48.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.226 -0.443 . . . . 71.31 110.899 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 17.4 p80 -161.85 153.12 18.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 74.02 110.875 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -129.89 46.62 2.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.179 -0.464 . . . . 73.02 110.856 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 m -90.78 151.82 21.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 51.53 111.094 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -148.38 112.49 5.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 74.23 110.894 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.6 136.23 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.696 -0.764 . . . . 42.34 112.459 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -144.15 127.52 16.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.41 110.842 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 t -115.57 116.5 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.33 111.091 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.515 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.4 p -129.95 153.72 48.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 73.43 111.152 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -79.88 150.98 30.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.873 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.565 ' HA ' HD12 ' A' ' 73' ' ' LEU . 12.4 tttp -94.01 20.16 8.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.194 -0.457 . . . . 60.22 110.849 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 35.1 p -94.04 -58.79 2.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 75.14 111.168 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -119.39 -26.39 5.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.209 -0.451 . . . . 72.52 110.94 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.5 5.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.856 -0.688 . . . . 53.34 112.495 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -97.95 160.4 28.54 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.586 0.707 . . . . 74.15 110.835 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.515 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.8 148.28 64.43 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.73 2.287 . . . . 61.23 112.318 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.411 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.4 mm -95.16 122.75 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.31 111.17 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.7 mt -107.4 116.28 50.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 42.2 111.136 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 99.41 33.26 5.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.499 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -89.57 129.41 36.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.805 0.336 . . . . 63.11 111.052 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 m -76.99 108.34 9.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 52.44 110.861 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.791 HG21 ' CD2' ' A' ' 42' ' ' PHE . 68.7 t -114.87 106.18 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 75.44 111.103 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 33' ' ' GLY . 18.3 m -123.9 151.21 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.123 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.685 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 4.0 mm-40 -81.83 166.78 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 74.12 110.908 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.06 -41.99 98.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 52.43 111.136 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 33.6 p -112.44 -22.06 11.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.233 -0.44 . . . . 64.03 111.123 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.685 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -100.77 75.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 63.21 111.072 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.4 p -86.67 -35.61 19.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 73.01 111.173 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -60.6 -30.77 70.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.282 -0.417 . . . . 74.23 111.18 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -94.46 31.2 1.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 74.3 110.867 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.425 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -61.12 139.01 47.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.701 -0.761 . . . . 61.22 112.513 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.484 ' HB ' HD11 ' A' ' 44' ' ' LEU . 0.3 OUTLIER -113.71 167.37 10.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.771 0.32 . . . . 73.43 111.168 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' H ' HG22 ' A' ' 34' ' ' THR . 7.9 pt -124.14 147.16 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 72.12 111.152 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 34.4 p -69.94 137.98 51.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 55.34 111.145 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.7 -179.52 7.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 34.54 110.856 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -57.0 -30.22 63.97 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 72.12 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -73.5 -18.75 61.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.85 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.08 28.21 14.13 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.738 -0.744 . . . . 75.31 112.529 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -134.2 168.35 19.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.856 0.36 . . . . 71.23 110.935 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.791 ' CD2' HG21 ' A' ' 24' ' ' VAL . 3.1 p90 -141.89 167.93 20.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 71.21 110.869 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 27.1 p -124.98 116.99 23.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.13 -0.486 . . . . 72.34 111.137 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 8.0 mp -136.58 120.79 17.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 72.23 110.915 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 26.7 m -106.94 112.05 24.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.092 -0.504 . . . . 73.42 110.886 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.95 156.16 69.49 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.661 0.743 . . . . 71.43 111.108 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -48.25 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.633 2.222 . . . . 60.01 112.338 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.6 p -110.51 152.11 12.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.118 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -80.63 58.49 3.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 63.41 110.942 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 94.9 p -72.84 -169.83 0.63 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 64.13 110.862 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.452 HG23 ' HG2' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -87.7 153.11 21.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 72.33 111.094 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.795 HD11 ' HB2' ' A' ' 66' ' ' ALA . 5.9 mp -126.27 126.13 43.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 62.04 110.889 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.652 ' HA ' HG22 ' A' ' 63' ' ' THR . 12.1 ttpt -95.63 122.2 38.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.869 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.74 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.8 mt -121.26 137.2 55.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 73.4 111.15 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.5 p -147.39 138.77 23.87 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.153 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -133.54 119.0 18.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 65.43 111.02 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.02 117.58 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.176 -0.465 . . . . 74.23 111.185 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.68 -52.89 0.82 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.781 -0.723 . . . . 45.03 112.458 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -110.34 170.19 8.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.952 0.406 . . . . 61.23 110.945 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -60.5 157.63 35.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.589 0.709 . . . . 75.3 110.902 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 166.87 26.02 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.723 2.282 . . . . 71.32 112.283 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.5 m -151.24 126.35 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 74.11 111.112 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.652 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.8 p -125.06 132.81 53.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.109 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.479 HG11 ' CG2' ' A' ' 72' ' ' VAL . 14.8 m -152.09 157.34 5.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.079 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.452 ' HG2' HG23 ' A' ' 51' ' ' THR . 39.6 mtpt -84.13 155.11 22.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 70.32 110.953 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.795 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.09 133.6 46.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 72.41 111.091 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.16 -179.67 8.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 63.13 111.101 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.73 -58.02 7.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 73.13 111.102 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 68' ' ' ALA . 41.0 mm -142.36 111.65 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 72.31 111.104 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.76 122.3 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 74.42 111.167 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -119.78 115.33 23.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.888 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.718 HG11 ' HB ' ' A' ' 62' ' ' VAL . 18.7 t -113.16 126.9 70.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 61.34 111.109 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.565 HD12 ' HA ' ' A' ' 13' ' ' LYS . 0.7 OUTLIER -83.34 140.59 32.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.894 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.402 HD12 ' HA ' ' A' ' 74' ' ' LEU . 1.5 tp -87.9 121.73 30.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.899 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -90.2 137.06 32.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.9 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -57.45 141.78 46.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 75.12 110.872 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -85.73 144.36 27.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.093 -0.503 . . . . 44.35 110.853 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.0 t -175.15 152.22 1.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.156 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 30.0 tt0 -82.14 121.41 26.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 74.23 110.887 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.5 mmt -68.89 103.52 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 74.23 110.901 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.568 HG22 ' H ' ' A' ' 83' ' ' GLU . 13.5 p -169.94 133.1 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.261 -0.427 . . . . 72.15 111.089 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -120.43 34.84 5.07 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.151 -0.477 . . . . 62.52 110.9 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.568 ' H ' HG22 ' A' ' 81' ' ' VAL . 32.8 tt0 -108.93 82.34 1.58 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 64.43 110.883 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.2 m -59.52 137.57 21.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.175 -0.466 . . . . 53.25 111.122 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.87 130.0 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.153 -0.476 . . . . 62.05 111.203 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.94 136.83 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 73.01 111.158 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 72.1 p -121.91 72.0 1.01 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 65.24 111.13 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.54 -126.38 8.43 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.849 -0.691 . . . . 61.42 112.457 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -172.46 155.47 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.983 0.42 . . . . 75.33 110.898 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.7 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 73.03 111.123 -179.941 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.725 0.297 . . . . 72.11 110.814 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 129.27 77.57 0.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.769 -0.729 . . . . 33.14 112.488 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -109.2 149.51 29.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 75.12 110.88 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 40.8 m170 -120.1 -179.2 3.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 62.11 110.865 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -125.93 126.13 43.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 72.04 110.818 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -167.65 169.93 11.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.31 110.844 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.4 t-80 -166.5 130.54 2.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.19 -0.459 . . . . 74.02 110.858 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.422 ' CD2' HG22 ' A' ' 6' ' ' THR . 23.9 p-80 -129.35 -47.79 1.19 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.265 -0.425 . . . . 73.02 110.801 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.422 HG22 ' CD2' ' A' ' 5' ' ' HIS . 14.7 t -126.81 165.16 19.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.189 -0.46 . . . . 51.53 111.14 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.5 pttp -129.43 152.66 48.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 74.23 110.929 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.12 145.26 0.51 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.719 -0.753 . . . . 42.34 112.466 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -152.61 128.35 10.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.875 0.369 . . . . 73.41 110.859 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.666 HG22 HD13 ' A' ' 54' ' ' ILE . 94.2 t -117.99 131.8 69.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 73.33 111.112 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.565 HG22 ' HA ' ' A' ' 18' ' ' PRO . 16.9 p -138.12 172.88 12.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 73.43 111.088 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.417 ' HB2' HD11 ' A' ' 19' ' ' ILE . 1.2 t -92.74 156.25 17.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 72.2 110.922 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -93.57 16.38 13.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 60.22 110.876 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.1 p -94.05 -59.07 2.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 75.14 111.095 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -120.68 -26.24 5.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.52 110.91 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.63 29.12 5.14 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.747 -0.74 . . . . 53.34 112.503 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -95.02 153.93 39.74 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.606 0.717 . . . . 74.15 110.889 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.565 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.7 135.75 31.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.73 2.286 . . . . 61.23 112.296 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.417 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -84.6 135.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 75.31 111.127 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.0 mt -114.29 125.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 42.2 111.104 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.86 33.83 10.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 62.52 112.492 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -86.17 162.67 18.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.72 0.295 . . . . 63.11 111.176 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.53 113.5 27.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 52.44 110.852 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.705 HG21 ' CD2' ' A' ' 42' ' ' PHE . 44.6 t -116.76 134.04 61.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 75.44 111.12 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.1 m -139.64 148.87 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 74.52 111.064 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.664 ' HG3' HG11 ' A' ' 46' ' ' VAL . 1.7 tm-20 -88.5 135.11 33.64 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 74.12 110.846 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.411 HG21 ' HB ' ' A' ' 51' ' ' THR . 21.0 p -55.5 -32.64 63.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 52.43 111.159 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.6 p -71.87 -22.36 61.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.186 -0.461 . . . . 64.03 111.105 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -178.64 134.61 0.14 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 63.21 111.091 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.3 p -87.8 -19.29 27.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.241 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.0 p -52.16 -30.33 26.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.213 -0.449 . . . . 74.23 111.092 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.9 p-10 -93.2 31.24 1.5 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.917 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.69 135.51 38.4 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 61.22 112.483 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.58 ' HB ' HD11 ' A' ' 44' ' ' LEU . 2.5 m -124.38 161.45 25.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 73.43 111.164 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -107.71 145.67 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 72.12 111.133 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 52.7 p -70.07 149.51 47.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 55.34 111.155 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -87.14 -175.83 5.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.43 . . . . 34.54 110.871 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -57.11 -30.69 64.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 72.12 110.869 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -99.79 22.09 11.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 73.22 110.882 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.32 28.31 72.1 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 75.31 112.521 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASN . . . . . 0.401 ' ND2' HG21 ' A' ' 6' ' ' THR . 64.7 m-20 -110.75 128.84 55.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.874 0.369 . . . . 71.23 110.906 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.705 ' CD2' HG21 ' A' ' 24' ' ' VAL . 1.6 p90 -116.57 167.32 11.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.827 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 2.6 t -121.42 116.87 25.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 72.34 111.138 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 7.0 mp -141.15 116.75 10.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 72.23 110.9 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.3 m -106.81 108.16 19.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 73.42 110.887 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.664 HG11 ' HG3' ' A' ' 26' ' ' GLU . 3.4 m -124.69 156.08 68.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.579 0.704 . . . . 71.43 111.128 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -48.41 0.73 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.693 2.262 . . . . 60.01 112.351 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -103.67 152.0 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.182 -0.463 . . . . 71.24 111.103 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -84.94 68.36 10.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 63.41 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.0 t -80.57 -169.94 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 64.13 110.87 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.411 ' HB ' HG21 ' A' ' 27' ' ' THR . 0.6 OUTLIER -88.86 159.31 17.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.179 -0.464 . . . . 72.33 111.094 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.436 ' CD2' HD22 ' A' ' 44' ' ' LEU . 16.0 mt -124.0 135.21 53.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.902 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.601 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.3 OUTLIER -105.7 129.86 53.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 74.21 110.915 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 10' ' ' VAL . 17.6 mt -123.7 134.67 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.097 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 25.2 p -149.78 139.48 21.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 62.11 111.134 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.499 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -138.22 125.88 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 65.43 110.879 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 57' ' ' ILE . 3.7 tp -50.94 107.93 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 74.23 111.163 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.89 -47.04 0.91 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.785 -0.721 . . . . 45.03 112.524 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -112.47 170.89 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.382 . . . . 61.23 110.951 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.2 mttt -68.4 158.19 85.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.54 0.686 . . . . 75.3 110.935 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.67 160.3 50.26 Favored 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.696 2.264 . . . . 71.32 112.339 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.472 HG13 ' HB ' ' A' ' 54' ' ' ILE . 13.0 p -151.26 139.76 14.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 74.11 111.188 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.601 HG22 ' HA ' ' A' ' 53' ' ' LYS . 1.4 p -132.14 134.83 45.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 60.11 111.175 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.408 HG21 HG22 ' A' ' 72' ' ' VAL . 25.0 m -144.54 151.91 15.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 74.21 111.147 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.92 155.4 27.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 70.32 110.874 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -90.56 120.87 32.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 72.41 111.131 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -146.34 178.64 8.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 63.13 111.137 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.43 -44.22 68.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.13 111.096 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 56.2 mt -147.31 112.14 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.449 . . . . 72.31 111.059 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.61 128.42 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.172 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 80.0 m-20 -95.91 137.56 34.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 74.11 110.892 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.466 HG21 ' CD1' ' A' ' 54' ' ' ILE . 21.2 t -124.51 148.98 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 61.34 111.192 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.58 125.74 40.84 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 72.02 110.873 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.499 HD21 ' HB3' ' A' ' 56' ' ' TYR . 2.4 tp -91.91 118.31 30.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 65.54 110.928 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -96.03 135.94 37.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 73.42 110.932 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -52.39 145.62 10.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.882 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -110.89 69.77 0.7 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.122 -0.49 . . . . 44.35 110.842 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -75.48 -38.5 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.43 111.126 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -82.51 60.15 5.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.23 110.949 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 50.0 mtp -67.89 131.25 45.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 74.23 110.866 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.3 p -171.63 133.78 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 72.15 111.111 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -74.26 153.87 39.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 62.52 110.879 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.39 67.68 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 64.43 110.938 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -117.61 96.1 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 53.25 111.136 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 p -54.63 145.89 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 62.05 111.127 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 47.6 t -66.74 130.82 32.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.053 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 37.2 p -101.28 140.16 35.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 65.24 111.135 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -83.03 62.83 4.58 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.726 -0.749 . . . . 61.42 112.538 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -135.41 144.38 46.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.005 0.431 . . . . 75.33 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 p . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 116.095 -0.502 . . . . 73.03 111.137 -179.975 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 32.1 mmt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.802 0.334 . . . . 72.11 110.955 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -132.86 148.92 19.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.766 -0.73 . . . . 33.14 112.572 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 18.3 m80 -129.39 133.08 47.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.829 0.347 . . . . 75.12 110.819 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -83.6 179.94 7.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 62.11 110.866 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 29.4 m80 -88.77 -177.46 5.53 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 72.04 110.85 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 10.2 t60 -137.01 164.81 27.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 71.31 110.835 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -104.29 151.84 22.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 74.02 110.866 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -90.16 119.99 30.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.253 -0.43 . . . . 73.02 110.876 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.2 t -126.43 171.15 11.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 51.53 111.119 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -96.18 -176.3 3.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 74.23 110.905 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.84 132.79 40.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 42.34 112.465 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -131.53 126.43 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.913 0.387 . . . . 73.41 110.861 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.58 HG12 HG13 ' A' ' 19' ' ' ILE . 30.5 t -118.08 128.9 75.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 73.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.22 167.02 16.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.14 -0.482 . . . . 73.43 111.137 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.59 144.33 25.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 72.2 110.835 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.4 tttm -92.78 15.62 14.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.125 -0.488 . . . . 60.22 110.844 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -58.49 2.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 75.14 111.119 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -117.97 -26.81 6.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.23 29.13 5.26 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.701 -0.762 . . . . 53.34 112.463 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -98.34 160.12 28.95 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.58 0.705 . . . . 74.15 110.886 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 143.65 51.91 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.709 2.273 . . . . 61.23 112.375 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.701 HD12 HD22 ' A' ' 74' ' ' LEU . 51.3 mm -83.13 110.0 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 75.31 111.137 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.1 mt -103.45 126.94 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.446 . . . . 42.2 111.116 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.29 33.2 23.61 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 62.52 112.478 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.697 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -87.22 131.37 34.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 63.11 111.07 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.3 m -80.19 107.57 13.09 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.129 -0.487 . . . . 52.44 110.842 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.841 HG22 HG23 ' A' ' 54' ' ' ILE . 60.9 t -106.66 105.86 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.112 -0.495 . . . . 75.44 111.112 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 28.2 m -120.6 133.65 66.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 74.52 111.126 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -91.96 141.52 28.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.474 . . . . 74.12 110.915 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.9 p -55.43 -31.66 62.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 52.43 111.152 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.7 p -71.54 -21.38 61.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.215 -0.448 . . . . 64.03 111.193 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.52 111.49 0.79 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 63.21 111.049 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 m -85.46 -34.65 21.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 73.01 111.156 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 61.8 p -66.8 -26.44 66.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 74.23 111.179 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -93.51 31.22 1.57 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.903 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -74.99 150.26 40.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.77 -0.729 . . . . 61.22 112.473 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.473 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -117.81 168.76 10.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.738 0.304 . . . . 73.43 111.157 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.0 pt -111.68 171.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 72.12 111.139 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.59 HG22 ' HD2' ' A' ' 42' ' ' PHE . 21.8 p -99.35 150.62 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 55.34 111.155 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.33 179.93 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.435 . . . . 34.54 110.88 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -59.33 -30.7 68.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.852 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -73.81 -19.48 60.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.899 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.92 28.08 11.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.739 -0.743 . . . . 75.31 112.525 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -132.43 160.21 37.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.853 0.358 . . . . 71.23 110.932 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.59 ' HD2' HG22 ' A' ' 36' ' ' THR . 16.6 p90 -138.37 166.08 25.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.881 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.8 t -126.0 119.15 26.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 72.34 111.178 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.596 HD13 ' N ' ' A' ' 45' ' ' SER . 0.3 OUTLIER -146.15 134.3 21.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 72.23 110.932 179.985 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.596 ' N ' HD13 ' A' ' 44' ' ' LEU . 38.5 p -106.89 122.63 46.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.485 . . . . 73.42 110.889 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 61.5 t -129.79 133.25 24.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.683 0.754 . . . . 71.43 111.093 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.5 Cg_endo -69.72 -48.51 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.664 2.242 . . . . 60.01 112.345 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 31.0 m -95.27 141.96 14.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.425 . . . . 71.24 111.162 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -79.39 59.05 2.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 63.41 110.83 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.4 t -80.07 -169.85 2.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 64.13 110.872 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 156.12 17.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 72.33 111.125 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.687 HD11 ' HB2' ' A' ' 66' ' ' ALA . 2.2 mp -129.05 132.22 47.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 62.04 110.903 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 22.8 tttp -106.76 123.25 47.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.245 -0.434 . . . . 74.21 110.909 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.841 HG23 HG22 ' A' ' 24' ' ' VAL . 34.8 mt -119.6 112.61 37.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 73.4 111.178 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.4 p -119.68 145.88 46.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.231 -0.44 . . . . 62.11 111.118 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.417 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -139.06 118.58 12.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 65.43 111.001 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.457 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.9 tt -51.0 107.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.133 -0.485 . . . . 74.23 111.103 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.86 -50.98 0.75 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.47 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -114.28 170.28 8.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.93 0.395 . . . . 61.23 110.92 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -58.22 158.2 14.7 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.3 110.932 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.8 167.79 23.48 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.627 2.218 . . . . 71.32 112.348 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.739 HG13 HG11 ' A' ' 72' ' ' VAL . 96.4 t -135.11 138.68 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 74.11 111.107 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.3 p -132.15 122.56 25.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.138 -0.483 . . . . 60.11 111.141 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 70' ' ' VAL . 6.1 m -152.92 149.9 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.113 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -81.92 157.25 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.88 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.687 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -61.73 130.65 46.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 72.41 111.113 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.52 160.71 38.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 63.13 111.108 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.67 -52.37 48.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 73.13 111.113 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 69.7 mt -129.14 111.62 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 72.31 111.155 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 64' ' ' VAL . 21.8 t -113.62 112.11 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.142 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 -113.66 112.34 23.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.862 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.739 HG11 HG13 ' A' ' 62' ' ' VAL . 39.4 t -129.27 148.16 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 61.34 111.12 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.9 mp -105.08 144.86 31.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.491 . . . . 72.02 110.909 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.701 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.83 122.23 31.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.961 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.8 mm-40 -90.17 140.9 29.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 73.42 110.945 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -58.45 141.23 52.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.904 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -98.96 149.95 22.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.1 -0.5 . . . . 44.35 110.905 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 p -141.67 175.01 10.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 74.43 111.143 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 49.0 tt0 -109.0 90.29 3.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.884 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 4.9 ptt? -125.73 167.24 15.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 74.23 110.874 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 15.8 m -149.63 124.85 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 72.15 111.113 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.3 p30 -60.41 159.1 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 62.52 110.835 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.0 mm-40 -126.48 45.12 2.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 64.43 110.84 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.38 140.25 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 53.25 111.142 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.5 p -131.96 138.67 52.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 62.05 111.16 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 44.0 t -105.8 108.02 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 73.01 111.14 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 11.0 p -99.08 168.12 10.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 65.24 111.134 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -74.21 -159.85 6.68 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.708 -0.758 . . . . 61.42 112.417 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -153.29 161.47 42.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.98 0.419 . . . . 75.33 110.852 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 18.2 m . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.146 -0.479 . . . . 73.03 111.172 179.961 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 71.4 mtm . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.824 0.345 . . . . 72.11 110.956 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.82 140.73 6.48 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.794 -0.717 . . . . 33.14 112.553 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -97.3 150.95 20.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 75.12 110.88 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -165.32 173.33 11.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.197 -0.456 . . . . 62.11 110.855 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 2.1 p-80 -130.35 164.91 23.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 72.04 110.838 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -140.5 158.21 44.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 71.31 110.937 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -128.07 165.69 19.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 74.02 110.89 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -132.54 110.3 10.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.423 . . . . 73.02 110.844 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 88.3 m -123.32 143.59 49.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.146 -0.479 . . . . 51.53 111.177 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.0 tptt -66.34 91.37 0.17 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.287 -0.415 . . . . 74.23 110.899 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.5 147.72 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.767 -0.73 . . . . 42.34 112.439 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -152.69 119.94 5.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.887 0.375 . . . . 73.41 110.946 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.655 HG12 HG13 ' A' ' 19' ' ' ILE . 21.7 t -98.48 122.66 50.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 73.33 111.106 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.07 176.68 6.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 73.43 111.094 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.4 t -97.38 164.0 12.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 72.2 110.925 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.0 tmtt? -104.55 -11.11 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 60.22 110.869 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 55.8 p -77.94 -58.62 3.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.289 -0.414 . . . . 75.14 111.089 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -117.86 -26.38 6.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 72.52 110.854 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 100.99 29.39 6.47 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.734 -0.746 . . . . 53.34 112.495 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -85.05 159.4 57.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.531 0.681 . . . . 74.15 110.978 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 127.89 15.26 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 61.23 112.377 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.756 HD12 HD22 ' A' ' 74' ' ' LEU . 50.1 mm -77.37 120.41 27.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 75.31 111.16 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.7 mt -102.98 141.5 18.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.099 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.42 33.24 86.72 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.718 -0.753 . . . . 62.52 112.521 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.698 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -82.58 122.16 27.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 63.11 111.094 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -74.17 107.5 6.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 52.44 110.837 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.668 HG13 HG12 ' A' ' 54' ' ' ILE . 24.2 t -107.37 106.07 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.128 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.669 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.7 m -124.89 138.06 55.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 74.52 111.102 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.697 ' HA ' HD23 ' A' ' 52' ' ' LEU . 55.4 tt0 -73.67 161.2 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 74.12 110.843 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 p -65.83 -41.82 91.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.466 . . . . 52.43 111.144 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 p -105.77 -22.18 13.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 64.03 111.08 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -116.18 68.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 63.21 111.165 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' HB ' ' A' ' 25' ' ' VAL . 96.5 m -81.53 -35.65 30.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.09 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 3.1 p -53.36 -32.17 48.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 74.23 111.139 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -94.95 31.16 1.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.916 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -65.95 138.95 37.79 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.811 -0.709 . . . . 61.22 112.517 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -117.22 168.72 10.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 73.43 111.155 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 pp -115.47 168.56 7.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.441 . . . . 72.12 111.093 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.605 HG22 ' HD2' ' A' ' 42' ' ' PHE . 70.3 p -101.29 150.76 22.66 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.168 -0.469 . . . . 55.34 111.129 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -90.88 -176.08 4.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.172 -0.467 . . . . 34.54 110.849 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.38 -30.73 68.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 72.12 110.854 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -73.87 -19.5 60.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 73.22 110.897 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.75 28.1 15.07 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.692 -0.766 . . . . 75.31 112.473 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 5.3 p-10 -128.22 157.78 39.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.338 . . . . 71.23 110.906 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.605 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.5 p90 -143.67 167.45 22.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.874 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -123.05 121.69 36.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.477 . . . . 72.34 111.188 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.585 HD22 HG23 ' A' ' 46' ' ' VAL . 2.0 tt -144.01 125.68 15.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.96 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.502 ' N ' HD23 ' A' ' 44' ' ' LEU . 45.0 t -101.72 114.92 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.262 -0.426 . . . . 73.42 110.842 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.585 HG23 HD22 ' A' ' 44' ' ' LEU . 58.3 t -120.6 133.29 24.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.579 0.704 . . . . 71.43 111.165 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.43 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -47.92 0.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.666 2.244 . . . . 60.01 112.343 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.6 m -96.9 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.157 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -111.64 62.38 0.62 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 63.41 110.891 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.6 t -86.88 -172.63 4.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 64.13 110.867 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.24 158.22 17.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.112 -0.495 . . . . 72.33 111.128 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.697 HD23 ' HA ' ' A' ' 26' ' ' GLU . 25.8 mt -128.32 143.13 50.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 62.04 110.947 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 7.1 ttpt -116.48 127.74 54.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 74.21 110.975 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.668 HG12 HG13 ' A' ' 24' ' ' VAL . 79.6 mt -120.01 137.97 52.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 73.4 111.055 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 39.0 p -148.28 138.59 22.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 62.11 111.183 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.75 ' HB3' HD21 ' A' ' 74' ' ' LEU . 15.6 t80 -136.01 126.85 27.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.233 -0.44 . . . . 65.43 110.903 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.434 HG23 ' O ' ' A' ' 57' ' ' ILE . 13.3 tt -51.17 118.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.101 -0.5 . . . . 74.23 111.139 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.16 -51.27 0.85 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.857 -0.687 . . . . 45.03 112.536 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -108.1 170.21 8.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.98 0.419 . . . . 61.23 110.917 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.4 mmtm -68.9 158.19 86.86 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.567 0.698 . . . . 75.3 110.933 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 165.82 29.68 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.729 2.286 . . . . 71.32 112.377 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.565 HG11 ' CG1' ' A' ' 72' ' ' VAL . 11.1 p -151.66 147.94 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.083 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.9 p -132.1 139.83 48.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 60.11 111.148 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.1 m -150.83 171.57 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 74.21 111.076 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.06 157.21 18.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 70.32 110.868 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -86.08 134.08 33.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 72.41 111.099 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.65 179.87 6.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 63.13 111.124 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.497 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -54.34 -57.88 9.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 73.13 111.096 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.497 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -132.13 111.69 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 72.31 111.104 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.82 125.27 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.125 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -95.86 136.76 35.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.878 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.565 ' CG1' HG11 ' A' ' 62' ' ' VAL . 21.7 t -120.96 149.48 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 61.34 111.109 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 10.3 mt -125.45 124.15 40.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.885 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.756 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.84 122.47 31.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 65.54 110.891 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -90.22 137.03 32.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.182 -0.463 . . . . 73.42 110.927 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -55.23 142.91 29.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 75.12 110.813 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -111.55 43.01 1.59 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.087 -0.506 . . . . 44.35 110.845 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.4 p -101.59 45.74 0.96 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 74.43 111.081 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -143.09 134.65 26.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 74.23 110.882 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 6.3 ttm -81.18 128.47 33.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.884 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -166.59 131.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.253 -0.43 . . . . 72.15 111.057 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.02 134.54 56.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.142 -0.481 . . . . 62.52 110.968 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -129.14 74.98 1.62 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 64.43 110.891 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.0 m -59.01 144.03 12.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 53.25 111.11 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 59.9 t -99.2 126.99 52.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 62.05 111.221 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.7 p -109.61 141.37 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 73.01 111.135 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.3 t -104.45 167.71 9.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 65.24 111.129 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 176.43 -65.54 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.803 -0.713 . . . . 61.42 112.566 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -115.83 143.74 44.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.927 0.394 . . . . 75.33 110.91 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.5 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.08 -0.509 . . . . 73.03 111.132 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 28.2 ttm . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.855 0.359 . . . . 72.11 110.813 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 165.79 136.49 2.02 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.718 -0.753 . . . . 33.14 112.455 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 47.9 p-80 -156.18 152.6 28.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.825 0.345 . . . . 75.12 110.86 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -89.84 120.31 30.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.23 -0.441 . . . . 62.11 110.868 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 81.6 t60 -127.47 124.37 38.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 72.04 110.874 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 58.4 55.01 5.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 71.31 110.907 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -169.16 133.22 1.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 74.02 110.92 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.561 ' HB3' HD13 ' A' ' 69' ' ' ILE . 6.5 t60 -169.71 174.95 5.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 73.02 110.869 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 t -68.81 173.84 4.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 51.53 111.195 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 mmpt? -60.35 -171.64 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.23 -0.441 . . . . 74.23 110.921 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.89 134.71 35.48 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.752 -0.737 . . . . 42.34 112.519 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -127.73 119.95 26.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.891 0.377 . . . . 73.41 110.931 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.591 HG12 HG13 ' A' ' 19' ' ' ILE . 45.0 t -105.15 126.46 60.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.153 -0.476 . . . . 73.33 111.069 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.499 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.0 OUTLIER -124.38 -178.7 4.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 73.43 111.094 179.988 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.74 163.72 13.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 72.2 110.881 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -103.64 -12.33 17.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.135 -0.484 . . . . 60.22 110.928 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -75.97 -58.72 3.11 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.197 -0.456 . . . . 75.14 111.17 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -119.44 -26.57 5.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 72.52 110.821 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.06 29.55 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.79 -0.719 . . . . 53.34 112.506 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.499 ' C ' HG22 ' A' ' 11' ' ' THR . 4.9 pt20 -83.15 154.85 67.14 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.593 0.711 . . . . 74.15 110.934 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 128.71 16.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.737 2.291 . . . . 61.23 112.314 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.721 HD12 HD22 ' A' ' 74' ' ' LEU . 34.1 mm -75.03 101.7 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.31 111.128 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.2 mt -99.05 138.07 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 42.2 111.122 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 77.18 33.6 44.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 62.52 112.467 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.559 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -89.45 135.04 33.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 63.11 111.109 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.2 m -80.59 107.55 13.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 52.44 110.86 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.724 HG22 HG12 ' A' ' 54' ' ' ILE . 48.7 t -104.07 122.49 56.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 75.44 111.122 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.667 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.0 m -142.08 136.74 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 74.52 111.125 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -73.58 159.95 32.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.86 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 29.9 p -62.21 -41.98 98.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.164 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.0 p -108.22 -22.08 12.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 64.03 111.099 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.81 68.67 0.68 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 63.21 111.156 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' HB ' ' A' ' 25' ' ' VAL . 92.9 m -82.82 -35.37 26.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.138 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.5 p -53.38 -31.18 43.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 74.23 111.06 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.468 ' O ' HD11 ' A' ' 44' ' ' LEU . 1.8 m-20 -94.9 31.16 1.9 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 74.3 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.07 141.23 44.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.723 -0.751 . . . . 61.22 112.556 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.5 t -123.64 168.89 12.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 73.43 111.171 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.5 pt -107.63 156.76 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.141 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.593 HG22 ' HD2' ' A' ' 42' ' ' PHE . 33.1 p -81.65 150.63 27.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.113 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -82.39 173.34 12.12 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.837 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -59.46 -30.71 68.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 72.12 110.871 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -74.0 -19.38 60.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.102 -0.499 . . . . 73.22 110.886 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.97 28.15 10.32 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.463 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -128.92 152.68 48.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.93 0.395 . . . . 71.23 110.873 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.593 ' HD2' HG22 ' A' ' 36' ' ' THR . 54.4 p90 -147.63 164.52 33.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 71.21 110.917 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -150.41 117.27 5.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 72.34 111.144 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 32' ' ' ASN . 1.5 tt -115.93 109.77 18.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 72.23 110.947 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 89.7 p -68.9 108.41 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 73.42 110.856 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.433 HG23 ' HD2' ' A' ' 47' ' ' PRO . 7.3 p -130.78 133.21 24.54 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 71.43 111.138 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.433 ' HD2' HG23 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -43.26 2.74 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.66 2.24 . . . . 60.01 112.381 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 29.6 m -77.91 150.06 5.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 71.24 111.176 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -100.35 72.25 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 63.41 110.884 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 t -105.8 -170.95 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 64.13 110.827 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.13 155.35 17.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 72.33 111.167 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.618 HD12 HG23 ' A' ' 64' ' ' VAL . 10.4 mt -111.25 146.95 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 62.04 110.902 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.7 tttt -130.31 121.94 27.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.894 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.724 HG12 HG22 ' A' ' 24' ' ' VAL . 5.3 mp -119.27 144.01 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 73.4 111.144 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 37.7 p -138.36 138.67 38.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 62.11 111.165 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.459 ' HB3' HD21 ' A' ' 74' ' ' LEU . 7.4 t80 -131.83 115.21 15.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.282 -0.417 . . . . 65.43 110.977 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.445 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.3 tp -51.15 116.46 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 74.23 111.095 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.37 -53.42 0.81 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 45.03 112.475 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -110.47 170.53 8.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.925 0.393 . . . . 61.23 110.953 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -60.77 157.86 36.26 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.564 0.697 . . . . 75.3 110.874 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 172.81 12.02 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.661 2.241 . . . . 71.32 112.336 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 HG11 ' A' ' 72' ' ' VAL . 7.4 p -151.38 146.3 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 74.11 111.128 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.7 p -131.93 143.51 50.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 60.11 111.172 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.618 HG23 HD12 ' A' ' 52' ' ' LEU . 35.0 m -142.22 130.22 20.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.083 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 11.2 pttt -72.82 156.75 38.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 70.32 110.916 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.84 95.89 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.285 -0.416 . . . . 72.41 111.132 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -134.11 -173.22 3.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 63.13 111.094 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -88.04 -44.52 10.91 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 73.13 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.561 HD13 ' HB3' ' A' ' 5' ' ' HIS . 63.4 mt -138.09 126.17 30.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 72.31 111.112 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 64' ' ' VAL . 7.2 p -139.71 126.93 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 74.42 111.159 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 71.0 m-80 -119.92 125.53 48.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 74.11 110.902 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 62' ' ' VAL . 20.2 t -137.15 149.07 25.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.449 . . . . 61.34 111.11 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.1 mp -105.02 143.54 33.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 72.02 110.907 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.721 HD22 HD12 ' A' ' 19' ' ' ILE . 2.1 tp -87.56 118.58 27.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 65.54 110.956 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -90.64 147.81 23.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -59.47 143.41 50.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.837 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -106.88 84.69 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 44.35 110.827 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.7 t -138.44 154.72 48.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 74.43 111.172 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 39.0 tp60 -66.5 115.45 6.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.251 -0.431 . . . . 74.23 110.953 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 21.7 mmt -57.44 170.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 74.23 110.842 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.2 m -128.32 111.22 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 72.15 111.099 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -126.82 36.05 4.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 62.52 110.83 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -85.88 90.88 8.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 64.43 110.827 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.56 113.45 29.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 53.25 111.204 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 46.3 t -134.19 145.41 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 62.05 111.119 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -74.3 151.84 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 73.01 111.174 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 5.2 t -161.8 159.51 27.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 65.24 111.177 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -108.96 147.88 16.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.685 -0.769 . . . . 61.42 112.427 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 15.6 t80 -100.54 142.5 31.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.901 0.381 . . . . 75.33 110.879 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 m . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 73.03 111.138 179.982 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.812 0.339 . . . . 72.11 110.908 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -142.51 -52.27 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.739 -0.743 . . . . 33.14 112.468 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -151.16 137.43 18.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.809 0.338 . . . . 75.12 110.854 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -86.96 130.17 34.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 62.11 110.932 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 14.9 t60 54.83 60.32 3.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 72.04 110.799 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.1 t-80 -139.65 133.45 30.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 71.31 110.886 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 24.1 p-80 -108.18 162.78 13.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 74.02 110.889 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -134.75 163.06 30.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 73.02 110.913 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.1 t -138.58 162.1 35.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.234 -0.439 . . . . 51.53 111.146 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.2 pttm -128.62 127.43 42.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 74.23 110.876 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.9 119.9 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.748 -0.739 . . . . 42.34 112.479 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -146.11 129.72 17.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.891 0.376 . . . . 73.41 110.826 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.633 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 95.3 t -123.02 133.37 69.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.091 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 18' ' ' PRO . 17.6 p -130.03 172.55 11.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.141 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.16 153.2 21.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.828 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.436 ' HG3' HD22 ' A' ' 73' ' ' LEU . 17.1 tttm -92.55 16.24 12.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 60.22 110.904 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.02 -58.86 2.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 75.14 111.112 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -119.05 -26.66 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 72.52 110.847 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.45 29.25 5.14 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 53.34 112.525 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -97.87 159.78 30.07 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 74.15 110.917 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.617 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.64 146.61 61.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.724 2.282 . . . . 61.23 112.39 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.507 HG21 ' CD2' ' A' ' 56' ' ' TYR . 28.4 mm -96.68 117.43 41.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.074 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 29.9 mt -101.6 150.13 6.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 42.2 111.045 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.21 47.19 83.43 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.733 -0.746 . . . . 62.52 112.404 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.435 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 159.32 15.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.862 0.363 . . . . 63.11 111.044 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.2 m -105.92 107.25 18.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.44 110.837 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.773 HG22 HG23 ' A' ' 54' ' ' ILE . 12.3 t -112.66 129.82 67.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 75.44 111.113 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.0 m -145.98 146.31 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 74.52 111.17 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -80.75 174.33 11.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.888 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.562 HG23 ' O ' ' A' ' 51' ' ' THR . 43.5 p -68.95 -42.12 77.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 52.43 111.16 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.5 p -112.49 -22.22 10.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 64.03 111.159 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -104.89 76.44 1.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 63.21 111.112 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 p -86.53 -36.26 19.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.229 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.1 p -58.42 -28.44 65.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.115 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.42 1.75 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.229 -0.441 . . . . 74.3 110.857 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.51 143.11 47.99 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.766 -0.731 . . . . 61.22 112.533 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 m -117.87 160.55 21.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.725 0.298 . . . . 73.43 111.156 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.435 HG22 ' O ' ' A' ' 22' ' ' ALA . 8.1 pt -116.41 149.31 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.088 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.576 HG22 ' HD2' ' A' ' 42' ' ' PHE . 15.9 p -69.87 150.64 46.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 55.34 111.202 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -84.15 -175.62 5.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 34.54 110.905 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -58.68 -30.65 67.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 72.12 110.882 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -99.4 21.99 11.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.884 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.4 28.18 71.95 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.669 -0.777 . . . . 75.31 112.533 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -110.44 131.34 55.14 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.835 0.35 . . . . 71.23 110.879 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.576 ' HD2' HG22 ' A' ' 36' ' ' THR . 20.2 p90 -127.69 167.7 16.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 71.21 110.949 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 43' ' ' THR . 4.7 t -137.44 118.99 14.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 72.34 111.083 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.483 HD13 HD21 ' A' ' 52' ' ' LEU . 0.7 OUTLIER -148.25 107.18 3.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 72.23 110.898 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.6 t -107.03 122.22 46.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 73.42 110.861 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -119.66 155.96 54.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.637 0.732 . . . . 71.43 111.048 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -48.39 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.644 2.229 . . . . 60.01 112.335 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.61 149.93 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 71.24 111.139 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -96.04 67.69 2.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 63.41 110.887 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.2 t -100.55 -169.29 1.7 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 64.13 110.89 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 27' ' ' THR . 0.2 OUTLIER -87.45 163.06 16.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 72.33 111.148 -179.918 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.606 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 0.2 OUTLIER -129.92 131.75 46.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.253 -0.431 . . . . 62.04 110.91 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -101.0 126.2 47.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.901 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 24' ' ' VAL . 2.5 mp -123.64 123.28 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 73.4 111.115 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 63.8 p -119.31 146.38 45.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 62.11 111.098 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.792 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.5 m-85 -129.14 154.62 46.55 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.185 -0.461 . . . . 65.43 110.947 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 57' ' ' ILE . 4.7 tp -91.31 108.39 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.495 . . . . 74.23 111.133 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.95 -51.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.734 -0.746 . . . . 45.03 112.453 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -106.17 170.87 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.919 0.39 . . . . 61.23 110.958 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -67.31 146.67 98.88 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.598 0.713 . . . . 75.3 110.909 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 175.93 7.43 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.699 2.266 . . . . 71.32 112.317 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.547 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.1 m -149.82 142.76 17.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 74.11 111.155 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 13.9 p -122.17 131.98 54.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 60.11 111.158 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.2 m -152.91 156.51 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.202 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.79 154.27 27.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 70.32 110.893 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.606 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -63.95 107.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 72.41 111.066 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -130.83 159.3 37.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 63.13 111.107 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.64 -55.74 23.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 73.13 111.118 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 64.4 mt -126.01 131.49 71.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 72.31 111.092 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 23.7 t -143.06 123.53 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 74.42 111.148 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 78.6 m-20 -119.86 109.43 15.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.848 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 26.6 t -125.18 148.87 29.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 61.34 111.169 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.436 HD22 ' HG3' ' A' ' 13' ' ' LYS . 4.6 mp -103.72 144.44 31.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 72.02 110.938 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.792 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.6 tp -88.87 118.49 28.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 65.54 110.9 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.03 129.55 45.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.896 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 147.56 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.836 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 63.7 t0 -111.71 119.82 39.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 44.35 110.849 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 17.7 p -106.92 139.49 41.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 74.43 111.146 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -70.22 152.22 44.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 2.1 tpp -123.95 106.88 10.78 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 74.23 110.901 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.8 t -106.79 56.46 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 72.15 111.067 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 42.1 m-20 -103.0 123.2 46.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 62.52 110.869 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -132.79 76.07 1.66 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 64.43 110.856 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.1 p -146.19 150.79 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 53.25 111.099 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.9 p -64.63 139.5 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 62.05 111.089 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.4 m -127.42 43.74 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.201 -0.454 . . . . 73.01 111.135 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 3.5 t -162.54 139.74 8.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 65.24 111.147 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.11 175.41 17.73 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.729 -0.748 . . . . 61.42 112.492 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 63.7 t80 -126.23 151.89 46.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 75.33 110.936 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 73.9 p . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 73.03 111.157 -180.0 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 6.6 mmt . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.788 0.327 . . . . 72.11 110.884 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 162.22 -147.74 14.19 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.739 -0.743 . . . . 33.14 112.473 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 4.1 t-160 -117.8 109.83 17.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.887 0.375 . . . . 75.12 110.878 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 15.5 p80 -108.74 36.49 2.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.151 -0.477 . . . . 62.11 110.901 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 16.2 t60 -91.35 71.62 6.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 72.04 110.881 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 35.1 t60 -106.59 83.58 1.88 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.256 -0.429 . . . . 71.31 110.83 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 26.6 t60 -169.21 111.78 0.51 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 74.02 110.931 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -124.28 147.42 48.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.433 . . . . 73.02 110.864 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.6 m -59.43 137.04 58.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 51.53 111.152 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -75.29 101.61 4.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.222 -0.444 . . . . 74.23 110.935 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 85.98 115.38 0.87 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 42.34 112.531 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -157.96 119.82 3.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.895 0.378 . . . . 73.41 110.852 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.663 HG11 ' OH ' ' A' ' 56' ' ' TYR . 43.3 t -111.29 137.2 44.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 111.197 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.642 HG22 ' HA ' ' A' ' 18' ' ' PRO . 11.3 p -132.07 179.08 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 73.43 111.109 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.608 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -100.24 153.09 19.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 72.2 110.823 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 16.3 tttm -92.71 17.98 9.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.08 -0.509 . . . . 60.22 110.917 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.608 HG21 ' OH ' ' A' ' 59' ' ' TYR . 34.8 p -94.2 -58.68 2.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.271 -0.422 . . . . 75.14 111.217 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -120.15 -26.83 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.282 -0.417 . . . . 72.52 110.85 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.24 29.19 5.23 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.492 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -99.05 160.26 28.12 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.621 0.724 . . . . 74.15 110.911 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.642 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.62 143.33 51.13 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 61.23 112.393 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.608 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -92.79 116.45 33.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.276 -0.42 . . . . 75.31 111.094 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 31.3 mt -98.42 150.18 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 42.2 111.107 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.05 48.25 72.97 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 62.52 112.449 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 158.27 15.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.799 0.333 . . . . 63.11 111.058 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.09 107.41 18.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 52.44 110.904 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.526 HG22 HG23 ' A' ' 54' ' ' ILE . 20.6 t -112.65 108.44 25.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.141 -0.482 . . . . 75.44 111.105 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.718 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.2 m -127.88 139.97 50.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 74.52 111.121 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.567 ' OE1' HD11 ' A' ' 44' ' ' LEU . 2.3 mp0 -91.2 167.36 12.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 74.12 110.91 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 53.5 p -82.11 -33.75 29.59 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 52.43 111.13 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.552 HG23 ' OG ' ' A' ' 50' ' ' SER . 20.2 p -79.42 -22.17 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 64.03 111.164 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.45 103.34 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 63.21 111.111 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.718 HG23 ' HB ' ' A' ' 25' ' ' VAL . 99.1 m -86.93 -35.44 18.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.194 -0.457 . . . . 73.01 111.155 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.2 p -53.99 -26.9 28.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.084 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -93.41 31.42 1.52 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 74.3 110.849 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -67.29 142.16 40.52 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 61.22 112.421 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.7 m -113.97 161.61 17.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.782 0.325 . . . . 73.43 111.108 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 14.6 pt -117.33 148.31 20.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.459 . . . . 72.12 111.156 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.581 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.1 p -71.33 150.69 44.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 55.34 111.108 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -86.59 -170.17 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 34.54 110.887 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -60.93 -30.65 70.34 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.152 -0.477 . . . . 72.12 110.974 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.67 17.88 12.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.485 . . . . 73.22 110.865 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.22 28.11 71.69 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.505 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -113.98 136.69 52.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 71.23 110.873 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.581 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.8 p90 -129.98 167.87 17.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.434 . . . . 71.21 110.925 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.1 t -123.36 117.44 25.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.166 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.567 HD11 ' OE1' ' A' ' 26' ' ' GLU . 0.5 OUTLIER -143.62 124.44 14.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.23 110.915 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.8 t -106.98 108.07 19.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.848 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 44' ' ' LEU . 19.1 m -139.95 152.57 68.09 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 71.43 111.113 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 170.61 16.09 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.705 2.27 . . . . 60.01 112.348 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.9 m -93.18 53.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.15 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -154.79 35.38 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 63.41 110.947 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.552 ' OG ' HG23 ' A' ' 28' ' ' THR . 7.7 t -155.53 163.52 39.89 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.174 -0.466 . . . . 64.13 110.826 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 164.06 12.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 72.33 111.102 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 84.9 mt -130.45 117.19 19.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 62.04 110.937 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.544 ' HA ' HG22 ' A' ' 63' ' ' THR . 37.3 tttt -102.27 123.55 46.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 74.21 110.868 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.526 HG23 HG22 ' A' ' 24' ' ' VAL . 3.3 mp -123.59 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 73.4 111.16 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.2 p -117.73 144.52 45.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 62.11 111.18 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.817 ' CD1' HD11 ' A' ' 74' ' ' LEU . 20.6 m-85 -126.5 155.03 42.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 65.43 110.994 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.0 tt -92.36 107.86 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.114 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.84 -50.96 0.82 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.791 -0.719 . . . . 45.03 112.494 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.608 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.8 m-85 -105.58 170.43 7.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 61.23 110.889 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -67.57 144.57 97.79 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.61 0.719 . . . . 75.3 110.87 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 176.99 6.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.605 2.203 . . . . 71.32 112.299 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.584 HG22 ' HE1' ' A' ' 56' ' ' TYR . 15.3 m -149.24 145.49 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 74.11 111.148 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 53' ' ' LYS . 4.9 p -129.12 138.37 51.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 60.11 111.101 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 70' ' ' VAL . 17.5 m -150.51 167.79 2.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.206 -0.452 . . . . 74.21 111.115 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -89.53 155.98 18.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.876 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -51.6 128.87 24.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 72.41 111.064 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -161.35 142.8 11.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 63.13 111.13 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.04 -49.32 66.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.085 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.3 mt -120.76 119.49 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.253 -0.43 . . . . 72.31 111.199 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 64' ' ' VAL . 6.7 p -129.52 122.64 55.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.42 111.123 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -119.86 113.62 20.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 74.11 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.8 t -127.71 148.94 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 61.34 111.112 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 11.6 mt -106.44 145.29 31.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.932 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.817 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -87.57 123.06 32.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.903 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -102.06 133.3 47.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 73.42 110.882 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -51.91 139.54 21.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 75.12 110.927 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -95.49 135.95 36.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.879 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.12 -41.17 1.62 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 74.43 111.092 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -53.92 122.55 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 74.23 110.942 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.6 ttm -124.71 169.74 11.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.901 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 m -147.55 -170.75 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 72.15 111.084 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -70.19 177.03 3.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 62.52 110.881 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 58.31 45.95 16.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 64.43 110.856 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.5 t -68.08 114.59 5.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 53.25 111.089 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 71.2 t -52.69 -63.14 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.137 -0.483 . . . . 62.05 111.131 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.0 t -99.13 112.43 31.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 73.01 111.105 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.65 151.71 26.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 65.24 111.177 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -155.26 -97.03 0.13 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 61.42 112.519 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -121.76 158.06 29.64 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.931 0.396 . . . . 75.33 110.983 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 73.03 111.211 179.957 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.8 tpp . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.803 0.335 . . . . 72.11 110.852 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 130.94 159.4 9.58 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 33.14 112.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 20.6 t60 -167.9 157.96 10.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.8 0.333 . . . . 75.12 110.858 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -153.02 176.36 11.96 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 62.11 110.896 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 15.7 p80 -138.08 158.75 43.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 72.04 110.902 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -129.26 52.13 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 71.31 110.86 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 70.6 m-70 -104.73 155.81 18.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 74.02 110.856 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 31.1 p-80 -122.6 114.42 20.6 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 73.02 110.893 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -115.19 171.5 7.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 51.53 111.101 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -116.0 -171.91 2.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.861 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.1 126.07 29.26 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 42.34 112.528 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -130.37 130.66 44.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 73.41 110.877 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.62 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.6 t -123.51 131.13 73.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 73.33 111.14 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.9 p -127.44 178.17 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.152 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 t -95.43 149.27 21.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.451 . . . . 72.2 110.828 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.405 ' HG3' HD13 ' A' ' 73' ' ' LEU . 33.8 tttm -90.05 12.26 18.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 60.22 110.909 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.443 HG21 ' OH ' ' A' ' 59' ' ' TYR . 41.4 p -93.61 -59.6 1.96 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.433 . . . . 75.14 111.182 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -118.69 -27.08 5.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 72.52 110.874 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.39 29.31 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.513 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -93.55 160.53 32.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.645 0.736 . . . . 74.15 110.918 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 138.21 37.18 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.606 2.204 . . . . 61.23 112.375 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 48.9 mm -85.64 120.07 35.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.259 -0.428 . . . . 75.31 111.105 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mt -105.93 140.97 22.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.161 -0.472 . . . . 42.2 111.101 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.41 50.41 21.25 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.452 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.545 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.06 159.0 15.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.771 0.32 . . . . 63.11 111.109 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.3 m -105.87 107.47 18.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 52.44 110.839 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.635 HG22 HG23 ' A' ' 54' ' ' ILE . 17.4 t -111.5 128.49 67.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.147 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.681 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.7 m -148.05 139.6 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.092 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.495 ' CD ' ' HB3' ' A' ' 29' ' ' ALA . 33.8 mt-10 -72.23 174.23 7.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.861 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.14 -35.21 49.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 52.43 111.146 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.5 p -112.4 -22.18 10.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 64.03 111.191 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.495 ' HB3' ' CD ' ' A' ' 26' ' ' GLU . . . -118.75 78.83 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.244 -0.435 . . . . 63.21 111.102 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.681 HG23 ' HB ' ' A' ' 25' ' ' VAL . 97.5 m -83.83 -39.21 20.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.01 111.11 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 p -53.59 -29.45 37.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 74.23 111.142 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -94.61 31.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.924 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -68.14 164.67 46.95 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.768 -0.729 . . . . 61.22 112.479 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -135.24 168.86 18.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.714 0.292 . . . . 73.43 111.178 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.545 HG22 ' O ' ' A' ' 22' ' ' ALA . 13.9 pt -121.59 151.35 24.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.19 -0.459 . . . . 72.12 111.104 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.547 HG22 ' HD2' ' A' ' 42' ' ' PHE . 22.8 p -74.27 150.66 40.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.13 -0.487 . . . . 55.34 111.151 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -94.39 -178.1 4.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 34.54 110.885 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -56.92 -30.32 63.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 72.12 110.94 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -73.2 -18.72 61.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 73.22 110.853 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.43 28.19 20.38 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 75.31 112.471 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 23.7 p30 -133.93 163.53 29.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 71.23 110.906 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.547 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.4 p90 -144.86 167.76 21.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.887 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -135.72 122.84 21.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.105 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -138.01 118.68 14.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.893 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 t -93.08 115.31 27.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.817 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.66 155.98 44.22 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.646 0.736 . . . . 71.43 111.144 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -48.46 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.724 2.283 . . . . 60.01 112.337 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -111.97 -176.59 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.43 . . . . 71.24 111.104 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -106.04 64.99 0.68 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 63.41 110.885 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.9 t -92.52 -169.83 2.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 64.13 110.86 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.73 162.59 16.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 72.33 111.16 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.547 HD11 ' HB2' ' A' ' 66' ' ' ALA . 11.1 mt -134.39 133.15 40.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 62.04 110.98 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.421 ' HA ' HG23 ' A' ' 63' ' ' THR . 9.6 ttpt -98.9 125.32 44.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.423 . . . . 74.21 110.876 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.635 HG23 HG22 ' A' ' 24' ' ' VAL . 8.7 mt -123.83 119.62 57.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 73.4 111.145 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 46.4 p -113.63 150.55 32.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.114 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.806 ' CD1' HD11 ' A' ' 74' ' ' LEU . 23.1 m-85 -132.37 151.97 51.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 65.43 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -90.7 107.98 19.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 74.23 111.096 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.05 -51.19 0.8 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.551 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.443 ' OH ' HG21 ' A' ' 14' ' ' THR . 8.8 m-85 -104.4 170.5 7.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.931 0.396 . . . . 61.23 110.878 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -67.09 145.39 98.8 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.505 0.669 . . . . 75.3 110.889 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 175.2 8.46 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.686 2.258 . . . . 71.32 112.348 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.579 HG21 HG11 ' A' ' 72' ' ' VAL . 16.8 m -149.91 142.26 17.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 74.11 111.121 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HA ' ' A' ' 53' ' ' LYS . 0.3 OUTLIER -121.84 129.54 52.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 60.11 111.114 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.5 m -152.85 154.3 7.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 74.21 111.118 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -88.35 153.12 21.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 70.32 110.865 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.547 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -55.86 138.57 48.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 72.41 111.088 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.479 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . . . -162.09 165.78 26.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 63.13 111.065 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.41 -56.76 16.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 73.13 111.139 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 61.7 mt -132.39 116.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 72.31 111.085 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.479 ' CG2' ' HB3' ' A' ' 67' ' ' ALA . 19.5 t -124.96 112.17 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 74.42 111.103 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 68.4 m-20 -102.04 109.31 20.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 74.11 110.898 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.579 HG11 HG21 ' A' ' 62' ' ' VAL . 21.9 t -116.5 147.15 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 61.34 111.141 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.405 HD13 ' HG3' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -115.79 145.6 42.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.862 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.806 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -93.62 121.3 34.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.222 -0.445 . . . . 65.54 110.921 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.13 137.14 45.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.276 -0.42 . . . . 73.42 110.925 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -51.08 137.34 21.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.481 . . . . 75.12 110.848 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -105.63 -35.07 7.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 44.35 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -56.09 143.31 33.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 74.43 111.111 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.5 mt-30 -125.76 60.28 1.27 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 74.23 110.913 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.03 109.28 2.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 74.23 110.861 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.6 t -143.39 120.96 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.202 -0.454 . . . . 72.15 111.078 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -70.31 131.72 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 62.52 110.823 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 81.0 mt-10 -124.53 89.09 3.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.152 -0.477 . . . . 64.43 110.892 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.17 128.16 45.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 53.25 111.101 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -59.07 169.32 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 62.05 111.138 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.2 p -175.18 142.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 73.01 111.095 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.54 -47.74 2.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 65.24 111.158 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -175.84 -176.75 44.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 61.42 112.478 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -158.64 146.56 18.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.972 0.415 . . . . 75.33 110.948 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 66.0 p . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 73.03 111.15 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.1 mpp? . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.831 0.348 . . . . 72.11 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 154.8 -54.05 0.43 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.731 -0.747 . . . . 33.14 112.559 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 52.28 47.21 25.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.933 0.397 . . . . 75.12 110.859 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 26.0 p80 -81.12 155.82 26.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.169 -0.468 . . . . 62.11 110.896 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 11.3 t60 -52.25 156.18 1.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 72.04 110.838 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -79.17 -59.56 2.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 71.31 110.836 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 6.0 t60 56.2 50.94 12.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.238 -0.437 . . . . 74.02 110.83 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.2 m170 -93.2 87.37 5.65 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 73.02 110.865 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.531 ' O ' HG23 ' A' ' 69' ' ' ILE . 2.9 m -106.48 143.43 34.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 51.53 111.128 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.9 mtmt -72.41 110.59 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 74.23 110.843 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.4 103.17 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.799 -0.715 . . . . 42.34 112.464 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -128.28 126.36 40.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 73.41 110.945 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.628 HG23 ' HE2' ' A' ' 42' ' ' PHE . 90.6 t -110.84 125.13 68.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 73.33 111.15 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -128.59 177.15 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.166 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.21 161.38 14.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.802 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.9 tmtm? -101.59 -5.41 25.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.097 -0.502 . . . . 60.22 110.913 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 43.5 p -78.41 -58.58 3.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 75.14 111.177 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -118.36 -26.25 6.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 72.52 110.906 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.58 29.29 6.32 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.787 -0.72 . . . . 53.34 112.513 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -90.21 159.95 41.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.588 0.709 . . . . 74.15 110.959 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 139.24 39.6 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.702 2.268 . . . . 61.23 112.364 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.65 HG22 ' HB2' ' A' ' 22' ' ' ALA . 44.1 mm -91.3 101.56 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.241 -0.436 . . . . 75.31 111.102 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.418 ' H ' HD12 ' A' ' 20' ' ' ILE . 3.2 mp -93.56 140.0 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 42.2 111.165 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.04 31.93 54.15 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.789 -0.72 . . . . 62.52 112.484 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.65 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -91.37 162.37 14.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.759 0.314 . . . . 63.11 111.088 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.7 m -105.79 107.29 18.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.471 . . . . 52.44 110.849 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.4 p -120.09 127.16 75.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 75.44 111.146 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.696 HG12 ' HA3' ' A' ' 33' ' ' GLY . 14.6 m -140.31 166.97 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 74.52 111.147 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.422 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 62.6 tt0 -92.49 132.48 36.77 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 74.12 110.86 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.44 HG21 ' HB ' ' A' ' 51' ' ' THR . 60.8 p -51.7 -35.03 41.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.121 -0.49 . . . . 52.43 111.124 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.6 p -95.37 -22.25 17.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 64.03 111.128 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.422 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -130.93 87.34 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.464 . . . . 63.21 111.104 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.2 p -86.81 -35.74 18.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 73.01 111.138 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.5 p -53.25 -30.56 38.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.139 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -93.96 31.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.417 . . . . 74.3 110.829 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.696 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.59 146.06 49.82 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.752 -0.737 . . . . 61.22 112.486 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.642 ' CG2' HD21 ' A' ' 44' ' ' LEU . 10.4 t -135.65 169.63 17.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.727 0.299 . . . . 73.43 111.178 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -107.9 157.55 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 72.12 111.149 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.411 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.0 p -76.22 150.97 36.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.099 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -79.49 -176.16 5.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 34.54 110.832 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -60.47 -30.62 69.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.208 -0.451 . . . . 72.12 110.838 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -99.44 20.87 12.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.197 -0.456 . . . . 73.22 110.882 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.28 27.98 71.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.781 -0.723 . . . . 75.31 112.392 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -107.04 143.43 35.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 71.23 110.955 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.628 ' HE2' HG23 ' A' ' 10' ' ' VAL . 24.1 p90 -144.57 161.79 38.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.21 110.872 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.558 ' C ' HD22 ' A' ' 44' ' ' LEU . 4.6 t -151.34 128.36 11.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 72.34 111.211 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.642 HD21 ' CG2' ' A' ' 34' ' ' THR . 3.0 mm? -130.63 159.8 36.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.23 110.846 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 6.1 m -95.52 108.23 20.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 73.42 110.798 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.434 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.9 t -133.35 133.19 22.53 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.611 0.72 . . . . 71.43 111.128 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.434 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.2 Cg_endo -69.74 -48.39 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.747 2.298 . . . . 60.01 112.331 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.451 HG23 ' H ' ' A' ' 50' ' ' SER . 19.4 m -99.72 -173.83 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 71.24 111.116 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.5 m-20 -107.13 45.66 0.98 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.899 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.451 ' H ' HG23 ' A' ' 48' ' ' VAL . 1.8 m -57.43 -179.55 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 64.13 110.89 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.44 ' HB ' HG21 ' A' ' 27' ' ' THR . 1.7 m -87.69 159.72 18.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 72.33 111.137 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.829 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.7 mp -125.76 135.12 51.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 62.04 110.9 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.4 ttpt -106.86 120.84 43.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.21 110.92 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.678 ' HB ' HG23 ' A' ' 62' ' ' VAL . 5.8 mt -117.45 138.98 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 73.4 111.095 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.1 p -150.71 138.65 20.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.11 111.101 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.684 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.4 t80 -133.98 122.32 22.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 65.43 110.963 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.435 HG23 ' O ' ' A' ' 57' ' ' ILE . 11.4 tt -51.57 115.08 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 74.23 111.159 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 131.23 -51.96 0.84 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.752 . . . . 45.03 112.467 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -107.98 170.18 8.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.9 0.381 . . . . 61.23 110.939 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -64.04 158.0 65.73 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.539 0.685 . . . . 75.3 110.914 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 164.26 35.15 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 71.32 112.357 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.678 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.8 m -150.83 141.08 16.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.197 -0.456 . . . . 74.11 111.133 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.9 p -130.25 140.1 50.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 60.11 111.041 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.912 HG11 HG22 ' A' ' 72' ' ' VAL . 8.6 m -147.55 148.0 16.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.097 -0.501 . . . . 74.21 111.093 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 6.9 mmmm -78.95 155.11 29.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 70.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.829 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -73.59 134.07 43.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 72.41 111.142 179.814 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.16 178.11 7.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.102 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.553 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.66 -57.32 9.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 73.13 111.13 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.553 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.78 111.77 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 72.31 111.084 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.493 HG21 ' HB ' ' A' ' 64' ' ' VAL . 12.2 p -118.84 141.82 36.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.127 -0.488 . . . . 74.42 111.136 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -115.89 134.98 54.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.912 HG22 HG11 ' A' ' 64' ' ' VAL . 22.4 t -122.83 149.18 26.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 61.34 111.143 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.34 133.37 54.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.176 -0.466 . . . . 72.02 110.934 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -90.54 121.49 32.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 65.54 110.928 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 50.3 mm-40 -92.38 145.29 24.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.155 -0.475 . . . . 73.42 110.862 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -58.45 140.4 53.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.17 -0.468 . . . . 75.12 110.929 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -91.03 136.42 33.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 44.35 110.851 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -159.69 153.55 23.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 74.43 111.171 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.8 mm-40 -73.68 168.64 18.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.277 -0.42 . . . . 74.23 110.882 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 35.3 mtt -76.25 165.16 25.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 74.23 110.895 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 67.3 t -58.99 -65.49 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 72.15 111.151 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -65.19 -179.65 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 62.52 110.892 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -124.05 44.55 2.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 64.43 110.823 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -104.94 69.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 53.25 111.118 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.555 HG12 HG23 ' A' ' 86' ' ' VAL . 45.8 t -131.78 120.66 45.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 62.05 111.102 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.555 HG23 HG12 ' A' ' 85' ' ' VAL . 46.8 t 54.4 80.38 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.01 111.143 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.2 t -99.16 162.18 13.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.131 -0.486 . . . . 65.24 111.117 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.6 -136.15 12.58 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.723 -0.751 . . . . 61.42 112.499 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 19.7 t80 -142.27 128.45 19.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.918 0.39 . . . . 75.33 110.949 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 72.1 p . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 73.03 111.195 179.993 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.4 ttt . . . . . 0 CA--C 1.526 0.043 0 CA-C-O 120.834 0.349 . . . . 72.11 110.864 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.51 -117.06 0.49 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.682 -0.771 . . . . 33.14 112.474 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 21.2 m170 56.63 63.23 2.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.851 0.358 . . . . 75.12 110.922 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.7 m-70 -127.12 140.09 52.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 62.11 110.86 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -64.48 169.23 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 72.04 110.874 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.8 m80 -141.61 110.01 5.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.88 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -109.9 108.86 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 74.02 110.845 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.5 m80 -92.01 71.46 5.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.189 -0.459 . . . . 73.02 110.966 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.3 m -67.36 141.89 56.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 51.53 111.169 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -108.03 93.98 4.82 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 74.23 110.88 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 73.68 127.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.752 -0.737 . . . . 42.34 112.514 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -158.34 127.29 5.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.847 0.356 . . . . 73.41 110.929 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.656 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 83.0 t -117.94 130.59 72.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.33 111.105 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.5 p -128.5 163.71 24.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 73.43 111.103 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.451 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.2 t -84.73 148.96 26.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 72.2 110.88 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttp -92.43 17.53 9.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 60.22 110.851 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.95 -58.75 2.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.14 111.103 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -119.58 -26.68 5.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 72.52 110.892 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.35 5.12 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.736 -0.745 . . . . 53.34 112.409 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -97.44 159.95 29.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 74.15 110.939 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.78 141.62 45.65 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.663 2.242 . . . . 61.23 112.365 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.626 HG21 ' CD2' ' A' ' 56' ' ' TYR . 33.7 mm -86.04 115.22 26.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 75.31 111.065 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.4 mt -104.04 137.27 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 42.2 111.111 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 75.33 47.55 12.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.486 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.97 158.33 15.51 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.77 0.319 . . . . 63.11 111.135 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.9 m -105.99 107.21 18.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 52.44 110.875 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.658 HG13 HG12 ' A' ' 54' ' ' ILE . 95.4 t -110.91 110.39 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 75.44 111.111 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.8 m -123.53 146.05 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 74.52 111.106 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.646 ' OE1' HD22 ' A' ' 52' ' ' LEU . 1.9 mm-40 -90.24 156.7 18.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 74.12 110.836 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 51.9 p -73.03 -32.91 65.41 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.115 -0.493 . . . . 52.43 111.19 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.7 p -85.19 -22.2 28.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 64.03 111.17 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.76 104.74 1.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 63.21 111.047 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.4 p -86.75 -34.82 19.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 73.01 111.081 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.5 p -53.15 -29.68 32.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.251 -0.432 . . . . 74.23 111.188 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -94.29 31.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 74.3 110.892 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -72.86 164.37 54.86 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.718 -0.753 . . . . 61.22 112.492 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.8 t -130.96 169.08 16.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.712 0.291 . . . . 73.43 111.226 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 pp -115.99 164.55 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.255 -0.43 . . . . 72.12 111.141 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.522 HG22 ' HD2' ' A' ' 42' ' ' PHE . 14.1 p -89.28 150.66 22.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.205 -0.452 . . . . 55.34 111.15 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -91.37 -179.14 5.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.185 -0.461 . . . . 34.54 110.883 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -56.95 -30.64 64.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 72.12 110.968 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 46.0 m-20 -73.62 -18.46 61.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 73.22 110.865 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.97 28.1 21.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 75.31 112.506 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -127.23 165.38 19.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.812 0.339 . . . . 71.23 110.885 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.522 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.5 p90 -153.29 166.75 31.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 71.21 110.845 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.84 125.86 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 72.34 111.158 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.614 HD13 ' CD ' ' A' ' 26' ' ' GLU . 1.0 OUTLIER -138.61 131.37 29.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 72.23 110.895 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.469 ' N ' HD23 ' A' ' 44' ' ' LEU . 16.5 t -98.07 117.79 33.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.85 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.8 156.18 46.75 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.665 0.745 . . . . 71.43 111.104 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 -48.51 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.699 2.266 . . . . 60.01 112.376 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.9 m -113.14 -177.5 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.208 -0.451 . . . . 71.24 111.134 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -100.6 39.43 1.37 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 63.41 110.836 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.7 t -63.91 -169.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 64.13 110.866 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.691 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.0 OUTLIER -87.65 161.43 17.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 72.33 111.132 -179.987 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.691 HD23 ' O ' ' A' ' 51' ' ' THR . 12.7 mt -129.85 127.59 40.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.121 -0.491 . . . . 62.04 110.915 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -102.26 122.3 43.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 74.21 110.921 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.658 HG12 HG13 ' A' ' 24' ' ' VAL . 58.1 mt -123.63 118.94 55.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.086 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 55.0 p -113.34 146.86 38.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 62.11 111.168 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.838 ' CD1' HD11 ' A' ' 74' ' ' LEU . 19.0 m-85 -126.28 155.15 42.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 65.43 110.892 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.65 107.76 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.072 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.88 -50.83 0.83 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.686 -0.769 . . . . 45.03 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -105.84 170.48 7.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.905 0.383 . . . . 61.23 110.952 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.8 mmtm -64.74 149.0 96.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.617 0.723 . . . . 75.3 110.882 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -179.15 2.73 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.722 2.281 . . . . 71.32 112.377 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.88 HG21 HG11 ' A' ' 72' ' ' VAL . 4.4 p -151.85 149.27 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.284 -0.416 . . . . 74.11 111.179 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.22 125.26 30.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.121 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.762 HG21 HG11 ' A' ' 70' ' ' VAL . 18.2 m -147.37 152.92 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.156 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -81.82 153.62 26.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 70.32 110.867 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.436 ' HA ' HD11 ' A' ' 52' ' ' LEU . . . -55.58 105.14 0.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.075 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ALA . . . . . 0.453 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -131.78 153.2 50.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.45 . . . . 63.13 111.129 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.09 -51.46 67.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 73.13 111.032 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 60.4 mt -120.03 115.48 47.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 72.31 111.199 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.762 HG11 HG21 ' A' ' 64' ' ' VAL . 20.1 t -126.63 106.61 15.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.222 -0.445 . . . . 74.42 111.197 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.2 m-20 -114.26 109.43 18.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.11 110.898 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.88 HG11 HG21 ' A' ' 62' ' ' VAL . 21.6 t -129.04 148.38 33.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 61.34 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.6 mp -100.86 145.15 28.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 72.02 110.943 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.838 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.5 tp -87.72 120.93 29.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 65.54 110.947 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -96.14 127.25 41.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.903 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.52 143.16 25.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.877 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -104.94 156.99 17.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 44.35 110.904 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.8 t -158.97 144.97 16.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 74.43 111.197 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -75.59 95.7 3.4 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.223 -0.444 . . . . 74.23 110.888 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 4.6 ttp -104.0 121.05 42.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 74.23 110.889 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.4 t -116.71 -54.79 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.263 -0.426 . . . . 72.15 111.167 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -102.96 37.02 2.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 62.52 110.854 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 39.46 41.71 0.75 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 64.43 110.96 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 57.5 t -70.59 85.28 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.101 -0.499 . . . . 53.25 111.155 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.9 p -105.55 136.18 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 62.05 111.11 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.4 m -57.77 -178.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 73.01 111.168 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.45 111.6 22.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 65.24 111.195 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -173.72 -43.23 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.768 -0.73 . . . . 61.42 112.501 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 58.1 t80 -165.16 146.7 7.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.994 0.426 . . . . 75.33 110.931 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 73.03 111.107 -179.953 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 11.9 mtt . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.788 0.328 . . . . 72.11 110.882 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.33 148.32 13.38 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.715 -0.755 . . . . 33.14 112.542 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -146.27 168.7 20.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.853 0.358 . . . . 75.12 110.803 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -124.3 123.67 40.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 62.11 110.86 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 30.5 m170 -120.6 38.96 3.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 72.04 110.854 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.3 t-80 -80.36 -45.02 18.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 71.31 110.889 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -127.24 68.53 1.28 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 74.02 110.833 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 25.7 t60 -103.84 57.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.163 -0.471 . . . . 73.02 110.858 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -106.26 149.47 26.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 51.53 111.192 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 65.4 mttt -65.0 134.36 53.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.44 . . . . 74.23 110.866 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.02 114.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.72 -0.753 . . . . 42.34 112.477 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.2 t30 -132.43 127.79 36.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.841 0.353 . . . . 73.41 110.927 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.537 HG12 HG13 ' A' ' 19' ' ' ILE . 21.3 t -115.94 134.25 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 73.33 111.138 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.413 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -146.69 153.84 40.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 73.43 111.167 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.1 t -85.69 150.6 24.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 72.2 110.875 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 tttt -94.28 20.76 7.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 60.22 110.911 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.22 -58.69 2.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 75.14 111.098 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -120.05 -25.95 5.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 72.52 110.847 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.87 29.02 5.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 53.34 112.519 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -98.05 155.55 36.89 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 74.15 110.941 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.413 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.66 136.86 34.34 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.724 2.283 . . . . 61.23 112.351 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.548 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 50.0 mm -78.0 124.32 36.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 75.31 111.114 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.9 mt -110.18 119.35 59.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 42.2 111.095 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.68 33.4 8.47 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.774 -0.727 . . . . 62.52 112.528 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -89.54 132.21 35.18 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.722 0.296 . . . . 63.11 111.089 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.7 m -79.73 109.74 14.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.84 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.577 HG13 HG12 ' A' ' 54' ' ' ILE . 98.3 t -113.78 106.05 19.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.15 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.778 HG12 ' HA3' ' A' ' 33' ' ' GLY . 20.1 m -120.64 139.03 49.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.16 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.447 ' OE1' HD13 ' A' ' 44' ' ' LEU . 1.5 pm0 -90.61 141.86 28.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 74.12 110.845 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.8 p -62.29 -31.6 72.22 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.074 -0.512 . . . . 52.43 111.166 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.717 HG21 HG13 ' A' ' 48' ' ' VAL . 64.8 p -71.71 -22.12 61.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 64.03 111.133 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.76 78.78 0.34 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 63.21 111.055 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 p -65.33 -35.62 81.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 73.01 111.184 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.7 m -54.09 -32.32 54.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.169 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.482 ' O ' HD11 ' A' ' 44' ' ' LEU . 35.6 t30 -93.47 30.59 1.7 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 74.3 110.941 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.778 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.94 148.4 50.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.731 -0.747 . . . . 61.22 112.483 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.628 HG22 HD12 ' A' ' 44' ' ' LEU . 14.6 t -125.58 168.98 12.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.768 0.318 . . . . 73.43 111.181 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.0 pt -107.37 172.57 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 72.12 111.096 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.444 HG22 ' CD2' ' A' ' 42' ' ' PHE . 37.4 p -97.85 150.68 21.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.113 -0.494 . . . . 55.34 111.067 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -80.57 -175.99 5.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.483 . . . . 34.54 110.864 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -59.52 -30.74 68.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.274 -0.421 . . . . 72.12 110.869 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -100.04 22.77 10.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.16 -0.473 . . . . 73.22 110.886 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.94 28.15 72.32 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.76 . . . . 75.31 112.523 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -107.33 127.77 53.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.23 110.82 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.444 ' CD2' HG22 ' A' ' 36' ' ' THR . 25.9 p90 -127.73 157.22 40.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.879 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.1 t -132.48 123.82 27.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 72.34 111.158 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.628 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.22 118.44 7.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 72.23 110.981 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.0 m -95.05 116.64 28.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 73.42 110.851 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -122.55 156.24 61.51 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.622 0.725 . . . . 71.43 111.155 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -35.88 11.83 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.667 2.245 . . . . 60.01 112.371 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.717 HG13 HG21 ' A' ' 28' ' ' THR . 14.5 p -131.51 140.23 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 71.24 111.164 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -104.21 79.7 1.63 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 63.41 110.876 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.9 t -89.37 -76.96 0.4 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 64.13 110.861 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.64 159.99 40.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 72.33 111.147 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 66' ' ' ALA . 15.6 mt -134.81 122.27 21.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 62.04 110.882 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HA ' HG22 ' A' ' 63' ' ' THR . 71.0 tttt -100.89 123.2 44.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.914 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.601 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.1 mt -121.12 138.4 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 73.4 111.149 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 47.2 p -148.82 138.66 22.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 62.11 111.11 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.667 ' HB3' HD21 ' A' ' 74' ' ' LEU . 12.6 t80 -133.98 122.8 23.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 65.43 110.927 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.419 HG23 ' O ' ' A' ' 57' ' ' ILE . 7.2 tt -51.82 120.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 74.23 111.098 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.73 -50.94 0.85 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 45.03 112.521 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -109.23 169.97 8.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 61.23 110.932 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -64.54 157.33 73.51 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.52 0.676 . . . . 75.3 110.936 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.79 165.16 31.93 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.675 2.25 . . . . 71.32 112.311 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.601 HG23 ' HB ' ' A' ' 54' ' ' ILE . 32.1 m -150.55 138.25 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 74.11 111.154 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 53' ' ' LYS . 5.1 p -131.76 140.85 49.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 60.11 111.171 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.0 m -145.92 175.66 2.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 74.21 111.11 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.41 149.9 25.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 70.32 110.9 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.615 ' HA ' HD12 ' A' ' 52' ' ' LEU . . . -75.43 118.37 18.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.181 -0.463 . . . . 72.41 111.137 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.97 -176.22 5.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 63.13 111.064 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.503 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -68.14 -57.66 5.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.153 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.503 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -126.69 114.26 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 72.31 111.139 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.87 127.45 58.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 74.42 111.136 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 71.4 m-80 -100.35 127.59 46.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 74.11 110.897 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.565 HG11 HG21 ' A' ' 62' ' ' VAL . 21.4 t -118.7 148.88 21.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.254 -0.43 . . . . 61.34 111.093 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 15.3 mt -119.43 131.47 55.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.124 -0.489 . . . . 72.02 110.936 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.667 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -87.86 121.9 30.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.955 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -90.36 144.01 26.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 73.42 110.94 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -58.97 139.87 56.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.12 110.864 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -91.23 -34.29 15.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 44.35 110.868 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.0 t -103.76 66.68 0.86 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 74.43 111.131 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -119.92 -48.83 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 74.23 110.893 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 8.3 tpp -76.77 116.98 17.94 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.416 . . . . 74.23 110.821 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.25 108.53 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 72.15 111.186 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -115.84 174.24 6.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 62.52 110.903 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -118.54 65.89 0.77 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 64.43 110.857 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.88 130.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 53.25 111.077 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.28 98.53 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 62.05 111.113 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.0 m -113.38 169.61 4.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 73.01 111.141 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.0 t -82.01 141.42 33.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 65.24 111.137 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.93 148.38 50.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.767 -0.73 . . . . 61.42 112.445 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -82.25 132.49 35.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.93 0.395 . . . . 75.33 110.942 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.03 111.157 -179.988 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 48.5 mtm . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.832 0.349 . . . . 72.11 110.904 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -134.95 103.65 0.48 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.732 -0.747 . . . . 33.14 112.443 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -136.62 128.31 28.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.84 0.352 . . . . 75.12 110.868 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 5.3 p80 -71.4 169.5 15.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 62.11 110.907 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -121.8 92.97 3.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.287 -0.415 . . . . 72.04 110.866 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -129.33 147.19 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 71.31 110.804 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 31.8 p80 -126.06 164.06 21.69 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 74.02 110.904 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 22.6 t60 -122.75 -64.56 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 73.02 110.875 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.7 m -104.57 121.62 43.89 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.143 -0.481 . . . . 51.53 111.176 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -101.29 92.24 4.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.272 -0.422 . . . . 74.23 110.891 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 86.06 117.17 0.95 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.762 -0.732 . . . . 42.34 112.516 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.0 120.19 3.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.771 0.32 . . . . 73.41 110.928 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.1 t -105.93 131.64 54.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 73.33 111.126 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.9 p -129.37 159.26 36.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.43 111.126 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -84.34 156.95 21.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.2 110.858 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -93.96 20.09 8.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.079 -0.509 . . . . 60.22 110.966 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.58 HG21 ' OH ' ' A' ' 59' ' ' TYR . 60.1 p -94.52 -58.42 2.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 75.14 111.131 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -122.26 -26.36 4.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 72.52 110.915 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.64 29.27 5.08 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.753 -0.737 . . . . 53.34 112.539 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -98.99 159.69 29.6 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.552 0.692 . . . . 74.15 110.953 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.71 147.72 63.82 Favored 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.745 2.296 . . . . 61.23 112.399 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.515 HG21 ' CD2' ' A' ' 56' ' ' TYR . 26.5 mm -94.6 114.97 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 75.31 111.084 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.472 HD13 ' CD2' ' A' ' 38' ' ' PHE . 40.4 mt -100.22 138.6 24.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 42.2 111.159 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.27 46.64 12.23 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.659 -0.781 . . . . 62.52 112.522 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.461 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -94.87 157.82 15.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 63.11 111.043 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -106.01 107.14 17.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 52.44 110.855 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.785 HG22 HG23 ' A' ' 54' ' ' ILE . 13.3 t -112.15 122.58 66.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 75.44 111.132 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -138.91 151.95 23.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 74.52 111.177 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.402 ' OE1' HG11 ' A' ' 46' ' ' VAL . 2.4 mm-40 -84.31 174.28 10.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 74.12 110.912 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.13 -42.29 69.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 52.43 111.185 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.7 p -112.91 -22.16 10.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 64.03 111.143 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -110.26 76.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 63.21 111.2 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.2 p -86.95 -34.38 19.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 73.01 111.141 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.3 m -53.16 -30.48 37.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.434 . . . . 74.23 111.096 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -93.16 30.99 1.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 74.3 110.852 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.95 138.98 46.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.78 -0.724 . . . . 61.22 112.455 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.535 ' OG1' HD23 ' A' ' 44' ' ' LEU . 3.5 m -116.97 160.45 20.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 73.43 111.162 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.461 HG22 ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.51 162.2 12.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 72.12 111.165 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.455 HG22 ' HD2' ' A' ' 42' ' ' PHE . 5.6 p -83.87 150.61 25.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 55.34 111.218 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -85.14 -175.89 5.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 34.54 110.91 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CD2' HD13 ' A' ' 20' ' ' ILE . 8.2 t80 -58.99 -30.18 67.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.237 -0.438 . . . . 72.12 110.851 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.56 13.54 13.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 73.22 110.862 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 28.0 71.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.757 -0.735 . . . . 75.31 112.419 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -126.81 142.59 51.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.863 0.363 . . . . 71.23 110.917 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.455 ' HD2' HG22 ' A' ' 36' ' ' THR . 30.9 p90 -132.39 168.01 18.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.469 . . . . 71.21 110.873 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.7 t -133.43 116.56 16.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 72.34 111.105 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.657 HD13 ' N ' ' A' ' 45' ' ' SER . 1.2 tm? -143.19 132.29 23.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 72.23 110.929 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' SER . . . . . 0.657 ' N ' HD13 ' A' ' 44' ' ' LEU . 79.2 p -107.35 124.84 50.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 73.42 110.902 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.402 HG11 ' OE1' ' A' ' 26' ' ' GLU . 3.5 m -113.61 155.95 44.2 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.702 0.763 . . . . 71.43 111.111 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -48.5 0.71 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.665 2.243 . . . . 60.01 112.362 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.3 m -112.37 179.68 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 71.24 111.189 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 75.2 m-80 -100.31 36.88 1.77 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 63.41 110.862 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.3 t -61.98 -172.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 64.13 110.844 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.0 154.95 19.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.057 -0.52 . . . . 72.33 111.186 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.723 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.3 mp -127.41 130.96 50.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 62.04 110.91 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -99.82 121.25 41.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 74.21 110.917 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.785 HG23 HG22 ' A' ' 24' ' ' VAL . 2.4 mp -117.92 119.14 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.295 -0.411 . . . . 73.4 111.14 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 44.5 p -116.08 144.32 44.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.187 -0.46 . . . . 62.11 111.149 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.8 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.3 m-85 -126.63 152.35 46.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 65.43 110.918 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.493 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -89.71 107.73 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.109 -0.496 . . . . 74.23 111.142 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.5 -50.47 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.49 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.58 ' OH ' HG21 ' A' ' 14' ' ' THR . 12.8 m-85 -103.62 170.69 7.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 61.23 110.925 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -67.95 145.17 97.71 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.58 0.705 . . . . 75.3 110.867 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 172.34 12.84 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.682 2.254 . . . . 71.32 112.382 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.539 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.5 m -150.08 143.66 17.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 74.11 111.128 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -122.49 134.76 54.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.246 -0.434 . . . . 60.11 111.168 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 70' ' ' VAL . 6.1 m -152.94 158.82 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 74.21 111.127 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -82.47 157.28 23.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 70.32 110.882 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.723 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.18 138.14 49.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 72.41 111.113 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.72 -177.59 4.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 63.13 111.093 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.37 -58.0 7.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 73.13 111.085 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -124.25 137.71 56.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.2 -0.454 . . . . 72.31 111.149 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 64' ' ' VAL . 6.1 p -143.61 120.92 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 74.42 111.142 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -119.98 110.55 16.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 74.11 110.831 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.446 HG11 HG21 ' A' ' 62' ' ' VAL . 22.2 t -116.37 146.32 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 61.34 111.128 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -102.14 135.33 43.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.185 -0.461 . . . . 72.02 110.932 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.8 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.53 120.87 29.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 65.54 110.919 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -95.69 142.9 27.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 73.42 110.905 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -55.02 141.25 34.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.12 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -124.44 120.2 31.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.264 -0.426 . . . . 44.35 110.946 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -134.65 141.06 46.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 74.43 111.164 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -106.67 152.75 23.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 74.23 110.89 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -113.29 85.2 2.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 74.23 110.876 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -175.36 134.37 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.237 -0.438 . . . . 72.15 111.113 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -55.31 131.81 46.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 62.52 110.855 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -106.75 86.21 2.29 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 64.43 110.926 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.9 m -59.67 157.22 2.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 53.25 111.152 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.2 p -52.92 135.74 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 62.05 111.129 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.4 m -111.87 175.94 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 73.01 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.5 p -64.02 -179.54 0.43 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.445 . . . . 65.24 111.165 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -79.88 151.03 33.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.774 -0.727 . . . . 61.42 112.489 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -90.8 156.11 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 75.33 110.966 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 p . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 73.03 111.151 -179.937 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.0 mmt . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.852 0.358 . . . . 72.11 110.886 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -88.52 -166.91 42.74 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.745 -0.74 . . . . 33.14 112.496 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 36.3 m170 -118.45 -44.22 2.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.837 0.351 . . . . 75.12 110.855 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -70.34 169.16 14.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 62.11 110.786 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 60.8 m170 -110.36 112.29 24.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 72.04 110.874 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -72.73 122.2 21.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.206 -0.452 . . . . 71.31 110.888 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -115.32 -42.22 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.02 110.877 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -62.42 156.56 22.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.267 -0.424 . . . . 73.02 110.849 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.1 m -94.42 154.02 17.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.205 -0.452 . . . . 51.53 111.179 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.34 133.65 51.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 74.23 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.53 124.79 0.86 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.705 -0.759 . . . . 42.34 112.529 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -152.74 119.95 5.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.36 . . . . 73.41 110.857 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.638 ' CG2' HD13 ' A' ' 54' ' ' ILE . 22.4 t -107.26 132.11 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 73.33 111.153 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.407 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.9 OUTLIER -136.22 160.38 38.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 73.43 111.072 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.16 154.1 35.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 72.2 110.851 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.6 tttp -96.46 12.91 29.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 60.22 110.845 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 74.3 p -93.86 -58.72 2.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.261 -0.427 . . . . 75.14 111.144 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -119.04 -26.57 5.93 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.229 -0.442 . . . . 72.52 110.935 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.32 29.25 5.18 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.748 . . . . 53.34 112.445 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLN . . . . . 0.407 ' C ' HG22 ' A' ' 11' ' ' THR . 47.0 mt-30 -90.45 160.46 39.26 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.598 0.713 . . . . 74.15 110.902 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 136.27 32.64 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.673 2.248 . . . . 61.23 112.368 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.4 mm -87.4 123.07 39.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.096 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.5 mt -107.92 128.23 63.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 42.2 111.118 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.53 32.87 14.68 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.686 -0.768 . . . . 62.52 112.501 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.42 127.76 36.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.792 0.329 . . . . 63.11 111.04 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -72.8 107.63 5.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.829 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.548 HG22 HG12 ' A' ' 54' ' ' ILE . 21.8 t -111.64 106.68 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.065 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.03 150.49 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 74.52 111.121 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.514 ' O ' HG23 ' A' ' 30' ' ' THR . 2.4 mp0 -92.57 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 74.12 110.851 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.9 p -56.14 -34.85 66.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.066 -0.515 . . . . 52.43 111.204 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 66.5 p -98.16 -22.09 16.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.24 -0.436 . . . . 64.03 111.208 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -133.48 65.81 1.57 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 63.21 111.065 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 26' ' ' GLU . 1.2 p -67.03 -35.32 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 73.01 111.17 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 88.8 m -64.1 -30.63 71.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 74.23 111.084 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -93.51 30.55 1.72 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.86 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -70.9 155.95 53.04 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.749 -0.739 . . . . 61.22 112.422 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -132.76 168.8 17.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.756 0.312 . . . . 73.43 111.199 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.89 150.83 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.191 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.2 p -70.38 150.14 46.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.186 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -91.3 -179.23 5.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 34.54 110.821 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -58.25 -30.64 66.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 72.12 110.846 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -73.84 -19.48 60.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.853 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.03 28.16 12.42 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.689 -0.767 . . . . 75.31 112.501 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -137.68 164.59 28.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.859 0.361 . . . . 71.23 110.925 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.524 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 27.6 p90 -138.78 167.46 21.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 71.21 110.835 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 43' ' ' THR . 5.0 t -119.86 120.38 36.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.114 -0.493 . . . . 72.34 111.187 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.3 mt -148.11 108.18 4.06 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.265 -0.425 . . . . 72.23 110.899 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.4 t -82.4 108.08 15.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.851 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.414 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.7 m -139.98 106.77 6.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.653 0.74 . . . . 71.43 111.129 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -32.54 18.45 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.762 2.308 . . . . 60.01 112.365 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.4 m -55.57 -30.61 26.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 71.24 111.138 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 67.32 40.11 2.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 63.41 110.866 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.0 m -74.73 -176.01 2.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 64.13 110.91 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.725 HG23 ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -86.95 150.05 24.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 72.33 111.186 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.1 mp -117.85 131.57 56.54 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.264 -0.425 . . . . 62.04 110.933 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.805 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.2 OUTLIER -99.83 128.48 45.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 74.21 110.87 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.638 HD13 ' CG2' ' A' ' 10' ' ' VAL . 45.0 mt -123.79 124.93 70.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.233 -0.44 . . . . 73.4 111.097 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' THR . . . . . 0.584 HG23 ' HD3' ' A' ' 53' ' ' LYS . 71.8 p -140.88 143.33 34.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.104 -0.498 . . . . 62.11 111.131 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.423 ' HB3' HD21 ' A' ' 74' ' ' LEU . 9.3 t80 -139.29 121.02 15.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.216 -0.447 . . . . 65.43 110.856 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.452 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.1 tt -50.91 107.68 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.083 -0.508 . . . . 74.23 111.141 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 138.94 -43.86 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 45.03 112.46 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -114.94 170.96 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.981 0.42 . . . . 61.23 110.902 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mmtt -66.29 153.64 92.09 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.596 0.712 . . . . 75.3 110.905 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.77 157.68 59.54 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.711 2.274 . . . . 71.32 112.331 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.529 ' CG2' HG11 ' A' ' 72' ' ' VAL . 26.8 m -150.93 137.93 13.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 74.11 111.141 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.805 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.2 p -131.96 142.24 49.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 60.11 111.107 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.605 HG11 HG22 ' A' ' 72' ' ' VAL . 15.5 m -149.55 156.32 7.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 74.21 111.141 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.725 ' HG3' HG23 ' A' ' 51' ' ' THR . 0.1 OUTLIER -80.51 157.29 26.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 70.32 110.934 179.892 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.861 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -77.4 137.59 38.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.276 -0.42 . . . . 72.41 111.147 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.59 178.65 7.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.439 . . . . 63.13 111.112 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.569 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.71 -49.61 62.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 73.13 111.087 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.71 111.79 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 72.31 111.144 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.12 128.1 73.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.079 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -115.39 125.98 53.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 74.11 110.887 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.605 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -120.05 149.01 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 61.34 111.132 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.5 mp -121.35 120.46 35.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 72.02 110.968 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.423 HD21 ' HB3' ' A' ' 56' ' ' TYR . 3.4 tp -88.06 116.55 26.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 65.54 110.873 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 17.0 pm0 -95.9 146.47 24.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 73.42 110.82 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.58 143.89 33.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.131 -0.486 . . . . 75.12 110.932 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -97.7 -34.44 10.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 44.35 110.862 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.3 p -139.56 169.01 18.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 74.43 111.168 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 2.3 pp0? -133.39 158.56 42.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 74.23 110.916 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -145.73 148.11 32.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.286 -0.416 . . . . 74.23 110.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.4 t -99.84 -44.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.259 -0.428 . . . . 72.15 111.117 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -127.47 172.4 10.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.101 -0.499 . . . . 62.52 110.933 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.52 82.4 6.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 64.43 110.86 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 68.9 t -89.29 117.37 32.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 53.25 111.147 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.5 p -80.03 138.02 20.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 62.05 111.085 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 41.7 t -138.97 121.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.117 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -64.05 128.26 35.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.141 -0.481 . . . . 65.24 111.128 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 132.27 119.87 2.1 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.782 -0.723 . . . . 61.42 112.54 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -142.7 164.1 31.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.95 0.405 . . . . 75.33 110.86 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.051 -0.522 . . . . 73.03 111.136 -179.97 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.1 mmt . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.845 0.355 . . . . 72.11 110.855 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 131.07 141.99 4.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 33.14 112.465 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -144.29 150.16 37.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.854 0.359 . . . . 75.12 110.901 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -144.75 144.04 30.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.265 -0.425 . . . . 62.11 110.921 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 3.3 m80 -74.99 163.38 27.68 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.233 -0.44 . . . . 72.04 110.882 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -66.18 172.34 3.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.253 -0.43 . . . . 71.31 110.901 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -99.83 109.16 21.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 74.02 110.872 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.0 t-80 -139.32 -55.18 0.58 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 73.02 110.835 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.589 ' O ' HG23 ' A' ' 69' ' ' ILE . 3.5 m -106.13 127.81 53.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 51.53 111.121 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -74.43 102.25 4.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.87 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.38 105.4 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.769 -0.729 . . . . 42.34 112.433 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -156.83 125.76 5.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.829 0.347 . . . . 73.41 110.881 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.654 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 93.1 t -112.35 130.17 66.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 73.33 111.075 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.511 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.0 p -128.84 164.31 23.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 73.43 111.11 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -85.32 149.95 25.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 72.2 110.801 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.35 18.17 8.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.111 -0.495 . . . . 60.22 110.918 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.93 2.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 75.14 111.157 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -119.95 -26.77 5.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 72.52 110.88 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.11 29.39 5.19 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.773 -0.727 . . . . 53.34 112.507 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.2 mm100 -96.9 160.3 29.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.672 0.749 . . . . 74.15 110.918 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.511 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.73 138.54 38.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.649 2.233 . . . . 61.23 112.381 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 49.9 mm -83.79 123.09 38.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.133 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.3 mt -108.24 140.75 25.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.161 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.63 51.99 17.95 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.81 -0.71 . . . . 62.52 112.48 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.595 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.05 155.75 16.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.805 0.336 . . . . 63.11 111.078 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.5 m -106.14 107.42 18.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 52.44 110.843 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.63 HG13 HG12 ' A' ' 54' ' ' ILE . 94.8 t -113.31 116.8 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 75.44 111.158 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 30' ' ' THR . 13.2 m -138.65 144.01 30.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 74.52 111.049 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HG3' HD22 ' A' ' 52' ' ' LEU . 1.7 mp0 -78.94 173.65 12.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.12 110.866 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 66.1 p -75.41 -36.26 60.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 52.43 111.143 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 38.9 p -112.37 -22.08 11.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 64.03 111.111 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB3' ' OE2' ' A' ' 26' ' ' GLU . . . -114.97 75.56 0.94 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 63.21 111.073 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.674 HG23 ' HB ' ' A' ' 25' ' ' VAL . 15.1 m -84.36 -35.9 22.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 73.01 111.18 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -57.38 -28.93 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 74.23 111.128 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -94.54 31.23 1.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.91 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -69.67 149.28 47.97 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.799 -0.715 . . . . 61.22 112.48 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.648 HG22 HD12 ' A' ' 44' ' ' LEU . 13.2 t -123.1 169.12 11.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.716 0.293 . . . . 73.43 111.139 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.595 HG22 ' O ' ' A' ' 22' ' ' ALA . 12.1 pt -124.42 156.64 32.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.148 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.57 HG22 ' HD2' ' A' ' 42' ' ' PHE . 35.6 p -81.79 149.05 28.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 55.34 111.115 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -91.62 -176.24 4.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.228 -0.442 . . . . 34.54 110.858 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.93 -30.62 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 72.12 110.892 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -73.8 -18.85 60.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 73.22 110.86 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.37 28.22 20.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.725 -0.75 . . . . 75.31 112.457 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.97 162.38 29.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.826 0.346 . . . . 71.23 110.901 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.57 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.2 p90 -146.02 164.14 33.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 71.21 110.921 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.7 t -128.5 116.28 19.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 72.34 111.14 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.648 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.5 107.46 3.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 72.23 110.877 179.917 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.6 m -68.82 107.93 3.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.83 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.773 HG11 HD21 ' A' ' 52' ' ' LEU . 58.2 t -139.97 133.41 15.31 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.62 0.724 . . . . 71.43 111.126 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.498 ' O ' ' HB3' ' A' ' 66' ' ' ALA . 53.9 Cg_endo -69.81 173.86 10.4 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.652 2.234 . . . . 60.01 112.384 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 48' ' ' VAL . 9.8 p -95.48 31.99 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.178 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -92.19 -36.04 13.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 63.41 110.912 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 6.3 p -123.47 176.98 5.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 64.13 110.84 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.509 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -97.72 176.88 5.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 72.33 111.164 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.773 HD21 HG11 ' A' ' 46' ' ' VAL . 71.6 mt -131.17 126.78 36.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 62.04 110.951 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -102.44 122.04 43.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 74.21 110.865 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.63 HG12 HG13 ' A' ' 24' ' ' VAL . 61.2 mt -123.79 117.73 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 73.4 111.145 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 65.0 p -113.19 148.58 35.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 62.11 111.122 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 21.9 m-85 -127.37 154.97 44.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 65.43 110.951 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.02 107.77 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 74.23 111.072 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 124.09 -51.23 0.82 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.707 -0.759 . . . . 45.03 112.429 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.93 170.66 7.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.995 0.426 . . . . 61.23 110.856 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 35.2 mttt -64.54 148.53 96.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.59 0.71 . . . . 75.3 110.878 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -178.75 2.51 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.268 . . . . 71.32 112.324 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.128 HG21 HG11 ' A' ' 72' ' ' VAL . 4.7 p -152.02 146.02 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 74.11 111.169 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.9 p -132.17 130.58 41.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 60.11 111.119 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 70' ' ' VAL . 8.1 m -152.62 155.15 6.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.28 -0.418 . . . . 74.21 111.069 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.3 ptpt -74.68 152.46 39.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 70.32 110.892 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 47' ' ' PRO . . . -58.26 120.74 9.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 72.41 111.098 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -148.49 150.76 33.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 63.13 111.089 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.81 -53.73 36.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.097 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.589 HG23 ' O ' ' A' ' 6' ' ' THR . 4.6 mp -117.17 133.28 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 72.31 111.204 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 64' ' ' VAL . 5.4 p -146.39 118.05 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.145 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -120.11 109.46 15.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.473 . . . . 74.11 110.904 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 1.128 HG11 HG21 ' A' ' 62' ' ' VAL . 22.0 t -126.79 144.14 37.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 61.34 111.15 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.0 mp -96.92 145.19 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 72.02 111.008 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.3 tp -87.77 121.49 30.25 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.281 -0.418 . . . . 65.54 110.931 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -98.71 136.11 39.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 73.42 110.888 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -55.05 140.46 37.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.88 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -106.4 86.84 2.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.861 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.0 p -127.02 -178.6 4.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.237 -0.438 . . . . 74.43 111.144 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -54.91 121.05 7.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 74.23 110.904 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 77.3 mmm -118.8 176.6 5.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 74.23 110.904 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.4 t -140.04 113.69 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 72.15 111.108 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -97.14 170.05 9.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.135 -0.484 . . . . 62.52 110.887 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 53.52 53.17 11.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 64.43 110.862 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 57.8 t -92.69 140.13 16.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 53.25 111.153 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.7 138.11 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 62.05 111.134 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.38 141.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 73.01 111.103 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.0 t -106.56 150.77 25.82 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.188 -0.46 . . . . 65.24 111.134 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -142.58 -104.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.705 -0.759 . . . . 61.42 112.497 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -93.32 150.74 20.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.918 0.39 . . . . 75.33 110.943 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 73.03 111.165 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 16.6 ptm . . . . . 0 N--CA 1.458 -0.042 0 CA-C-O 120.844 0.354 . . . . 72.11 110.866 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 160.18 161.27 11.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 33.14 112.508 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 12.4 t60 -152.05 121.45 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.833 0.349 . . . . 75.12 110.843 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -105.53 167.34 9.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 62.11 110.879 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -117.37 137.92 52.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 72.04 110.849 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.5 p80 -58.32 154.23 13.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 71.31 110.841 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 34.2 p-80 -120.1 140.67 50.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 74.02 110.917 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.2 t-160 -118.43 61.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.196 -0.456 . . . . 73.02 110.845 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.414 ' HB ' HD13 ' A' ' 69' ' ' ILE . 0.3 OUTLIER -87.68 149.49 24.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 51.53 111.061 -179.878 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -152.35 -176.07 5.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 74.23 110.879 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.17 127.29 32.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 42.34 112.481 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 5.9 t30 -151.23 127.64 10.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 73.41 110.896 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' OH ' ' A' ' 56' ' ' TYR . 90.7 t -118.29 130.61 72.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 73.33 111.136 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.602 HG22 ' HA ' ' A' ' 18' ' ' PRO . 20.3 p -127.14 169.39 13.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 73.43 111.163 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.21 155.1 19.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.2 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -92.63 18.64 8.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 60.22 110.848 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.64 2.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 75.14 111.165 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -120.85 -26.42 5.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.3 -0.409 . . . . 72.52 110.832 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.79 29.05 5.12 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.491 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -100.63 154.19 37.31 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.566 0.698 . . . . 74.15 110.93 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.602 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.8 Cg_endo -69.7 147.2 62.75 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.756 2.304 . . . . 61.23 112.335 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.486 HG21 ' CD2' ' A' ' 56' ' ' TYR . 15.5 mm -93.5 120.38 42.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 75.31 111.066 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.07 150.81 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 42.2 111.103 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.61 48.33 82.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.474 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.28 167.65 11.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 63.11 111.028 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.0 m -106.34 106.62 17.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.163 -0.471 . . . . 52.44 110.856 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.697 HG13 HG13 ' A' ' 54' ' ' ILE . 5.9 t -110.42 128.86 66.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 75.44 111.122 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.8 m -148.44 137.99 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 74.52 111.143 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.674 ' OE2' HG11 ' A' ' 46' ' ' VAL . 15.7 tt0 -82.87 129.27 34.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 74.12 110.878 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.44 HG22 ' O ' ' A' ' 51' ' ' THR . 1.2 t -51.4 -33.21 29.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.168 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 42.1 p -89.45 -22.24 22.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 64.03 111.1 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -148.61 98.66 2.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 63.21 111.115 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 66.3 p -86.69 -32.83 20.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 73.01 111.189 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.3 m -52.78 -29.69 28.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.169 -0.469 . . . . 74.23 111.135 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -93.25 31.08 1.53 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.247 -0.433 . . . . 74.3 110.841 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -66.44 150.53 51.93 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.71 -0.757 . . . . 61.22 112.474 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.526 ' CG2' HD11 ' A' ' 44' ' ' LEU . 13.5 t -135.76 169.43 17.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 73.43 111.151 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.45 HG22 ' O ' ' A' ' 22' ' ' ALA . 17.9 pt -113.16 152.08 14.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 72.12 111.146 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 42' ' ' PHE . 10.0 p -69.98 150.72 46.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 55.34 111.119 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -81.26 -177.43 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.84 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -60.32 -30.61 69.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 72.12 110.867 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -97.42 20.38 11.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.22 110.867 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.27 27.94 71.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.719 -0.753 . . . . 75.31 112.474 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -108.5 139.38 43.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 71.23 110.919 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.472 ' HE2' HG23 ' A' ' 10' ' ' VAL . 13.2 p90 -133.49 168.13 19.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 71.21 110.928 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.508 ' C ' HD12 ' A' ' 44' ' ' LEU . 25.6 p -145.1 117.69 8.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 72.34 111.092 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.577 HD22 HD22 ' A' ' 52' ' ' LEU . 7.4 mp -126.59 109.58 12.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 72.23 110.889 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -99.89 117.91 35.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.845 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.674 HG11 ' OE2' ' A' ' 26' ' ' GLU . 3.6 m -138.34 155.9 73.79 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 71.43 111.124 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 -48.34 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.634 2.223 . . . . 60.01 112.381 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.18 150.72 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 71.24 111.111 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -91.3 46.07 1.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 63.41 110.91 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 84.0 p -66.4 -169.83 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 64.13 110.819 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.44 ' O ' HG22 ' A' ' 27' ' ' THR . 0.2 OUTLIER -94.64 160.74 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.503 . . . . 72.33 111.165 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.667 HD23 ' HG3' ' A' ' 26' ' ' GLU . 19.1 mt -121.15 117.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.931 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -97.82 114.58 26.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.867 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.697 HG13 HG13 ' A' ' 24' ' ' VAL . 4.0 mp -115.62 121.2 66.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 73.4 111.168 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 43.8 p -117.14 145.26 43.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 62.11 111.04 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.544 ' OH ' HG21 ' A' ' 10' ' ' VAL . 18.7 m-85 -125.81 155.29 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.481 . . . . 65.43 110.903 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.498 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.5 107.38 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.11 -0.496 . . . . 74.23 111.158 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.07 -46.16 1.1 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 45.03 112.467 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -111.82 170.89 7.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 61.23 110.828 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -63.6 150.75 89.74 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.568 0.699 . . . . 75.3 110.927 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 178.2 4.83 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.645 2.23 . . . . 71.32 112.371 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.666 HG21 HG11 ' A' ' 72' ' ' VAL . 3.7 p -152.03 147.9 14.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.088 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.6 p -132.14 130.82 41.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.174 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.65 HG11 HG21 ' A' ' 70' ' ' VAL . 19.5 m -141.66 145.97 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.263 -0.426 . . . . 74.21 111.125 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.97 157.18 37.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.965 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.18 98.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 72.41 111.155 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.15 178.2 6.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 63.13 111.071 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -86.36 -42.37 13.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.16 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.414 HD13 ' HB ' ' A' ' 6' ' ' THR . 54.6 mt -129.87 125.48 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.239 -0.437 . . . . 72.31 111.137 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.65 HG21 HG11 ' A' ' 64' ' ' VAL . 6.3 p -146.44 122.14 3.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 74.42 111.133 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 77.0 m-20 -120.12 119.74 34.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 74.11 110.856 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.666 HG11 HG21 ' A' ' 62' ' ' VAL . 27.8 t -133.03 147.02 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 61.34 111.173 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 24.8 mt -98.17 135.19 40.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 72.02 110.912 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' A' ' 56' ' ' TYR . 4.4 tp -89.32 117.89 28.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 65.54 110.89 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -94.07 132.53 38.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.42 110.867 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -56.65 145.84 27.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.097 -0.501 . . . . 75.12 110.936 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -111.88 97.87 6.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 44.35 110.861 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.0 p -107.06 100.65 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 74.43 111.129 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -66.37 117.05 8.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.409 . . . . 74.23 110.979 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 20.2 mtt -52.39 128.94 27.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 74.23 110.83 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.5 m -113.86 67.62 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.15 111.113 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -70.57 164.39 24.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 62.52 110.815 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -153.98 43.74 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 64.43 110.962 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 70.4 t 50.78 87.33 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 53.25 111.166 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.8 p -163.55 143.36 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 62.05 111.163 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.6 m -77.32 146.85 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.125 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 151.49 47.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 65.24 111.124 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -110.13 148.1 17.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.717 . . . . 61.42 112.489 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 53.6 t80 -91.59 144.87 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.931 0.396 . . . . 75.33 110.924 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 23.3 p . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 73.03 111.172 179.99 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.0 ptp . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.828 0.346 . . . . 72.11 110.877 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -140.92 163.4 26.62 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.784 -0.722 . . . . 33.14 112.547 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 43.9 p-80 -118.02 164.73 14.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 75.12 110.837 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -154.69 162.22 41.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 62.11 110.841 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -69.75 140.42 53.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 72.04 110.855 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -89.09 -63.09 1.34 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 71.31 110.864 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -92.7 161.58 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 74.02 110.913 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.8 m170 -115.45 154.06 29.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.414 . . . . 73.02 110.793 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -96.48 145.28 25.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.135 -0.484 . . . . 51.53 111.175 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -72.41 102.22 3.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 74.23 110.91 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.84 117.72 0.38 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.691 -0.766 . . . . 42.34 112.464 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -158.13 119.85 3.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.843 0.354 . . . . 73.41 110.909 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.643 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 87.1 t -108.84 130.91 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 73.33 111.143 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 18' ' ' PRO . 3.7 p -127.31 169.5 13.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.108 -0.497 . . . . 73.43 111.113 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.512 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.4 t -89.16 150.09 22.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.457 . . . . 72.2 110.832 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.5 ' CG ' HD13 ' A' ' 73' ' ' LEU . 14.9 tttm -90.83 15.0 12.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 60.22 110.882 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.74 -58.47 2.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 75.14 111.178 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -118.86 -26.66 5.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 72.52 110.828 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.28 29.29 6.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 53.34 112.503 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -96.93 160.16 29.81 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.533 0.682 . . . . 74.15 110.916 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.78 132.96 24.38 Favored 'Trans proline' 0 N--CA 1.465 -0.162 0 C-N-CA 122.664 2.242 . . . . 61.23 112.337 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.551 HG21 ' CD2' ' A' ' 56' ' ' TYR . 25.4 mm -77.67 118.11 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.164 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.493 HD13 ' CD2' ' A' ' 38' ' ' PHE . 23.8 mt -108.7 132.62 56.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 42.2 111.142 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.9 31.98 19.21 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.736 -0.745 . . . . 62.52 112.462 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -86.39 153.94 21.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.777 0.322 . . . . 63.11 111.114 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -106.86 107.04 17.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.429 . . . . 52.44 110.865 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.763 HG23 HG12 ' A' ' 54' ' ' ILE . 4.1 p -118.81 130.13 74.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 75.44 111.106 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.524 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.9 m -146.01 163.8 10.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 74.52 111.108 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLU . . . . . 0.685 ' OE1' HG21 ' A' ' 46' ' ' VAL . 4.1 mm-40 -85.24 172.82 10.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 74.12 110.931 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.58 -42.03 65.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 52.43 111.162 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -112.55 -21.98 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.198 -0.455 . . . . 64.03 111.155 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.16 64.55 0.84 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 63.21 111.109 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 21.8 p -78.52 -35.24 46.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.224 -0.444 . . . . 73.01 111.176 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.1 p -53.23 -30.93 40.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.097 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -93.78 31.33 1.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.968 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.81 148.37 50.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.794 -0.717 . . . . 61.22 112.434 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . 0.582 HG22 HD11 ' A' ' 44' ' ' LEU . 13.2 t -135.49 170.57 15.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.76 0.314 . . . . 73.43 111.194 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 11.6 pt -122.94 152.38 27.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 72.12 111.119 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.549 HG22 ' HD2' ' A' ' 42' ' ' PHE . 18.1 p -70.85 150.94 45.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 55.34 111.145 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -91.0 -177.02 4.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 34.54 110.896 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.493 ' CD2' HD13 ' A' ' 20' ' ' ILE . 0.4 OUTLIER -60.2 -30.01 69.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 72.12 110.883 -179.876 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -73.17 -18.52 61.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.46 28.04 20.74 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 75.31 112.452 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -129.65 166.88 18.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.887 0.375 . . . . 71.23 110.922 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PHE . . . . . 0.549 ' HD2' HG22 ' A' ' 36' ' ' THR . 26.8 p90 -151.35 167.92 26.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 71.21 110.865 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.5 t -134.66 125.61 27.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 72.34 111.1 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.697 HD22 HD21 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -130.73 128.84 41.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 72.23 110.898 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.9 t -105.04 119.97 40.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 73.42 110.801 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.685 HG21 ' OE1' ' A' ' 26' ' ' GLU . 58.0 t -139.0 133.23 16.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.614 0.721 . . . . 71.43 111.157 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.6 Cg_endo -69.77 -48.35 0.73 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.725 2.283 . . . . 60.01 112.325 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.0 m -86.65 171.64 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.259 -0.428 . . . . 71.24 111.12 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -111.08 81.75 1.48 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 63.41 110.829 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.7 t -109.39 -169.41 1.47 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.185 -0.461 . . . . 64.13 110.924 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.54 161.93 17.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.461 . . . . 72.33 111.133 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LEU . . . . . 0.697 HD21 HD22 ' A' ' 44' ' ' LEU . 0.4 OUTLIER -128.42 130.18 47.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 62.04 110.91 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -101.98 124.45 47.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.858 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.763 HG12 HG23 ' A' ' 24' ' ' VAL . 10.3 mt -123.64 119.57 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.448 . . . . 73.4 111.115 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 51.2 p -117.78 144.32 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 62.11 111.152 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 25.0 m-85 -126.22 155.06 42.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.21 -0.45 . . . . 65.43 110.94 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.492 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.24 107.72 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 74.23 111.144 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 121.17 -51.1 0.8 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 45.03 112.513 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -101.5 170.75 8.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.897 0.379 . . . . 61.23 110.906 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 57.0 mttt -68.6 143.61 95.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.551 0.691 . . . . 75.3 110.963 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.73 174.22 9.8 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.713 2.275 . . . . 71.32 112.391 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.555 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.8 m -150.24 140.37 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 74.11 111.168 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -125.76 130.25 51.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 60.11 111.148 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.9 m -153.41 159.23 3.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.283 -0.417 . . . . 74.21 111.143 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -73.07 157.23 37.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.32 110.9 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.691 ' HB2' HD12 ' A' ' 52' ' ' LEU . . . -71.89 138.31 48.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 72.41 111.078 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -159.91 167.54 27.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 63.13 111.096 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.37 -57.14 13.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 73.13 111.064 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.5 135.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 72.31 111.143 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.1 p -146.48 120.72 2.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 74.42 111.185 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -120.01 109.81 15.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 74.11 110.848 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 10' ' ' VAL . 36.7 t -123.65 135.18 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 61.34 111.148 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.5 HD13 ' CG ' ' A' ' 13' ' ' LYS . 4.5 pp -92.71 145.49 24.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 72.02 110.955 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.61 121.33 29.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 65.54 110.878 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 59.5 mt-10 -97.69 136.76 37.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.941 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -55.13 139.74 40.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 75.12 110.88 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -107.75 127.91 54.11 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 44.35 110.818 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 69.9 p -137.61 172.26 13.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.105 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 -90.2 47.89 1.5 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 74.23 110.962 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 1.8 mpt? 58.4 52.27 7.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 74.23 110.894 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.6 m -133.23 69.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.238 -0.437 . . . . 72.15 111.144 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -108.58 163.37 13.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 62.52 110.936 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -103.09 68.66 0.99 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 64.43 110.895 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -66.24 145.1 14.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 53.25 111.124 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.0 p -54.88 131.99 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 62.05 111.152 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 39.2 t -80.56 111.17 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.287 -0.415 . . . . 73.01 111.179 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 70.9 p -87.81 -39.58 14.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 65.24 111.202 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.77 -102.6 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.745 -0.74 . . . . 61.42 112.481 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.19 134.48 48.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.008 0.432 . . . . 75.33 110.884 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 p . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.122 -0.49 . . . . 73.03 111.157 -179.976 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.513 -0.235 . . . . 42.34 112.513 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -158.0 122.26 4.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.347 . . . . 73.41 110.93 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 19' ' ' ILE . 21.8 t -114.22 128.67 71.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.13 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.464 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -136.18 152.07 50.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 73.43 111.188 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.83 148.84 28.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 72.2 110.893 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.56 21.89 6.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.142 -0.481 . . . . 60.22 110.901 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.407 HG21 ' OH ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -94.0 -58.58 2.2 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 75.14 111.17 179.964 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -119.14 -25.98 6.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.263 -0.426 . . . . 72.52 110.883 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.8 29.02 5.12 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 53.34 112.499 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -101.14 160.5 26.47 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.559 0.695 . . . . 74.15 110.888 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.464 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.6 Cg_endo -69.73 145.46 57.39 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.688 2.259 . . . . 61.23 112.329 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.728 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 47.4 mm -83.07 115.63 25.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 75.31 111.171 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.3 mt -104.83 113.1 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.471 . . . . 42.2 111.191 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.51 32.66 6.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.5 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.728 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -91.06 128.14 36.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.858 0.361 . . . . 63.11 111.062 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.0 m -81.25 107.19 13.83 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.215 -0.448 . . . . 52.44 110.853 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.709 HG23 HG13 ' A' ' 54' ' ' ILE . 3.0 p -120.09 122.7 69.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.088 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.757 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.6 m -134.27 174.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 74.52 111.138 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 35.3 mp0 -91.17 166.14 13.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 74.12 110.92 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -65.43 -41.99 92.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.145 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.1 p -112.56 -22.16 10.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 64.03 111.083 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.601 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -101.32 65.65 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 63.21 111.086 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 87.5 m -77.34 -35.71 54.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 73.01 111.096 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.7 p -57.07 -31.6 65.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.23 111.169 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.664 ' O ' HD21 ' A' ' 44' ' ' LEU . 1.7 m-20 -94.45 31.41 1.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.3 110.929 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.757 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.36 152.37 49.64 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.781 -0.723 . . . . 61.22 112.499 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.593 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -135.56 168.46 19.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.74 0.305 . . . . 73.43 111.138 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.6 pt -116.55 167.72 9.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 72.12 111.134 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.499 HG22 ' HD2' ' A' ' 42' ' ' PHE . 23.0 p -89.74 150.61 22.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 55.34 111.174 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -95.22 -178.93 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 34.54 110.915 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -57.79 -30.44 65.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.48 . . . . 72.12 110.885 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -73.55 -19.39 60.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.152 -0.476 . . . . 73.22 110.892 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.7 28.26 12.83 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 120.736 -0.745 . . . . 75.31 112.458 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -136.58 166.07 24.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.914 0.388 . . . . 71.23 110.93 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.548 ' CZ ' HG21 ' A' ' 24' ' ' VAL . 24.2 p90 -142.66 164.75 29.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 71.21 110.902 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -123.46 117.79 25.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.166 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.664 HD21 ' O ' ' A' ' 32' ' ' ASN . 0.3 OUTLIER -144.44 134.97 24.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.41 . . . . 72.23 110.903 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.582 ' N ' HD13 ' A' ' 44' ' ' LEU . 1.2 t -107.02 121.85 45.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 73.42 110.846 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.5 t -126.92 133.26 24.84 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.565 0.698 . . . . 71.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.0 Cg_endo -69.69 -48.42 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.731 2.288 . . . . 60.01 112.353 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.77 149.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 71.24 111.167 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 70.8 m-80 -85.16 64.39 8.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 63.41 110.92 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -92.49 -179.56 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 64.13 110.812 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.71 156.08 19.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.075 -0.512 . . . . 72.33 111.17 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mt -115.24 124.9 52.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.275 -0.42 . . . . 62.04 110.888 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.584 ' HA ' HG22 ' A' ' 63' ' ' THR . 28.8 tttt -95.64 122.43 38.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 74.21 110.885 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.709 HG13 HG23 ' A' ' 24' ' ' VAL . 2.2 mp -118.65 134.55 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 73.4 111.131 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 45.7 p -142.55 138.74 31.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 62.11 111.123 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -134.31 119.13 18.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 65.43 110.95 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -51.49 112.46 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.132 -0.486 . . . . 74.23 111.175 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 133.98 -52.14 0.82 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.783 -0.723 . . . . 45.03 112.473 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.407 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.1 m-85 -108.27 170.0 8.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.379 . . . . 61.23 110.919 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -62.81 158.24 53.87 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.553 0.692 . . . . 75.3 110.885 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.44 42.09 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.677 2.251 . . . . 71.32 112.334 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.1 m -150.72 138.5 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.155 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 53' ' ' LYS . 34.6 p -131.37 139.52 49.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 60.11 111.166 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.701 HG11 HG22 ' A' ' 72' ' ' VAL . 26.5 m -146.69 147.05 18.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 74.21 111.153 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -66.04 157.1 31.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.982 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.99 125.9 29.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 72.41 111.168 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -156.79 166.49 33.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 63.13 111.106 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.23 -43.34 78.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.117 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.0 mt -140.48 112.11 4.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 72.31 111.11 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.514 HG21 ' HB ' ' A' ' 64' ' ' VAL . 7.7 p -130.49 128.83 64.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.131 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -102.71 133.55 47.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 74.11 110.877 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.701 HG22 HG11 ' A' ' 64' ' ' VAL . 21.5 t -122.29 148.89 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 61.34 111.1 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 13.2 mt -122.0 127.82 50.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 72.02 110.885 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.653 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.4 tp -88.19 121.58 30.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 65.54 110.866 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -90.39 144.42 25.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 73.42 110.921 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -58.24 141.33 51.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 75.12 110.897 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.7 t0 . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 44.35 110.863 179.931 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 N-CA-C 112.493 -0.243 . . . . 42.34 112.493 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -153.64 120.12 5.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 73.41 110.895 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.73 ' HB ' HG21 ' A' ' 36' ' ' THR . 22.4 t -109.7 129.8 63.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 73.33 111.175 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.55 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.7 p -136.57 176.55 8.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.209 -0.45 . . . . 73.43 111.148 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.601 ' OG ' HD11 ' A' ' 19' ' ' ILE . 0.3 OUTLIER -103.27 150.98 23.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.2 110.863 -179.846 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.564 ' HG3' HD12 ' A' ' 73' ' ' LEU . 1.3 tmmt? -93.48 19.26 8.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 60.22 110.894 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.13 -58.72 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.244 -0.435 . . . . 75.14 111.146 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -120.17 -26.42 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 72.52 110.851 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.34 29.39 5.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.742 -0.742 . . . . 53.34 112.485 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.7 mm100 -100.35 160.24 27.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 74.15 110.911 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.55 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.9 Cg_endo -69.72 137.67 36.14 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.715 2.277 . . . . 61.23 112.368 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.601 HD11 ' OG ' ' A' ' 12' ' ' SER . 42.6 mm -87.15 125.33 40.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 75.31 111.177 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.4 mt -104.89 113.47 42.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 42.2 111.134 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.04 33.03 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.486 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.66 119.26 26.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.754 0.312 . . . . 63.11 111.073 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.23 107.53 5.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 52.44 110.859 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.622 HG13 HG13 ' A' ' 54' ' ' ILE . 57.0 t -109.99 106.5 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.102 -0.499 . . . . 75.44 111.121 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.4 m -114.97 140.76 34.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.132 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.502 ' CD ' HG11 ' A' ' 46' ' ' VAL . 18.8 tt0 -85.79 133.52 33.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 74.12 110.857 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.6 p -54.51 -35.86 63.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 52.43 111.098 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.3 p -78.97 -22.09 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.267 -0.424 . . . . 64.03 111.133 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.51 110.69 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 63.21 111.079 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -86.51 -33.93 20.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.111 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 77.7 p -53.18 -29.59 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 74.23 111.154 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -94.26 31.19 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.3 110.885 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -73.25 141.18 29.65 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.801 -0.714 . . . . 61.22 112.46 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.423 HG21 ' O ' ' A' ' 43' ' ' THR . 0.2 OUTLIER -113.41 168.9 9.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.737 0.303 . . . . 73.43 111.146 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.405 ' H ' HG22 ' A' ' 34' ' ' THR . 4.8 pt -124.13 148.59 28.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 72.12 111.119 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.73 HG21 ' HB ' ' A' ' 10' ' ' VAL . 9.9 p -73.93 150.74 40.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 55.34 111.174 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -99.79 -175.33 2.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 34.54 110.873 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -56.38 -31.47 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.886 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -76.78 -18.88 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.462 . . . . 73.22 110.905 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.25 28.84 10.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 75.31 112.518 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -135.99 159.88 40.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.822 0.344 . . . . 71.23 110.931 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.494 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 30.9 p90 -140.2 168.0 20.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 71.21 110.893 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.423 ' O ' HG21 ' A' ' 34' ' ' THR . 39.2 p -109.53 116.17 31.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 72.34 111.165 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.67 107.48 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 72.23 110.909 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 29.1 t -106.95 120.12 41.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 73.42 110.86 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.502 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.2 m -129.99 156.19 79.49 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.651 0.739 . . . . 71.43 111.109 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -48.02 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.7 2.267 . . . . 60.01 112.352 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 m -101.94 175.79 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 71.24 111.12 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -106.55 58.89 0.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.897 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.5 p -72.7 -170.2 0.66 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.493 . . . . 64.13 110.857 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.471 ' C ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -89.14 152.43 21.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 72.33 111.133 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.847 HD13 ' HB2' ' A' ' 66' ' ' ALA . 10.0 mp -122.31 121.64 37.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 62.04 110.877 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 47.2 tttt -96.88 123.14 40.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.888 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.622 HG13 HG13 ' A' ' 24' ' ' VAL . 5.4 mp -116.56 132.23 66.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.446 . . . . 73.4 111.121 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.6 p -143.08 138.56 29.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 62.11 111.121 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.824 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -137.72 127.63 25.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.19 -0.459 . . . . 65.43 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.42 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.6 tp -51.63 119.98 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.489 . . . . 74.23 111.119 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.99 -51.12 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.775 -0.726 . . . . 45.03 112.479 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -108.61 170.12 8.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.933 0.397 . . . . 61.23 110.916 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -69.92 158.11 88.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.57 0.7 . . . . 75.3 110.914 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 164.56 34.12 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.681 2.254 . . . . 71.32 112.304 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.466 HG11 ' CG1' ' A' ' 72' ' ' VAL . 14.5 p -151.4 149.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.126 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.7 p -132.02 132.56 43.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.124 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.749 HG11 HG22 ' A' ' 72' ' ' VAL . 31.0 m -137.72 172.17 14.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.439 . . . . 74.21 111.16 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.38 156.82 18.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.901 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.847 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -93.18 130.07 38.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 72.41 111.045 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.55 -175.55 3.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 63.13 111.072 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.512 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -53.35 -49.53 66.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 73.13 111.097 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 68' ' ' ALA . 43.9 mm -139.2 114.2 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 72.31 111.156 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.31 125.13 67.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 74.42 111.088 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -98.68 135.06 40.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.91 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.749 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -128.33 147.6 32.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 61.34 111.153 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.564 HD12 ' HG3' ' A' ' 13' ' ' LYS . 1.2 pt? -127.12 138.09 53.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.214 -0.448 . . . . 72.02 110.922 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.824 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.2 tp -88.83 124.93 34.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 65.54 110.943 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -90.29 136.85 32.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 73.42 110.855 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -58.99 140.17 55.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.12 110.945 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 44.35 110.904 -179.987 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.498 -0.241 . . . . 42.34 112.498 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -118.39 128.19 54.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.915 0.388 . . . . 73.41 110.875 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.477 HG22 ' HB ' ' A' ' 72' ' ' VAL . 89.2 t -119.7 129.17 75.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 73.33 111.08 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.45 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.9 p -129.7 178.1 6.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.43 111.162 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 t -97.2 151.02 20.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.263 -0.426 . . . . 72.2 110.892 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.428 ' HG3' HD12 ' A' ' 73' ' ' LEU . 7.2 tmtt? -92.05 15.43 13.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 60.22 110.938 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.0 p -94.07 -59.07 2.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.238 -0.437 . . . . 75.14 111.117 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -120.44 -26.63 5.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 72.52 110.844 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.16 29.19 5.26 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.539 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -94.26 160.15 32.56 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.592 0.71 . . . . 74.15 110.913 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.45 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.2 Cg_endo -69.67 139.5 40.7 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.703 2.269 . . . . 61.23 112.342 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.641 HG22 ' HB2' ' A' ' 22' ' ' ALA . 49.2 mm -83.97 113.56 23.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.104 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 22.6 mt -101.06 128.88 52.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 42.2 111.085 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.96 32.61 26.01 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.769 -0.729 . . . . 62.52 112.486 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.641 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -90.96 135.64 33.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.796 0.331 . . . . 63.11 111.093 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -85.6 107.2 17.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 52.44 110.804 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.722 HG23 HG13 ' A' ' 54' ' ' ILE . 2.9 p -118.33 122.39 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 75.44 111.107 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.726 HG12 ' HA3' ' A' ' 33' ' ' GLY . 16.2 m -134.61 151.83 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.149 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.528 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 13.8 tp10 -75.62 132.65 40.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 74.12 110.897 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.8 p -51.52 -34.93 38.39 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.091 -0.504 . . . . 52.43 111.153 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -96.68 -22.08 17.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 64.03 111.132 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.528 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -127.19 89.75 3.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.451 . . . . 63.21 111.104 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.8 p -86.79 -35.65 19.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.136 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 91.1 m -56.68 -31.0 64.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 74.23 111.146 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -93.13 30.74 1.58 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.19 -0.459 . . . . 74.3 110.865 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.726 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.52 147.01 50.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.782 -0.723 . . . . 61.22 112.517 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.616 HG22 HD11 ' A' ' 44' ' ' LEU . 13.6 t -135.49 168.94 18.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.787 0.327 . . . . 73.43 111.112 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.7 pt -110.98 158.15 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.116 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.506 HG22 ' HD2' ' A' ' 42' ' ' PHE . 39.2 p -80.34 150.68 29.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 55.34 111.143 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.37 176.3 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 34.54 110.893 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -56.95 -30.18 63.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 72.12 110.858 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -73.12 -19.05 61.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 73.22 110.914 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.62 28.26 17.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 75.31 112.462 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 26.4 p30 -131.95 165.43 23.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 71.23 110.878 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.619 ' CE1' HG21 ' A' ' 24' ' ' VAL . 26.7 p90 -148.51 168.04 23.76 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 71.21 110.851 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 43' ' ' THR . 4.9 t -128.99 120.11 25.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.079 -0.51 . . . . 72.34 111.134 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 34' ' ' THR . 0.2 OUTLIER -127.84 111.14 13.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 72.23 110.894 179.92 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.9 m -93.38 111.91 23.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.145 -0.48 . . . . 73.42 110.817 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -128.35 156.1 77.39 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.57 0.7 . . . . 71.43 111.159 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.76 -48.19 0.77 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.67 2.247 . . . . 60.01 112.396 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.8 p -106.13 151.79 8.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 71.24 111.101 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -79.26 60.88 3.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 63.41 110.905 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -75.82 -170.4 1.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 64.13 110.825 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.86 157.52 17.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.105 -0.498 . . . . 72.33 111.122 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.474 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 2.8 mp -120.09 128.58 53.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 62.04 110.882 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.524 ' HA ' HG22 ' A' ' 63' ' ' THR . 64.1 tttt -100.75 123.14 44.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.881 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.722 HG13 HG23 ' A' ' 24' ' ' VAL . 3.7 mp -120.55 134.22 64.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 73.4 111.102 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.1 p -145.76 140.07 26.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 62.11 111.148 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.688 ' HB3' HD21 ' A' ' 74' ' ' LEU . 14.9 t80 -135.6 121.39 19.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 65.43 110.963 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.431 HG23 ' O ' ' A' ' 57' ' ' ILE . 10.8 tt -50.88 117.18 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.094 -0.503 . . . . 74.23 111.105 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.52 -50.76 0.88 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.439 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -109.68 169.98 8.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.969 0.414 . . . . 61.23 110.947 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -64.27 157.73 69.18 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.55 0.69 . . . . 75.3 110.868 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.66 162.26 42.72 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.707 2.272 . . . . 71.32 112.361 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.559 HG23 ' HB ' ' A' ' 54' ' ' ILE . 30.2 m -150.51 133.29 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.097 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.524 HG22 ' HA ' ' A' ' 53' ' ' LYS . 25.2 p -126.9 142.8 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.181 -0.463 . . . . 60.11 111.088 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.829 HG11 HG22 ' A' ' 72' ' ' VAL . 30.3 m -151.15 151.37 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 74.21 111.146 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt -73.98 157.32 36.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 70.32 110.898 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.474 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -71.12 134.18 46.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 72.41 111.11 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.476 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -164.68 161.79 20.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.437 . . . . 63.13 111.11 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.97 -40.36 60.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.13 111.066 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.0 mt -140.86 111.79 3.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 72.31 111.103 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.514 HG11 ' CG2' ' A' ' 64' ' ' VAL . 20.7 t -124.08 112.0 30.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 74.42 111.099 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -96.74 116.6 29.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.926 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.829 HG22 HG11 ' A' ' 64' ' ' VAL . 24.3 t -115.06 148.77 17.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 61.34 111.115 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.428 HD12 ' HG3' ' A' ' 13' ' ' LYS . 0.6 OUTLIER -121.2 139.21 53.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 72.02 110.959 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.688 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -91.21 122.54 33.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 65.54 110.956 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -90.53 141.37 28.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.853 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -59.06 140.53 55.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 75.12 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.8 t0 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.154 -0.476 . . . . 44.35 110.87 179.968 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 N-CA-C 112.487 -0.245 . . . . 42.34 112.487 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.75 127.51 40.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.87 0.367 . . . . 73.41 110.916 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.447 HG23 ' HE2' ' A' ' 42' ' ' PHE . 88.5 t -117.04 125.26 73.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 73.33 111.111 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.2 p -122.79 169.63 10.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 73.43 111.172 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.54 149.62 21.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 72.2 110.897 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -93.21 18.18 9.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.484 . . . . 60.22 110.882 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.21 -58.82 2.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 75.14 111.089 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -120.53 -25.97 5.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 72.52 110.91 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.97 29.13 5.03 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.672 -0.775 . . . . 53.34 112.509 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -98.29 154.13 37.76 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.62 0.724 . . . . 74.15 110.916 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.82 143.08 49.45 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.684 2.256 . . . . 61.23 112.334 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.448 ' CD1' HD22 ' A' ' 74' ' ' LEU . 47.3 mm -83.32 108.11 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 75.31 111.199 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.1 mt -101.46 126.57 55.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 42.2 111.078 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 42.11 7.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.748 -0.739 . . . . 62.52 112.47 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -94.89 162.39 13.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 63.11 111.096 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.2 m -105.62 107.53 18.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 52.44 110.859 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.728 HG13 HG13 ' A' ' 54' ' ' ILE . 43.4 t -110.43 106.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 75.44 111.085 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.9 m -124.64 138.01 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 74.52 111.101 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.512 ' CD ' HG11 ' A' ' 46' ' ' VAL . 10.6 mt-10 -72.02 173.53 8.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.861 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.2 p -76.35 -35.55 58.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.121 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 17.7 p -112.38 -22.14 11.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 64.03 111.104 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -117.2 77.2 1.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.24 -0.436 . . . . 63.21 111.05 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.6 p -86.72 -35.36 19.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.245 -0.434 . . . . 73.01 111.119 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 45.8 p -53.33 -30.2 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.23 111.159 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -94.76 31.3 1.85 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 74.3 110.907 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -59.38 136.1 50.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.485 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 5.0 m -111.15 157.87 19.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.758 0.313 . . . . 73.43 111.128 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -108.59 150.51 11.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 72.12 111.101 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.622 HG22 ' HD2' ' A' ' 42' ' ' PHE . 6.0 p -72.26 149.66 44.33 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.183 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -83.6 -175.44 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 34.54 110.859 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -58.88 -30.86 68.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 72.12 110.901 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.9 21.44 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 73.22 110.906 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.17 27.46 70.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.709 -0.757 . . . . 75.31 112.471 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -108.79 134.91 50.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.829 0.347 . . . . 71.23 110.89 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.622 ' HD2' HG22 ' A' ' 36' ' ' THR . 18.5 p90 -133.54 167.93 19.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 71.21 110.856 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.29 121.42 12.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.162 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.5 mt -120.93 127.81 52.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.209 -0.451 . . . . 72.23 110.907 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -106.93 113.65 27.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 73.42 110.852 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.512 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.3 m -139.2 156.21 72.15 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.657 0.741 . . . . 71.43 111.138 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -48.35 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.651 2.234 . . . . 60.01 112.352 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.66 149.4 5.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 71.24 111.151 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -88.9 52.1 2.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 63.41 110.863 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.1 t -68.53 -169.78 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.992 0.425 . . . . 64.13 110.812 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.554 ' O ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -87.63 157.14 19.19 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.148 -0.478 . . . . 72.33 111.187 -179.955 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 66' ' ' ALA . 7.4 mp -125.39 125.01 42.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 62.04 110.874 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.434 ' HA ' HG22 ' A' ' 63' ' ' THR . 43.1 tttt -102.64 126.89 49.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.194 -0.457 . . . . 74.21 110.912 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.728 HG13 HG13 ' A' ' 24' ' ' VAL . 3.9 mp -123.29 139.33 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 73.4 111.144 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 74.1 p -140.94 139.23 34.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 62.11 111.188 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.471 ' HB3' HD21 ' A' ' 74' ' ' LEU . 17.4 t80 -133.05 119.8 20.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.43 110.926 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.42 116.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 74.23 111.141 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 130.35 -55.13 0.77 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 45.03 112.525 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -108.87 170.63 7.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.984 0.421 . . . . 61.23 110.915 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -62.01 157.72 49.54 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.555 0.693 . . . . 75.3 110.935 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 170.77 15.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.667 2.245 . . . . 71.32 112.367 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.66 ' CG2' HG11 ' A' ' 72' ' ' VAL . 14.6 p -151.49 140.92 15.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 74.11 111.135 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 53' ' ' LYS . 11.4 p -131.95 135.35 46.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 60.11 111.183 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.503 HG11 HG21 ' A' ' 72' ' ' VAL . 6.8 m -152.17 149.24 13.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 74.21 111.2 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.3 mmtm -69.08 153.99 42.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.914 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.654 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -77.43 65.42 2.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 72.41 111.134 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -90.21 -175.1 4.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 63.13 111.045 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.736 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -64.3 -55.08 23.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 73.13 111.137 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.736 HD13 ' O ' ' A' ' 68' ' ' ALA . 17.4 mm -128.76 137.14 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 72.31 111.076 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.5 HG21 HG21 ' A' ' 64' ' ' VAL . 5.7 p -145.7 119.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 74.42 111.111 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -120.24 109.52 15.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 74.11 110.855 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.66 HG11 ' CG2' ' A' ' 62' ' ' VAL . 17.2 t -124.59 149.1 28.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 61.34 111.19 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -103.39 145.73 29.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.02 110.945 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.471 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.6 tp -87.25 120.45 28.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 65.54 110.89 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -90.36 140.4 29.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 73.42 110.872 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -59.1 142.08 52.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 75.12 110.908 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.4 t70 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 44.35 110.866 179.983 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.459 -0.257 . . . . 42.34 112.459 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -144.15 127.52 16.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.41 110.842 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 t -115.57 116.5 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.33 111.091 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.515 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.4 p -129.95 153.72 48.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 73.43 111.152 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -79.88 150.98 30.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.873 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.565 ' HA ' HD12 ' A' ' 73' ' ' LEU . 12.4 tttp -94.01 20.16 8.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.194 -0.457 . . . . 60.22 110.849 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 35.1 p -94.04 -58.79 2.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 75.14 111.168 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -119.39 -26.39 5.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.209 -0.451 . . . . 72.52 110.94 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.5 5.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.856 -0.688 . . . . 53.34 112.495 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -97.95 160.4 28.54 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.586 0.707 . . . . 74.15 110.835 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.515 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.8 148.28 64.43 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.73 2.287 . . . . 61.23 112.318 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.411 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.4 mm -95.16 122.75 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.31 111.17 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.7 mt -107.4 116.28 50.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 42.2 111.136 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 99.41 33.26 5.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.499 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -89.57 129.41 36.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.805 0.336 . . . . 63.11 111.052 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 m -76.99 108.34 9.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 52.44 110.861 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.791 HG21 ' CD2' ' A' ' 42' ' ' PHE . 68.7 t -114.87 106.18 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 75.44 111.103 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 33' ' ' GLY . 18.3 m -123.9 151.21 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.123 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.685 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 4.0 mm-40 -81.83 166.78 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 74.12 110.908 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.06 -41.99 98.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 52.43 111.136 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 33.6 p -112.44 -22.06 11.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.233 -0.44 . . . . 64.03 111.123 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.685 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -100.77 75.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 63.21 111.072 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.4 p -86.67 -35.61 19.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 73.01 111.173 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -60.6 -30.77 70.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.282 -0.417 . . . . 74.23 111.18 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -94.46 31.2 1.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 74.3 110.867 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.425 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -61.12 139.01 47.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.701 -0.761 . . . . 61.22 112.513 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.484 ' HB ' HD11 ' A' ' 44' ' ' LEU . 0.3 OUTLIER -113.71 167.37 10.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.771 0.32 . . . . 73.43 111.168 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.433 ' H ' HG22 ' A' ' 34' ' ' THR . 7.9 pt -124.14 147.16 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 72.12 111.152 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 34.4 p -69.94 137.98 51.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 55.34 111.145 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.7 -179.52 7.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 34.54 110.856 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -57.0 -30.22 63.97 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 72.12 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -73.5 -18.75 61.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.85 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.08 28.21 14.13 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.738 -0.744 . . . . 75.31 112.529 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -134.2 168.35 19.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.856 0.36 . . . . 71.23 110.935 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.791 ' CD2' HG21 ' A' ' 24' ' ' VAL . 3.1 p90 -141.89 167.93 20.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 71.21 110.869 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 27.1 p -124.98 116.99 23.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.13 -0.486 . . . . 72.34 111.137 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 8.0 mp -136.58 120.79 17.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 72.23 110.915 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 26.7 m -106.94 112.05 24.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.092 -0.504 . . . . 73.42 110.886 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.95 156.16 69.49 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.661 0.743 . . . . 71.43 111.108 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -48.25 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.633 2.222 . . . . 60.01 112.338 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.6 p -110.51 152.11 12.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.118 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -80.63 58.49 3.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 63.41 110.942 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 94.9 p -72.84 -169.83 0.63 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 64.13 110.862 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.452 HG23 ' HG2' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -87.7 153.11 21.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 72.33 111.094 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.795 HD11 ' HB2' ' A' ' 66' ' ' ALA . 5.9 mp -126.27 126.13 43.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 62.04 110.889 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.652 ' HA ' HG22 ' A' ' 63' ' ' THR . 12.1 ttpt -95.63 122.2 38.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.869 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.74 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.8 mt -121.26 137.2 55.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 73.4 111.15 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.5 p -147.39 138.77 23.87 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.153 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -133.54 119.0 18.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 65.43 111.02 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.02 117.58 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.176 -0.465 . . . . 74.23 111.185 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.68 -52.89 0.82 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.781 -0.723 . . . . 45.03 112.458 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -110.34 170.19 8.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.952 0.406 . . . . 61.23 110.945 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -60.5 157.63 35.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.589 0.709 . . . . 75.3 110.902 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 166.87 26.02 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.723 2.282 . . . . 71.32 112.283 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.5 m -151.24 126.35 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 74.11 111.112 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.652 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.8 p -125.06 132.81 53.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.109 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.479 HG11 ' CG2' ' A' ' 72' ' ' VAL . 14.8 m -152.09 157.34 5.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.079 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.452 ' HG2' HG23 ' A' ' 51' ' ' THR . 39.6 mtpt -84.13 155.11 22.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 70.32 110.953 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.795 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.09 133.6 46.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 72.41 111.091 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.16 -179.67 8.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 63.13 111.101 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.73 -58.02 7.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 73.13 111.102 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 68' ' ' ALA . 41.0 mm -142.36 111.65 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 72.31 111.104 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.76 122.3 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 74.42 111.167 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -119.78 115.33 23.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.888 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.718 HG11 ' HB ' ' A' ' 62' ' ' VAL . 18.7 t -113.16 126.9 70.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 61.34 111.109 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.565 HD12 ' HA ' ' A' ' 13' ' ' LYS . 0.7 OUTLIER -83.34 140.59 32.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.894 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.402 HD12 ' HA ' ' A' ' 74' ' ' LEU . 1.5 tp -87.9 121.73 30.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.899 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -90.2 137.06 32.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.9 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -57.45 141.78 46.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 75.12 110.872 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.093 -0.503 . . . . 44.35 110.853 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.303 0 N-CA-C 112.466 -0.254 . . . . 42.34 112.466 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -152.61 128.35 10.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.875 0.369 . . . . 73.41 110.859 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.666 HG22 HD13 ' A' ' 54' ' ' ILE . 94.2 t -117.99 131.8 69.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 73.33 111.112 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.565 HG22 ' HA ' ' A' ' 18' ' ' PRO . 16.9 p -138.12 172.88 12.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 73.43 111.088 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.417 ' HB2' HD11 ' A' ' 19' ' ' ILE . 1.2 t -92.74 156.25 17.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 72.2 110.922 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -93.57 16.38 13.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 60.22 110.876 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.1 p -94.05 -59.07 2.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 75.14 111.095 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -120.68 -26.24 5.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.52 110.91 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.63 29.12 5.14 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.747 -0.74 . . . . 53.34 112.503 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -95.02 153.93 39.74 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.606 0.717 . . . . 74.15 110.889 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.565 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.7 135.75 31.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.73 2.286 . . . . 61.23 112.296 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.417 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -84.6 135.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 75.31 111.127 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.0 mt -114.29 125.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 42.2 111.104 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.86 33.83 10.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 62.52 112.492 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -86.17 162.67 18.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.72 0.295 . . . . 63.11 111.176 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.53 113.5 27.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 52.44 110.852 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.705 HG21 ' CD2' ' A' ' 42' ' ' PHE . 44.6 t -116.76 134.04 61.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 75.44 111.12 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.1 m -139.64 148.87 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 74.52 111.064 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.664 ' HG3' HG11 ' A' ' 46' ' ' VAL . 1.7 tm-20 -88.5 135.11 33.64 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 74.12 110.846 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.411 HG21 ' HB ' ' A' ' 51' ' ' THR . 21.0 p -55.5 -32.64 63.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 52.43 111.159 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.6 p -71.87 -22.36 61.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.186 -0.461 . . . . 64.03 111.105 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -178.64 134.61 0.14 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 63.21 111.091 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.3 p -87.8 -19.29 27.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.241 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.0 p -52.16 -30.33 26.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.213 -0.449 . . . . 74.23 111.092 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.9 p-10 -93.2 31.24 1.5 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.917 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.69 135.51 38.4 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 61.22 112.483 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.58 ' HB ' HD11 ' A' ' 44' ' ' LEU . 2.5 m -124.38 161.45 25.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 73.43 111.164 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -107.71 145.67 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 72.12 111.133 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 52.7 p -70.07 149.51 47.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 55.34 111.155 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -87.14 -175.83 5.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.43 . . . . 34.54 110.871 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -57.11 -30.69 64.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 72.12 110.869 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -99.79 22.09 11.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 73.22 110.882 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.32 28.31 72.1 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 75.31 112.521 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 64.7 m-20 -110.75 128.84 55.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.874 0.369 . . . . 71.23 110.906 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.705 ' CD2' HG21 ' A' ' 24' ' ' VAL . 1.6 p90 -116.57 167.32 11.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.827 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 2.6 t -121.42 116.87 25.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 72.34 111.138 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 7.0 mp -141.15 116.75 10.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 72.23 110.9 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.3 m -106.81 108.16 19.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 73.42 110.887 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.664 HG11 ' HG3' ' A' ' 26' ' ' GLU . 3.4 m -124.69 156.08 68.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.579 0.704 . . . . 71.43 111.128 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -48.41 0.73 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.693 2.262 . . . . 60.01 112.351 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -103.67 152.0 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.182 -0.463 . . . . 71.24 111.103 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -84.94 68.36 10.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 63.41 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.0 t -80.57 -169.94 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 64.13 110.87 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.411 ' HB ' HG21 ' A' ' 27' ' ' THR . 0.6 OUTLIER -88.86 159.31 17.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.179 -0.464 . . . . 72.33 111.094 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.436 ' CD2' HD22 ' A' ' 44' ' ' LEU . 16.0 mt -124.0 135.21 53.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.902 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.601 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.3 OUTLIER -105.7 129.86 53.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 74.21 110.915 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 10' ' ' VAL . 17.6 mt -123.7 134.67 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.097 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 25.2 p -149.78 139.48 21.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 62.11 111.134 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.499 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -138.22 125.88 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 65.43 110.879 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 57' ' ' ILE . 3.7 tp -50.94 107.93 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 74.23 111.163 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.89 -47.04 0.91 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.785 -0.721 . . . . 45.03 112.524 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -112.47 170.89 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.382 . . . . 61.23 110.951 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.2 mttt -68.4 158.19 85.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.54 0.686 . . . . 75.3 110.935 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.67 160.3 50.26 Favored 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.696 2.264 . . . . 71.32 112.339 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.472 HG13 ' HB ' ' A' ' 54' ' ' ILE . 13.0 p -151.26 139.76 14.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 74.11 111.188 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.601 HG22 ' HA ' ' A' ' 53' ' ' LYS . 1.4 p -132.14 134.83 45.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 60.11 111.175 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.408 HG21 HG22 ' A' ' 72' ' ' VAL . 25.0 m -144.54 151.91 15.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 74.21 111.147 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.92 155.4 27.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 70.32 110.874 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -90.56 120.87 32.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 72.41 111.131 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -146.34 178.64 8.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 63.13 111.137 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.43 -44.22 68.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.13 111.096 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 56.2 mt -147.31 112.14 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.449 . . . . 72.31 111.059 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.61 128.42 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.172 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.9 m120 -95.91 137.56 34.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 74.11 110.892 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.466 HG21 ' CD1' ' A' ' 54' ' ' ILE . 21.2 t -124.51 148.98 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 61.34 111.192 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.58 125.74 40.84 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 72.02 110.873 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.499 HD21 ' HB3' ' A' ' 56' ' ' TYR . 2.4 tp -91.91 118.31 30.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 65.54 110.928 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -96.03 135.94 37.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 73.42 110.932 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -52.39 145.62 10.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.882 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 41.8 t0 . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.122 -0.49 . . . . 44.35 110.842 -179.961 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.342 0 N-CA-C 112.465 -0.254 . . . . 42.34 112.465 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -131.53 126.43 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.913 0.387 . . . . 73.41 110.861 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.58 HG12 HG13 ' A' ' 19' ' ' ILE . 30.5 t -118.08 128.9 75.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 73.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.22 167.02 16.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.14 -0.482 . . . . 73.43 111.137 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.59 144.33 25.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 72.2 110.835 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.4 tttm -92.78 15.62 14.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.125 -0.488 . . . . 60.22 110.844 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -58.49 2.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 75.14 111.119 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -117.97 -26.81 6.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.23 29.13 5.26 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.701 -0.762 . . . . 53.34 112.463 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -98.34 160.12 28.95 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.58 0.705 . . . . 74.15 110.886 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 143.65 51.91 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.709 2.273 . . . . 61.23 112.375 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.701 HD12 HD22 ' A' ' 74' ' ' LEU . 51.3 mm -83.13 110.0 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 75.31 111.137 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.1 mt -103.45 126.94 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.446 . . . . 42.2 111.116 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.29 33.2 23.61 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 62.52 112.478 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.697 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -87.22 131.37 34.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 63.11 111.07 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.3 m -80.19 107.57 13.09 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.129 -0.487 . . . . 52.44 110.842 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.841 HG22 HG23 ' A' ' 54' ' ' ILE . 60.9 t -106.66 105.86 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.112 -0.495 . . . . 75.44 111.112 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 28.2 m -120.6 133.65 66.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 74.52 111.126 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -91.96 141.52 28.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.474 . . . . 74.12 110.915 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.9 p -55.43 -31.66 62.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 52.43 111.152 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.7 p -71.54 -21.38 61.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.215 -0.448 . . . . 64.03 111.193 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.52 111.49 0.79 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 63.21 111.049 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 m -85.46 -34.65 21.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 73.01 111.156 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 61.8 p -66.8 -26.44 66.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 74.23 111.179 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -93.51 31.22 1.57 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.903 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -74.99 150.26 40.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.77 -0.729 . . . . 61.22 112.473 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.473 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -117.81 168.76 10.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.738 0.304 . . . . 73.43 111.157 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.0 pt -111.68 171.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 72.12 111.139 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.59 HG22 ' HD2' ' A' ' 42' ' ' PHE . 21.8 p -99.35 150.62 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 55.34 111.155 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.33 179.93 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.435 . . . . 34.54 110.88 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -59.33 -30.7 68.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.852 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -73.81 -19.48 60.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.899 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.92 28.08 11.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.739 -0.743 . . . . 75.31 112.525 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -132.43 160.21 37.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.853 0.358 . . . . 71.23 110.932 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.59 ' HD2' HG22 ' A' ' 36' ' ' THR . 16.6 p90 -138.37 166.08 25.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.881 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.8 t -126.0 119.15 26.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 72.34 111.178 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.596 HD13 ' N ' ' A' ' 45' ' ' SER . 0.3 OUTLIER -146.15 134.3 21.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 72.23 110.932 179.985 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.596 ' N ' HD13 ' A' ' 44' ' ' LEU . 38.5 p -106.89 122.63 46.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.485 . . . . 73.42 110.889 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 61.5 t -129.79 133.25 24.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.683 0.754 . . . . 71.43 111.093 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.5 Cg_endo -69.72 -48.51 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.664 2.242 . . . . 60.01 112.345 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 31.0 m -95.27 141.96 14.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.425 . . . . 71.24 111.162 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -79.39 59.05 2.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 63.41 110.83 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.4 t -80.07 -169.85 2.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 64.13 110.872 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 156.12 17.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 72.33 111.125 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.687 HD11 ' HB2' ' A' ' 66' ' ' ALA . 2.2 mp -129.05 132.22 47.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 62.04 110.903 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 22.8 tttp -106.76 123.25 47.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.245 -0.434 . . . . 74.21 110.909 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.841 HG23 HG22 ' A' ' 24' ' ' VAL . 34.8 mt -119.6 112.61 37.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 73.4 111.178 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.4 p -119.68 145.88 46.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.231 -0.44 . . . . 62.11 111.118 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.417 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -139.06 118.58 12.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 65.43 111.001 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.457 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.9 tt -51.0 107.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.133 -0.485 . . . . 74.23 111.103 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.86 -50.98 0.75 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.47 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -114.28 170.28 8.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.93 0.395 . . . . 61.23 110.92 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -58.22 158.2 14.7 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.3 110.932 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.8 167.79 23.48 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.627 2.218 . . . . 71.32 112.348 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.739 HG13 HG11 ' A' ' 72' ' ' VAL . 96.4 t -135.11 138.68 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 74.11 111.107 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.3 p -132.15 122.56 25.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.138 -0.483 . . . . 60.11 111.141 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 70' ' ' VAL . 6.1 m -152.92 149.9 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.113 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -81.92 157.25 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.88 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.687 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -61.73 130.65 46.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 72.41 111.113 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.52 160.71 38.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 63.13 111.108 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.67 -52.37 48.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 73.13 111.113 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 69.7 mt -129.14 111.62 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 72.31 111.155 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 64' ' ' VAL . 21.8 t -113.62 112.11 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.142 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -113.66 112.34 23.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.862 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.739 HG11 HG13 ' A' ' 62' ' ' VAL . 39.4 t -129.27 148.16 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 61.34 111.12 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.9 mp -105.08 144.86 31.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.491 . . . . 72.02 110.909 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.701 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.83 122.23 31.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.961 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.8 mm-40 -90.17 140.9 29.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 73.42 110.945 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -58.45 141.23 52.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.904 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.1 -0.5 . . . . 44.35 110.905 179.964 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.3 0 N-CA-C 112.439 -0.264 . . . . 42.34 112.439 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.69 119.94 5.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.887 0.375 . . . . 73.41 110.946 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.655 HG12 HG13 ' A' ' 19' ' ' ILE . 21.7 t -98.48 122.66 50.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 73.33 111.106 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.07 176.68 6.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 73.43 111.094 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.4 t -97.38 164.0 12.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 72.2 110.925 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.0 tmtt? -104.55 -11.11 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 60.22 110.869 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 55.8 p -77.94 -58.62 3.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.289 -0.414 . . . . 75.14 111.089 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -117.86 -26.38 6.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 72.52 110.854 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 100.99 29.39 6.47 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.734 -0.746 . . . . 53.34 112.495 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -85.05 159.4 57.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.531 0.681 . . . . 74.15 110.978 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 127.89 15.26 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 61.23 112.377 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.756 HD12 HD22 ' A' ' 74' ' ' LEU . 50.1 mm -77.37 120.41 27.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 75.31 111.16 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.7 mt -102.98 141.5 18.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.099 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.42 33.24 86.72 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.718 -0.753 . . . . 62.52 112.521 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.698 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -82.58 122.16 27.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 63.11 111.094 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -74.17 107.5 6.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 52.44 110.837 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.668 HG13 HG12 ' A' ' 54' ' ' ILE . 24.2 t -107.37 106.07 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.128 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.669 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.7 m -124.89 138.06 55.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 74.52 111.102 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.697 ' HA ' HD23 ' A' ' 52' ' ' LEU . 55.4 tt0 -73.67 161.2 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 74.12 110.843 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 p -65.83 -41.82 91.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.466 . . . . 52.43 111.144 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 p -105.77 -22.18 13.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 64.03 111.08 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -116.18 68.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 63.21 111.165 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' HB ' ' A' ' 25' ' ' VAL . 96.5 m -81.53 -35.65 30.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.09 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 3.1 p -53.36 -32.17 48.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 74.23 111.139 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -94.95 31.16 1.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.916 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -65.95 138.95 37.79 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.811 -0.709 . . . . 61.22 112.517 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -117.22 168.72 10.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 73.43 111.155 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 pp -115.47 168.56 7.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.441 . . . . 72.12 111.093 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.605 HG22 ' HD2' ' A' ' 42' ' ' PHE . 70.3 p -101.29 150.76 22.66 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.168 -0.469 . . . . 55.34 111.129 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -90.88 -176.08 4.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.172 -0.467 . . . . 34.54 110.849 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.38 -30.73 68.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 72.12 110.854 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -73.87 -19.5 60.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 73.22 110.897 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.75 28.1 15.07 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.692 -0.766 . . . . 75.31 112.473 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -128.22 157.78 39.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.338 . . . . 71.23 110.906 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.605 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.5 p90 -143.67 167.45 22.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.874 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -123.05 121.69 36.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.477 . . . . 72.34 111.188 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.585 HD22 HG23 ' A' ' 46' ' ' VAL . 2.0 tt -144.01 125.68 15.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.96 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.502 ' N ' HD23 ' A' ' 44' ' ' LEU . 45.0 t -101.72 114.92 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.262 -0.426 . . . . 73.42 110.842 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.585 HG23 HD22 ' A' ' 44' ' ' LEU . 58.3 t -120.6 133.29 24.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.579 0.704 . . . . 71.43 111.165 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.43 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -47.92 0.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.666 2.244 . . . . 60.01 112.343 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.6 m -96.9 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.157 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -111.64 62.38 0.62 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 63.41 110.891 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.6 t -86.88 -172.63 4.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 64.13 110.867 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.24 158.22 17.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.112 -0.495 . . . . 72.33 111.128 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.697 HD23 ' HA ' ' A' ' 26' ' ' GLU . 25.8 mt -128.32 143.13 50.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 62.04 110.947 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 7.1 ttpt -116.48 127.74 54.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 74.21 110.975 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.668 HG12 HG13 ' A' ' 24' ' ' VAL . 79.6 mt -120.01 137.97 52.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 73.4 111.055 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 39.0 p -148.28 138.59 22.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 62.11 111.183 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.75 ' HB3' HD21 ' A' ' 74' ' ' LEU . 15.6 t80 -136.01 126.85 27.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.233 -0.44 . . . . 65.43 110.903 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.434 HG23 ' O ' ' A' ' 57' ' ' ILE . 13.3 tt -51.17 118.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.101 -0.5 . . . . 74.23 111.139 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.16 -51.27 0.85 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.857 -0.687 . . . . 45.03 112.536 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -108.1 170.21 8.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.98 0.419 . . . . 61.23 110.917 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.4 mmtm -68.9 158.19 86.86 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.567 0.698 . . . . 75.3 110.933 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 165.82 29.68 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.729 2.286 . . . . 71.32 112.377 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.565 HG11 ' CG1' ' A' ' 72' ' ' VAL . 11.1 p -151.66 147.94 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.083 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.9 p -132.1 139.83 48.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 60.11 111.148 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.1 m -150.83 171.57 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 74.21 111.076 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.06 157.21 18.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 70.32 110.868 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -86.08 134.08 33.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 72.41 111.099 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.65 179.87 6.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 63.13 111.124 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.497 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -54.34 -57.88 9.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 73.13 111.096 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.497 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -132.13 111.69 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 72.31 111.104 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.82 125.27 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.125 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -95.86 136.76 35.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.878 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.565 ' CG1' HG11 ' A' ' 62' ' ' VAL . 21.7 t -120.96 149.48 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 61.34 111.109 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 10.3 mt -125.45 124.15 40.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.885 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.756 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.84 122.47 31.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 65.54 110.891 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -90.22 137.03 32.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.182 -0.463 . . . . 73.42 110.927 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -55.23 142.91 29.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 75.12 110.813 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.4 t70 . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.087 -0.506 . . . . 44.35 110.845 179.948 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.519 -0.232 . . . . 42.34 112.519 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -127.73 119.95 26.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.891 0.377 . . . . 73.41 110.931 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.591 HG12 HG13 ' A' ' 19' ' ' ILE . 45.0 t -105.15 126.46 60.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.153 -0.476 . . . . 73.33 111.069 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.499 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.0 OUTLIER -124.38 -178.7 4.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 73.43 111.094 179.988 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.74 163.72 13.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 72.2 110.881 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -103.64 -12.33 17.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.135 -0.484 . . . . 60.22 110.928 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -75.97 -58.72 3.11 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.197 -0.456 . . . . 75.14 111.17 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -119.44 -26.57 5.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 72.52 110.821 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.06 29.55 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.79 -0.719 . . . . 53.34 112.506 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.499 ' C ' HG22 ' A' ' 11' ' ' THR . 4.9 pt20 -83.15 154.85 67.14 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.593 0.711 . . . . 74.15 110.934 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 128.71 16.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.737 2.291 . . . . 61.23 112.314 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.721 HD12 HD22 ' A' ' 74' ' ' LEU . 34.1 mm -75.03 101.7 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.31 111.128 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.2 mt -99.05 138.07 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 42.2 111.122 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 77.18 33.6 44.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 62.52 112.467 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.559 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -89.45 135.04 33.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 63.11 111.109 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.2 m -80.59 107.55 13.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 52.44 110.86 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.724 HG22 HG12 ' A' ' 54' ' ' ILE . 48.7 t -104.07 122.49 56.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 75.44 111.122 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.667 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.0 m -142.08 136.74 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 74.52 111.125 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -73.58 159.95 32.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.86 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 29.9 p -62.21 -41.98 98.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.164 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.0 p -108.22 -22.08 12.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 64.03 111.099 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.81 68.67 0.68 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 63.21 111.156 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' HB ' ' A' ' 25' ' ' VAL . 92.9 m -82.82 -35.37 26.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.138 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.5 p -53.38 -31.18 43.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 74.23 111.06 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.468 ' O ' HD11 ' A' ' 44' ' ' LEU . 1.8 m-20 -94.9 31.16 1.9 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 74.3 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.07 141.23 44.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.723 -0.751 . . . . 61.22 112.556 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.5 t -123.64 168.89 12.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 73.43 111.171 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.5 pt -107.63 156.76 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.141 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.593 HG22 ' HD2' ' A' ' 42' ' ' PHE . 33.1 p -81.65 150.63 27.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.113 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -82.39 173.34 12.12 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.837 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -59.46 -30.71 68.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 72.12 110.871 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -74.0 -19.38 60.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.102 -0.499 . . . . 73.22 110.886 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.97 28.15 10.32 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.463 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -128.92 152.68 48.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.93 0.395 . . . . 71.23 110.873 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.593 ' HD2' HG22 ' A' ' 36' ' ' THR . 54.4 p90 -147.63 164.52 33.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 71.21 110.917 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -150.41 117.27 5.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 72.34 111.144 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 32' ' ' ASN . 1.5 tt -115.93 109.77 18.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 72.23 110.947 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 89.7 p -68.9 108.41 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 73.42 110.856 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.433 HG23 ' HD2' ' A' ' 47' ' ' PRO . 7.3 p -130.78 133.21 24.54 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 71.43 111.138 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.433 ' HD2' HG23 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -43.26 2.74 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.66 2.24 . . . . 60.01 112.381 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 29.6 m -77.91 150.06 5.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 71.24 111.176 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -100.35 72.25 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 63.41 110.884 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 t -105.8 -170.95 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 64.13 110.827 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.13 155.35 17.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 72.33 111.167 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.618 HD12 HG23 ' A' ' 64' ' ' VAL . 10.4 mt -111.25 146.95 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 62.04 110.902 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.7 tttt -130.31 121.94 27.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.894 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.724 HG12 HG22 ' A' ' 24' ' ' VAL . 5.3 mp -119.27 144.01 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 73.4 111.144 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 37.7 p -138.36 138.67 38.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 62.11 111.165 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.459 ' HB3' HD21 ' A' ' 74' ' ' LEU . 7.4 t80 -131.83 115.21 15.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.282 -0.417 . . . . 65.43 110.977 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.445 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.3 tp -51.15 116.46 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 74.23 111.095 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.37 -53.42 0.81 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 45.03 112.475 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -110.47 170.53 8.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.925 0.393 . . . . 61.23 110.953 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -60.77 157.86 36.26 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.564 0.697 . . . . 75.3 110.874 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 172.81 12.02 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.661 2.241 . . . . 71.32 112.336 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 HG11 ' A' ' 72' ' ' VAL . 7.4 p -151.38 146.3 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 74.11 111.128 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.7 p -131.93 143.51 50.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 60.11 111.172 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.618 HG23 HD12 ' A' ' 52' ' ' LEU . 35.0 m -142.22 130.22 20.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.083 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 11.2 pttt -72.82 156.75 38.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 70.32 110.916 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.84 95.89 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.285 -0.416 . . . . 72.41 111.132 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -134.11 -173.22 3.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 63.13 111.094 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -88.04 -44.52 10.91 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 73.13 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.4 mt -138.09 126.17 30.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 72.31 111.112 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 64' ' ' VAL . 7.2 p -139.71 126.93 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 74.42 111.159 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -119.92 125.53 48.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 74.11 110.902 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 62' ' ' VAL . 20.2 t -137.15 149.07 25.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.449 . . . . 61.34 111.11 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.1 mp -105.02 143.54 33.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 72.02 110.907 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.721 HD22 HD12 ' A' ' 19' ' ' ILE . 2.1 tp -87.56 118.58 27.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 65.54 110.956 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -90.64 147.81 23.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -59.47 143.41 50.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.837 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 29.9 t70 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 44.35 110.827 -179.99 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.479 -0.249 . . . . 42.34 112.479 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.11 129.72 17.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.891 0.376 . . . . 73.41 110.826 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.633 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 95.3 t -123.02 133.37 69.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.091 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 18' ' ' PRO . 17.6 p -130.03 172.55 11.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.141 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.16 153.2 21.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.828 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.436 ' HG3' HD22 ' A' ' 73' ' ' LEU . 17.1 tttm -92.55 16.24 12.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 60.22 110.904 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.02 -58.86 2.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 75.14 111.112 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -119.05 -26.66 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 72.52 110.847 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.45 29.25 5.14 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 53.34 112.525 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -97.87 159.78 30.07 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 74.15 110.917 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.617 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.64 146.61 61.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.724 2.282 . . . . 61.23 112.39 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.507 HG21 ' CD2' ' A' ' 56' ' ' TYR . 28.4 mm -96.68 117.43 41.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.074 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 29.9 mt -101.6 150.13 6.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 42.2 111.045 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.21 47.19 83.43 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.733 -0.746 . . . . 62.52 112.404 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.435 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 159.32 15.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.862 0.363 . . . . 63.11 111.044 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.2 m -105.92 107.25 18.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.44 110.837 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.773 HG22 HG23 ' A' ' 54' ' ' ILE . 12.3 t -112.66 129.82 67.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 75.44 111.113 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.0 m -145.98 146.31 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 74.52 111.17 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -80.75 174.33 11.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.888 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.562 HG23 ' O ' ' A' ' 51' ' ' THR . 43.5 p -68.95 -42.12 77.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 52.43 111.16 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.5 p -112.49 -22.22 10.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 64.03 111.159 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -104.89 76.44 1.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 63.21 111.112 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 p -86.53 -36.26 19.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.229 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.1 p -58.42 -28.44 65.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.115 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.42 1.75 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.229 -0.441 . . . . 74.3 110.857 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.51 143.11 47.99 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.766 -0.731 . . . . 61.22 112.533 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 m -117.87 160.55 21.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.725 0.298 . . . . 73.43 111.156 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.435 HG22 ' O ' ' A' ' 22' ' ' ALA . 8.1 pt -116.41 149.31 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.088 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.576 HG22 ' HD2' ' A' ' 42' ' ' PHE . 15.9 p -69.87 150.64 46.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 55.34 111.202 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -84.15 -175.62 5.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 34.54 110.905 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -58.68 -30.65 67.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 72.12 110.882 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -99.4 21.99 11.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.884 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.4 28.18 71.95 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.669 -0.777 . . . . 75.31 112.533 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -110.44 131.34 55.14 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.835 0.35 . . . . 71.23 110.879 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.576 ' HD2' HG22 ' A' ' 36' ' ' THR . 20.2 p90 -127.69 167.7 16.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 71.21 110.949 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 43' ' ' THR . 4.7 t -137.44 118.99 14.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 72.34 111.083 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.483 HD13 HD21 ' A' ' 52' ' ' LEU . 0.7 OUTLIER -148.25 107.18 3.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 72.23 110.898 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.6 t -107.03 122.22 46.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 73.42 110.861 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -119.66 155.96 54.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.637 0.732 . . . . 71.43 111.048 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -48.39 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.644 2.229 . . . . 60.01 112.335 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.61 149.93 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 71.24 111.139 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -96.04 67.69 2.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 63.41 110.887 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.2 t -100.55 -169.29 1.7 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 64.13 110.89 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 27' ' ' THR . 0.2 OUTLIER -87.45 163.06 16.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 72.33 111.148 -179.918 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.606 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 0.2 OUTLIER -129.92 131.75 46.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.253 -0.431 . . . . 62.04 110.91 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -101.0 126.2 47.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.901 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 24' ' ' VAL . 2.5 mp -123.64 123.28 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 73.4 111.115 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 63.8 p -119.31 146.38 45.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 62.11 111.098 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.792 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.5 m-85 -129.14 154.62 46.55 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.185 -0.461 . . . . 65.43 110.947 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 57' ' ' ILE . 4.7 tp -91.31 108.39 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.495 . . . . 74.23 111.133 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.95 -51.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.734 -0.746 . . . . 45.03 112.453 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -106.17 170.87 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.919 0.39 . . . . 61.23 110.958 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -67.31 146.67 98.88 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.598 0.713 . . . . 75.3 110.909 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 175.93 7.43 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.699 2.266 . . . . 71.32 112.317 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.547 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.1 m -149.82 142.76 17.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 74.11 111.155 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 13.9 p -122.17 131.98 54.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 60.11 111.158 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.2 m -152.91 156.51 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.202 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.79 154.27 27.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 70.32 110.893 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.606 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -63.95 107.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 72.41 111.066 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -130.83 159.3 37.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 63.13 111.107 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.64 -55.74 23.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 73.13 111.118 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 64.4 mt -126.01 131.49 71.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 72.31 111.092 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 23.7 t -143.06 123.53 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 74.42 111.148 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -119.86 109.43 15.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.848 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 26.6 t -125.18 148.87 29.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 61.34 111.169 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.436 HD22 ' HG3' ' A' ' 13' ' ' LYS . 4.6 mp -103.72 144.44 31.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 72.02 110.938 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.792 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.6 tp -88.87 118.49 28.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 65.54 110.9 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.03 129.55 45.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.896 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 147.56 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.836 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 63.7 t0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 44.35 110.849 -179.995 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.531 -0.227 . . . . 42.34 112.531 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -157.96 119.82 3.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.895 0.378 . . . . 73.41 110.852 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.663 HG11 ' OH ' ' A' ' 56' ' ' TYR . 43.3 t -111.29 137.2 44.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 111.197 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.642 HG22 ' HA ' ' A' ' 18' ' ' PRO . 11.3 p -132.07 179.08 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 73.43 111.109 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.608 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -100.24 153.09 19.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 72.2 110.823 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 16.3 tttm -92.71 17.98 9.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.08 -0.509 . . . . 60.22 110.917 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.608 HG21 ' OH ' ' A' ' 59' ' ' TYR . 34.8 p -94.2 -58.68 2.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.271 -0.422 . . . . 75.14 111.217 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -120.15 -26.83 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.282 -0.417 . . . . 72.52 110.85 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.24 29.19 5.23 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.492 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -99.05 160.26 28.12 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.621 0.724 . . . . 74.15 110.911 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.642 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.62 143.33 51.13 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 61.23 112.393 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.608 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -92.79 116.45 33.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.276 -0.42 . . . . 75.31 111.094 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 31.3 mt -98.42 150.18 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 42.2 111.107 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.05 48.25 72.97 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 62.52 112.449 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 158.27 15.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.799 0.333 . . . . 63.11 111.058 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.09 107.41 18.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 52.44 110.904 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.526 HG22 HG23 ' A' ' 54' ' ' ILE . 20.6 t -112.65 108.44 25.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.141 -0.482 . . . . 75.44 111.105 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.718 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.2 m -127.88 139.97 50.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 74.52 111.121 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.567 ' OE1' HD11 ' A' ' 44' ' ' LEU . 2.3 mp0 -91.2 167.36 12.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 74.12 110.91 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 53.5 p -82.11 -33.75 29.59 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 52.43 111.13 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.552 HG23 ' OG ' ' A' ' 50' ' ' SER . 20.2 p -79.42 -22.17 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 64.03 111.164 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.45 103.34 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 63.21 111.111 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.718 HG23 ' HB ' ' A' ' 25' ' ' VAL . 99.1 m -86.93 -35.44 18.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.194 -0.457 . . . . 73.01 111.155 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.2 p -53.99 -26.9 28.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.084 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -93.41 31.42 1.52 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 74.3 110.849 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -67.29 142.16 40.52 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 61.22 112.421 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.7 m -113.97 161.61 17.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.782 0.325 . . . . 73.43 111.108 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 14.6 pt -117.33 148.31 20.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.459 . . . . 72.12 111.156 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.581 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.1 p -71.33 150.69 44.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 55.34 111.108 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -86.59 -170.17 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 34.54 110.887 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -60.93 -30.65 70.34 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.152 -0.477 . . . . 72.12 110.974 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.67 17.88 12.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.485 . . . . 73.22 110.865 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.22 28.11 71.69 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.505 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -113.98 136.69 52.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 71.23 110.873 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.581 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.8 p90 -129.98 167.87 17.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.434 . . . . 71.21 110.925 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.1 t -123.36 117.44 25.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.166 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.567 HD11 ' OE1' ' A' ' 26' ' ' GLU . 0.5 OUTLIER -143.62 124.44 14.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.23 110.915 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.8 t -106.98 108.07 19.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.848 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 44' ' ' LEU . 19.1 m -139.95 152.57 68.09 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 71.43 111.113 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 170.61 16.09 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.705 2.27 . . . . 60.01 112.348 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.9 m -93.18 53.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.15 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -154.79 35.38 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 63.41 110.947 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.552 ' OG ' HG23 ' A' ' 28' ' ' THR . 7.7 t -155.53 163.52 39.89 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.174 -0.466 . . . . 64.13 110.826 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 164.06 12.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 72.33 111.102 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 84.9 mt -130.45 117.19 19.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 62.04 110.937 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.544 ' HA ' HG22 ' A' ' 63' ' ' THR . 37.3 tttt -102.27 123.55 46.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 74.21 110.868 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.526 HG23 HG22 ' A' ' 24' ' ' VAL . 3.3 mp -123.59 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 73.4 111.16 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.2 p -117.73 144.52 45.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 62.11 111.18 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.817 ' CD1' HD11 ' A' ' 74' ' ' LEU . 20.6 m-85 -126.5 155.03 42.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 65.43 110.994 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.0 tt -92.36 107.86 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.114 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.84 -50.96 0.82 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.791 -0.719 . . . . 45.03 112.494 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.608 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.8 m-85 -105.58 170.43 7.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 61.23 110.889 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -67.57 144.57 97.79 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.61 0.719 . . . . 75.3 110.87 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 176.99 6.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.605 2.203 . . . . 71.32 112.299 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.584 HG22 ' HE1' ' A' ' 56' ' ' TYR . 15.3 m -149.24 145.49 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 74.11 111.148 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 53' ' ' LYS . 4.9 p -129.12 138.37 51.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 60.11 111.101 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 70' ' ' VAL . 17.5 m -150.51 167.79 2.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.206 -0.452 . . . . 74.21 111.115 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -89.53 155.98 18.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.876 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -51.6 128.87 24.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 72.41 111.064 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -161.35 142.8 11.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 63.13 111.13 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.04 -49.32 66.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.085 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.3 mt -120.76 119.49 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.253 -0.43 . . . . 72.31 111.199 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 64' ' ' VAL . 6.7 p -129.52 122.64 55.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.42 111.123 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -119.86 113.62 20.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 74.11 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.8 t -127.71 148.94 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 61.34 111.112 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 11.6 mt -106.44 145.29 31.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.932 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.817 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -87.57 123.06 32.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.903 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -102.06 133.3 47.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 73.42 110.882 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -51.91 139.54 21.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 75.12 110.927 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.879 -179.992 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.528 -0.229 . . . . 42.34 112.528 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -130.37 130.66 44.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 73.41 110.877 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.62 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.6 t -123.51 131.13 73.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 73.33 111.14 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.9 p -127.44 178.17 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.152 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 t -95.43 149.27 21.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.451 . . . . 72.2 110.828 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.405 ' HG3' HD13 ' A' ' 73' ' ' LEU . 33.8 tttm -90.05 12.26 18.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 60.22 110.909 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.443 HG21 ' OH ' ' A' ' 59' ' ' TYR . 41.4 p -93.61 -59.6 1.96 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.433 . . . . 75.14 111.182 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -118.69 -27.08 5.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 72.52 110.874 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.39 29.31 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.513 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -93.55 160.53 32.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.645 0.736 . . . . 74.15 110.918 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 138.21 37.18 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.606 2.204 . . . . 61.23 112.375 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 48.9 mm -85.64 120.07 35.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.259 -0.428 . . . . 75.31 111.105 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mt -105.93 140.97 22.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.161 -0.472 . . . . 42.2 111.101 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.41 50.41 21.25 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.452 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.545 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.06 159.0 15.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.771 0.32 . . . . 63.11 111.109 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.3 m -105.87 107.47 18.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 52.44 110.839 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.635 HG22 HG23 ' A' ' 54' ' ' ILE . 17.4 t -111.5 128.49 67.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.147 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.681 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.7 m -148.05 139.6 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.092 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.495 ' CD ' ' HB3' ' A' ' 29' ' ' ALA . 33.8 mt-10 -72.23 174.23 7.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.861 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.14 -35.21 49.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 52.43 111.146 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.5 p -112.4 -22.18 10.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 64.03 111.191 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.495 ' HB3' ' CD ' ' A' ' 26' ' ' GLU . . . -118.75 78.83 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.244 -0.435 . . . . 63.21 111.102 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.681 HG23 ' HB ' ' A' ' 25' ' ' VAL . 97.5 m -83.83 -39.21 20.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.01 111.11 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 p -53.59 -29.45 37.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 74.23 111.142 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -94.61 31.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.924 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -68.14 164.67 46.95 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.768 -0.729 . . . . 61.22 112.479 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -135.24 168.86 18.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.714 0.292 . . . . 73.43 111.178 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.545 HG22 ' O ' ' A' ' 22' ' ' ALA . 13.9 pt -121.59 151.35 24.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.19 -0.459 . . . . 72.12 111.104 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.547 HG22 ' HD2' ' A' ' 42' ' ' PHE . 22.8 p -74.27 150.66 40.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.13 -0.487 . . . . 55.34 111.151 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -94.39 -178.1 4.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 34.54 110.885 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -56.92 -30.32 63.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 72.12 110.94 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -73.2 -18.72 61.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 73.22 110.853 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.43 28.19 20.38 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 75.31 112.471 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 23.7 p30 -133.93 163.53 29.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 71.23 110.906 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.547 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.4 p90 -144.86 167.76 21.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.887 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -135.72 122.84 21.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.105 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -138.01 118.68 14.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.893 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 t -93.08 115.31 27.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.817 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.66 155.98 44.22 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.646 0.736 . . . . 71.43 111.144 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -48.46 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.724 2.283 . . . . 60.01 112.337 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -111.97 -176.59 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.43 . . . . 71.24 111.104 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -106.04 64.99 0.68 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 63.41 110.885 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.9 t -92.52 -169.83 2.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 64.13 110.86 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.73 162.59 16.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 72.33 111.16 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.547 HD11 ' HB2' ' A' ' 66' ' ' ALA . 11.1 mt -134.39 133.15 40.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 62.04 110.98 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.421 ' HA ' HG23 ' A' ' 63' ' ' THR . 9.6 ttpt -98.9 125.32 44.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.423 . . . . 74.21 110.876 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.635 HG23 HG22 ' A' ' 24' ' ' VAL . 8.7 mt -123.83 119.62 57.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 73.4 111.145 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 46.4 p -113.63 150.55 32.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.114 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.806 ' CD1' HD11 ' A' ' 74' ' ' LEU . 23.1 m-85 -132.37 151.97 51.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 65.43 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -90.7 107.98 19.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 74.23 111.096 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.05 -51.19 0.8 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.551 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.443 ' OH ' HG21 ' A' ' 14' ' ' THR . 8.8 m-85 -104.4 170.5 7.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.931 0.396 . . . . 61.23 110.878 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -67.09 145.39 98.8 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.505 0.669 . . . . 75.3 110.889 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 175.2 8.46 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.686 2.258 . . . . 71.32 112.348 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.579 HG21 HG11 ' A' ' 72' ' ' VAL . 16.8 m -149.91 142.26 17.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 74.11 111.121 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HA ' ' A' ' 53' ' ' LYS . 0.3 OUTLIER -121.84 129.54 52.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 60.11 111.114 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.5 m -152.85 154.3 7.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 74.21 111.118 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -88.35 153.12 21.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 70.32 110.865 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.547 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -55.86 138.57 48.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 72.41 111.088 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.479 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . . . -162.09 165.78 26.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 63.13 111.065 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.41 -56.76 16.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 73.13 111.139 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 61.7 mt -132.39 116.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 72.31 111.085 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.479 ' CG2' ' HB3' ' A' ' 67' ' ' ALA . 19.5 t -124.96 112.17 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 74.42 111.103 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -102.04 109.31 20.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 74.11 110.898 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.579 HG11 HG21 ' A' ' 62' ' ' VAL . 21.9 t -116.5 147.15 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 61.34 111.141 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.405 HD13 ' HG3' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -115.79 145.6 42.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.862 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.806 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -93.62 121.3 34.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.222 -0.445 . . . . 65.54 110.921 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.13 137.14 45.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.276 -0.42 . . . . 73.42 110.925 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -51.08 137.34 21.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.481 . . . . 75.12 110.848 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 32.3 t0 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 44.35 110.873 179.988 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.464 -0.254 . . . . 42.34 112.464 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.28 126.36 40.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 73.41 110.945 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.628 HG23 ' HE2' ' A' ' 42' ' ' PHE . 90.6 t -110.84 125.13 68.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 73.33 111.15 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -128.59 177.15 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.166 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.21 161.38 14.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.802 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.9 tmtm? -101.59 -5.41 25.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.097 -0.502 . . . . 60.22 110.913 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 43.5 p -78.41 -58.58 3.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 75.14 111.177 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -118.36 -26.25 6.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 72.52 110.906 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.58 29.29 6.32 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.787 -0.72 . . . . 53.34 112.513 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -90.21 159.95 41.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.588 0.709 . . . . 74.15 110.959 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 139.24 39.6 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.702 2.268 . . . . 61.23 112.364 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.65 HG22 ' HB2' ' A' ' 22' ' ' ALA . 44.1 mm -91.3 101.56 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.241 -0.436 . . . . 75.31 111.102 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.418 ' H ' HD12 ' A' ' 20' ' ' ILE . 3.2 mp -93.56 140.0 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 42.2 111.165 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.04 31.93 54.15 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.789 -0.72 . . . . 62.52 112.484 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.65 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -91.37 162.37 14.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.759 0.314 . . . . 63.11 111.088 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.7 m -105.79 107.29 18.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.471 . . . . 52.44 110.849 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.4 p -120.09 127.16 75.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 75.44 111.146 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.696 HG12 ' HA3' ' A' ' 33' ' ' GLY . 14.6 m -140.31 166.97 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 74.52 111.147 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.422 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 62.6 tt0 -92.49 132.48 36.77 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 74.12 110.86 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.44 HG21 ' HB ' ' A' ' 51' ' ' THR . 60.8 p -51.7 -35.03 41.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.121 -0.49 . . . . 52.43 111.124 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.6 p -95.37 -22.25 17.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 64.03 111.128 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.422 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -130.93 87.34 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.464 . . . . 63.21 111.104 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.2 p -86.81 -35.74 18.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 73.01 111.138 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.5 p -53.25 -30.56 38.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.139 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -93.96 31.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.417 . . . . 74.3 110.829 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.696 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.59 146.06 49.82 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.752 -0.737 . . . . 61.22 112.486 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.642 ' CG2' HD21 ' A' ' 44' ' ' LEU . 10.4 t -135.65 169.63 17.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.727 0.299 . . . . 73.43 111.178 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -107.9 157.55 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 72.12 111.149 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.411 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.0 p -76.22 150.97 36.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.099 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -79.49 -176.16 5.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 34.54 110.832 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -60.47 -30.62 69.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.208 -0.451 . . . . 72.12 110.838 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -99.44 20.87 12.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.197 -0.456 . . . . 73.22 110.882 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.28 27.98 71.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.781 -0.723 . . . . 75.31 112.392 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -107.04 143.43 35.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 71.23 110.955 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.628 ' HE2' HG23 ' A' ' 10' ' ' VAL . 24.1 p90 -144.57 161.79 38.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.21 110.872 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.558 ' C ' HD22 ' A' ' 44' ' ' LEU . 4.6 t -151.34 128.36 11.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 72.34 111.211 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.642 HD21 ' CG2' ' A' ' 34' ' ' THR . 3.0 mm? -130.63 159.8 36.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.23 110.846 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 6.1 m -95.52 108.23 20.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 73.42 110.798 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.434 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.9 t -133.35 133.19 22.53 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.611 0.72 . . . . 71.43 111.128 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.434 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.2 Cg_endo -69.74 -48.39 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.747 2.298 . . . . 60.01 112.331 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.451 HG23 ' H ' ' A' ' 50' ' ' SER . 19.4 m -99.72 -173.83 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 71.24 111.116 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.5 m-20 -107.13 45.66 0.98 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.899 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.451 ' H ' HG23 ' A' ' 48' ' ' VAL . 1.8 m -57.43 -179.55 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 64.13 110.89 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.44 ' HB ' HG21 ' A' ' 27' ' ' THR . 1.7 m -87.69 159.72 18.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 72.33 111.137 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.829 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.7 mp -125.76 135.12 51.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 62.04 110.9 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.4 ttpt -106.86 120.84 43.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.21 110.92 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.678 ' HB ' HG23 ' A' ' 62' ' ' VAL . 5.8 mt -117.45 138.98 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 73.4 111.095 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.1 p -150.71 138.65 20.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.11 111.101 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.684 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.4 t80 -133.98 122.32 22.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 65.43 110.963 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.435 HG23 ' O ' ' A' ' 57' ' ' ILE . 11.4 tt -51.57 115.08 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 74.23 111.159 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 131.23 -51.96 0.84 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.752 . . . . 45.03 112.467 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -107.98 170.18 8.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.9 0.381 . . . . 61.23 110.939 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -64.04 158.0 65.73 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.539 0.685 . . . . 75.3 110.914 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 164.26 35.15 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 71.32 112.357 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.678 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.8 m -150.83 141.08 16.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.197 -0.456 . . . . 74.11 111.133 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.9 p -130.25 140.1 50.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 60.11 111.041 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.912 HG11 HG22 ' A' ' 72' ' ' VAL . 8.6 m -147.55 148.0 16.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.097 -0.501 . . . . 74.21 111.093 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 6.9 mmmm -78.95 155.11 29.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 70.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.829 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -73.59 134.07 43.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 72.41 111.142 179.814 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.16 178.11 7.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.102 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.553 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.66 -57.32 9.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 73.13 111.13 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.553 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.78 111.77 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 72.31 111.084 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.493 HG21 ' HB ' ' A' ' 64' ' ' VAL . 12.2 p -118.84 141.82 36.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.127 -0.488 . . . . 74.42 111.136 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -115.89 134.98 54.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.912 HG22 HG11 ' A' ' 64' ' ' VAL . 22.4 t -122.83 149.18 26.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 61.34 111.143 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.34 133.37 54.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.176 -0.466 . . . . 72.02 110.934 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -90.54 121.49 32.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 65.54 110.928 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 50.3 mm-40 -92.38 145.29 24.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.155 -0.475 . . . . 73.42 110.862 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -58.45 140.4 53.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.17 -0.468 . . . . 75.12 110.929 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 44.35 110.851 -179.971 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.514 -0.235 . . . . 42.34 112.514 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -158.34 127.29 5.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.847 0.356 . . . . 73.41 110.929 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.656 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 83.0 t -117.94 130.59 72.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.33 111.105 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.5 p -128.5 163.71 24.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 73.43 111.103 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.451 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.2 t -84.73 148.96 26.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 72.2 110.88 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttp -92.43 17.53 9.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 60.22 110.851 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.95 -58.75 2.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.14 111.103 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -119.58 -26.68 5.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 72.52 110.892 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.35 5.12 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.736 -0.745 . . . . 53.34 112.409 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -97.44 159.95 29.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 74.15 110.939 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.78 141.62 45.65 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.663 2.242 . . . . 61.23 112.365 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.626 HG21 ' CD2' ' A' ' 56' ' ' TYR . 33.7 mm -86.04 115.22 26.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 75.31 111.065 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.4 mt -104.04 137.27 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 42.2 111.111 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 75.33 47.55 12.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.486 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.97 158.33 15.51 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.77 0.319 . . . . 63.11 111.135 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.9 m -105.99 107.21 18.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 52.44 110.875 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.658 HG13 HG12 ' A' ' 54' ' ' ILE . 95.4 t -110.91 110.39 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 75.44 111.111 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.8 m -123.53 146.05 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 74.52 111.106 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.646 ' OE1' HD22 ' A' ' 52' ' ' LEU . 1.9 mm-40 -90.24 156.7 18.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 74.12 110.836 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 51.9 p -73.03 -32.91 65.41 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.115 -0.493 . . . . 52.43 111.19 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.7 p -85.19 -22.2 28.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 64.03 111.17 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.76 104.74 1.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 63.21 111.047 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.4 p -86.75 -34.82 19.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 73.01 111.081 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.5 p -53.15 -29.68 32.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.251 -0.432 . . . . 74.23 111.188 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -94.29 31.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 74.3 110.892 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -72.86 164.37 54.86 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.718 -0.753 . . . . 61.22 112.492 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.8 t -130.96 169.08 16.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.712 0.291 . . . . 73.43 111.226 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 pp -115.99 164.55 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.255 -0.43 . . . . 72.12 111.141 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.522 HG22 ' HD2' ' A' ' 42' ' ' PHE . 14.1 p -89.28 150.66 22.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.205 -0.452 . . . . 55.34 111.15 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -91.37 -179.14 5.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.185 -0.461 . . . . 34.54 110.883 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -56.95 -30.64 64.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 72.12 110.968 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 46.0 m-20 -73.62 -18.46 61.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 73.22 110.865 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.97 28.1 21.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 75.31 112.506 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -127.23 165.38 19.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.812 0.339 . . . . 71.23 110.885 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.522 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.5 p90 -153.29 166.75 31.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 71.21 110.845 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.84 125.86 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 72.34 111.158 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.614 HD13 ' CD ' ' A' ' 26' ' ' GLU . 1.0 OUTLIER -138.61 131.37 29.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 72.23 110.895 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.469 ' N ' HD23 ' A' ' 44' ' ' LEU . 16.5 t -98.07 117.79 33.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.85 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.8 156.18 46.75 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.665 0.745 . . . . 71.43 111.104 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 -48.51 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.699 2.266 . . . . 60.01 112.376 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.9 m -113.14 -177.5 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.208 -0.451 . . . . 71.24 111.134 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -100.6 39.43 1.37 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 63.41 110.836 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.7 t -63.91 -169.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 64.13 110.866 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.691 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.0 OUTLIER -87.65 161.43 17.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 72.33 111.132 -179.987 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.691 HD23 ' O ' ' A' ' 51' ' ' THR . 12.7 mt -129.85 127.59 40.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.121 -0.491 . . . . 62.04 110.915 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -102.26 122.3 43.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 74.21 110.921 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.658 HG12 HG13 ' A' ' 24' ' ' VAL . 58.1 mt -123.63 118.94 55.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.086 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 55.0 p -113.34 146.86 38.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 62.11 111.168 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.838 ' CD1' HD11 ' A' ' 74' ' ' LEU . 19.0 m-85 -126.28 155.15 42.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 65.43 110.892 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.65 107.76 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.072 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.88 -50.83 0.83 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.686 -0.769 . . . . 45.03 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -105.84 170.48 7.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.905 0.383 . . . . 61.23 110.952 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.8 mmtm -64.74 149.0 96.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.617 0.723 . . . . 75.3 110.882 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -179.15 2.73 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.722 2.281 . . . . 71.32 112.377 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.88 HG21 HG11 ' A' ' 72' ' ' VAL . 4.4 p -151.85 149.27 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.284 -0.416 . . . . 74.11 111.179 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.22 125.26 30.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.121 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.762 HG21 HG11 ' A' ' 70' ' ' VAL . 18.2 m -147.37 152.92 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.156 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -81.82 153.62 26.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 70.32 110.867 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.436 ' HA ' HD11 ' A' ' 52' ' ' LEU . . . -55.58 105.14 0.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.075 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . 0.453 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -131.78 153.2 50.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.45 . . . . 63.13 111.129 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.09 -51.46 67.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 73.13 111.032 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 60.4 mt -120.03 115.48 47.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 72.31 111.199 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.762 HG11 HG21 ' A' ' 64' ' ' VAL . 20.1 t -126.63 106.61 15.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.222 -0.445 . . . . 74.42 111.197 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -114.26 109.43 18.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.11 110.898 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.88 HG11 HG21 ' A' ' 62' ' ' VAL . 21.6 t -129.04 148.38 33.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 61.34 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.6 mp -100.86 145.15 28.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 72.02 110.943 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.838 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.5 tp -87.72 120.93 29.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 65.54 110.947 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -96.14 127.25 41.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.903 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.52 143.16 25.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.877 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 44.35 110.904 179.981 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.345 0 N-CA-C 112.477 -0.249 . . . . 42.34 112.477 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -132.43 127.79 36.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.841 0.353 . . . . 73.41 110.927 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.537 HG12 HG13 ' A' ' 19' ' ' ILE . 21.3 t -115.94 134.25 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 73.33 111.138 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.413 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -146.69 153.84 40.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 73.43 111.167 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.1 t -85.69 150.6 24.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 72.2 110.875 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 tttt -94.28 20.76 7.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 60.22 110.911 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.22 -58.69 2.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 75.14 111.098 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -120.05 -25.95 5.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 72.52 110.847 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.87 29.02 5.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 53.34 112.519 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -98.05 155.55 36.89 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 74.15 110.941 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.413 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.66 136.86 34.34 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.724 2.283 . . . . 61.23 112.351 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.548 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 50.0 mm -78.0 124.32 36.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 75.31 111.114 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.9 mt -110.18 119.35 59.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 42.2 111.095 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.68 33.4 8.47 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.774 -0.727 . . . . 62.52 112.528 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -89.54 132.21 35.18 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.722 0.296 . . . . 63.11 111.089 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.7 m -79.73 109.74 14.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.84 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.577 HG13 HG12 ' A' ' 54' ' ' ILE . 98.3 t -113.78 106.05 19.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.15 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.778 HG12 ' HA3' ' A' ' 33' ' ' GLY . 20.1 m -120.64 139.03 49.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.16 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.447 ' OE1' HD13 ' A' ' 44' ' ' LEU . 1.5 pm0 -90.61 141.86 28.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 74.12 110.845 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.8 p -62.29 -31.6 72.22 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.074 -0.512 . . . . 52.43 111.166 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.717 HG21 HG13 ' A' ' 48' ' ' VAL . 64.8 p -71.71 -22.12 61.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 64.03 111.133 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.76 78.78 0.34 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 63.21 111.055 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 p -65.33 -35.62 81.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 73.01 111.184 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.7 m -54.09 -32.32 54.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.169 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.482 ' O ' HD11 ' A' ' 44' ' ' LEU . 35.6 t30 -93.47 30.59 1.7 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 74.3 110.941 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.778 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.94 148.4 50.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.731 -0.747 . . . . 61.22 112.483 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.628 HG22 HD12 ' A' ' 44' ' ' LEU . 14.6 t -125.58 168.98 12.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.768 0.318 . . . . 73.43 111.181 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.0 pt -107.37 172.57 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 72.12 111.096 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.444 HG22 ' CD2' ' A' ' 42' ' ' PHE . 37.4 p -97.85 150.68 21.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.113 -0.494 . . . . 55.34 111.067 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -80.57 -175.99 5.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.483 . . . . 34.54 110.864 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -59.52 -30.74 68.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.274 -0.421 . . . . 72.12 110.869 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -100.04 22.77 10.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.16 -0.473 . . . . 73.22 110.886 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.94 28.15 72.32 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.76 . . . . 75.31 112.523 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -107.33 127.77 53.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.23 110.82 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.444 ' CD2' HG22 ' A' ' 36' ' ' THR . 25.9 p90 -127.73 157.22 40.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.879 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.1 t -132.48 123.82 27.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 72.34 111.158 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.628 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.22 118.44 7.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 72.23 110.981 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.0 m -95.05 116.64 28.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 73.42 110.851 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -122.55 156.24 61.51 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.622 0.725 . . . . 71.43 111.155 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -35.88 11.83 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.667 2.245 . . . . 60.01 112.371 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.717 HG13 HG21 ' A' ' 28' ' ' THR . 14.5 p -131.51 140.23 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 71.24 111.164 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -104.21 79.7 1.63 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 63.41 110.876 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.9 t -89.37 -76.96 0.4 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 64.13 110.861 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.64 159.99 40.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 72.33 111.147 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 66' ' ' ALA . 15.6 mt -134.81 122.27 21.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 62.04 110.882 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HA ' HG22 ' A' ' 63' ' ' THR . 71.0 tttt -100.89 123.2 44.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.914 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.601 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.1 mt -121.12 138.4 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 73.4 111.149 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 47.2 p -148.82 138.66 22.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 62.11 111.11 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.667 ' HB3' HD21 ' A' ' 74' ' ' LEU . 12.6 t80 -133.98 122.8 23.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 65.43 110.927 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.419 HG23 ' O ' ' A' ' 57' ' ' ILE . 7.2 tt -51.82 120.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 74.23 111.098 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.73 -50.94 0.85 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 45.03 112.521 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -109.23 169.97 8.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 61.23 110.932 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -64.54 157.33 73.51 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.52 0.676 . . . . 75.3 110.936 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.79 165.16 31.93 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.675 2.25 . . . . 71.32 112.311 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.601 HG23 ' HB ' ' A' ' 54' ' ' ILE . 32.1 m -150.55 138.25 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 74.11 111.154 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 53' ' ' LYS . 5.1 p -131.76 140.85 49.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 60.11 111.171 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.0 m -145.92 175.66 2.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 74.21 111.11 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.41 149.9 25.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 70.32 110.9 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.615 ' HA ' HD12 ' A' ' 52' ' ' LEU . . . -75.43 118.37 18.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.181 -0.463 . . . . 72.41 111.137 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.97 -176.22 5.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 63.13 111.064 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.503 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -68.14 -57.66 5.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.153 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.503 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -126.69 114.26 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 72.31 111.139 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.87 127.45 58.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 74.42 111.136 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 36.0 m120 -100.35 127.59 46.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 74.11 110.897 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.565 HG11 HG21 ' A' ' 62' ' ' VAL . 21.4 t -118.7 148.88 21.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.254 -0.43 . . . . 61.34 111.093 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 15.3 mt -119.43 131.47 55.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.124 -0.489 . . . . 72.02 110.936 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.667 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -87.86 121.9 30.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.955 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -90.36 144.01 26.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 73.42 110.94 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -58.97 139.87 56.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.12 110.864 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 44.35 110.868 179.97 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.338 0 N-CA-C 112.516 -0.234 . . . . 42.34 112.516 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.0 120.19 3.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.771 0.32 . . . . 73.41 110.928 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.1 t -105.93 131.64 54.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 73.33 111.126 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.9 p -129.37 159.26 36.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.43 111.126 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -84.34 156.95 21.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.2 110.858 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -93.96 20.09 8.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.079 -0.509 . . . . 60.22 110.966 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.58 HG21 ' OH ' ' A' ' 59' ' ' TYR . 60.1 p -94.52 -58.42 2.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 75.14 111.131 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -122.26 -26.36 4.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 72.52 110.915 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.64 29.27 5.08 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.753 -0.737 . . . . 53.34 112.539 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -98.99 159.69 29.6 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.552 0.692 . . . . 74.15 110.953 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.71 147.72 63.82 Favored 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.745 2.296 . . . . 61.23 112.399 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.515 HG21 ' CD2' ' A' ' 56' ' ' TYR . 26.5 mm -94.6 114.97 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 75.31 111.084 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.472 HD13 ' CD2' ' A' ' 38' ' ' PHE . 40.4 mt -100.22 138.6 24.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 42.2 111.159 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.27 46.64 12.23 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.659 -0.781 . . . . 62.52 112.522 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.461 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -94.87 157.82 15.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 63.11 111.043 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -106.01 107.14 17.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 52.44 110.855 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.785 HG22 HG23 ' A' ' 54' ' ' ILE . 13.3 t -112.15 122.58 66.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 75.44 111.132 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -138.91 151.95 23.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 74.52 111.177 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.402 ' OE1' HG11 ' A' ' 46' ' ' VAL . 2.4 mm-40 -84.31 174.28 10.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 74.12 110.912 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.13 -42.29 69.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 52.43 111.185 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.7 p -112.91 -22.16 10.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 64.03 111.143 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -110.26 76.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 63.21 111.2 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.2 p -86.95 -34.38 19.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 73.01 111.141 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.3 m -53.16 -30.48 37.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.434 . . . . 74.23 111.096 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -93.16 30.99 1.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 74.3 110.852 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.95 138.98 46.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.78 -0.724 . . . . 61.22 112.455 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.535 ' OG1' HD23 ' A' ' 44' ' ' LEU . 3.5 m -116.97 160.45 20.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 73.43 111.162 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.461 HG22 ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.51 162.2 12.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 72.12 111.165 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.455 HG22 ' HD2' ' A' ' 42' ' ' PHE . 5.6 p -83.87 150.61 25.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 55.34 111.218 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -85.14 -175.89 5.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 34.54 110.91 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CD2' HD13 ' A' ' 20' ' ' ILE . 8.2 t80 -58.99 -30.18 67.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.237 -0.438 . . . . 72.12 110.851 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.56 13.54 13.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 73.22 110.862 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 28.0 71.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.757 -0.735 . . . . 75.31 112.419 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -126.81 142.59 51.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.863 0.363 . . . . 71.23 110.917 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.455 ' HD2' HG22 ' A' ' 36' ' ' THR . 30.9 p90 -132.39 168.01 18.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.469 . . . . 71.21 110.873 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.7 t -133.43 116.56 16.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 72.34 111.105 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.657 HD13 ' N ' ' A' ' 45' ' ' SER . 1.2 tm? -143.19 132.29 23.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 72.23 110.929 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . 0.657 ' N ' HD13 ' A' ' 44' ' ' LEU . 79.2 p -107.35 124.84 50.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 73.42 110.902 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.402 HG11 ' OE1' ' A' ' 26' ' ' GLU . 3.5 m -113.61 155.95 44.2 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.702 0.763 . . . . 71.43 111.111 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -48.5 0.71 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.665 2.243 . . . . 60.01 112.362 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.3 m -112.37 179.68 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 71.24 111.189 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 75.2 m-80 -100.31 36.88 1.77 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 63.41 110.862 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.3 t -61.98 -172.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 64.13 110.844 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.0 154.95 19.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.057 -0.52 . . . . 72.33 111.186 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.723 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.3 mp -127.41 130.96 50.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 62.04 110.91 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -99.82 121.25 41.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 74.21 110.917 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.785 HG23 HG22 ' A' ' 24' ' ' VAL . 2.4 mp -117.92 119.14 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.295 -0.411 . . . . 73.4 111.14 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 44.5 p -116.08 144.32 44.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.187 -0.46 . . . . 62.11 111.149 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.8 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.3 m-85 -126.63 152.35 46.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 65.43 110.918 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.493 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -89.71 107.73 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.109 -0.496 . . . . 74.23 111.142 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.5 -50.47 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.49 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.58 ' OH ' HG21 ' A' ' 14' ' ' THR . 12.8 m-85 -103.62 170.69 7.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 61.23 110.925 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -67.95 145.17 97.71 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.58 0.705 . . . . 75.3 110.867 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 172.34 12.84 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.682 2.254 . . . . 71.32 112.382 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.539 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.5 m -150.08 143.66 17.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 74.11 111.128 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -122.49 134.76 54.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.246 -0.434 . . . . 60.11 111.168 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 70' ' ' VAL . 6.1 m -152.94 158.82 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 74.21 111.127 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -82.47 157.28 23.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 70.32 110.882 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.723 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.18 138.14 49.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 72.41 111.113 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.72 -177.59 4.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 63.13 111.093 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.37 -58.0 7.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 73.13 111.085 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -124.25 137.71 56.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.2 -0.454 . . . . 72.31 111.149 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 64' ' ' VAL . 6.1 p -143.61 120.92 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 74.42 111.142 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -119.98 110.55 16.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 74.11 110.831 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.446 HG11 HG21 ' A' ' 62' ' ' VAL . 22.2 t -116.37 146.32 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 61.34 111.128 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -102.14 135.33 43.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.185 -0.461 . . . . 72.02 110.932 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.8 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.53 120.87 29.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 65.54 110.919 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -95.69 142.9 27.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 73.42 110.905 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -55.02 141.25 34.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.12 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 13.0 t70 . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 116.264 -0.426 . . . . 44.35 110.946 179.951 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.348 0 N-CA-C 112.529 -0.228 . . . . 42.34 112.529 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -152.74 119.95 5.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.36 . . . . 73.41 110.857 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.638 ' CG2' HD13 ' A' ' 54' ' ' ILE . 22.4 t -107.26 132.11 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 73.33 111.153 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.407 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.9 OUTLIER -136.22 160.38 38.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 73.43 111.072 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.16 154.1 35.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 72.2 110.851 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.6 tttp -96.46 12.91 29.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 60.22 110.845 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 74.3 p -93.86 -58.72 2.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.261 -0.427 . . . . 75.14 111.144 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -119.04 -26.57 5.93 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.229 -0.442 . . . . 72.52 110.935 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.32 29.25 5.18 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.748 . . . . 53.34 112.445 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . 0.407 ' C ' HG22 ' A' ' 11' ' ' THR . 47.0 mt-30 -90.45 160.46 39.26 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.598 0.713 . . . . 74.15 110.902 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 136.27 32.64 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.673 2.248 . . . . 61.23 112.368 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.4 mm -87.4 123.07 39.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.096 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.5 mt -107.92 128.23 63.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 42.2 111.118 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.53 32.87 14.68 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.686 -0.768 . . . . 62.52 112.501 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.42 127.76 36.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.792 0.329 . . . . 63.11 111.04 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -72.8 107.63 5.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.829 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.548 HG22 HG12 ' A' ' 54' ' ' ILE . 21.8 t -111.64 106.68 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.065 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.03 150.49 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 74.52 111.121 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.514 ' O ' HG23 ' A' ' 30' ' ' THR . 2.4 mp0 -92.57 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 74.12 110.851 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.9 p -56.14 -34.85 66.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.066 -0.515 . . . . 52.43 111.204 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 66.5 p -98.16 -22.09 16.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.24 -0.436 . . . . 64.03 111.208 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -133.48 65.81 1.57 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 63.21 111.065 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 26' ' ' GLU . 1.2 p -67.03 -35.32 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 73.01 111.17 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 88.8 m -64.1 -30.63 71.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 74.23 111.084 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -93.51 30.55 1.72 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.86 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -70.9 155.95 53.04 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.749 -0.739 . . . . 61.22 112.422 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -132.76 168.8 17.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.756 0.312 . . . . 73.43 111.199 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.89 150.83 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.191 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.2 p -70.38 150.14 46.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.186 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -91.3 -179.23 5.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 34.54 110.821 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -58.25 -30.64 66.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 72.12 110.846 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -73.84 -19.48 60.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.853 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.03 28.16 12.42 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.689 -0.767 . . . . 75.31 112.501 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -137.68 164.59 28.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.859 0.361 . . . . 71.23 110.925 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.524 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 27.6 p90 -138.78 167.46 21.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 71.21 110.835 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 43' ' ' THR . 5.0 t -119.86 120.38 36.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.114 -0.493 . . . . 72.34 111.187 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.3 mt -148.11 108.18 4.06 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.265 -0.425 . . . . 72.23 110.899 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.4 t -82.4 108.08 15.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.851 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.414 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.7 m -139.98 106.77 6.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.653 0.74 . . . . 71.43 111.129 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -32.54 18.45 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.762 2.308 . . . . 60.01 112.365 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.4 m -55.57 -30.61 26.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 71.24 111.138 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 67.32 40.11 2.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 63.41 110.866 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.0 m -74.73 -176.01 2.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 64.13 110.91 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.725 HG23 ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -86.95 150.05 24.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 72.33 111.186 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.1 mp -117.85 131.57 56.54 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.264 -0.425 . . . . 62.04 110.933 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . 0.805 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.2 OUTLIER -99.83 128.48 45.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 74.21 110.87 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.638 HD13 ' CG2' ' A' ' 10' ' ' VAL . 45.0 mt -123.79 124.93 70.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.233 -0.44 . . . . 73.4 111.097 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . 0.584 HG23 ' HD3' ' A' ' 53' ' ' LYS . 71.8 p -140.88 143.33 34.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.104 -0.498 . . . . 62.11 111.131 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.423 ' HB3' HD21 ' A' ' 74' ' ' LEU . 9.3 t80 -139.29 121.02 15.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.216 -0.447 . . . . 65.43 110.856 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.452 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.1 tt -50.91 107.68 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.083 -0.508 . . . . 74.23 111.141 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 138.94 -43.86 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 45.03 112.46 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -114.94 170.96 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.981 0.42 . . . . 61.23 110.902 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mmtt -66.29 153.64 92.09 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.596 0.712 . . . . 75.3 110.905 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.77 157.68 59.54 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.711 2.274 . . . . 71.32 112.331 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.529 ' CG2' HG11 ' A' ' 72' ' ' VAL . 26.8 m -150.93 137.93 13.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 74.11 111.141 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.805 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.2 p -131.96 142.24 49.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 60.11 111.107 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.605 HG11 HG22 ' A' ' 72' ' ' VAL . 15.5 m -149.55 156.32 7.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 74.21 111.141 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.725 ' HG3' HG23 ' A' ' 51' ' ' THR . 0.1 OUTLIER -80.51 157.29 26.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 70.32 110.934 179.892 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.861 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -77.4 137.59 38.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.276 -0.42 . . . . 72.41 111.147 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.59 178.65 7.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.439 . . . . 63.13 111.112 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.569 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.71 -49.61 62.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 73.13 111.087 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.71 111.79 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 72.31 111.144 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.12 128.1 73.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.079 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.1 m120 -115.39 125.98 53.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 74.11 110.887 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.605 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -120.05 149.01 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 61.34 111.132 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.5 mp -121.35 120.46 35.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 72.02 110.968 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.423 HD21 ' HB3' ' A' ' 56' ' ' TYR . 3.4 tp -88.06 116.55 26.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 65.54 110.873 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 17.0 pm0 -95.9 146.47 24.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 73.42 110.82 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.58 143.89 33.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.131 -0.486 . . . . 75.12 110.932 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 44.35 110.862 179.995 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 N-CA-C 112.433 -0.267 . . . . 42.34 112.433 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -156.83 125.76 5.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.829 0.347 . . . . 73.41 110.881 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.654 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 93.1 t -112.35 130.17 66.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 73.33 111.075 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.511 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.0 p -128.84 164.31 23.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 73.43 111.11 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -85.32 149.95 25.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 72.2 110.801 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.35 18.17 8.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.111 -0.495 . . . . 60.22 110.918 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.93 2.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 75.14 111.157 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -119.95 -26.77 5.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 72.52 110.88 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.11 29.39 5.19 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.773 -0.727 . . . . 53.34 112.507 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.2 mm100 -96.9 160.3 29.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.672 0.749 . . . . 74.15 110.918 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.511 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.73 138.54 38.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.649 2.233 . . . . 61.23 112.381 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 49.9 mm -83.79 123.09 38.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.133 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.3 mt -108.24 140.75 25.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.161 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.63 51.99 17.95 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.81 -0.71 . . . . 62.52 112.48 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.595 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.05 155.75 16.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.805 0.336 . . . . 63.11 111.078 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.5 m -106.14 107.42 18.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 52.44 110.843 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.63 HG13 HG12 ' A' ' 54' ' ' ILE . 94.8 t -113.31 116.8 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 75.44 111.158 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 30' ' ' THR . 13.2 m -138.65 144.01 30.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 74.52 111.049 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HG3' HD22 ' A' ' 52' ' ' LEU . 1.7 mp0 -78.94 173.65 12.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.12 110.866 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 66.1 p -75.41 -36.26 60.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 52.43 111.143 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 38.9 p -112.37 -22.08 11.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 64.03 111.111 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB3' ' OE2' ' A' ' 26' ' ' GLU . . . -114.97 75.56 0.94 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 63.21 111.073 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.674 HG23 ' HB ' ' A' ' 25' ' ' VAL . 15.1 m -84.36 -35.9 22.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 73.01 111.18 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -57.38 -28.93 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 74.23 111.128 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -94.54 31.23 1.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.91 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -69.67 149.28 47.97 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.799 -0.715 . . . . 61.22 112.48 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.648 HG22 HD12 ' A' ' 44' ' ' LEU . 13.2 t -123.1 169.12 11.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.716 0.293 . . . . 73.43 111.139 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.595 HG22 ' O ' ' A' ' 22' ' ' ALA . 12.1 pt -124.42 156.64 32.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.148 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.57 HG22 ' HD2' ' A' ' 42' ' ' PHE . 35.6 p -81.79 149.05 28.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 55.34 111.115 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -91.62 -176.24 4.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.228 -0.442 . . . . 34.54 110.858 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.93 -30.62 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 72.12 110.892 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -73.8 -18.85 60.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 73.22 110.86 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.37 28.22 20.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.725 -0.75 . . . . 75.31 112.457 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.97 162.38 29.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.826 0.346 . . . . 71.23 110.901 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.57 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.2 p90 -146.02 164.14 33.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 71.21 110.921 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.7 t -128.5 116.28 19.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 72.34 111.14 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.648 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.5 107.46 3.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 72.23 110.877 179.917 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.6 m -68.82 107.93 3.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.83 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.773 HG11 HD21 ' A' ' 52' ' ' LEU . 58.2 t -139.97 133.41 15.31 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.62 0.724 . . . . 71.43 111.126 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.498 ' O ' ' HB3' ' A' ' 66' ' ' ALA . 53.9 Cg_endo -69.81 173.86 10.4 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.652 2.234 . . . . 60.01 112.384 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 48' ' ' VAL . 9.8 p -95.48 31.99 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.178 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -92.19 -36.04 13.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 63.41 110.912 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 6.3 p -123.47 176.98 5.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 64.13 110.84 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.509 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -97.72 176.88 5.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 72.33 111.164 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.773 HD21 HG11 ' A' ' 46' ' ' VAL . 71.6 mt -131.17 126.78 36.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 62.04 110.951 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -102.44 122.04 43.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 74.21 110.865 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.63 HG12 HG13 ' A' ' 24' ' ' VAL . 61.2 mt -123.79 117.73 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 73.4 111.145 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 65.0 p -113.19 148.58 35.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 62.11 111.122 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 21.9 m-85 -127.37 154.97 44.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 65.43 110.951 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.02 107.77 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 74.23 111.072 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 124.09 -51.23 0.82 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.707 -0.759 . . . . 45.03 112.429 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.93 170.66 7.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.995 0.426 . . . . 61.23 110.856 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 35.2 mttt -64.54 148.53 96.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.59 0.71 . . . . 75.3 110.878 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -178.75 2.51 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.268 . . . . 71.32 112.324 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.128 HG21 HG11 ' A' ' 72' ' ' VAL . 4.7 p -152.02 146.02 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 74.11 111.169 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.9 p -132.17 130.58 41.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 60.11 111.119 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 70' ' ' VAL . 8.1 m -152.62 155.15 6.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.28 -0.418 . . . . 74.21 111.069 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.3 ptpt -74.68 152.46 39.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 70.32 110.892 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 47' ' ' PRO . . . -58.26 120.74 9.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 72.41 111.098 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -148.49 150.76 33.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 63.13 111.089 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.81 -53.73 36.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.097 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 4.6 mp -117.17 133.28 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 72.31 111.204 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 64' ' ' VAL . 5.4 p -146.39 118.05 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.145 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 32.9 m120 -120.11 109.46 15.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.473 . . . . 74.11 110.904 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 1.128 HG11 HG21 ' A' ' 62' ' ' VAL . 22.0 t -126.79 144.14 37.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 61.34 111.15 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.0 mp -96.92 145.19 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 72.02 111.008 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.3 tp -87.77 121.49 30.25 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.281 -0.418 . . . . 65.54 110.931 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -98.71 136.11 39.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 73.42 110.888 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -55.05 140.46 37.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.88 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.0 t0 . . . . . 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.861 -179.993 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 N-CA-C 112.481 -0.248 . . . . 42.34 112.481 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -151.23 127.64 10.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 73.41 110.896 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' OH ' ' A' ' 56' ' ' TYR . 90.7 t -118.29 130.61 72.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 73.33 111.136 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.602 HG22 ' HA ' ' A' ' 18' ' ' PRO . 20.3 p -127.14 169.39 13.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 73.43 111.163 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.21 155.1 19.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.2 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -92.63 18.64 8.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 60.22 110.848 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.64 2.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 75.14 111.165 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -120.85 -26.42 5.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.3 -0.409 . . . . 72.52 110.832 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.79 29.05 5.12 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.491 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -100.63 154.19 37.31 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.566 0.698 . . . . 74.15 110.93 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.602 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.8 Cg_endo -69.7 147.2 62.75 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.756 2.304 . . . . 61.23 112.335 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.486 HG21 ' CD2' ' A' ' 56' ' ' TYR . 15.5 mm -93.5 120.38 42.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 75.31 111.066 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.07 150.81 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 42.2 111.103 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.61 48.33 82.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.474 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.28 167.65 11.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 63.11 111.028 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.0 m -106.34 106.62 17.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.163 -0.471 . . . . 52.44 110.856 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.697 HG13 HG13 ' A' ' 54' ' ' ILE . 5.9 t -110.42 128.86 66.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 75.44 111.122 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.8 m -148.44 137.99 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 74.52 111.143 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.674 ' OE2' HG11 ' A' ' 46' ' ' VAL . 15.7 tt0 -82.87 129.27 34.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 74.12 110.878 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.44 HG22 ' O ' ' A' ' 51' ' ' THR . 1.2 t -51.4 -33.21 29.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.168 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 42.1 p -89.45 -22.24 22.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 64.03 111.1 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -148.61 98.66 2.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 63.21 111.115 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 66.3 p -86.69 -32.83 20.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 73.01 111.189 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.3 m -52.78 -29.69 28.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.169 -0.469 . . . . 74.23 111.135 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -93.25 31.08 1.53 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.247 -0.433 . . . . 74.3 110.841 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -66.44 150.53 51.93 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.71 -0.757 . . . . 61.22 112.474 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.526 ' CG2' HD11 ' A' ' 44' ' ' LEU . 13.5 t -135.76 169.43 17.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 73.43 111.151 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.45 HG22 ' O ' ' A' ' 22' ' ' ALA . 17.9 pt -113.16 152.08 14.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 72.12 111.146 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 42' ' ' PHE . 10.0 p -69.98 150.72 46.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 55.34 111.119 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -81.26 -177.43 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.84 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -60.32 -30.61 69.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 72.12 110.867 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -97.42 20.38 11.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.22 110.867 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.27 27.94 71.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.719 -0.753 . . . . 75.31 112.474 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -108.5 139.38 43.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 71.23 110.919 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.472 ' HE2' HG23 ' A' ' 10' ' ' VAL . 13.2 p90 -133.49 168.13 19.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 71.21 110.928 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.508 ' C ' HD12 ' A' ' 44' ' ' LEU . 25.6 p -145.1 117.69 8.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 72.34 111.092 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.577 HD22 HD22 ' A' ' 52' ' ' LEU . 7.4 mp -126.59 109.58 12.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 72.23 110.889 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -99.89 117.91 35.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.845 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.674 HG11 ' OE2' ' A' ' 26' ' ' GLU . 3.6 m -138.34 155.9 73.79 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 71.43 111.124 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 -48.34 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.634 2.223 . . . . 60.01 112.381 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.18 150.72 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 71.24 111.111 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -91.3 46.07 1.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 63.41 110.91 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 84.0 p -66.4 -169.83 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 64.13 110.819 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.44 ' O ' HG22 ' A' ' 27' ' ' THR . 0.2 OUTLIER -94.64 160.74 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.503 . . . . 72.33 111.165 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.667 HD23 ' HG3' ' A' ' 26' ' ' GLU . 19.1 mt -121.15 117.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.931 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -97.82 114.58 26.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.867 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.697 HG13 HG13 ' A' ' 24' ' ' VAL . 4.0 mp -115.62 121.2 66.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 73.4 111.168 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 43.8 p -117.14 145.26 43.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 62.11 111.04 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.544 ' OH ' HG21 ' A' ' 10' ' ' VAL . 18.7 m-85 -125.81 155.29 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.481 . . . . 65.43 110.903 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.498 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.5 107.38 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.11 -0.496 . . . . 74.23 111.158 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.07 -46.16 1.1 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 45.03 112.467 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -111.82 170.89 7.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 61.23 110.828 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -63.6 150.75 89.74 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.568 0.699 . . . . 75.3 110.927 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 178.2 4.83 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.645 2.23 . . . . 71.32 112.371 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.666 HG21 HG11 ' A' ' 72' ' ' VAL . 3.7 p -152.03 147.9 14.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.088 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.6 p -132.14 130.82 41.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.174 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.65 HG11 HG21 ' A' ' 70' ' ' VAL . 19.5 m -141.66 145.97 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.263 -0.426 . . . . 74.21 111.125 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.97 157.18 37.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.965 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.18 98.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 72.41 111.155 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.15 178.2 6.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 63.13 111.071 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -86.36 -42.37 13.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.16 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -129.87 125.48 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.239 -0.437 . . . . 72.31 111.137 179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.65 HG21 HG11 ' A' ' 64' ' ' VAL . 6.3 p -146.44 122.14 3.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 74.42 111.133 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -120.12 119.74 34.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 74.11 110.856 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.666 HG11 HG21 ' A' ' 62' ' ' VAL . 27.8 t -133.03 147.02 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 61.34 111.173 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 24.8 mt -98.17 135.19 40.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 72.02 110.912 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' A' ' 56' ' ' TYR . 4.4 tp -89.32 117.89 28.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 65.54 110.89 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -94.07 132.53 38.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.42 110.867 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -56.65 145.84 27.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.097 -0.501 . . . . 75.12 110.936 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 14.9 t70 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 44.35 110.861 -179.941 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.464 -0.255 . . . . 42.34 112.464 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -158.13 119.85 3.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.843 0.354 . . . . 73.41 110.909 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.643 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 87.1 t -108.84 130.91 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 73.33 111.143 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 18' ' ' PRO . 3.7 p -127.31 169.5 13.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.108 -0.497 . . . . 73.43 111.113 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.512 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.4 t -89.16 150.09 22.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.457 . . . . 72.2 110.832 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . 0.5 ' CG ' HD13 ' A' ' 73' ' ' LEU . 14.9 tttm -90.83 15.0 12.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 60.22 110.882 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.74 -58.47 2.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 75.14 111.178 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -118.86 -26.66 5.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 72.52 110.828 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.28 29.29 6.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 53.34 112.503 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -96.93 160.16 29.81 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.533 0.682 . . . . 74.15 110.916 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.78 132.96 24.38 Favored 'Trans proline' 0 N--CA 1.465 -0.162 0 C-N-CA 122.664 2.242 . . . . 61.23 112.337 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.551 HG21 ' CD2' ' A' ' 56' ' ' TYR . 25.4 mm -77.67 118.11 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.164 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.493 HD13 ' CD2' ' A' ' 38' ' ' PHE . 23.8 mt -108.7 132.62 56.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 42.2 111.142 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.9 31.98 19.21 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.736 -0.745 . . . . 62.52 112.462 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -86.39 153.94 21.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.777 0.322 . . . . 63.11 111.114 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -106.86 107.04 17.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.429 . . . . 52.44 110.865 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.763 HG23 HG12 ' A' ' 54' ' ' ILE . 4.1 p -118.81 130.13 74.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 75.44 111.106 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.524 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.9 m -146.01 163.8 10.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 74.52 111.108 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . 0.685 ' OE1' HG21 ' A' ' 46' ' ' VAL . 4.1 mm-40 -85.24 172.82 10.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 74.12 110.931 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.58 -42.03 65.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 52.43 111.162 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -112.55 -21.98 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.198 -0.455 . . . . 64.03 111.155 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.16 64.55 0.84 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 63.21 111.109 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 21.8 p -78.52 -35.24 46.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.224 -0.444 . . . . 73.01 111.176 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.1 p -53.23 -30.93 40.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.097 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -93.78 31.33 1.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.968 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.81 148.37 50.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.794 -0.717 . . . . 61.22 112.434 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . 0.582 HG22 HD11 ' A' ' 44' ' ' LEU . 13.2 t -135.49 170.57 15.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.76 0.314 . . . . 73.43 111.194 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 11.6 pt -122.94 152.38 27.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 72.12 111.119 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.549 HG22 ' HD2' ' A' ' 42' ' ' PHE . 18.1 p -70.85 150.94 45.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 55.34 111.145 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -91.0 -177.02 4.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 34.54 110.896 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.493 ' CD2' HD13 ' A' ' 20' ' ' ILE . 0.4 OUTLIER -60.2 -30.01 69.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 72.12 110.883 -179.876 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -73.17 -18.52 61.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.46 28.04 20.74 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 75.31 112.452 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -129.65 166.88 18.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.887 0.375 . . . . 71.23 110.922 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PHE . . . . . 0.549 ' HD2' HG22 ' A' ' 36' ' ' THR . 26.8 p90 -151.35 167.92 26.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 71.21 110.865 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.5 t -134.66 125.61 27.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 72.34 111.1 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.697 HD22 HD21 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -130.73 128.84 41.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 72.23 110.898 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.9 t -105.04 119.97 40.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 73.42 110.801 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.685 HG21 ' OE1' ' A' ' 26' ' ' GLU . 58.0 t -139.0 133.23 16.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.614 0.721 . . . . 71.43 111.157 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.6 Cg_endo -69.77 -48.35 0.73 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.725 2.283 . . . . 60.01 112.325 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.0 m -86.65 171.64 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.259 -0.428 . . . . 71.24 111.12 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -111.08 81.75 1.48 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 63.41 110.829 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.7 t -109.39 -169.41 1.47 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.185 -0.461 . . . . 64.13 110.924 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.54 161.93 17.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.461 . . . . 72.33 111.133 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' LEU . . . . . 0.697 HD21 HD22 ' A' ' 44' ' ' LEU . 0.4 OUTLIER -128.42 130.18 47.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 62.04 110.91 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -101.98 124.45 47.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.858 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.763 HG12 HG23 ' A' ' 24' ' ' VAL . 10.3 mt -123.64 119.57 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.448 . . . . 73.4 111.115 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 51.2 p -117.78 144.32 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 62.11 111.152 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 25.0 m-85 -126.22 155.06 42.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.21 -0.45 . . . . 65.43 110.94 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.492 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.24 107.72 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 74.23 111.144 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 121.17 -51.1 0.8 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 45.03 112.513 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -101.5 170.75 8.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.897 0.379 . . . . 61.23 110.906 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 57.0 mttt -68.6 143.61 95.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.551 0.691 . . . . 75.3 110.963 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.73 174.22 9.8 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.713 2.275 . . . . 71.32 112.391 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.555 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.8 m -150.24 140.37 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 74.11 111.168 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -125.76 130.25 51.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 60.11 111.148 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.9 m -153.41 159.23 3.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.283 -0.417 . . . . 74.21 111.143 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -73.07 157.23 37.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.32 110.9 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.691 ' HB2' HD12 ' A' ' 52' ' ' LEU . . . -71.89 138.31 48.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 72.41 111.078 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -159.91 167.54 27.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 63.13 111.096 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.37 -57.14 13.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 73.13 111.064 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.5 135.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 72.31 111.143 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.1 p -146.48 120.72 2.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 74.42 111.185 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -120.01 109.81 15.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 74.11 110.848 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 10' ' ' VAL . 36.7 t -123.65 135.18 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 61.34 111.148 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.5 HD13 ' CG ' ' A' ' 13' ' ' LYS . 4.5 pp -92.71 145.49 24.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 72.02 110.955 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.61 121.33 29.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 65.54 110.878 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 59.5 mt-10 -97.69 136.76 37.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.941 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -55.13 139.74 40.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 75.12 110.88 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 44.35 110.818 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.807 0.337 . . . . 72.11 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -96.66 118.58 6.06 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.764 -0.731 . . . . 33.14 112.532 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 61.1 t60 -73.9 117.01 15.18 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.788 0.328 . . . . 75.12 110.881 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 -103.38 135.01 45.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.161 -0.472 . . . . 62.11 110.89 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -84.95 142.85 29.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.22 -0.445 . . . . 72.04 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 46.4 m80 -99.99 99.67 10.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.242 -0.435 . . . . 71.31 110.873 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 80.4 m-70 -116.75 176.84 4.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.188 -0.46 . . . . 74.02 110.897 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.2 t-80 -88.61 79.19 7.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 73.02 110.807 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 87.1 m -122.28 144.81 48.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 51.53 111.075 -179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 50.3 mttt -108.86 114.73 28.76 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 74.23 110.914 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.07 155.55 0.19 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 42.34 112.513 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -158.0 122.26 4.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.83 0.347 . . . . 73.41 110.93 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.647 HG12 HG13 ' A' ' 19' ' ' ILE . 21.8 t -114.22 128.67 71.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.13 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.464 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -136.18 152.07 50.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.151 -0.477 . . . . 73.43 111.188 -179.958 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -81.83 148.84 28.63 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 72.2 110.893 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -94.56 21.89 6.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.142 -0.481 . . . . 60.22 110.901 -179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.407 HG21 ' OH ' ' A' ' 59' ' ' TYR . 0.0 OUTLIER -94.0 -58.58 2.2 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 75.14 111.17 179.964 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -119.14 -25.98 6.04 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.263 -0.426 . . . . 72.52 110.883 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.8 29.02 5.12 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.717 -0.754 . . . . 53.34 112.499 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.7 mt-30 -101.14 160.5 26.47 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.559 0.695 . . . . 74.15 110.888 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.464 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.6 Cg_endo -69.73 145.46 57.39 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.688 2.259 . . . . 61.23 112.329 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.728 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 47.4 mm -83.07 115.63 25.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 75.31 111.171 179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.3 mt -104.83 113.1 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.163 -0.471 . . . . 42.2 111.191 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 96.51 32.66 6.52 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.5 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.728 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -91.06 128.14 36.76 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.858 0.361 . . . . 63.11 111.062 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.0 m -81.25 107.19 13.83 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.215 -0.448 . . . . 52.44 110.853 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.709 HG23 HG13 ' A' ' 54' ' ' ILE . 3.0 p -120.09 122.7 69.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.088 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.757 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.6 m -134.27 174.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.106 -0.497 . . . . 74.52 111.138 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 35.3 mp0 -91.17 166.14 13.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 74.12 110.92 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -65.43 -41.99 92.9 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.145 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.1 p -112.56 -22.16 10.93 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.235 -0.439 . . . . 64.03 111.083 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.601 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -101.32 65.65 1.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 63.21 111.086 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 87.5 m -77.34 -35.71 54.47 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.246 -0.434 . . . . 73.01 111.096 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.7 p -57.07 -31.6 65.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 74.23 111.169 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.664 ' O ' HD21 ' A' ' 44' ' ' LEU . 1.7 m-20 -94.45 31.41 1.75 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.3 110.929 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.757 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.36 152.37 49.64 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.781 -0.723 . . . . 61.22 112.499 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.593 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -135.56 168.46 19.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.74 0.305 . . . . 73.43 111.138 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.6 pt -116.55 167.72 9.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.202 -0.454 . . . . 72.12 111.134 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.499 HG22 ' HD2' ' A' ' 42' ' ' PHE . 23.0 p -89.74 150.61 22.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 55.34 111.174 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 -95.22 -178.93 4.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.25 -0.432 . . . . 34.54 110.915 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -57.79 -30.44 65.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.48 . . . . 72.12 110.885 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -73.55 -19.39 60.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.152 -0.476 . . . . 73.22 110.892 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.7 28.26 12.83 Favored Glycine 0 N--CA 1.453 -0.207 0 C-N-CA 120.736 -0.745 . . . . 75.31 112.458 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -136.58 166.07 24.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.914 0.388 . . . . 71.23 110.93 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.548 ' CZ ' HG21 ' A' ' 24' ' ' VAL . 24.2 p90 -142.66 164.75 29.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 71.21 110.902 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -123.46 117.79 25.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.166 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.664 HD21 ' O ' ' A' ' 32' ' ' ASN . 0.3 OUTLIER -144.44 134.97 24.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.41 . . . . 72.23 110.903 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.582 ' N ' HD13 ' A' ' 44' ' ' LEU . 1.2 t -107.02 121.85 45.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.154 -0.475 . . . . 73.42 110.846 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.5 t -126.92 133.26 24.84 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.565 0.698 . . . . 71.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.0 Cg_endo -69.69 -48.42 0.74 Allowed 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.731 2.288 . . . . 60.01 112.353 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.6 t -89.77 149.76 3.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.192 -0.458 . . . . 71.24 111.167 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 70.8 m-80 -85.16 64.39 8.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.214 -0.448 . . . . 63.41 110.92 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 m -92.49 -179.56 5.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 64.13 110.812 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.71 156.08 19.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.075 -0.512 . . . . 72.33 111.17 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 5.9 mt -115.24 124.9 52.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.275 -0.42 . . . . 62.04 110.888 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.584 ' HA ' HG22 ' A' ' 63' ' ' THR . 28.8 tttt -95.64 122.43 38.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 74.21 110.885 179.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.709 HG13 HG23 ' A' ' 24' ' ' VAL . 2.2 mp -118.65 134.55 61.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.171 -0.468 . . . . 73.4 111.131 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 45.7 p -142.55 138.74 31.06 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 62.11 111.123 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -134.31 119.13 18.3 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 65.43 110.95 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -51.49 112.46 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.132 -0.486 . . . . 74.23 111.175 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 133.98 -52.14 0.82 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.783 -0.723 . . . . 45.03 112.473 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.407 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.1 m-85 -108.27 170.0 8.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.895 0.379 . . . . 61.23 110.919 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 23.7 mttt -62.81 158.24 53.87 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.553 0.692 . . . . 75.3 110.885 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.78 162.44 42.09 Favored 'Trans proline' 0 C--O 1.231 0.172 0 C-N-CA 122.677 2.251 . . . . 71.32 112.334 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.622 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.1 m -150.72 138.5 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.155 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 53' ' ' LYS . 34.6 p -131.37 139.52 49.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.217 -0.447 . . . . 60.11 111.166 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.701 HG11 HG22 ' A' ' 72' ' ' VAL . 26.5 m -146.69 147.05 18.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.192 -0.458 . . . . 74.21 111.153 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 9.6 mttp -66.04 157.1 31.86 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.982 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -75.99 125.9 29.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.24 -0.436 . . . . 72.41 111.168 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -156.79 166.49 33.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.25 -0.432 . . . . 63.13 111.106 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.23 -43.34 78.52 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.117 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.0 mt -140.48 112.11 4.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.186 -0.461 . . . . 72.31 111.11 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.514 HG21 ' HB ' ' A' ' 64' ' ' VAL . 7.7 p -130.49 128.83 64.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.131 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -102.71 133.55 47.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.185 -0.461 . . . . 74.11 110.877 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.701 HG22 HG11 ' A' ' 64' ' ' VAL . 21.5 t -122.29 148.89 25.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 61.34 111.1 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 13.2 mt -122.0 127.82 50.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 72.02 110.885 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.653 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.4 tp -88.19 121.58 30.76 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.17 -0.468 . . . . 65.54 110.866 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 6.2 tt0 -90.39 144.42 25.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.2 -0.455 . . . . 73.42 110.921 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -58.24 141.33 51.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 75.12 110.897 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.7 t0 -103.95 147.84 26.88 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 44.35 110.863 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 13.8 p 49.93 38.65 16.71 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 74.43 111.047 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -147.81 120.28 8.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 74.23 110.941 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 11.2 ttm -99.78 103.83 15.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.249 -0.432 . . . . 74.23 110.861 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 25.4 t -129.79 110.4 19.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 72.15 111.128 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -92.02 127.97 37.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.858 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -109.14 66.8 0.64 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.206 -0.452 . . . . 64.43 110.882 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 13.4 p -129.25 147.59 33.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 53.25 111.13 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.7 p -157.2 144.24 10.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 62.05 111.092 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.5 p -158.5 134.45 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.171 -0.468 . . . . 73.01 111.14 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 32.2 p -120.21 -178.0 3.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 65.24 111.088 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 168.43 -134.33 3.19 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.741 -0.743 . . . . 61.42 112.485 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.5 t80 -58.97 148.64 29.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.901 0.382 . . . . 75.33 110.979 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.115 -0.493 . . . . 73.03 111.074 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 1.5 mpt? . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.8 0.333 . . . . 72.11 110.897 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -81.06 -82.75 0.79 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.741 -0.742 . . . . 33.14 112.497 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -114.56 -175.26 2.64 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.854 0.359 . . . . 75.12 110.875 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 54.5 p-80 -143.74 142.95 31.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.226 -0.443 . . . . 62.11 110.848 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 82.9 m-70 -139.71 154.89 47.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 72.04 110.86 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -59.46 -50.39 74.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.199 -0.455 . . . . 71.31 110.899 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 1.1 p80 -156.65 -176.57 6.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 74.02 110.869 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -128.21 62.09 1.44 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.221 -0.445 . . . . 73.02 110.837 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 12.7 t -81.8 167.02 19.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.44 . . . . 51.53 111.164 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 23.0 mmtm -144.77 121.3 11.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 74.23 110.9 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.94 152.48 0.35 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.735 -0.745 . . . . 42.34 112.493 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.8 t-20 -153.64 120.12 5.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.899 0.381 . . . . 73.41 110.895 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.73 ' HB ' HG21 ' A' ' 36' ' ' THR . 22.4 t -109.7 129.8 63.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.139 -0.482 . . . . 73.33 111.175 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.55 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.7 p -136.57 176.55 8.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.209 -0.45 . . . . 73.43 111.148 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.601 ' OG ' HD11 ' A' ' 19' ' ' ILE . 0.3 OUTLIER -103.27 150.98 23.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.191 -0.459 . . . . 72.2 110.863 -179.846 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.564 ' HG3' HD12 ' A' ' 73' ' ' LEU . 1.3 tmmt? -93.48 19.26 8.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.133 -0.485 . . . . 60.22 110.894 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.13 -58.72 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.244 -0.435 . . . . 75.14 111.146 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -120.17 -26.42 5.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.188 -0.46 . . . . 72.52 110.851 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.34 29.39 5.12 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.742 -0.742 . . . . 53.34 112.485 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 2.7 mm100 -100.35 160.24 27.55 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.599 0.714 . . . . 74.15 110.911 -179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.55 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.9 Cg_endo -69.72 137.67 36.14 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.715 2.277 . . . . 61.23 112.368 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.601 HD11 ' OG ' ' A' ' 12' ' ' SER . 42.6 mm -87.15 125.33 40.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.236 -0.438 . . . . 75.31 111.177 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.4 mt -104.89 113.47 42.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 42.2 111.134 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 100.04 33.03 5.36 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.486 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.66 119.26 26.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.754 0.312 . . . . 63.11 111.073 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -73.23 107.53 5.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 52.44 110.859 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.622 HG13 HG13 ' A' ' 54' ' ' ILE . 57.0 t -109.99 106.5 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.102 -0.499 . . . . 75.44 111.121 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.4 m -114.97 140.76 34.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.132 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.502 ' CD ' HG11 ' A' ' 46' ' ' VAL . 18.8 tt0 -85.79 133.52 33.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.153 -0.476 . . . . 74.12 110.857 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.6 p -54.51 -35.86 63.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.108 -0.496 . . . . 52.43 111.098 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 22.3 p -78.97 -22.09 46.14 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.267 -0.424 . . . . 64.03 111.133 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -161.51 110.69 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 63.21 111.079 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 64.5 p -86.51 -33.93 20.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.111 -179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 77.7 p -53.18 -29.59 32.65 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 74.23 111.154 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -94.26 31.19 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 74.3 110.885 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -73.25 141.18 29.65 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.801 -0.714 . . . . 61.22 112.46 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.423 HG21 ' O ' ' A' ' 43' ' ' THR . 0.2 OUTLIER -113.41 168.9 9.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.737 0.303 . . . . 73.43 111.146 -179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.405 ' H ' HG22 ' A' ' 34' ' ' THR . 4.8 pt -124.13 148.59 28.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.268 -0.424 . . . . 72.12 111.119 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.73 HG21 ' HB ' ' A' ' 10' ' ' VAL . 9.9 p -73.93 150.74 40.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.146 -0.479 . . . . 55.34 111.174 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -99.79 -175.33 2.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.192 -0.458 . . . . 34.54 110.873 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -56.38 -31.47 63.85 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 72.12 110.886 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -76.78 -18.88 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.185 -0.462 . . . . 73.22 110.905 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.25 28.84 10.16 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.704 -0.76 . . . . 75.31 112.518 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -135.99 159.88 40.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.822 0.344 . . . . 71.23 110.931 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.494 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 30.9 p90 -140.2 168.0 20.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 71.21 110.893 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.423 ' O ' HG21 ' A' ' 34' ' ' THR . 39.2 p -109.53 116.17 31.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 72.34 111.165 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -141.67 107.48 5.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 72.23 110.909 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 29.1 t -106.95 120.12 41.19 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 73.42 110.86 -179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.502 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.2 m -129.99 156.19 79.49 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.651 0.739 . . . . 71.43 111.109 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -48.02 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.7 2.267 . . . . 60.01 112.352 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.0 m -101.94 175.79 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 71.24 111.12 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -106.55 58.89 0.64 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.897 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.5 p -72.7 -170.2 0.66 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.114 -0.493 . . . . 64.13 110.857 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.471 ' C ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -89.14 152.43 21.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.134 -0.485 . . . . 72.33 111.133 -179.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.847 HD13 ' HB2' ' A' ' 66' ' ' ALA . 10.0 mp -122.31 121.64 37.21 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.234 -0.439 . . . . 62.04 110.877 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 47.2 tttt -96.88 123.14 40.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.888 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.622 HG13 HG13 ' A' ' 24' ' ' VAL . 5.4 mp -116.56 132.23 66.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.218 -0.446 . . . . 73.4 111.121 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.6 p -143.08 138.56 29.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.12 -0.491 . . . . 62.11 111.121 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.824 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -137.72 127.63 25.63 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.19 -0.459 . . . . 65.43 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.42 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.6 tp -51.63 119.98 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.123 -0.489 . . . . 74.23 111.119 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.99 -51.12 0.85 Allowed Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.775 -0.726 . . . . 45.03 112.479 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -108.61 170.12 8.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.933 0.397 . . . . 61.23 110.916 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 22.3 mtmt -69.92 158.11 88.07 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.57 0.7 . . . . 75.3 110.914 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 164.56 34.12 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.681 2.254 . . . . 71.32 112.304 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.466 HG11 ' CG1' ' A' ' 72' ' ' VAL . 14.5 p -151.4 149.09 14.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.168 -0.469 . . . . 74.11 111.126 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.7 p -132.02 132.56 43.53 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.124 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.749 HG11 HG22 ' A' ' 72' ' ' VAL . 31.0 m -137.72 172.17 14.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.439 . . . . 74.21 111.16 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.38 156.82 18.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.446 . . . . 70.32 110.901 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.847 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -93.18 130.07 38.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 72.41 111.045 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.55 -175.55 3.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.209 -0.451 . . . . 63.13 111.072 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.512 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -53.35 -49.53 66.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.229 -0.441 . . . . 73.13 111.097 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 68' ' ' ALA . 43.9 mm -139.2 114.2 8.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.456 . . . . 72.31 111.156 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.31 125.13 67.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.142 -0.481 . . . . 74.42 111.088 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -98.68 135.06 40.72 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 74.11 110.91 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.749 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -128.33 147.6 32.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.189 -0.46 . . . . 61.34 111.153 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.564 HD12 ' HG3' ' A' ' 13' ' ' LYS . 1.2 pt? -127.12 138.09 53.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.214 -0.448 . . . . 72.02 110.922 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.824 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.2 tp -88.83 124.93 34.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.203 -0.453 . . . . 65.54 110.943 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -90.29 136.85 32.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 73.42 110.855 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -58.99 140.17 55.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 75.12 110.945 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -96.41 36.15 1.39 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 44.35 110.904 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 14.1 t -102.48 140.59 36.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.156 -0.474 . . . . 74.43 111.165 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -143.92 117.49 9.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.23 110.931 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 9.8 mtp -108.09 79.66 1.29 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 74.23 110.85 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 16.7 m -79.11 58.65 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 72.15 111.103 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -57.99 158.72 6.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.22 -0.445 . . . . 62.52 110.86 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.6 mp0 -119.5 61.78 0.82 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 64.43 110.873 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.8 t -106.25 119.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 53.25 111.147 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.7 p -155.36 144.33 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 62.05 111.155 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.6 t -139.3 144.77 28.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.169 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 9.9 t -137.64 158.7 43.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.203 -0.453 . . . . 65.24 111.1 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 146.56 122.69 1.42 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.703 -0.761 . . . . 61.42 112.491 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -133.54 163.69 28.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.95 0.405 . . . . 75.33 110.947 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.5 p . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.142 -0.481 . . . . 73.03 111.121 -179.972 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.0 mpt? . . . . . 0 C--O 1.23 0.062 0 CA-C-O 120.834 0.349 . . . . 72.11 110.867 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.93 -107.92 0.2 Allowed Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.805 -0.712 . . . . 33.14 112.594 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 23.3 m80 56.56 50.09 13.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.832 0.349 . . . . 75.12 110.856 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -123.06 37.47 4.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 62.11 110.87 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -72.77 -36.21 67.62 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.238 -0.437 . . . . 72.04 110.884 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.3 p80 -71.62 139.9 49.52 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.122 -0.49 . . . . 71.31 110.877 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 -73.37 -179.34 3.38 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.234 -0.439 . . . . 74.02 110.854 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -73.57 94.4 2.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.181 -0.463 . . . . 73.02 110.883 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.499 HG21 HD22 ' A' ' 41' ' ' ASN . 15.1 t -134.19 170.01 16.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.153 -0.476 . . . . 51.53 111.116 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.74 139.55 47.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.461 . . . . 74.23 110.936 179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.49 96.18 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.653 -0.784 . . . . 42.34 112.498 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -118.39 128.19 54.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.915 0.388 . . . . 73.41 110.875 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.477 HG22 ' HB ' ' A' ' 72' ' ' VAL . 89.2 t -119.7 129.17 75.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.15 -0.477 . . . . 73.33 111.08 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.45 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.9 p -129.7 178.1 6.75 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 73.43 111.162 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.6 t -97.2 151.02 20.24 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.263 -0.426 . . . . 72.2 110.892 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.428 ' HG3' HD12 ' A' ' 73' ' ' LEU . 7.2 tmtt? -92.05 15.43 13.36 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 60.22 110.938 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 37.0 p -94.07 -59.07 2.05 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.238 -0.437 . . . . 75.14 111.117 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 53.9 m-20 -120.44 -26.63 5.35 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 72.52 110.844 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.16 29.19 5.26 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.539 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -94.26 160.15 32.56 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.592 0.71 . . . . 74.15 110.913 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.2 Cg_endo -69.67 139.5 40.7 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.703 2.269 . . . . 61.23 112.342 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.641 HG22 ' HB2' ' A' ' 22' ' ' ALA . 49.2 mm -83.97 113.56 23.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.104 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 22.6 mt -101.06 128.88 52.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 42.2 111.085 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.96 32.61 26.01 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.769 -0.729 . . . . 62.52 112.486 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.641 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -90.96 135.64 33.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.796 0.331 . . . . 63.11 111.093 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.7 m -85.6 107.2 17.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.234 -0.439 . . . . 52.44 110.804 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.722 HG23 HG13 ' A' ' 54' ' ' ILE . 2.9 p -118.33 122.39 69.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.106 -0.497 . . . . 75.44 111.107 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.726 HG12 ' HA3' ' A' ' 33' ' ' GLY . 16.2 m -134.61 151.83 32.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.149 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.528 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 13.8 tp10 -75.62 132.65 40.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.193 -0.458 . . . . 74.12 110.897 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 72.8 p -51.52 -34.93 38.39 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.091 -0.504 . . . . 52.43 111.153 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -96.68 -22.08 17.22 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 64.03 111.132 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.528 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -127.19 89.75 3.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.207 -0.451 . . . . 63.21 111.104 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 6.8 p -86.79 -35.65 19.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.136 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 91.1 m -56.68 -31.0 64.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 74.23 111.146 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 54.0 m-20 -93.13 30.74 1.58 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.19 -0.459 . . . . 74.3 110.865 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.726 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.52 147.01 50.65 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.782 -0.723 . . . . 61.22 112.517 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.616 HG22 HD11 ' A' ' 44' ' ' LEU . 13.6 t -135.49 168.94 18.29 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.787 0.327 . . . . 73.43 111.112 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 8.7 pt -110.98 158.15 11.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.12 111.116 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.506 HG22 ' HD2' ' A' ' 42' ' ' PHE . 39.2 p -80.34 150.68 29.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.15 -0.477 . . . . 55.34 111.143 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -90.37 176.3 6.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 34.54 110.893 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -56.95 -30.18 63.82 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.195 -0.457 . . . . 72.12 110.858 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -73.12 -19.05 61.22 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.207 -0.451 . . . . 73.22 110.914 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 90.62 28.26 17.04 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 75.31 112.462 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.499 HD22 HG21 ' A' ' 6' ' ' THR . 26.4 p30 -131.95 165.43 23.93 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.845 0.355 . . . . 71.23 110.878 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.619 ' CE1' HG21 ' A' ' 24' ' ' VAL . 26.7 p90 -148.51 168.04 23.76 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.227 -0.442 . . . . 71.21 110.851 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 43' ' ' THR . 4.9 t -128.99 120.11 25.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.079 -0.51 . . . . 72.34 111.134 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.616 HD11 HG22 ' A' ' 34' ' ' THR . 0.2 OUTLIER -127.84 111.14 13.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 72.23 110.894 179.92 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.9 m -93.38 111.91 23.68 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.145 -0.48 . . . . 73.42 110.817 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -128.35 156.1 77.39 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.57 0.7 . . . . 71.43 111.159 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.76 -48.19 0.77 Allowed 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.67 2.247 . . . . 60.01 112.396 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.8 p -106.13 151.79 8.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 71.24 111.101 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -79.26 60.88 3.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 63.41 110.905 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.5 t -75.82 -170.4 1.32 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 64.13 110.825 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -90.86 157.52 17.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.105 -0.498 . . . . 72.33 111.122 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.474 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 2.8 mp -120.09 128.58 53.6 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 62.04 110.882 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.524 ' HA ' HG22 ' A' ' 63' ' ' THR . 64.1 tttt -100.75 123.14 44.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.881 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.722 HG13 HG23 ' A' ' 24' ' ' VAL . 3.7 mp -120.55 134.22 64.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.208 -0.451 . . . . 73.4 111.102 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.1 p -145.76 140.07 26.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.106 -0.497 . . . . 62.11 111.148 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.688 ' HB3' HD21 ' A' ' 74' ' ' LEU . 14.9 t80 -135.6 121.39 19.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 65.43 110.963 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.431 HG23 ' O ' ' A' ' 57' ' ' ILE . 10.8 tt -50.88 117.18 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.094 -0.503 . . . . 74.23 111.105 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.52 -50.76 0.88 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.439 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -109.68 169.98 8.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.969 0.414 . . . . 61.23 110.947 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 19.4 mttm -64.27 157.73 69.18 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.55 0.69 . . . . 75.3 110.868 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.66 162.26 42.72 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.707 2.272 . . . . 71.32 112.361 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.559 HG23 ' HB ' ' A' ' 54' ' ' ILE . 30.2 m -150.51 133.29 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.097 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.524 HG22 ' HA ' ' A' ' 53' ' ' LYS . 25.2 p -126.9 142.8 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.181 -0.463 . . . . 60.11 111.088 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.829 HG11 HG22 ' A' ' 72' ' ' VAL . 30.3 m -151.15 151.37 12.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 74.21 111.146 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 29.5 ttpt -73.98 157.32 36.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 70.32 110.898 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.474 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -71.12 134.18 46.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 72.41 111.11 179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.476 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -164.68 161.79 20.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.437 . . . . 63.13 111.11 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.97 -40.36 60.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.265 -0.425 . . . . 73.13 111.066 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.0 mt -140.86 111.79 3.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 72.31 111.103 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.514 HG11 ' CG2' ' A' ' 64' ' ' VAL . 20.7 t -124.08 112.0 30.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.477 . . . . 74.42 111.099 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -96.74 116.6 29.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 74.11 110.926 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.829 HG22 HG11 ' A' ' 64' ' ' VAL . 24.3 t -115.06 148.77 17.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.208 -0.451 . . . . 61.34 111.115 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.428 HD12 ' HG3' ' A' ' 13' ' ' LYS . 0.6 OUTLIER -121.2 139.21 53.67 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.184 -0.462 . . . . 72.02 110.959 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.688 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -91.21 122.54 33.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.234 -0.439 . . . . 65.54 110.956 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -90.53 141.37 28.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.853 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -59.06 140.53 55.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 75.12 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -120.88 83.07 2.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.154 -0.476 . . . . 44.35 110.87 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 24.7 p -90.97 165.37 13.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 74.43 111.143 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -54.94 173.31 0.09 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.933 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.2 ttm -55.76 171.24 0.23 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 74.23 110.922 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.4 m -107.15 -35.91 3.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 72.15 111.159 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -97.96 36.43 1.56 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 62.52 110.857 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -85.72 95.22 9.32 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 64.43 110.955 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.3 t -91.09 73.02 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.153 -0.476 . . . . 53.25 111.074 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 12.3 p -98.34 145.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.15 -0.477 . . . . 62.05 111.224 179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.6 m -55.13 151.05 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 73.01 111.117 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -67.36 141.65 57.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 65.24 111.159 -179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.19 70.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.739 -0.743 . . . . 61.42 112.487 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 28.6 t80 -81.29 136.86 35.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.977 0.418 . . . . 75.33 110.873 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.246 0 CA-C-N 116.14 -0.482 . . . . 73.03 111.138 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.5 ttm . . . . . 0 N--CA 1.458 -0.062 0 CA-C-O 120.799 0.333 . . . . 72.11 110.868 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -165.42 -170.4 30.31 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.709 -0.758 . . . . 33.14 112.493 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 5.4 t-160 -171.05 140.73 1.57 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.822 0.344 . . . . 75.12 110.886 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 40.7 m80 -137.13 169.11 18.33 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.198 -0.455 . . . . 62.11 110.852 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -113.55 -179.31 3.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 72.04 110.876 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -135.92 173.96 11.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 71.31 110.9 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 19.5 m80 -95.43 162.72 13.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 74.02 110.842 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.4 p80 -133.51 52.71 2.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.241 -0.436 . . . . 73.02 110.869 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.715 ' O ' HD12 ' A' ' 69' ' ' ILE . 0.2 OUTLIER -93.41 167.16 11.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 51.53 111.183 -179.977 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.83 -173.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 74.23 110.881 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -50.46 126.74 24.98 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.778 -0.725 . . . . 42.34 112.487 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -129.75 127.51 40.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.87 0.367 . . . . 73.41 110.916 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.447 HG23 ' HE2' ' A' ' 42' ' ' PHE . 88.5 t -117.04 125.26 73.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 73.33 111.111 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.2 p -122.79 169.63 10.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 73.43 111.172 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -91.54 149.62 21.59 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 72.2 110.897 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -93.21 18.18 9.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.134 -0.484 . . . . 60.22 110.882 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.21 -58.82 2.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.21 -0.45 . . . . 75.14 111.089 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 76.5 m-20 -120.53 -25.97 5.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.255 -0.43 . . . . 72.52 110.91 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.97 29.13 5.03 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.672 -0.775 . . . . 53.34 112.509 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -98.29 154.13 37.76 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.62 0.724 . . . . 74.15 110.916 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.82 143.08 49.45 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.684 2.256 . . . . 61.23 112.334 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.448 ' CD1' HD22 ' A' ' 74' ' ' LEU . 47.3 mm -83.32 108.11 15.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 75.31 111.199 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 36.1 mt -101.46 126.57 55.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.231 -0.44 . . . . 42.2 111.078 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.64 42.11 7.0 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.748 -0.739 . . . . 62.52 112.47 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -94.89 162.39 13.77 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.791 0.329 . . . . 63.11 111.096 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 59.2 m -105.62 107.53 18.57 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 52.44 110.859 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.728 HG13 HG13 ' A' ' 54' ' ' ILE . 43.4 t -110.43 106.17 20.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.474 . . . . 75.44 111.085 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.9 m -124.64 138.01 55.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 74.52 111.101 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.512 ' CD ' HG11 ' A' ' 46' ' ' VAL . 10.6 mt-10 -72.02 173.53 8.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.861 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.2 p -76.35 -35.55 58.66 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.121 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 17.7 p -112.38 -22.14 11.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 64.03 111.104 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -117.2 77.2 1.1 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.24 -0.436 . . . . 63.21 111.05 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.6 p -86.72 -35.36 19.29 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.245 -0.434 . . . . 73.01 111.119 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 45.8 p -53.33 -30.2 37.94 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.23 111.159 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 20.0 m-20 -94.76 31.3 1.85 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 74.3 110.907 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -59.38 136.1 50.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.74 -0.743 . . . . 61.22 112.485 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 5.0 m -111.15 157.87 19.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.758 0.313 . . . . 73.43 111.128 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 5.3 pt -108.59 150.51 11.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.23 -0.441 . . . . 72.12 111.101 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.622 HG22 ' HD2' ' A' ' 42' ' ' PHE . 6.0 p -72.26 149.66 44.33 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.183 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -83.6 -175.44 5.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 34.54 110.859 179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -58.88 -30.86 68.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.16 -0.473 . . . . 72.12 110.901 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.9 21.44 11.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.115 -0.493 . . . . 73.22 110.906 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.17 27.46 70.6 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.709 -0.757 . . . . 75.31 112.471 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -108.79 134.91 50.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.829 0.347 . . . . 71.23 110.89 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.622 ' HD2' HG22 ' A' ' 36' ' ' THR . 18.5 p90 -133.54 167.93 19.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.46 . . . . 71.21 110.856 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.29 121.42 12.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.162 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 2.5 mt -120.93 127.81 52.18 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.209 -0.451 . . . . 72.23 110.907 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 3.3 t -106.93 113.65 27.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.131 -0.486 . . . . 73.42 110.852 -179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.512 HG11 ' CD ' ' A' ' 26' ' ' GLU . 3.3 m -139.2 156.21 72.15 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.657 0.741 . . . . 71.43 111.138 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -48.35 0.73 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.651 2.234 . . . . 60.01 112.352 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.66 149.4 5.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.202 -0.454 . . . . 71.24 111.151 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -88.9 52.1 2.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 63.41 110.863 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.1 t -68.53 -169.78 0.17 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.992 0.425 . . . . 64.13 110.812 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.554 ' O ' HD12 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -87.63 157.14 19.19 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.148 -0.478 . . . . 72.33 111.187 -179.955 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 66' ' ' ALA . 7.4 mp -125.39 125.01 42.72 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.238 -0.437 . . . . 62.04 110.874 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.434 ' HA ' HG22 ' A' ' 63' ' ' THR . 43.1 tttt -102.64 126.89 49.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.194 -0.457 . . . . 74.21 110.912 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.728 HG13 HG13 ' A' ' 24' ' ' VAL . 3.9 mp -123.29 139.33 50.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.445 . . . . 73.4 111.144 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 74.1 p -140.94 139.23 34.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 62.11 111.188 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.471 ' HB3' HD21 ' A' ' 74' ' ' LEU . 17.4 t80 -133.05 119.8 20.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 65.43 110.926 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.42 116.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.142 -0.481 . . . . 74.23 111.141 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 130.35 -55.13 0.77 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.758 -0.734 . . . . 45.03 112.525 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -108.87 170.63 7.92 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.984 0.421 . . . . 61.23 110.915 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -62.01 157.72 49.54 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.555 0.693 . . . . 75.3 110.935 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 170.77 15.86 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.667 2.245 . . . . 71.32 112.367 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.66 ' CG2' HG11 ' A' ' 72' ' ' VAL . 14.6 p -151.49 140.92 15.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.247 -0.433 . . . . 74.11 111.135 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 53' ' ' LYS . 11.4 p -131.95 135.35 46.52 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.179 -0.464 . . . . 60.11 111.183 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.503 HG11 HG21 ' A' ' 72' ' ' VAL . 6.8 m -152.17 149.24 13.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.232 -0.44 . . . . 74.21 111.2 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.3 mmtm -69.08 153.99 42.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 70.32 110.914 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.654 ' HB2' HD13 ' A' ' 52' ' ' LEU . . . -77.43 65.42 2.97 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.226 -0.443 . . . . 72.41 111.134 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -90.21 -175.1 4.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.164 -0.471 . . . . 63.13 111.045 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.736 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -64.3 -55.08 23.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.226 -0.443 . . . . 73.13 111.137 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.736 HD13 ' O ' ' A' ' 68' ' ' ALA . 17.4 mm -128.76 137.14 58.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.441 . . . . 72.31 111.076 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.5 HG21 HG21 ' A' ' 64' ' ' VAL . 5.7 p -145.7 119.21 2.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 74.42 111.111 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -120.24 109.52 15.5 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 74.11 110.855 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.66 HG11 ' CG2' ' A' ' 62' ' ' VAL . 17.2 t -124.59 149.1 28.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 61.34 111.19 179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -103.39 145.73 29.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.02 110.945 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.471 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.6 tp -87.25 120.45 28.54 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 65.54 110.89 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -90.36 140.4 29.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.238 -0.437 . . . . 73.42 110.872 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -59.1 142.08 52.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 75.12 110.908 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -103.56 98.72 8.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 44.35 110.866 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.9 p -95.01 177.71 5.8 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.232 -0.44 . . . . 74.43 111.141 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -52.1 137.13 28.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 74.23 110.826 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -52.26 134.36 33.61 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.165 -0.471 . . . . 74.23 110.956 179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.7 m -108.41 67.65 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.426 . . . . 72.15 111.035 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 20.0 p-10 -54.67 156.42 3.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.434 . . . . 62.52 110.847 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -120.22 74.02 1.02 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 64.43 110.895 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.1 p -135.98 136.58 49.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.162 -0.472 . . . . 53.25 111.079 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 36.1 t -132.12 146.3 33.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.178 -0.465 . . . . 62.05 111.17 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 33.5 m -90.47 -176.9 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.205 -0.452 . . . . 73.01 111.092 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.9 t -86.14 157.84 19.92 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.091 -0.504 . . . . 65.24 111.132 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -110.56 -47.4 0.8 Allowed Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.747 -0.739 . . . . 61.42 112.437 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -72.13 141.61 49.14 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.941 0.401 . . . . 75.33 110.887 -179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 43.0 p . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 73.03 111.159 179.989 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.23 0.047 0 CA-C-O 120.841 0.353 . . . . 72.11 110.862 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 146.37 43.03 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.717 -0.754 . . . . 33.14 112.474 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 12.9 m-70 -56.21 166.53 0.8 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.81 0.338 . . . . 75.12 110.828 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 21.7 p80 -123.14 145.06 48.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.169 -0.469 . . . . 62.11 110.84 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 54.2 m80 -148.79 -179.54 7.07 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 72.04 110.894 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -115.26 141.0 48.62 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.226 -0.443 . . . . 71.31 110.899 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 17.4 p80 -161.85 153.12 18.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 74.02 110.875 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -129.89 46.62 2.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.179 -0.464 . . . . 73.02 110.856 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.5 m -90.78 151.82 21.04 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 51.53 111.094 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -148.38 112.49 5.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 74.23 110.894 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 68.6 136.23 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.696 -0.764 . . . . 42.34 112.459 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 -144.15 127.52 16.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.41 110.842 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 21.2 t -115.57 116.5 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 73.33 111.091 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.515 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.4 p -129.95 153.72 48.08 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.137 -0.483 . . . . 73.43 111.152 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.411 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -79.88 150.98 30.43 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.873 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.565 ' HA ' HD12 ' A' ' 73' ' ' LEU . 12.4 tttp -94.01 20.16 8.2 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.194 -0.457 . . . . 60.22 110.849 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 35.1 p -94.04 -58.79 2.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 75.14 111.168 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -119.39 -26.39 5.84 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.209 -0.451 . . . . 72.52 110.94 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.5 5.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.856 -0.688 . . . . 53.34 112.495 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -97.95 160.4 28.54 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.586 0.707 . . . . 74.15 110.835 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.515 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.8 148.28 64.43 Favored 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.73 2.287 . . . . 61.23 112.318 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.411 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.4 mm -95.16 122.75 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 75.31 111.17 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 17.7 mt -107.4 116.28 50.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.236 -0.438 . . . . 42.2 111.136 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 99.41 33.26 5.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.499 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.522 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -89.57 129.41 36.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.805 0.336 . . . . 63.11 111.052 -179.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 m -76.99 108.34 9.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.454 . . . . 52.44 110.861 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.791 HG21 ' CD2' ' A' ' 42' ' ' PHE . 68.7 t -114.87 106.18 20.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 75.44 111.103 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.425 HG12 ' HA3' ' A' ' 33' ' ' GLY . 18.3 m -123.9 151.21 28.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.52 111.123 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.685 ' HB2' ' HB3' ' A' ' 29' ' ' ALA . 4.0 mm-40 -81.83 166.78 19.68 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 74.12 110.908 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.06 -41.99 98.72 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.176 -0.465 . . . . 52.43 111.136 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 33.6 p -112.44 -22.06 11.03 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.233 -0.44 . . . . 64.03 111.123 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.685 ' HB3' ' HB2' ' A' ' 26' ' ' GLU . . . -100.77 75.5 1.72 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.195 -0.457 . . . . 63.21 111.072 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 12.4 p -86.67 -35.61 19.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 73.01 111.173 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -60.6 -30.77 70.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.282 -0.417 . . . . 74.23 111.18 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.6 t30 -94.46 31.2 1.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.159 -0.473 . . . . 74.3 110.867 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.425 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -61.12 139.01 47.68 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.701 -0.761 . . . . 61.22 112.513 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.484 ' HB ' HD11 ' A' ' 44' ' ' LEU . 0.3 OUTLIER -113.71 167.37 10.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.771 0.32 . . . . 73.43 111.168 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.433 ' H ' HG22 ' A' ' 34' ' ' THR . 7.9 pt -124.14 147.16 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 72.12 111.152 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 34.4 p -69.94 137.98 51.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 55.34 111.145 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.7 -179.52 7.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 34.54 110.856 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -57.0 -30.22 63.97 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.193 -0.458 . . . . 72.12 110.859 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -73.5 -18.75 61.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.234 -0.439 . . . . 73.22 110.85 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 92.08 28.21 14.13 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.738 -0.744 . . . . 75.31 112.529 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -134.2 168.35 19.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.856 0.36 . . . . 71.23 110.935 -179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.791 ' CD2' HG21 ' A' ' 24' ' ' VAL . 3.1 p90 -141.89 167.93 20.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 71.21 110.869 -179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 27.1 p -124.98 116.99 23.04 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.13 -0.486 . . . . 72.34 111.137 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 8.0 mp -136.58 120.79 17.88 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.189 -0.459 . . . . 72.23 110.915 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 26.7 m -106.94 112.05 24.82 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.092 -0.504 . . . . 73.42 110.886 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.3 m -124.95 156.16 69.49 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.661 0.743 . . . . 71.43 111.108 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 -48.25 0.74 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.633 2.222 . . . . 60.01 112.338 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.6 p -110.51 152.11 12.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.118 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.4 p30 -80.63 58.49 3.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.113 -0.494 . . . . 63.41 110.942 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 94.9 p -72.84 -169.83 0.63 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 64.13 110.862 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.452 HG23 ' HG2' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -87.7 153.11 21.62 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.153 -0.476 . . . . 72.33 111.094 -179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.795 HD11 ' HB2' ' A' ' 66' ' ' ALA . 5.9 mp -126.27 126.13 43.49 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 62.04 110.889 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.652 ' HA ' HG22 ' A' ' 63' ' ' THR . 12.1 ttpt -95.63 122.2 38.14 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.191 -0.459 . . . . 74.21 110.869 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.74 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.8 mt -121.26 137.2 55.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 73.4 111.15 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 34.5 p -147.39 138.77 23.87 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.153 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 26.3 t80 -133.54 119.0 18.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.429 . . . . 65.43 111.02 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.4 tp -51.02 117.58 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.176 -0.465 . . . . 74.23 111.185 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.68 -52.89 0.82 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.781 -0.723 . . . . 45.03 112.458 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.9 m-85 -110.34 170.19 8.25 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.952 0.406 . . . . 61.23 110.945 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 49.7 mttt -60.5 157.63 35.13 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.589 0.709 . . . . 75.3 110.902 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 166.87 26.02 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.723 2.282 . . . . 71.32 112.283 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.74 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.5 m -151.24 126.35 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 74.11 111.112 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.652 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.8 p -125.06 132.81 53.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.109 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.479 HG11 ' CG2' ' A' ' 72' ' ' VAL . 14.8 m -152.09 157.34 5.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.079 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.452 ' HG2' HG23 ' A' ' 51' ' ' THR . 39.6 mtpt -84.13 155.11 22.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.126 -0.488 . . . . 70.32 110.953 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.795 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.09 133.6 46.38 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.251 -0.431 . . . . 72.41 111.091 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.16 -179.67 8.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.095 -0.502 . . . . 63.13 111.101 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.474 ' O ' HD13 ' A' ' 69' ' ' ILE . . . -51.73 -58.02 7.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.455 . . . . 73.13 111.102 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.474 HD13 ' O ' ' A' ' 68' ' ' ALA . 41.0 mm -142.36 111.65 2.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.141 -0.481 . . . . 72.31 111.104 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.4 p -121.76 122.3 66.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 74.42 111.167 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.7 m120 -119.78 115.33 23.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.206 -0.452 . . . . 74.11 110.888 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.718 HG11 ' HB ' ' A' ' 62' ' ' VAL . 18.7 t -113.16 126.9 70.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.162 -0.472 . . . . 61.34 111.109 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.565 HD12 ' HA ' ' A' ' 13' ' ' LYS . 0.7 OUTLIER -83.34 140.59 32.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.894 179.99 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.402 HD12 ' HA ' ' A' ' 74' ' ' LEU . 1.5 tp -87.9 121.73 30.67 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.899 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.5 tt0 -90.2 137.06 32.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.9 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -57.45 141.78 46.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.157 -0.474 . . . . 75.12 110.872 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -85.73 144.36 27.83 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.093 -0.503 . . . . 44.35 110.853 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.0 t -175.15 152.22 1.41 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 74.43 111.156 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 30.0 tt0 -82.14 121.41 26.55 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 74.23 110.887 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.5 mmt -68.89 103.52 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 74.23 110.901 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.568 HG22 ' H ' ' A' ' 83' ' ' GLU . 13.5 p -169.94 133.1 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.261 -0.427 . . . . 72.15 111.089 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -120.43 34.84 5.07 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.151 -0.477 . . . . 62.52 110.9 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.568 ' H ' HG22 ' A' ' 81' ' ' VAL . 32.8 tt0 -108.93 82.34 1.58 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 64.43 110.883 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.2 m -59.52 137.57 21.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.175 -0.466 . . . . 53.25 111.122 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 46.0 t -135.87 130.0 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.153 -0.476 . . . . 62.05 111.203 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 11.5 p -151.94 136.83 10.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 73.01 111.158 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 72.1 p -121.91 72.0 1.01 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.221 -0.445 . . . . 65.24 111.13 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.54 -126.38 8.43 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.849 -0.691 . . . . 61.42 112.457 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -172.46 155.47 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.983 0.42 . . . . 75.33 110.898 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 35.7 p . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.115 -0.493 . . . . 73.03 111.123 -179.941 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.725 0.297 . . . . 72.11 110.814 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 129.27 77.57 0.2 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.769 -0.729 . . . . 33.14 112.488 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 6.8 p-80 -109.2 149.51 29.28 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.793 0.33 . . . . 75.12 110.88 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 40.8 m170 -120.1 -179.2 3.86 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 62.11 110.865 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -125.93 126.13 43.88 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 72.04 110.818 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.1 p80 -167.65 169.93 11.45 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.152 -0.476 . . . . 71.31 110.844 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.4 t-80 -166.5 130.54 2.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.19 -0.459 . . . . 74.02 110.858 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.548 ' CE1' HG22 ' A' ' 6' ' ' THR . 7.2 p80 -129.35 -47.79 1.19 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.265 -0.425 . . . . 73.02 110.801 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.548 HG22 ' CE1' ' A' ' 5' ' ' HIS . 14.7 t -126.81 165.16 19.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.189 -0.46 . . . . 51.53 111.14 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 10.5 pttp -129.43 152.66 48.74 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.225 -0.443 . . . . 74.23 110.929 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 72.12 145.26 0.51 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.719 -0.753 . . . . 42.34 112.466 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -152.61 128.35 10.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.875 0.369 . . . . 73.41 110.859 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.666 HG22 HD13 ' A' ' 54' ' ' ILE . 94.2 t -117.99 131.8 69.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.149 -0.478 . . . . 73.33 111.112 179.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.565 HG22 ' HA ' ' A' ' 18' ' ' PRO . 16.9 p -138.12 172.88 12.27 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.154 -0.475 . . . . 73.43 111.088 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.417 ' HB2' HD11 ' A' ' 19' ' ' ILE . 1.2 t -92.74 156.25 17.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.131 -0.486 . . . . 72.2 110.922 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttt -93.57 16.38 13.85 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.152 -0.476 . . . . 60.22 110.876 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 41.1 p -94.05 -59.07 2.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 75.14 111.095 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -120.68 -26.24 5.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.207 -0.451 . . . . 72.52 110.91 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.63 29.12 5.14 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.747 -0.74 . . . . 53.34 112.503 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -95.02 153.93 39.74 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.606 0.717 . . . . 74.15 110.889 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.565 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.7 135.75 31.39 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.73 2.286 . . . . 61.23 112.296 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.417 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -84.6 135.83 24.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.46 . . . . 75.31 111.127 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 21.0 mt -114.29 125.12 71.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 42.2 111.104 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 87.86 33.83 10.67 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.746 -0.74 . . . . 62.52 112.492 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HB3' ' CG2' ' A' ' 36' ' ' THR . . . -86.17 162.67 18.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.72 0.295 . . . . 63.11 111.176 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.53 113.5 27.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 52.44 110.852 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.705 HG21 ' CD2' ' A' ' 42' ' ' PHE . 44.6 t -116.76 134.04 61.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.16 -0.473 . . . . 75.44 111.12 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 9.1 m -139.64 148.87 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 74.52 111.064 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.664 ' HG3' HG11 ' A' ' 46' ' ' VAL . 1.7 tm-20 -88.5 135.11 33.64 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.091 -0.504 . . . . 74.12 110.846 -179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.411 HG21 ' HB ' ' A' ' 51' ' ' THR . 21.0 p -55.5 -32.64 63.05 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 52.43 111.159 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.6 p -71.87 -22.36 61.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.186 -0.461 . . . . 64.03 111.105 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -178.64 134.61 0.14 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.242 -0.436 . . . . 63.21 111.091 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 71.3 p -87.8 -19.29 27.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.185 -0.462 . . . . 73.01 111.241 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.0 p -52.16 -30.33 26.27 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.213 -0.449 . . . . 74.23 111.092 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 19.9 p-10 -93.2 31.24 1.5 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.917 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -64.69 135.51 38.4 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.73 -0.748 . . . . 61.22 112.483 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.58 ' HB ' HD11 ' A' ' 44' ' ' LEU . 2.5 m -124.38 161.45 25.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.747 0.308 . . . . 73.43 111.164 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pt -107.71 145.67 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.262 -0.426 . . . . 72.12 111.133 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 22' ' ' ALA . 52.7 p -70.07 149.51 47.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.162 -0.472 . . . . 55.34 111.155 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 76.8 m-20 -87.14 -175.83 5.47 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.255 -0.43 . . . . 34.54 110.871 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -57.11 -30.69 64.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.243 -0.435 . . . . 72.12 110.869 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -99.79 22.09 11.56 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 73.22 110.882 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.32 28.31 72.1 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.765 -0.731 . . . . 75.31 112.521 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . 0.401 ' ND2' HG21 ' A' ' 6' ' ' THR . 64.7 m-20 -110.75 128.84 55.9 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.874 0.369 . . . . 71.23 110.906 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.705 ' CD2' HG21 ' A' ' 24' ' ' VAL . 1.6 p90 -116.57 167.32 11.17 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.151 -0.477 . . . . 71.21 110.827 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.646 ' C ' HD12 ' A' ' 44' ' ' LEU . 2.6 t -121.42 116.87 25.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.114 -0.494 . . . . 72.34 111.138 -179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.646 HD12 ' C ' ' A' ' 43' ' ' THR . 7.0 mp -141.15 116.75 10.24 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 72.23 110.9 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.3 m -106.81 108.16 19.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.474 . . . . 73.42 110.887 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.664 HG11 ' HG3' ' A' ' 26' ' ' GLU . 3.4 m -124.69 156.08 68.72 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.579 0.704 . . . . 71.43 111.128 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.72 -48.41 0.73 Allowed 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.693 2.262 . . . . 60.01 112.351 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 10.7 p -103.67 152.0 6.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.182 -0.463 . . . . 71.24 111.103 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -84.94 68.36 10.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.466 . . . . 63.41 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.0 t -80.57 -169.94 2.37 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 64.13 110.87 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.411 ' HB ' HG21 ' A' ' 27' ' ' THR . 0.6 OUTLIER -88.86 159.31 17.76 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.179 -0.464 . . . . 72.33 111.094 -179.904 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.436 ' CD2' HD22 ' A' ' 44' ' ' LEU . 16.0 mt -124.0 135.21 53.47 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.902 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.601 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.3 OUTLIER -105.7 129.86 53.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 74.21 110.915 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.666 HD13 HG22 ' A' ' 10' ' ' VAL . 17.6 mt -123.7 134.67 65.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.097 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 25.2 p -149.78 139.48 21.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 62.11 111.134 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.499 ' HB3' HD21 ' A' ' 74' ' ' LEU . 10.3 t80 -138.22 125.88 22.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.131 -0.486 . . . . 65.43 110.879 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 57' ' ' ILE . 3.7 tp -50.94 107.93 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.122 -0.49 . . . . 74.23 111.163 179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.89 -47.04 0.91 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.785 -0.721 . . . . 45.03 112.524 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.1 m-85 -112.47 170.89 7.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.901 0.382 . . . . 61.23 110.951 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.2 mttt -68.4 158.19 85.57 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.54 0.686 . . . . 75.3 110.935 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.67 160.3 50.26 Favored 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.696 2.264 . . . . 71.32 112.339 179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.472 HG13 ' HB ' ' A' ' 54' ' ' ILE . 13.0 p -151.26 139.76 14.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 74.11 111.188 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.601 HG22 ' HA ' ' A' ' 53' ' ' LYS . 1.4 p -132.14 134.83 45.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 60.11 111.175 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.408 HG21 HG22 ' A' ' 72' ' ' VAL . 25.0 m -144.54 151.91 15.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 74.21 111.147 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.92 155.4 27.36 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 70.32 110.874 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -90.56 120.87 32.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.207 -0.451 . . . . 72.41 111.131 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -146.34 178.64 8.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.199 -0.455 . . . . 63.13 111.137 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.43 -44.22 68.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.13 111.096 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 56.2 mt -147.31 112.14 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.211 -0.449 . . . . 72.31 111.059 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 6.7 p -129.61 128.42 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.172 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.9 m120 -95.91 137.56 34.8 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.18 -0.464 . . . . 74.11 110.892 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.466 HG21 ' CD1' ' A' ' 54' ' ' ILE . 21.2 t -124.51 148.98 28.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.167 -0.47 . . . . 61.34 111.192 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.58 125.74 40.84 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.225 -0.443 . . . . 72.02 110.873 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.499 HD21 ' HB3' ' A' ' 56' ' ' TYR . 2.4 tp -91.91 118.31 30.62 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.25 -0.432 . . . . 65.54 110.928 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -96.03 135.94 37.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 73.42 110.932 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -52.39 145.62 10.93 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.882 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -110.89 69.77 0.7 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.122 -0.49 . . . . 44.35 110.842 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.7 p -75.48 -38.5 59.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.248 -0.433 . . . . 74.43 111.126 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -82.51 60.15 5.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 74.23 110.949 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 50.0 mtp -67.89 131.25 45.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.216 -0.447 . . . . 74.23 110.866 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.3 p -171.63 133.78 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 72.15 111.111 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -74.26 153.87 39.22 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 62.52 110.879 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.39 67.68 0.72 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 64.43 110.938 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -117.61 96.1 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.134 -0.484 . . . . 53.25 111.136 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 p -54.63 145.89 4.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 62.05 111.127 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 47.6 t -66.74 130.82 32.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.184 -0.462 . . . . 73.01 111.053 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 37.2 p -101.28 140.16 35.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.475 . . . . 65.24 111.135 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -83.03 62.83 4.58 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.726 -0.749 . . . . 61.42 112.538 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -135.41 144.38 46.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.005 0.431 . . . . 75.33 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.7 p . . . . . 0 C--N 1.331 -0.239 0 CA-C-N 116.095 -0.502 . . . . 73.03 111.137 -179.975 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 32.1 mmt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.802 0.334 . . . . 72.11 110.955 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -132.86 148.92 19.45 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.766 -0.73 . . . . 33.14 112.572 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 18.3 m80 -129.39 133.08 47.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.829 0.347 . . . . 75.12 110.819 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -83.6 179.94 7.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.174 -0.466 . . . . 62.11 110.866 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 29.4 m80 -88.77 -177.46 5.53 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 72.04 110.85 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 10.2 t60 -137.01 164.81 27.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.206 -0.452 . . . . 71.31 110.835 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -104.29 151.84 22.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 74.02 110.866 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -90.16 119.99 30.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.253 -0.43 . . . . 73.02 110.876 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.2 t -126.43 171.15 11.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 51.53 111.119 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 30.5 mmtp -96.18 -176.3 3.63 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 74.23 110.905 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.84 132.79 40.68 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 42.34 112.465 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 -131.53 126.43 34.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.913 0.387 . . . . 73.41 110.861 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.58 HG12 HG13 ' A' ' 19' ' ' ILE . 30.5 t -118.08 128.9 75.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.471 . . . . 73.33 111.167 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.22 167.02 16.01 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.14 -0.482 . . . . 73.43 111.137 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.59 144.33 25.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 72.2 110.835 -179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 18.4 tttm -92.78 15.62 14.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.125 -0.488 . . . . 60.22 110.844 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -58.49 2.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 75.14 111.119 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -117.97 -26.81 6.32 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 72.52 110.85 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.23 29.13 5.26 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.701 -0.762 . . . . 53.34 112.463 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -98.34 160.12 28.95 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.58 0.705 . . . . 74.15 110.886 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.68 143.65 51.91 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.709 2.273 . . . . 61.23 112.375 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.701 HD12 HD22 ' A' ' 74' ' ' LEU . 51.3 mm -83.13 110.0 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 75.31 111.137 179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.1 mt -103.45 126.94 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.22 -0.446 . . . . 42.2 111.116 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.29 33.2 23.61 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.795 -0.717 . . . . 62.52 112.478 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.697 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -87.22 131.37 34.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.343 . . . . 63.11 111.07 179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 67.3 m -80.19 107.57 13.09 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.129 -0.487 . . . . 52.44 110.842 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.841 HG22 HG23 ' A' ' 54' ' ' ILE . 60.9 t -106.66 105.86 19.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.112 -0.495 . . . . 75.44 111.112 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 28.2 m -120.6 133.65 66.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.14 -0.482 . . . . 74.52 111.126 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -91.96 141.52 28.54 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.474 . . . . 74.12 110.915 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.9 p -55.43 -31.66 62.07 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 52.43 111.152 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.7 p -71.54 -21.38 61.91 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.215 -0.448 . . . . 64.03 111.193 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -166.52 111.49 0.79 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 63.21 111.049 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 5.1 m -85.46 -34.65 21.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 73.01 111.156 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 61.8 p -66.8 -26.44 66.95 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.255 -0.429 . . . . 74.23 111.179 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -93.51 31.22 1.57 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 74.3 110.903 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -74.99 150.26 40.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.77 -0.729 . . . . 61.22 112.473 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.473 ' HB ' HD23 ' A' ' 44' ' ' LEU . 13.6 t -117.81 168.76 10.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.738 0.304 . . . . 73.43 111.157 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.0 pt -111.68 171.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 72.12 111.139 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.59 HG22 ' HD2' ' A' ' 42' ' ' PHE . 21.8 p -99.35 150.62 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 55.34 111.155 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.33 179.93 5.77 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.242 -0.435 . . . . 34.54 110.88 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -59.33 -30.7 68.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 72.12 110.852 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -73.81 -19.48 60.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.15 -0.477 . . . . 73.22 110.899 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.92 28.08 11.56 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.739 -0.743 . . . . 75.31 112.525 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -132.43 160.21 37.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.853 0.358 . . . . 71.23 110.932 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.59 ' HD2' HG22 ' A' ' 36' ' ' THR . 16.6 p90 -138.37 166.08 25.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.881 -179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.8 t -126.0 119.15 26.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 72.34 111.178 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.596 HD13 ' N ' ' A' ' 45' ' ' SER . 0.3 OUTLIER -146.15 134.3 21.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.246 -0.434 . . . . 72.23 110.932 179.985 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.596 ' N ' HD13 ' A' ' 44' ' ' LEU . 38.5 p -106.89 122.63 46.8 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.134 -0.485 . . . . 73.42 110.889 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.44 HG13 ' HD2' ' A' ' 47' ' ' PRO . 61.5 t -129.79 133.25 24.81 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.683 0.754 . . . . 71.43 111.093 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.44 ' HD2' HG13 ' A' ' 46' ' ' VAL . 54.5 Cg_endo -69.72 -48.51 0.71 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.664 2.242 . . . . 60.01 112.345 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 31.0 m -95.27 141.96 14.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.425 . . . . 71.24 111.162 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 74.0 m-20 -79.39 59.05 2.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.177 -0.465 . . . . 63.41 110.83 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 7.4 t -80.07 -169.85 2.22 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 64.13 110.872 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 156.12 17.95 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.13 -0.486 . . . . 72.33 111.125 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.687 HD11 ' HB2' ' A' ' 66' ' ' ALA . 2.2 mp -129.05 132.22 47.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 62.04 110.903 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 22.8 tttp -106.76 123.25 47.86 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.245 -0.434 . . . . 74.21 110.909 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.841 HG23 HG22 ' A' ' 24' ' ' VAL . 34.8 mt -119.6 112.61 37.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 73.4 111.178 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 30.4 p -119.68 145.88 46.09 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.231 -0.44 . . . . 62.11 111.118 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.417 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.7 t80 -139.06 118.58 12.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 65.43 111.001 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.457 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.9 tt -51.0 107.75 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.133 -0.485 . . . . 74.23 111.103 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.86 -50.98 0.75 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.47 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -114.28 170.28 8.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.93 0.395 . . . . 61.23 110.92 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 1.4 mttt -58.22 158.2 14.7 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.573 0.701 . . . . 75.3 110.932 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.8 167.79 23.48 Favored 'Trans proline' 0 C--N 1.342 0.204 0 C-N-CA 122.627 2.218 . . . . 71.32 112.348 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.739 HG13 HG11 ' A' ' 72' ' ' VAL . 96.4 t -135.11 138.68 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.205 -0.452 . . . . 74.11 111.107 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 1.3 p -132.15 122.56 25.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.138 -0.483 . . . . 60.11 111.141 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.524 HG21 HG11 ' A' ' 70' ' ' VAL . 6.1 m -152.92 149.9 13.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 74.21 111.113 179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -81.92 157.25 24.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.88 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.687 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -61.73 130.65 46.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 72.41 111.113 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -157.52 160.71 38.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.269 -0.423 . . . . 63.13 111.108 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.67 -52.37 48.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.225 -0.443 . . . . 73.13 111.113 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 69.7 mt -129.14 111.62 23.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 72.31 111.155 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.524 HG11 HG21 ' A' ' 64' ' ' VAL . 21.8 t -113.62 112.11 38.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 74.42 111.142 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 17.3 m120 -113.66 112.34 23.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.862 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.739 HG11 HG13 ' A' ' 62' ' ' VAL . 39.4 t -129.27 148.16 33.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.122 -0.49 . . . . 61.34 111.12 179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.9 mp -105.08 144.86 31.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.491 . . . . 72.02 110.909 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.701 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.83 122.23 31.21 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.961 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.8 mm-40 -90.17 140.9 29.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 73.42 110.945 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 13.2 mt-10 -58.45 141.23 52.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.904 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -98.96 149.95 22.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.1 -0.5 . . . . 44.35 110.905 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.1 p -141.67 175.01 10.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.213 -0.449 . . . . 74.43 111.143 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 49.0 tt0 -109.0 90.29 3.25 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.884 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 4.9 ptt? -125.73 167.24 15.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 74.23 110.874 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 15.8 m -149.63 124.85 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.215 -0.448 . . . . 72.15 111.113 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.3 p30 -60.41 159.1 10.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.166 -0.47 . . . . 62.52 110.835 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.0 mm-40 -126.48 45.12 2.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.234 -0.439 . . . . 64.43 110.84 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 7.5 p -103.38 140.25 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 53.25 111.142 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.5 p -131.96 138.67 52.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.212 -0.449 . . . . 62.05 111.16 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 44.0 t -105.8 108.02 24.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.238 -0.437 . . . . 73.01 111.14 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 11.0 p -99.08 168.12 10.28 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.126 -0.488 . . . . 65.24 111.134 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -74.21 -159.85 6.68 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.708 -0.758 . . . . 61.42 112.417 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 13.9 t80 -153.29 161.47 42.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.98 0.419 . . . . 75.33 110.852 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 18.2 m . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.146 -0.479 . . . . 73.03 111.172 179.961 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 71.4 mtm . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.824 0.345 . . . . 72.11 110.956 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.82 140.73 6.48 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.794 -0.717 . . . . 33.14 112.553 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -97.3 150.95 20.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.378 . . . . 75.12 110.88 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 26.4 p80 -165.32 173.33 11.3 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.197 -0.456 . . . . 62.11 110.855 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 2.1 p-80 -130.35 164.91 23.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.248 -0.433 . . . . 72.04 110.838 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 28.0 m170 -140.5 158.21 44.34 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 71.31 110.937 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 15.4 m80 -128.07 165.69 19.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.231 -0.44 . . . . 74.02 110.89 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 11.5 p80 -132.54 110.3 10.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.268 -0.423 . . . . 73.02 110.844 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 88.3 m -123.32 143.59 49.98 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.146 -0.479 . . . . 51.53 111.177 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 18.0 tptt -66.34 91.37 0.17 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.287 -0.415 . . . . 74.23 110.899 179.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 66.5 147.72 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.767 -0.73 . . . . 42.34 112.439 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -152.69 119.94 5.89 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.887 0.375 . . . . 73.41 110.946 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.655 HG12 HG13 ' A' ' 19' ' ' ILE . 21.7 t -98.48 122.66 50.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 73.33 111.106 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -126.07 176.68 6.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.153 -0.476 . . . . 73.43 111.094 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.4 t -97.38 164.0 12.65 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 72.2 110.925 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 7.0 tmtt? -104.55 -11.11 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.138 -0.483 . . . . 60.22 110.869 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 55.8 p -77.94 -58.62 3.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.289 -0.414 . . . . 75.14 111.089 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -117.86 -26.38 6.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 72.52 110.854 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 100.99 29.39 6.47 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.734 -0.746 . . . . 53.34 112.495 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -85.05 159.4 57.13 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.531 0.681 . . . . 74.15 110.978 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 127.89 15.26 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.648 2.232 . . . . 61.23 112.377 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.756 HD12 HD22 ' A' ' 74' ' ' LEU . 50.1 mm -77.37 120.41 27.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.261 -0.427 . . . . 75.31 111.16 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.7 mt -102.98 141.5 18.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.099 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.42 33.24 86.72 Favored Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.718 -0.753 . . . . 62.52 112.521 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.698 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -82.58 122.16 27.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 63.11 111.094 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.2 m -74.17 107.5 6.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.171 -0.468 . . . . 52.44 110.837 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.668 HG13 HG12 ' A' ' 54' ' ' ILE . 24.2 t -107.37 106.07 19.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.119 -0.491 . . . . 75.44 111.128 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.669 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.7 m -124.89 138.06 55.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.197 -0.456 . . . . 74.52 111.102 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.697 ' HA ' HD23 ' A' ' 52' ' ' LEU . 55.4 tt0 -73.67 161.2 30.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.133 -0.485 . . . . 74.12 110.843 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 13.7 p -65.83 -41.82 91.33 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.176 -0.466 . . . . 52.43 111.144 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 p -105.77 -22.18 13.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.159 -0.473 . . . . 64.03 111.08 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -116.18 68.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.233 -0.44 . . . . 63.21 111.165 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' HB ' ' A' ' 25' ' ' VAL . 96.5 m -81.53 -35.65 30.1 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.09 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 3.1 p -53.36 -32.17 48.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.22 -0.446 . . . . 74.23 111.139 -179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -94.95 31.16 1.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.916 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -65.95 138.95 37.79 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.811 -0.709 . . . . 61.22 112.517 179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.6 t -117.22 168.72 10.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.789 0.328 . . . . 73.43 111.155 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 2.4 pp -115.47 168.56 7.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.231 -0.441 . . . . 72.12 111.093 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.605 HG22 ' HD2' ' A' ' 42' ' ' PHE . 70.3 p -101.29 150.76 22.66 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.168 -0.469 . . . . 55.34 111.129 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t0 -90.88 -176.08 4.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.172 -0.467 . . . . 34.54 110.849 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -59.38 -30.73 68.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 72.12 110.854 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -73.87 -19.5 60.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.193 -0.458 . . . . 73.22 110.897 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.75 28.1 15.07 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.692 -0.766 . . . . 75.31 112.473 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -128.22 157.78 39.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.811 0.338 . . . . 71.23 110.906 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.605 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.5 p90 -143.67 167.45 22.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.241 -0.436 . . . . 71.21 110.874 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.0 t -123.05 121.69 36.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.152 -0.477 . . . . 72.34 111.188 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.585 HD22 HG23 ' A' ' 46' ' ' VAL . 2.0 tt -144.01 125.68 15.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.96 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.502 ' N ' HD23 ' A' ' 44' ' ' LEU . 45.0 t -101.72 114.92 29.41 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.262 -0.426 . . . . 73.42 110.842 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.585 HG23 HD22 ' A' ' 44' ' ' LEU . 58.3 t -120.6 133.29 24.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.579 0.704 . . . . 71.43 111.165 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.43 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -47.92 0.82 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.666 2.244 . . . . 60.01 112.343 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 35.6 m -96.9 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.157 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -111.64 62.38 0.62 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 63.41 110.891 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.6 t -86.88 -172.63 4.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 64.13 110.867 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.24 158.22 17.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.112 -0.495 . . . . 72.33 111.128 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.697 HD23 ' HA ' ' A' ' 26' ' ' GLU . 25.8 mt -128.32 143.13 50.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.219 -0.446 . . . . 62.04 110.947 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 7.1 ttpt -116.48 127.74 54.84 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 74.21 110.975 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.668 HG12 HG13 ' A' ' 24' ' ' VAL . 79.6 mt -120.01 137.97 52.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.258 -0.428 . . . . 73.4 111.055 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 39.0 p -148.28 138.59 22.69 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.219 -0.446 . . . . 62.11 111.183 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.75 ' HB3' HD21 ' A' ' 74' ' ' LEU . 15.6 t80 -136.01 126.85 27.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.233 -0.44 . . . . 65.43 110.903 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.434 HG23 ' O ' ' A' ' 57' ' ' ILE . 13.3 tt -51.17 118.59 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.101 -0.5 . . . . 74.23 111.139 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.16 -51.27 0.85 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.857 -0.687 . . . . 45.03 112.536 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -108.1 170.21 8.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.98 0.419 . . . . 61.23 110.917 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 6.4 mmtm -68.9 158.19 86.86 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.567 0.698 . . . . 75.3 110.933 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 165.82 29.68 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.729 2.286 . . . . 71.32 112.377 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.565 HG11 ' CG1' ' A' ' 72' ' ' VAL . 11.1 p -151.66 147.94 14.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 74.11 111.083 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 40.9 p -132.1 139.83 48.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.479 . . . . 60.11 111.148 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 31.1 m -150.83 171.57 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 74.21 111.076 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.06 157.21 18.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 70.32 110.868 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -86.08 134.08 33.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 72.41 111.099 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.65 179.87 6.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.213 -0.449 . . . . 63.13 111.124 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.497 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -54.34 -57.88 9.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.201 -0.454 . . . . 73.13 111.096 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.497 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -132.13 111.69 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.446 . . . . 72.31 111.104 179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.82 125.27 68.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.125 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -95.86 136.76 35.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.878 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.565 ' CG1' HG11 ' A' ' 62' ' ' VAL . 21.7 t -120.96 149.48 23.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 61.34 111.109 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 10.3 mt -125.45 124.15 40.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.885 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.756 HD22 HD12 ' A' ' 19' ' ' ILE . 1.4 tp -87.84 122.47 31.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.169 -0.469 . . . . 65.54 110.891 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -90.22 137.03 32.68 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.182 -0.463 . . . . 73.42 110.927 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.4 pt-20 -55.23 142.91 29.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.214 -0.448 . . . . 75.12 110.813 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -111.55 43.01 1.59 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.087 -0.506 . . . . 44.35 110.845 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 41.4 p -101.59 45.74 0.96 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 74.43 111.081 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -143.09 134.65 26.38 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.246 -0.434 . . . . 74.23 110.882 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 6.3 ttm -81.18 128.47 33.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.884 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.5 p -166.59 131.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.253 -0.43 . . . . 72.15 111.057 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.02 134.54 56.31 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.142 -0.481 . . . . 62.52 110.968 179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -129.14 74.98 1.62 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.172 -0.467 . . . . 64.43 110.891 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 6.0 m -59.01 144.03 12.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 53.25 111.11 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 59.9 t -99.2 126.99 52.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.17 -0.468 . . . . 62.05 111.221 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.7 p -109.61 141.37 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 73.01 111.135 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.3 t -104.45 167.71 9.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.238 -0.437 . . . . 65.24 111.129 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 176.43 -65.54 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.803 -0.713 . . . . 61.42 112.566 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 32.8 t80 -115.83 143.74 44.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.927 0.394 . . . . 75.33 110.91 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 2.5 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.08 -0.509 . . . . 73.03 111.132 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 28.2 ttm . . . . . 0 C--O 1.23 0.057 0 CA-C-O 120.855 0.359 . . . . 72.11 110.813 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 165.79 136.49 2.02 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.718 -0.753 . . . . 33.14 112.455 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 47.9 p-80 -156.18 152.6 28.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.825 0.345 . . . . 75.12 110.86 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 79.7 m-70 -89.84 120.31 30.97 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.23 -0.441 . . . . 62.11 110.868 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 81.6 t60 -127.47 124.37 38.22 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 72.04 110.874 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 58.4 55.01 5.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 71.31 110.907 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -169.16 133.22 1.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.188 -0.46 . . . . 74.02 110.92 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.561 ' HB3' HD13 ' A' ' 69' ' ' ILE . 6.5 t60 -169.71 174.95 5.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.209 -0.45 . . . . 73.02 110.869 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.5 t -68.81 173.84 4.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.226 -0.443 . . . . 51.53 111.195 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.3 mmpt? -60.35 -171.64 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.23 -0.441 . . . . 74.23 110.921 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -51.89 134.71 35.48 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.752 -0.737 . . . . 42.34 112.519 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -127.73 119.95 26.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.891 0.377 . . . . 73.41 110.931 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.591 HG12 HG13 ' A' ' 19' ' ' ILE . 45.0 t -105.15 126.46 60.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.153 -0.476 . . . . 73.33 111.069 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.499 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.0 OUTLIER -124.38 -178.7 4.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 73.43 111.094 179.988 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -94.74 163.72 13.24 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.184 -0.462 . . . . 72.2 110.881 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -103.64 -12.33 17.11 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.135 -0.484 . . . . 60.22 110.928 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -75.97 -58.72 3.11 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.197 -0.456 . . . . 75.14 111.17 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 30.7 t0 -119.44 -26.57 5.77 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.269 -0.423 . . . . 72.52 110.821 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.06 29.55 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.79 -0.719 . . . . 53.34 112.506 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.499 ' C ' HG22 ' A' ' 11' ' ' THR . 4.9 pt20 -83.15 154.85 67.14 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.593 0.711 . . . . 74.15 110.934 -179.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 128.71 16.43 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.737 2.291 . . . . 61.23 112.314 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.721 HD12 HD22 ' A' ' 74' ' ' LEU . 34.1 mm -75.03 101.7 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.31 111.128 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.2 mt -99.05 138.07 24.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 42.2 111.122 179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 77.18 33.6 44.25 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 62.52 112.467 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.559 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -89.45 135.04 33.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 63.11 111.109 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 6.2 m -80.59 107.55 13.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.28 -0.418 . . . . 52.44 110.86 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.724 HG22 HG12 ' A' ' 54' ' ' ILE . 48.7 t -104.07 122.49 56.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 75.44 111.122 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.667 ' HB ' HG23 ' A' ' 30' ' ' THR . 17.0 m -142.08 136.74 29.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 74.52 111.125 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 42.7 tt0 -73.58 159.95 32.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 74.12 110.86 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 29.9 p -62.21 -41.98 98.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.43 111.164 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.0 p -108.22 -22.08 12.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.164 -0.471 . . . . 64.03 111.099 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.81 68.67 0.68 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.247 -0.433 . . . . 63.21 111.156 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' HB ' ' A' ' 25' ' ' VAL . 92.9 m -82.82 -35.37 26.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.466 . . . . 73.01 111.138 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.5 p -53.38 -31.18 43.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 74.23 111.06 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.468 ' O ' HD11 ' A' ' 44' ' ' LEU . 1.8 m-20 -94.9 31.16 1.9 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.292 -0.413 . . . . 74.3 110.904 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -64.07 141.23 44.6 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.723 -0.751 . . . . 61.22 112.556 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 14.5 t -123.64 168.89 12.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.766 0.317 . . . . 73.43 111.171 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 6.5 pt -107.63 156.76 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 72.12 111.141 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.593 HG22 ' HD2' ' A' ' 42' ' ' PHE . 33.1 p -81.65 150.63 27.97 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.113 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 -82.39 173.34 12.12 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.837 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -59.46 -30.71 68.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.149 -0.478 . . . . 72.12 110.871 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -74.0 -19.38 60.67 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.102 -0.499 . . . . 73.22 110.886 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 94.97 28.15 10.32 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.463 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -128.92 152.68 48.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.93 0.395 . . . . 71.23 110.873 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.593 ' HD2' HG22 ' A' ' 36' ' ' THR . 54.4 p90 -147.63 164.52 33.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.146 -0.479 . . . . 71.21 110.917 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -150.41 117.27 5.88 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 72.34 111.144 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.468 HD11 ' O ' ' A' ' 32' ' ' ASN . 1.5 tt -115.93 109.77 18.05 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 72.23 110.947 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 89.7 p -68.9 108.41 3.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.454 . . . . 73.42 110.856 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.433 HG23 ' HD2' ' A' ' 47' ' ' PRO . 7.3 p -130.78 133.21 24.54 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.577 0.703 . . . . 71.43 111.138 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.433 ' HD2' HG23 ' A' ' 46' ' ' VAL . 53.7 Cg_endo -69.78 -43.26 2.74 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.66 2.24 . . . . 60.01 112.381 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 29.6 m -77.91 150.06 5.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 71.24 111.176 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -100.35 72.25 1.6 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 63.41 110.884 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.8 t -105.8 -170.95 1.82 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.16 -0.473 . . . . 64.13 110.827 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.13 155.35 17.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 72.33 111.167 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.618 HD12 HG23 ' A' ' 64' ' ' VAL . 10.4 mt -111.25 146.95 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.243 -0.435 . . . . 62.04 110.902 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.7 tttt -130.31 121.94 27.01 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.198 -0.455 . . . . 74.21 110.894 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.724 HG12 HG22 ' A' ' 24' ' ' VAL . 5.3 mp -119.27 144.01 28.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 73.4 111.144 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 37.7 p -138.36 138.67 38.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.21 -0.45 . . . . 62.11 111.165 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.459 ' HB3' HD21 ' A' ' 74' ' ' LEU . 7.4 t80 -131.83 115.21 15.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.282 -0.417 . . . . 65.43 110.977 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.445 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.3 tp -51.15 116.46 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 74.23 111.095 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 129.37 -53.42 0.81 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.725 -0.75 . . . . 45.03 112.475 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -110.47 170.53 8.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.925 0.393 . . . . 61.23 110.953 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 46.0 mttt -60.77 157.86 36.26 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.564 0.697 . . . . 75.3 110.874 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 172.81 12.02 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.661 2.241 . . . . 71.32 112.336 179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.69 HG23 HG11 ' A' ' 72' ' ' VAL . 7.4 p -151.38 146.3 15.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 74.11 111.128 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 19.7 p -131.93 143.51 50.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.19 -0.459 . . . . 60.11 111.172 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.618 HG23 HD12 ' A' ' 52' ' ' LEU . 35.0 m -142.22 130.22 20.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.083 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 11.2 pttt -72.82 156.75 38.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 70.32 110.916 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.84 95.89 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.285 -0.416 . . . . 72.41 111.132 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -134.11 -173.22 3.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.45 . . . . 63.13 111.094 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -88.04 -44.52 10.91 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.219 -0.446 . . . . 73.13 111.076 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.561 HD13 ' HB3' ' A' ' 5' ' ' HIS . 63.4 mt -138.09 126.17 30.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.211 -0.45 . . . . 72.31 111.112 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 64' ' ' VAL . 7.2 p -139.71 126.93 24.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.187 -0.461 . . . . 74.42 111.159 179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -119.92 125.53 48.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.226 -0.443 . . . . 74.11 110.902 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.69 HG11 HG23 ' A' ' 62' ' ' VAL . 20.2 t -137.15 149.07 25.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.449 . . . . 61.34 111.11 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 1.1 mp -105.02 143.54 33.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.139 -0.482 . . . . 72.02 110.907 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.721 HD22 HD12 ' A' ' 19' ' ' ILE . 2.1 tp -87.56 118.58 27.13 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 65.54 110.956 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -90.64 147.81 23.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.42 110.859 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -59.47 143.41 50.05 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.188 -0.46 . . . . 75.12 110.837 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -106.88 84.69 2.03 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.082 -0.508 . . . . 44.35 110.827 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.7 t -138.44 154.72 48.87 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 74.43 111.172 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 39.0 tp60 -66.5 115.45 6.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.251 -0.431 . . . . 74.23 110.953 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 21.7 mmt -57.44 170.47 0.53 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 74.23 110.842 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.2 m -128.32 111.22 23.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 72.15 111.099 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 4.1 t0 -126.82 36.05 4.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.186 -0.461 . . . . 62.52 110.83 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.2 mm-40 -85.88 90.88 8.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 64.43 110.827 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.56 113.45 29.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 53.25 111.204 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 46.3 t -134.19 145.41 33.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.224 -0.444 . . . . 62.05 111.119 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 27.5 m -74.3 151.84 7.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.191 -0.459 . . . . 73.01 111.174 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 5.2 t -161.8 159.51 27.13 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 65.24 111.177 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -108.96 147.88 16.82 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.685 -0.769 . . . . 61.42 112.427 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 15.6 t80 -100.54 142.5 31.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.901 0.381 . . . . 75.33 110.879 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 14.0 m . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.094 -0.503 . . . . 73.03 111.138 179.982 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.812 0.339 . . . . 72.11 110.908 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -142.51 -52.27 0.04 OUTLIER Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.739 -0.743 . . . . 33.14 112.468 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -151.16 137.43 18.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.809 0.338 . . . . 75.12 110.854 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -86.96 130.17 34.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 62.11 110.932 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 14.9 t60 54.83 60.32 3.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 72.04 110.799 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 5.1 t-80 -139.65 133.45 30.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.178 -0.465 . . . . 71.31 110.886 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 24.1 p-80 -108.18 162.78 13.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 74.02 110.889 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -134.75 163.06 30.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.232 -0.44 . . . . 73.02 110.913 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 15.1 t -138.58 162.1 35.42 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.234 -0.439 . . . . 51.53 111.146 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.2 pttm -128.62 127.43 42.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.179 -0.464 . . . . 74.23 110.876 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 69.9 119.9 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.748 -0.739 . . . . 42.34 112.479 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -146.11 129.72 17.0 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.891 0.376 . . . . 73.41 110.826 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.633 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 95.3 t -123.02 133.37 69.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.188 -0.46 . . . . 73.33 111.091 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 18' ' ' PRO . 17.6 p -130.03 172.55 11.62 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 73.43 111.141 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -89.16 153.2 21.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.205 -0.452 . . . . 72.2 110.828 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.436 ' HG3' HD22 ' A' ' 73' ' ' LEU . 17.1 tttm -92.55 16.24 12.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 60.22 110.904 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -94.02 -58.86 2.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.186 -0.461 . . . . 75.14 111.112 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -119.05 -26.66 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.178 -0.464 . . . . 72.52 110.847 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.45 29.25 5.14 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.714 -0.755 . . . . 53.34 112.525 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 23.0 mt-30 -97.87 159.78 30.07 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.594 0.711 . . . . 74.15 110.917 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.617 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.64 146.61 61.42 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.724 2.282 . . . . 61.23 112.39 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.507 HG21 ' CD2' ' A' ' 56' ' ' TYR . 28.4 mm -96.68 117.43 41.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.244 -0.435 . . . . 75.31 111.074 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 29.9 mt -101.6 150.13 6.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.176 -0.465 . . . . 42.2 111.045 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.21 47.19 83.43 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.733 -0.746 . . . . 62.52 112.404 179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.435 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 159.32 15.08 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.862 0.363 . . . . 63.11 111.044 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 2.2 m -105.92 107.25 18.15 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 52.44 110.837 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.773 HG22 HG23 ' A' ' 54' ' ' ILE . 12.3 t -112.66 129.82 67.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 75.44 111.113 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.0 m -145.98 146.31 19.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 74.52 111.17 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -80.75 174.33 11.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 74.12 110.888 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.562 HG23 ' O ' ' A' ' 51' ' ' THR . 43.5 p -68.95 -42.12 77.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 52.43 111.16 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 15.5 p -112.49 -22.22 10.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.146 -0.479 . . . . 64.03 111.159 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -104.89 76.44 1.26 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.241 -0.436 . . . . 63.21 111.112 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 p -86.53 -36.26 19.06 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.229 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.1 p -58.42 -28.44 65.23 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.115 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -94.45 31.42 1.75 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.229 -0.441 . . . . 74.3 110.857 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -60.51 143.11 47.99 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.766 -0.731 . . . . 61.22 112.533 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 3.7 m -117.87 160.55 21.22 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.725 0.298 . . . . 73.43 111.156 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.435 HG22 ' O ' ' A' ' 22' ' ' ALA . 8.1 pt -116.41 149.31 18.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.088 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.576 HG22 ' HD2' ' A' ' 42' ' ' PHE . 15.9 p -69.87 150.64 46.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.148 -0.478 . . . . 55.34 111.202 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 40.8 m-20 -84.15 -175.62 5.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.241 -0.436 . . . . 34.54 110.905 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -58.68 -30.65 67.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.228 -0.442 . . . . 72.12 110.882 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -99.4 21.99 11.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.457 . . . . 73.22 110.884 179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.4 28.18 71.95 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.669 -0.777 . . . . 75.31 112.533 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 40.7 m-20 -110.44 131.34 55.14 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.835 0.35 . . . . 71.23 110.879 -179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.576 ' HD2' HG22 ' A' ' 36' ' ' THR . 20.2 p90 -127.69 167.7 16.08 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 71.21 110.949 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 43' ' ' THR . 4.7 t -137.44 118.99 14.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 72.34 111.083 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.483 HD13 HD21 ' A' ' 52' ' ' LEU . 0.7 OUTLIER -148.25 107.18 3.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 72.23 110.898 179.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.6 t -107.03 122.22 46.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.166 -0.47 . . . . 73.42 110.861 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -119.66 155.96 54.13 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.637 0.732 . . . . 71.43 111.048 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 -48.39 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.644 2.229 . . . . 60.01 112.335 179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.61 149.93 4.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.191 -0.459 . . . . 71.24 111.139 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 21.9 m120 -96.04 67.69 2.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.213 -0.449 . . . . 63.41 110.887 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.2 t -100.55 -169.29 1.7 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 64.13 110.89 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.562 ' O ' HG23 ' A' ' 27' ' ' THR . 0.2 OUTLIER -87.45 163.06 16.93 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.46 . . . . 72.33 111.148 -179.918 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.606 ' CD1' ' HB2' ' A' ' 66' ' ' ALA . 0.2 OUTLIER -129.92 131.75 46.11 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.253 -0.431 . . . . 62.04 110.91 179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 5.3 ttpt -101.0 126.2 47.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.901 179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.773 HG23 HG22 ' A' ' 24' ' ' VAL . 2.5 mp -123.64 123.28 66.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 73.4 111.115 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 63.8 p -119.31 146.38 45.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.192 -0.458 . . . . 62.11 111.098 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.792 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.5 m-85 -129.14 154.62 46.55 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.185 -0.461 . . . . 65.43 110.947 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 57' ' ' ILE . 4.7 tp -91.31 108.39 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.112 -0.495 . . . . 74.23 111.133 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.95 -51.28 0.82 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.734 -0.746 . . . . 45.03 112.453 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.4 m-85 -106.17 170.87 7.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.919 0.39 . . . . 61.23 110.958 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 5.5 mttm -67.31 146.67 98.88 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.598 0.713 . . . . 75.3 110.909 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 175.93 7.43 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.699 2.266 . . . . 71.32 112.317 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.547 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.1 m -149.82 142.76 17.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 74.11 111.155 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 13.9 p -122.17 131.98 54.23 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 60.11 111.158 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.2 m -152.91 156.51 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 74.21 111.202 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.79 154.27 27.28 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 70.32 110.893 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.606 ' HB2' ' CD1' ' A' ' 52' ' ' LEU . . . -63.95 107.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 72.41 111.066 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -130.83 159.3 37.77 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 63.13 111.107 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.64 -55.74 23.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 73.13 111.118 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 64.4 mt -126.01 131.49 71.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 72.31 111.092 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 23.7 t -143.06 123.53 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.455 . . . . 74.42 111.148 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.3 m120 -119.86 109.43 15.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 74.11 110.848 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 26.6 t -125.18 148.87 29.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.175 -0.466 . . . . 61.34 111.169 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.436 HD22 ' HG3' ' A' ' 13' ' ' LYS . 4.6 mp -103.72 144.44 31.47 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 72.02 110.938 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.792 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.6 tp -88.87 118.49 28.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.143 -0.481 . . . . 65.54 110.9 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -99.03 129.55 45.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.163 -0.472 . . . . 73.42 110.896 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -48.19 147.56 2.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.836 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 63.7 t0 -111.71 119.82 39.94 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.48 . . . . 44.35 110.849 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 17.7 p -106.92 139.49 41.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.178 -0.465 . . . . 74.43 111.146 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -70.22 152.22 44.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.204 -0.453 . . . . 74.23 110.916 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 2.1 tpp -123.95 106.88 10.78 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 74.23 110.901 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.8 t -106.79 56.46 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.226 -0.443 . . . . 72.15 111.067 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 42.1 m-20 -103.0 123.2 46.14 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 62.52 110.869 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 -132.79 76.07 1.66 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.155 -0.475 . . . . 64.43 110.856 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 11.1 p -146.19 150.79 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 53.25 111.099 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.9 p -64.63 139.5 21.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 62.05 111.089 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 6.4 m -127.42 43.74 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.201 -0.454 . . . . 73.01 111.135 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 3.5 t -162.54 139.74 8.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 65.24 111.147 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -111.11 175.41 17.73 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.729 -0.748 . . . . 61.42 112.492 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 63.7 t80 -126.23 151.89 46.81 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.932 0.396 . . . . 75.33 110.936 -179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 73.9 p . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 73.03 111.157 -180.0 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 6.6 mmt . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.788 0.327 . . . . 72.11 110.884 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 162.22 -147.74 14.19 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.739 -0.743 . . . . 33.14 112.473 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 4.1 t-160 -117.8 109.83 17.05 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.887 0.375 . . . . 75.12 110.878 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 15.5 p80 -108.74 36.49 2.83 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.151 -0.477 . . . . 62.11 110.901 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 16.2 t60 -91.35 71.62 6.1 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 72.04 110.881 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 35.1 t60 -106.59 83.58 1.88 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.256 -0.429 . . . . 71.31 110.83 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 26.6 t60 -169.21 111.78 0.51 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.246 -0.434 . . . . 74.02 110.931 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -124.28 147.42 48.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.246 -0.433 . . . . 73.02 110.864 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.6 m -59.43 137.04 58.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 51.53 111.152 -179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 36.7 mttt -75.29 101.61 4.76 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.222 -0.444 . . . . 74.23 110.935 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 85.98 115.38 0.87 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.752 -0.737 . . . . 42.34 112.531 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -157.96 119.82 3.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.895 0.378 . . . . 73.41 110.852 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.663 HG11 ' OH ' ' A' ' 56' ' ' TYR . 43.3 t -111.29 137.2 44.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.106 -0.497 . . . . 73.33 111.197 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.642 HG22 ' HA ' ' A' ' 18' ' ' PRO . 11.3 p -132.07 179.08 6.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.452 . . . . 73.43 111.109 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.608 ' HB2' HD11 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -100.24 153.09 19.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.142 -0.481 . . . . 72.2 110.823 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 16.3 tttm -92.71 17.98 9.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.08 -0.509 . . . . 60.22 110.917 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.608 HG21 ' OH ' ' A' ' 59' ' ' TYR . 34.8 p -94.2 -58.68 2.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.271 -0.422 . . . . 75.14 111.217 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -120.15 -26.83 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.282 -0.417 . . . . 72.52 110.85 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.24 29.19 5.23 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.492 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 14.6 mt-30 -99.05 160.26 28.12 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.621 0.724 . . . . 74.15 110.911 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.642 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.9 Cg_endo -69.62 143.33 51.13 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.743 2.295 . . . . 61.23 112.393 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.608 HD11 ' HB2' ' A' ' 12' ' ' SER . 51.6 mm -92.79 116.45 33.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.276 -0.42 . . . . 75.31 111.094 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 31.3 mt -98.42 150.18 4.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 42.2 111.107 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.05 48.25 72.97 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.709 -0.758 . . . . 62.52 112.449 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.04 158.27 15.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.799 0.333 . . . . 63.11 111.058 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.09 107.41 18.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.209 -0.45 . . . . 52.44 110.904 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.526 HG22 HG23 ' A' ' 54' ' ' ILE . 20.6 t -112.65 108.44 25.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.141 -0.482 . . . . 75.44 111.105 180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.718 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.2 m -127.88 139.97 50.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 74.52 111.121 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.567 ' OE1' HD11 ' A' ' 44' ' ' LEU . 2.3 mp0 -91.2 167.36 12.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.168 -0.469 . . . . 74.12 110.91 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 53.5 p -82.11 -33.75 29.59 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.162 -0.472 . . . . 52.43 111.13 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.552 HG23 ' OG ' ' A' ' 50' ' ' SER . 20.2 p -79.42 -22.17 44.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.197 -0.456 . . . . 64.03 111.164 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.45 103.34 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 63.21 111.111 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.718 HG23 ' HB ' ' A' ' 25' ' ' VAL . 99.1 m -86.93 -35.44 18.92 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.194 -0.457 . . . . 73.01 111.155 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 68.2 p -53.99 -26.9 28.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.084 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 53.3 t30 -93.41 31.42 1.52 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.207 -0.451 . . . . 74.3 110.849 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -67.29 142.16 40.52 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.772 -0.728 . . . . 61.22 112.421 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 2.7 m -113.97 161.61 17.45 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.782 0.325 . . . . 73.43 111.108 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 14.6 pt -117.33 148.31 20.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.189 -0.459 . . . . 72.12 111.156 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.581 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.1 p -71.33 150.69 44.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 55.34 111.108 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -86.59 -170.17 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.178 -0.464 . . . . 34.54 110.887 179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -60.93 -30.65 70.34 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.152 -0.477 . . . . 72.12 110.974 -179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -94.67 17.88 12.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.132 -0.485 . . . . 73.22 110.865 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.22 28.11 71.69 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.712 -0.756 . . . . 75.31 112.505 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -113.98 136.69 52.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.875 0.369 . . . . 71.23 110.873 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.581 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.8 p90 -129.98 167.87 17.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.246 -0.434 . . . . 71.21 110.925 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.1 t -123.36 117.44 25.23 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.149 -0.478 . . . . 72.34 111.166 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.567 HD11 ' OE1' ' A' ' 26' ' ' GLU . 0.5 OUTLIER -143.62 124.44 14.24 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.236 -0.438 . . . . 72.23 110.915 179.952 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.8 t -106.98 108.07 19.41 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.848 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 44' ' ' LEU . 19.1 m -139.95 152.57 68.09 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.65 0.738 . . . . 71.43 111.113 179.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.69 170.61 16.09 Favored 'Trans proline' 0 C--O 1.232 0.189 0 C-N-CA 122.705 2.27 . . . . 60.01 112.348 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.9 m -93.18 53.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.267 -0.424 . . . . 71.24 111.15 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 7.8 t30 -154.79 35.38 0.4 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 63.41 110.947 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.552 ' OG ' HG23 ' A' ' 28' ' ' THR . 7.7 t -155.53 163.52 39.89 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.174 -0.466 . . . . 64.13 110.826 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -98.73 164.06 12.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 72.33 111.102 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . . . . . . . . . 84.9 mt -130.45 117.19 19.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.161 -0.472 . . . . 62.04 110.937 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.544 ' HA ' HG22 ' A' ' 63' ' ' THR . 37.3 tttt -102.27 123.55 46.29 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.233 -0.439 . . . . 74.21 110.868 179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.526 HG23 HG22 ' A' ' 24' ' ' VAL . 3.3 mp -123.59 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.211 -0.45 . . . . 73.4 111.16 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.2 p -117.73 144.52 45.21 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 62.11 111.18 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.817 ' CD1' HD11 ' A' ' 74' ' ' LEU . 20.6 m-85 -126.5 155.03 42.96 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.435 . . . . 65.43 110.994 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.0 tt -92.36 107.86 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.114 179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.84 -50.96 0.82 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.791 -0.719 . . . . 45.03 112.494 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.608 ' OH ' HG21 ' A' ' 14' ' ' THR . 10.8 m-85 -105.58 170.43 7.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.999 0.428 . . . . 61.23 110.889 -179.79 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -67.57 144.57 97.79 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.61 0.719 . . . . 75.3 110.87 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.85 176.99 6.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.605 2.203 . . . . 71.32 112.299 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.584 HG22 ' HE1' ' A' ' 56' ' ' TYR . 15.3 m -149.24 145.49 17.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 74.11 111.148 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.544 HG22 ' HA ' ' A' ' 53' ' ' LYS . 4.9 p -129.12 138.37 51.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 60.11 111.101 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 70' ' ' VAL . 17.5 m -150.51 167.79 2.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.206 -0.452 . . . . 74.21 111.115 179.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 20.8 ptmt -89.53 155.98 18.93 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.876 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -51.6 128.87 24.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.18 -0.464 . . . . 72.41 111.064 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -161.35 142.8 11.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 63.13 111.13 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -53.04 -49.32 66.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.085 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 63.3 mt -120.76 119.49 59.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.253 -0.43 . . . . 72.31 111.199 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.786 HG21 HG21 ' A' ' 64' ' ' VAL . 6.7 p -129.52 122.64 55.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.42 111.123 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 25.4 m120 -119.86 113.62 20.85 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 74.11 110.892 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 20.8 t -127.71 148.94 32.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.171 -0.468 . . . . 61.34 111.112 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 11.6 mt -106.44 145.29 31.95 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 72.02 110.932 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.817 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -87.57 123.06 32.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.167 -0.469 . . . . 65.54 110.903 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -102.06 133.3 47.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.218 -0.446 . . . . 73.42 110.882 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -51.91 139.54 21.98 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.195 -0.457 . . . . 75.12 110.927 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 -95.49 135.95 36.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.879 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -128.12 -41.17 1.62 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 74.43 111.092 -179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 17.8 tm0? -53.92 122.55 10.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 74.23 110.942 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 7.6 ttm -124.71 169.74 11.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.901 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 m -147.55 -170.75 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 72.15 111.084 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -70.19 177.03 3.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.148 -0.478 . . . . 62.52 110.881 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 58.31 45.95 16.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 64.43 110.856 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 58.5 t -68.08 114.59 5.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.152 -0.476 . . . . 53.25 111.089 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 71.2 t -52.69 -63.14 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.137 -0.483 . . . . 62.05 111.131 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 36.0 t -99.13 112.43 31.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 73.01 111.105 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.65 151.71 26.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.2 -0.455 . . . . 65.24 111.177 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -155.26 -97.03 0.13 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.736 -0.745 . . . . 61.42 112.519 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 17.9 t80 -121.76 158.06 29.64 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.931 0.396 . . . . 75.33 110.983 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.5 m . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 73.03 111.211 179.957 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.8 tpp . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.803 0.335 . . . . 72.11 110.852 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 130.94 159.4 9.58 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 33.14 112.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 20.6 t60 -167.9 157.96 10.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.8 0.333 . . . . 75.12 110.858 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -153.02 176.36 11.96 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 62.11 110.896 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 15.7 p80 -138.08 158.75 43.7 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.319 -0.4 . . . . 72.04 110.902 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -129.26 52.13 1.99 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 71.31 110.86 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 70.6 m-70 -104.73 155.81 18.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.256 -0.429 . . . . 74.02 110.856 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 31.1 p-80 -122.6 114.42 20.6 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.23 -0.441 . . . . 73.02 110.893 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -115.19 171.5 7.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.241 -0.436 . . . . 51.53 111.101 -179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 11.2 mttm -116.0 -171.91 2.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.861 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.1 126.07 29.26 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.767 -0.73 . . . . 42.34 112.528 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -130.37 130.66 44.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.343 . . . . 73.41 110.877 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.62 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.6 t -123.51 131.13 73.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.207 -0.451 . . . . 73.33 111.14 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.9 p -127.44 178.17 6.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.152 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.3 t -95.43 149.27 21.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.451 . . . . 72.2 110.828 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.405 ' HG3' HD13 ' A' ' 73' ' ' LEU . 33.8 tttm -90.05 12.26 18.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 60.22 110.909 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.443 HG21 ' OH ' ' A' ' 59' ' ' TYR . 41.4 p -93.61 -59.6 1.96 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.433 . . . . 75.14 111.182 179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -118.69 -27.08 5.95 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.218 -0.446 . . . . 72.52 110.874 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 104.39 29.31 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.766 -0.73 . . . . 53.34 112.513 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 36.9 mt-30 -93.55 160.53 32.75 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.645 0.736 . . . . 74.15 110.918 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 138.21 37.18 Favored 'Trans proline' 0 C--O 1.233 0.23 0 C-N-CA 122.606 2.204 . . . . 61.23 112.375 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 48.9 mm -85.64 120.07 35.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.259 -0.428 . . . . 75.31 111.105 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 24.5 mt -105.93 140.97 22.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.161 -0.472 . . . . 42.2 111.101 179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.41 50.41 21.25 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 62.52 112.452 179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.545 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.06 159.0 15.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.771 0.32 . . . . 63.11 111.109 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 66.3 m -105.87 107.47 18.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 52.44 110.839 -179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.635 HG22 HG23 ' A' ' 54' ' ' ILE . 17.4 t -111.5 128.49 67.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.147 179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.681 ' HB ' HG23 ' A' ' 30' ' ' THR . 15.7 m -148.05 139.6 17.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.206 -0.452 . . . . 74.52 111.092 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.495 ' CD ' ' HB3' ' A' ' 29' ' ' ALA . 33.8 mt-10 -72.23 174.23 7.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 74.12 110.861 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -78.14 -35.21 49.24 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 52.43 111.146 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.5 p -112.4 -22.18 10.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.238 -0.437 . . . . 64.03 111.191 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.495 ' HB3' ' CD ' ' A' ' 26' ' ' GLU . . . -118.75 78.83 1.31 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.244 -0.435 . . . . 63.21 111.102 179.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.681 HG23 ' HB ' ' A' ' 25' ' ' VAL . 97.5 m -83.83 -39.21 20.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.01 111.11 -179.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 p -53.59 -29.45 37.59 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 74.23 111.142 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -94.61 31.14 1.84 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.924 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -68.14 164.67 46.95 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.768 -0.729 . . . . 61.22 112.479 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.4 t -135.24 168.86 18.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.714 0.292 . . . . 73.43 111.178 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.545 HG22 ' O ' ' A' ' 22' ' ' ALA . 13.9 pt -121.59 151.35 24.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.19 -0.459 . . . . 72.12 111.104 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.547 HG22 ' HD2' ' A' ' 42' ' ' PHE . 22.8 p -74.27 150.66 40.12 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.13 -0.487 . . . . 55.34 111.151 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -94.39 -178.1 4.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 34.54 110.885 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -56.92 -30.32 63.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.215 -0.448 . . . . 72.12 110.94 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -73.2 -18.72 61.22 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.084 -0.507 . . . . 73.22 110.853 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.43 28.19 20.38 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.708 -0.758 . . . . 75.31 112.471 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 23.7 p30 -133.93 163.53 29.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.858 0.361 . . . . 71.23 110.906 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.547 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.4 p90 -144.86 167.76 21.84 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 71.21 110.887 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.0 t -135.72 122.84 21.55 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.122 -0.49 . . . . 72.34 111.105 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -138.01 118.68 14.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.893 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 38.5 t -93.08 115.31 27.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.817 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.66 155.98 44.22 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.646 0.736 . . . . 71.43 111.144 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 -48.46 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.724 2.283 . . . . 60.01 112.337 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 33.4 m -111.97 -176.59 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.255 -0.43 . . . . 71.24 111.104 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -106.04 64.99 0.68 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.141 -0.482 . . . . 63.41 110.885 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.9 t -92.52 -169.83 2.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.14 -0.482 . . . . 64.13 110.86 -179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.73 162.59 16.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 72.33 111.16 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.547 HD11 ' HB2' ' A' ' 66' ' ' ALA . 11.1 mt -134.39 133.15 40.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 62.04 110.98 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.421 ' HA ' HG23 ' A' ' 63' ' ' THR . 9.6 ttpt -98.9 125.32 44.28 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.268 -0.423 . . . . 74.21 110.876 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.635 HG23 HG22 ' A' ' 24' ' ' VAL . 8.7 mt -123.83 119.62 57.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.209 -0.451 . . . . 73.4 111.145 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 46.4 p -113.63 150.55 32.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 62.11 111.114 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.806 ' CD1' HD11 ' A' ' 74' ' ' LEU . 23.1 m-85 -132.37 151.97 51.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.226 -0.443 . . . . 65.43 110.925 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.49 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -90.7 107.98 19.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.124 -0.489 . . . . 74.23 111.096 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.05 -51.19 0.8 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.752 -0.737 . . . . 45.03 112.551 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.443 ' OH ' HG21 ' A' ' 14' ' ' THR . 8.8 m-85 -104.4 170.5 7.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.931 0.396 . . . . 61.23 110.878 -179.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 3.7 mttt -67.09 145.39 98.8 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.505 0.669 . . . . 75.3 110.889 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 175.2 8.46 Favored 'Trans proline' 0 C--O 1.232 0.179 0 C-N-CA 122.686 2.258 . . . . 71.32 112.348 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.579 HG21 HG11 ' A' ' 72' ' ' VAL . 16.8 m -149.91 142.26 17.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.217 -0.447 . . . . 74.11 111.121 179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.421 HG23 ' HA ' ' A' ' 53' ' ' LYS . 0.3 OUTLIER -121.84 129.54 52.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 60.11 111.114 -179.929 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 6.5 m -152.85 154.3 7.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.186 -0.461 . . . . 74.21 111.118 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 4.7 ptmm? -88.35 153.12 21.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.161 -0.472 . . . . 70.32 110.865 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.547 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -55.86 138.57 48.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.216 -0.447 . . . . 72.41 111.088 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.479 ' HB3' ' CG2' ' A' ' 70' ' ' VAL . . . -162.09 165.78 26.68 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 63.13 111.065 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.41 -56.76 16.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 73.13 111.139 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 61.7 mt -132.39 116.33 28.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 72.31 111.085 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.479 ' CG2' ' HB3' ' A' ' 67' ' ' ALA . 19.5 t -124.96 112.17 30.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.095 -0.502 . . . . 74.42 111.103 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -102.04 109.31 20.99 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.193 -0.458 . . . . 74.11 110.898 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.579 HG11 HG21 ' A' ' 62' ' ' VAL . 21.9 t -116.5 147.15 20.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 61.34 111.141 179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.405 HD13 ' HG3' ' A' ' 13' ' ' LYS . 0.2 OUTLIER -115.79 145.6 42.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.138 -0.483 . . . . 72.02 110.862 180.0 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.806 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.1 tp -93.62 121.3 34.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.222 -0.445 . . . . 65.54 110.921 179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.13 137.14 45.76 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.276 -0.42 . . . . 73.42 110.925 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -51.08 137.34 21.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.143 -0.481 . . . . 75.12 110.848 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 32.3 t0 -105.63 -35.07 7.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.163 -0.471 . . . . 44.35 110.873 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 6.9 t -56.09 143.31 33.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.163 -0.471 . . . . 74.43 111.111 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.5 mt-30 -125.76 60.28 1.27 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 74.23 110.913 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -158.03 109.28 2.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 74.23 110.861 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.6 t -143.39 120.96 6.21 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.202 -0.454 . . . . 72.15 111.078 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -70.31 131.72 44.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 62.52 110.823 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 81.0 mt-10 -124.53 89.09 3.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.152 -0.477 . . . . 64.43 110.892 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 59.5 t -94.17 128.16 45.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 53.25 111.101 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 6.1 m -59.07 169.32 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.15 -0.477 . . . . 62.05 111.138 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.2 p -175.18 142.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 73.01 111.095 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -116.54 -47.74 2.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 65.24 111.158 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -175.84 -176.75 44.33 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.762 -0.732 . . . . 61.42 112.478 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 35.8 t80 -158.64 146.56 18.12 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.972 0.415 . . . . 75.33 110.948 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 66.0 p . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 73.03 111.15 179.991 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.1 mpp? . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.831 0.348 . . . . 72.11 110.919 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 154.8 -54.05 0.43 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.731 -0.747 . . . . 33.14 112.559 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 2.7 t-80 52.28 47.21 25.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.933 0.397 . . . . 75.12 110.859 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 26.0 p80 -81.12 155.82 26.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.169 -0.468 . . . . 62.11 110.896 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 11.3 t60 -52.25 156.18 1.76 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 72.04 110.838 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -79.17 -59.56 2.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.166 -0.47 . . . . 71.31 110.836 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 6.0 t60 56.2 50.94 12.51 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.238 -0.437 . . . . 74.02 110.83 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 26.2 m170 -93.2 87.37 5.65 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.156 -0.475 . . . . 73.02 110.865 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.531 ' O ' HG23 ' A' ' 69' ' ' ILE . 2.9 m -106.48 143.43 34.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.173 -0.467 . . . . 51.53 111.128 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 28.9 mtmt -72.41 110.59 6.93 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 74.23 110.843 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.4 103.17 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.799 -0.715 . . . . 42.34 112.464 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.28 126.36 40.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.804 0.335 . . . . 73.41 110.945 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.628 HG23 ' HE2' ' A' ' 42' ' ' PHE . 90.6 t -110.84 125.13 68.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.209 -0.451 . . . . 73.33 111.15 179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -128.59 177.15 7.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.191 -0.459 . . . . 73.43 111.166 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.21 161.38 14.28 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.221 -0.445 . . . . 72.2 110.802 -179.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 4.9 tmtm? -101.59 -5.41 25.15 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.097 -0.502 . . . . 60.22 110.913 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 43.5 p -78.41 -58.58 3.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 75.14 111.177 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -118.36 -26.25 6.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.228 -0.442 . . . . 72.52 110.906 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 101.58 29.29 6.32 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.787 -0.72 . . . . 53.34 112.513 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -90.21 159.95 41.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.588 0.709 . . . . 74.15 110.959 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.8 139.24 39.6 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.702 2.268 . . . . 61.23 112.364 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.65 HG22 ' HB2' ' A' ' 22' ' ' ALA . 44.1 mm -91.3 101.56 12.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.241 -0.436 . . . . 75.31 111.102 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.418 ' H ' HD12 ' A' ' 20' ' ' ILE . 3.2 mp -93.56 140.0 17.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.139 -0.482 . . . . 42.2 111.165 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.04 31.93 54.15 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.789 -0.72 . . . . 62.52 112.484 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.65 ' HB2' HG22 ' A' ' 19' ' ' ILE . . . -91.37 162.37 14.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.759 0.314 . . . . 63.11 111.088 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.7 m -105.79 107.29 18.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.165 -0.471 . . . . 52.44 110.849 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 4.4 p -120.09 127.16 75.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.123 -0.489 . . . . 75.44 111.146 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.696 HG12 ' HA3' ' A' ' 33' ' ' GLY . 14.6 m -140.31 166.97 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 74.52 111.147 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.422 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 62.6 tt0 -92.49 132.48 36.77 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.195 -0.457 . . . . 74.12 110.86 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.44 HG21 ' HB ' ' A' ' 51' ' ' THR . 60.8 p -51.7 -35.03 41.23 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.121 -0.49 . . . . 52.43 111.124 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 10.6 p -95.37 -22.25 17.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 64.03 111.128 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.422 ' HB3' ' HB3' ' A' ' 26' ' ' GLU . . . -130.93 87.34 2.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.178 -0.464 . . . . 63.21 111.104 179.85 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 4.2 p -86.81 -35.74 18.94 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.158 -0.474 . . . . 73.01 111.138 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 65.5 p -53.25 -30.56 38.9 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.212 -0.449 . . . . 74.23 111.139 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -93.96 31.51 1.63 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.284 -0.417 . . . . 74.3 110.829 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.696 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.59 146.06 49.82 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.752 -0.737 . . . . 61.22 112.486 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.642 ' CG2' HD21 ' A' ' 44' ' ' LEU . 10.4 t -135.65 169.63 17.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.727 0.299 . . . . 73.43 111.178 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -107.9 157.55 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.241 -0.436 . . . . 72.12 111.149 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.411 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.0 p -76.22 150.97 36.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 55.34 111.099 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -79.49 -176.16 5.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 34.54 110.832 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -60.47 -30.62 69.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.208 -0.451 . . . . 72.12 110.838 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -99.44 20.87 12.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.197 -0.456 . . . . 73.22 110.882 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.28 27.98 71.54 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.781 -0.723 . . . . 75.31 112.392 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 10.3 p30 -107.04 143.43 35.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.806 0.336 . . . . 71.23 110.955 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.628 ' HE2' HG23 ' A' ' 10' ' ' VAL . 24.1 p90 -144.57 161.79 38.24 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.21 110.872 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.558 ' C ' HD22 ' A' ' 44' ' ' LEU . 4.6 t -151.34 128.36 11.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 72.34 111.211 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.642 HD21 ' CG2' ' A' ' 34' ' ' THR . 3.0 mm? -130.63 159.8 36.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 72.23 110.846 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 6.1 m -95.52 108.23 20.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.141 -0.481 . . . . 73.42 110.798 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.434 HG13 ' HD2' ' A' ' 47' ' ' PRO . 58.9 t -133.35 133.19 22.53 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.611 0.72 . . . . 71.43 111.128 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.434 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.2 Cg_endo -69.74 -48.39 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.747 2.298 . . . . 60.01 112.331 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.451 HG23 ' H ' ' A' ' 50' ' ' SER . 19.4 m -99.72 -173.83 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.461 . . . . 71.24 111.116 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 49.5 m-20 -107.13 45.66 0.98 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 63.41 110.899 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.451 ' H ' HG23 ' A' ' 48' ' ' VAL . 1.8 m -57.43 -179.55 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.172 -0.467 . . . . 64.13 110.89 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.44 ' HB ' HG21 ' A' ' 27' ' ' THR . 1.7 m -87.69 159.72 18.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 72.33 111.137 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.829 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.7 mp -125.76 135.12 51.69 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 62.04 110.9 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.4 ttpt -106.86 120.84 43.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.21 110.92 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.678 ' HB ' HG23 ' A' ' 62' ' ' VAL . 5.8 mt -117.45 138.98 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.207 -0.451 . . . . 73.4 111.095 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 81.1 p -150.71 138.65 20.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.13 -0.486 . . . . 62.11 111.101 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.684 ' HB3' HD21 ' A' ' 74' ' ' LEU . 13.4 t80 -133.98 122.32 22.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.178 -0.464 . . . . 65.43 110.963 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.435 HG23 ' O ' ' A' ' 57' ' ' ILE . 11.4 tt -51.57 115.08 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.097 -0.501 . . . . 74.23 111.159 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 131.23 -51.96 0.84 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.72 -0.752 . . . . 45.03 112.467 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -107.98 170.18 8.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.9 0.381 . . . . 61.23 110.939 -179.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 10.6 mtmm -64.04 158.0 65.73 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.539 0.685 . . . . 75.3 110.914 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 164.26 35.15 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 71.32 112.357 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.678 HG23 ' HB ' ' A' ' 54' ' ' ILE . 27.8 m -150.83 141.08 16.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.197 -0.456 . . . . 74.11 111.133 179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.9 p -130.25 140.1 50.72 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.157 -0.474 . . . . 60.11 111.041 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.912 HG11 HG22 ' A' ' 72' ' ' VAL . 8.6 m -147.55 148.0 16.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 116.097 -0.501 . . . . 74.21 111.093 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 6.9 mmmm -78.95 155.11 29.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 70.32 110.919 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.829 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -73.59 134.07 43.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.289 -0.414 . . . . 72.41 111.142 179.814 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.16 178.11 7.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.243 -0.435 . . . . 63.13 111.102 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.553 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.66 -57.32 9.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.249 -0.432 . . . . 73.13 111.13 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.553 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.78 111.77 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 72.31 111.084 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.493 HG21 ' HB ' ' A' ' 64' ' ' VAL . 12.2 p -118.84 141.82 36.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.127 -0.488 . . . . 74.42 111.136 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 21.3 m120 -115.89 134.98 54.43 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 74.11 110.901 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.912 HG22 HG11 ' A' ' 64' ' ' VAL . 22.4 t -122.83 149.18 26.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 61.34 111.143 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -123.34 133.37 54.14 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.176 -0.466 . . . . 72.02 110.934 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.684 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -90.54 121.49 32.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 65.54 110.928 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 50.3 mm-40 -92.38 145.29 24.58 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.155 -0.475 . . . . 73.42 110.862 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -58.45 140.4 53.94 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.17 -0.468 . . . . 75.12 110.929 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -91.03 136.42 33.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 44.35 110.851 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 1.9 t -159.69 153.55 23.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 74.43 111.171 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.8 mm-40 -73.68 168.64 18.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.277 -0.42 . . . . 74.23 110.882 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 35.3 mtt -76.25 165.16 25.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 74.23 110.895 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 67.3 t -58.99 -65.49 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.192 -0.458 . . . . 72.15 111.151 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -65.19 -179.65 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 62.52 110.892 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -124.05 44.55 2.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.16 -0.473 . . . . 64.43 110.823 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 21.8 t -104.94 69.54 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 53.25 111.118 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.555 HG12 HG23 ' A' ' 86' ' ' VAL . 45.8 t -131.78 120.66 45.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.214 -0.448 . . . . 62.05 111.102 -179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.555 HG23 HG12 ' A' ' 85' ' ' VAL . 46.8 t 54.4 80.38 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.01 111.143 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.2 t -99.16 162.18 13.2 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.131 -0.486 . . . . 65.24 111.117 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.6 -136.15 12.58 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.723 -0.751 . . . . 61.42 112.499 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 19.7 t80 -142.27 128.45 19.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.918 0.39 . . . . 75.33 110.949 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 72.1 p . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.124 -0.489 . . . . 73.03 111.195 179.993 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 2.4 ttt . . . . . 0 CA--C 1.526 0.043 0 CA-C-O 120.834 0.349 . . . . 72.11 110.864 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -176.51 -117.06 0.49 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.682 -0.771 . . . . 33.14 112.474 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 21.2 m170 56.63 63.23 2.02 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.851 0.358 . . . . 75.12 110.922 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 20.7 m-70 -127.12 140.09 52.51 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.191 -0.459 . . . . 62.11 110.86 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 13.6 m-70 -64.48 169.23 4.98 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.241 -0.436 . . . . 72.04 110.874 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.8 m80 -141.61 110.01 5.98 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.88 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 -109.9 108.86 19.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.213 -0.449 . . . . 74.02 110.845 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.5 m80 -92.01 71.46 5.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.189 -0.459 . . . . 73.02 110.966 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.3 m -67.36 141.89 56.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 51.53 111.169 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 9.4 mtpm? -108.03 93.98 4.82 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 74.23 110.88 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 73.68 127.31 0.13 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.752 -0.737 . . . . 42.34 112.514 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -158.34 127.29 5.58 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.847 0.356 . . . . 73.41 110.929 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.656 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 83.0 t -117.94 130.59 72.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.33 111.105 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.48 HG22 ' HA ' ' A' ' 18' ' ' PRO . 1.5 p -128.5 163.71 24.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 73.43 111.103 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.451 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.2 t -84.73 148.96 26.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.2 -0.455 . . . . 72.2 110.88 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 10.9 tttp -92.43 17.53 9.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.171 -0.468 . . . . 60.22 110.851 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.95 -58.75 2.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.259 -0.428 . . . . 75.14 111.103 -179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -119.58 -26.68 5.69 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 72.52 110.892 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.39 29.35 5.12 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.736 -0.745 . . . . 53.34 112.409 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 6.4 mm-40 -97.44 159.95 29.95 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 74.15 110.939 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.48 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.78 141.62 45.65 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.663 2.242 . . . . 61.23 112.365 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.626 HG21 ' CD2' ' A' ' 56' ' ' TYR . 33.7 mm -86.04 115.22 26.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 75.31 111.065 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 23.4 mt -104.04 137.27 33.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.152 -0.476 . . . . 42.2 111.111 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 75.33 47.55 12.57 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.763 -0.732 . . . . 62.52 112.486 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.97 158.33 15.51 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.77 0.319 . . . . 63.11 111.135 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.9 m -105.99 107.21 18.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 52.44 110.875 -179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.658 HG13 HG12 ' A' ' 54' ' ' ILE . 95.4 t -110.91 110.39 32.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 75.44 111.111 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.8 m -123.53 146.05 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.201 -0.454 . . . . 74.52 111.106 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.646 ' OE1' HD22 ' A' ' 52' ' ' LEU . 1.9 mm-40 -90.24 156.7 18.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 74.12 110.836 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 51.9 p -73.03 -32.91 65.41 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.115 -0.493 . . . . 52.43 111.19 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 44.7 p -85.19 -22.2 28.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 64.03 111.17 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -160.76 104.74 1.37 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.12 -0.491 . . . . 63.21 111.047 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 51.4 p -86.75 -34.82 19.51 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 73.01 111.081 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 58.5 p -53.15 -29.68 32.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.251 -0.432 . . . . 74.23 111.188 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.6 t30 -94.29 31.34 1.73 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.246 -0.434 . . . . 74.3 110.892 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -72.86 164.37 54.86 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.718 -0.753 . . . . 61.22 112.492 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.8 t -130.96 169.08 16.29 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.712 0.291 . . . . 73.43 111.226 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 pp -115.99 164.55 12.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.255 -0.43 . . . . 72.12 111.141 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.522 HG22 ' HD2' ' A' ' 42' ' ' PHE . 14.1 p -89.28 150.66 22.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.205 -0.452 . . . . 55.34 111.15 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -91.37 -179.14 5.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.185 -0.461 . . . . 34.54 110.883 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -56.95 -30.64 64.22 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 72.12 110.968 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 46.0 m-20 -73.62 -18.46 61.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.13 -0.486 . . . . 73.22 110.865 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 88.97 28.1 21.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.727 -0.749 . . . . 75.31 112.506 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -127.23 165.38 19.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.812 0.339 . . . . 71.23 110.885 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.522 ' HD2' HG22 ' A' ' 36' ' ' THR . 27.5 p90 -153.29 166.75 31.59 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 71.21 110.845 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.9 t -143.84 125.86 15.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 72.34 111.158 -179.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.614 HD13 ' CD ' ' A' ' 26' ' ' GLU . 1.0 OUTLIER -138.61 131.37 29.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 72.23 110.895 -179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.469 ' N ' HD23 ' A' ' 44' ' ' LEU . 16.5 t -98.07 117.79 33.22 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.85 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -115.8 156.18 46.75 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.665 0.745 . . . . 71.43 111.104 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.66 -48.51 0.72 Allowed 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.699 2.266 . . . . 60.01 112.376 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 27.9 m -113.14 -177.5 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.208 -0.451 . . . . 71.24 111.134 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -100.6 39.43 1.37 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 63.41 110.836 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.7 t -63.91 -169.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.234 -0.439 . . . . 64.13 110.866 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.691 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.0 OUTLIER -87.65 161.43 17.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.139 -0.482 . . . . 72.33 111.132 -179.987 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.691 HD23 ' O ' ' A' ' 51' ' ' THR . 12.7 mt -129.85 127.59 40.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.121 -0.491 . . . . 62.04 110.915 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -102.26 122.3 43.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.237 -0.438 . . . . 74.21 110.921 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.658 HG12 HG13 ' A' ' 24' ' ' VAL . 58.1 mt -123.63 118.94 55.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.221 -0.445 . . . . 73.4 111.086 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 55.0 p -113.34 146.86 38.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 62.11 111.168 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.838 ' CD1' HD11 ' A' ' 74' ' ' LEU . 19.0 m-85 -126.28 155.15 42.38 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 65.43 110.892 -179.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.65 107.76 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 74.23 111.072 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.88 -50.83 0.83 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.686 -0.769 . . . . 45.03 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.4 m-85 -105.84 170.48 7.88 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.905 0.383 . . . . 61.23 110.952 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 12.8 mmtm -64.74 149.0 96.62 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.617 0.723 . . . . 75.3 110.882 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -179.15 2.73 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.722 2.281 . . . . 71.32 112.377 179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.88 HG21 HG11 ' A' ' 72' ' ' VAL . 4.4 p -151.85 149.27 13.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.284 -0.416 . . . . 74.11 111.179 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.22 125.26 30.7 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.204 -0.453 . . . . 60.11 111.121 -179.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.762 HG21 HG11 ' A' ' 70' ' ' VAL . 18.2 m -147.37 152.92 12.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 74.21 111.156 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 8.3 mttm -81.82 153.62 26.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.454 . . . . 70.32 110.867 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.436 ' HA ' HD11 ' A' ' 52' ' ' LEU . . . -55.58 105.14 0.16 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.075 179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . 0.453 ' HB3' HG22 ' A' ' 70' ' ' VAL . . . -131.78 153.2 50.35 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.211 -0.45 . . . . 63.13 111.129 179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.09 -51.46 67.79 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.182 -0.463 . . . . 73.13 111.032 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 60.4 mt -120.03 115.48 47.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 72.31 111.199 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.762 HG11 HG21 ' A' ' 64' ' ' VAL . 20.1 t -126.63 106.61 15.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.222 -0.445 . . . . 74.42 111.197 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -114.26 109.43 18.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.11 110.898 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.88 HG11 HG21 ' A' ' 62' ' ' VAL . 21.6 t -129.04 148.38 33.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.465 . . . . 61.34 111.13 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.6 mp -100.86 145.15 28.95 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.195 -0.457 . . . . 72.02 110.943 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.838 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.5 tp -87.72 120.93 29.52 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.138 -0.483 . . . . 65.54 110.947 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -96.14 127.25 41.98 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.243 -0.435 . . . . 73.42 110.903 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -54.52 143.16 25.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.167 -0.469 . . . . 75.12 110.877 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -104.94 156.99 17.53 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 44.35 110.904 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 2.8 t -158.97 144.97 16.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 74.43 111.197 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -75.59 95.7 3.4 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.223 -0.444 . . . . 74.23 110.888 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 4.6 ttp -104.0 121.05 42.35 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.23 -0.441 . . . . 74.23 110.889 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.4 t -116.71 -54.79 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.263 -0.426 . . . . 72.15 111.167 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -102.96 37.02 2.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.115 -0.493 . . . . 62.52 110.854 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 39.46 41.71 0.75 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.215 -0.448 . . . . 64.43 110.96 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 57.5 t -70.59 85.28 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.101 -0.499 . . . . 53.25 111.155 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 14.9 p -105.55 136.18 40.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 62.05 111.11 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 31.4 m -57.77 -178.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.143 -0.48 . . . . 73.01 111.168 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.45 111.6 22.92 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.132 -0.485 . . . . 65.24 111.195 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -173.72 -43.23 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.768 -0.73 . . . . 61.42 112.501 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 58.1 t80 -165.16 146.7 7.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.994 0.426 . . . . 75.33 110.931 -179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 8.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.084 -0.507 . . . . 73.03 111.107 -179.953 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 11.9 mtt . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.788 0.328 . . . . 72.11 110.882 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -166.33 148.32 13.38 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.715 -0.755 . . . . 33.14 112.542 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -146.27 168.7 20.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.853 0.358 . . . . 75.12 110.803 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 81.5 m-70 -124.3 123.67 40.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 62.11 110.86 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 30.5 m170 -120.6 38.96 3.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 72.04 110.854 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 1.3 t-80 -80.36 -45.02 18.45 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 71.31 110.889 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 33.8 p-80 -127.24 68.53 1.28 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.139 -0.482 . . . . 74.02 110.833 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 25.7 t60 -103.84 57.68 0.73 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.163 -0.471 . . . . 73.02 110.858 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 1.1 m -106.26 149.47 26.86 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.215 -0.448 . . . . 51.53 111.192 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 65.4 mttt -65.0 134.36 53.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.231 -0.44 . . . . 74.23 110.866 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.02 114.62 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.72 -0.753 . . . . 42.34 112.477 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -132.43 127.79 36.11 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.841 0.353 . . . . 73.41 110.927 -179.877 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.537 HG12 HG13 ' A' ' 19' ' ' ILE . 21.3 t -115.94 134.25 59.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 73.33 111.138 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.413 HG22 ' HA ' ' A' ' 18' ' ' PRO . 0.8 OUTLIER -146.69 153.84 40.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.23 -0.441 . . . . 73.43 111.167 -179.977 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.1 t -85.69 150.6 24.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 72.2 110.875 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.7 tttt -94.28 20.76 7.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 60.22 110.911 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.22 -58.69 2.15 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 75.14 111.098 179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -120.05 -25.95 5.66 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 72.52 110.847 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.87 29.02 5.1 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 53.34 112.519 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -98.05 155.55 36.89 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 74.15 110.941 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.413 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.7 Cg_endo -69.66 136.86 34.34 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.724 2.283 . . . . 61.23 112.351 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.548 ' CG2' ' HB2' ' A' ' 22' ' ' ALA . 50.0 mm -78.0 124.32 36.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.279 -0.419 . . . . 75.31 111.114 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 26.9 mt -110.18 119.35 59.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.171 -0.468 . . . . 42.2 111.095 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 90.68 33.4 8.47 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.774 -0.727 . . . . 62.52 112.528 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HB2' ' CG2' ' A' ' 19' ' ' ILE . . . -89.54 132.21 35.18 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.722 0.296 . . . . 63.11 111.089 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 21.7 m -79.73 109.74 14.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.84 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.577 HG13 HG12 ' A' ' 54' ' ' ILE . 98.3 t -113.78 106.05 19.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.15 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.778 HG12 ' HA3' ' A' ' 33' ' ' GLY . 20.1 m -120.64 139.03 49.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.194 -0.457 . . . . 74.52 111.16 179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.447 ' OE1' HD13 ' A' ' 44' ' ' LEU . 1.5 pm0 -90.61 141.86 28.34 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.121 -0.491 . . . . 74.12 110.845 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 39.8 p -62.29 -31.6 72.22 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.074 -0.512 . . . . 52.43 111.166 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.717 HG21 HG13 ' A' ' 48' ' ' VAL . 64.8 p -71.71 -22.12 61.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 64.03 111.133 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -164.76 78.78 0.34 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 63.21 111.055 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 p -65.33 -35.62 81.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.197 -0.456 . . . . 73.01 111.184 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 94.7 m -54.09 -32.32 54.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.207 -0.451 . . . . 74.23 111.169 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.482 ' O ' HD11 ' A' ' 44' ' ' LEU . 35.6 t30 -93.47 30.59 1.7 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.231 -0.441 . . . . 74.3 110.941 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.778 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -62.94 148.4 50.08 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.731 -0.747 . . . . 61.22 112.483 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.628 HG22 HD12 ' A' ' 44' ' ' LEU . 14.6 t -125.58 168.98 12.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.768 0.318 . . . . 73.43 111.181 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 12.0 pt -107.37 172.57 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.179 -0.464 . . . . 72.12 111.096 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.444 HG22 ' CD2' ' A' ' 42' ' ' PHE . 37.4 p -97.85 150.68 21.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.113 -0.494 . . . . 55.34 111.067 -179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -80.57 -175.99 5.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.483 . . . . 34.54 110.864 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -59.52 -30.74 68.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.274 -0.421 . . . . 72.12 110.869 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 33.1 t0 -100.04 22.77 10.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.16 -0.473 . . . . 73.22 110.886 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.94 28.15 72.32 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.705 -0.76 . . . . 75.31 112.523 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -107.33 127.77 53.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.906 0.384 . . . . 71.23 110.82 -179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.444 ' CD2' HG22 ' A' ' 36' ' ' THR . 25.9 p90 -127.73 157.22 40.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.138 -0.483 . . . . 71.21 110.879 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.1 t -132.48 123.82 27.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.144 -0.48 . . . . 72.34 111.158 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.628 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.22 118.44 7.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.273 -0.421 . . . . 72.23 110.981 179.93 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.0 m -95.05 116.64 28.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.222 -0.444 . . . . 73.42 110.851 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 3.2 m -122.55 156.24 61.51 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.622 0.725 . . . . 71.43 111.155 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -35.88 11.83 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.667 2.245 . . . . 60.01 112.371 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.717 HG13 HG21 ' A' ' 28' ' ' THR . 14.5 p -131.51 140.23 48.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.252 -0.431 . . . . 71.24 111.164 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -104.21 79.7 1.63 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.168 -0.469 . . . . 63.41 110.876 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.9 t -89.37 -76.96 0.4 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 64.13 110.861 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -139.64 159.99 40.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.132 -0.485 . . . . 72.33 111.147 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 66' ' ' ALA . 15.6 mt -134.81 122.27 21.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.247 -0.433 . . . . 62.04 110.882 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.546 ' HA ' HG22 ' A' ' 63' ' ' THR . 71.0 tttt -100.89 123.2 44.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.914 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.601 ' HB ' HG23 ' A' ' 62' ' ' VAL . 74.1 mt -121.12 138.4 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 73.4 111.149 179.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 47.2 p -148.82 138.66 22.08 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 62.11 111.11 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.667 ' HB3' HD21 ' A' ' 74' ' ' LEU . 12.6 t80 -133.98 122.8 23.58 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.232 -0.44 . . . . 65.43 110.927 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.419 HG23 ' O ' ' A' ' 57' ' ' ILE . 7.2 tt -51.82 120.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.117 -0.492 . . . . 74.23 111.098 179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 125.73 -50.94 0.85 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.721 -0.752 . . . . 45.03 112.521 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.3 m-85 -109.23 169.97 8.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 61.23 110.932 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -64.54 157.33 73.51 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.52 0.676 . . . . 75.3 110.936 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -69.79 165.16 31.93 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.675 2.25 . . . . 71.32 112.311 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.601 HG23 ' HB ' ' A' ' 54' ' ' ILE . 32.1 m -150.55 138.25 13.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 74.11 111.154 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 53' ' ' LYS . 5.1 p -131.76 140.85 49.34 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 60.11 111.171 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 9.0 m -145.92 175.66 2.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.204 -0.453 . . . . 74.21 111.11 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.41 149.9 25.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.146 -0.479 . . . . 70.32 110.9 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.615 ' HA ' HD12 ' A' ' 52' ' ' LEU . . . -75.43 118.37 18.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.181 -0.463 . . . . 72.41 111.137 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -150.97 -176.22 5.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 63.13 111.064 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.503 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -68.14 -57.66 5.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 73.13 111.153 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.503 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -126.69 114.26 36.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.228 -0.442 . . . . 72.31 111.139 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 7.5 p -131.87 127.45 58.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.204 -0.453 . . . . 74.42 111.136 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 36.0 m120 -100.35 127.59 46.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 74.11 110.897 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.565 HG11 HG21 ' A' ' 62' ' ' VAL . 21.4 t -118.7 148.88 21.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.254 -0.43 . . . . 61.34 111.093 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 15.3 mt -119.43 131.47 55.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.124 -0.489 . . . . 72.02 110.936 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.667 HD21 ' HB3' ' A' ' 56' ' ' TYR . 1.3 tp -87.86 121.9 30.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.955 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -90.36 144.01 26.22 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.214 -0.448 . . . . 73.42 110.94 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -58.97 139.87 56.25 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 75.12 110.864 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -91.23 -34.29 15.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 44.35 110.868 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 3.0 t -103.76 66.68 0.86 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.194 -0.457 . . . . 74.43 111.131 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -119.92 -48.83 2.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 74.23 110.893 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 8.3 tpp -76.77 116.98 17.94 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.286 -0.416 . . . . 74.23 110.821 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.25 108.53 22.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 72.15 111.186 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -115.84 174.24 6.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.219 -0.446 . . . . 62.52 110.903 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 6.3 tp10 -118.54 65.89 0.77 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.206 -0.452 . . . . 64.43 110.857 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 47.9 t -103.88 130.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.159 -0.473 . . . . 53.25 111.077 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.28 98.53 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 62.05 111.113 179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.0 m -113.38 169.61 4.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.171 -0.468 . . . . 73.01 111.141 179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.0 t -82.01 141.42 33.26 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.171 -0.468 . . . . 65.24 111.137 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -62.93 148.38 50.07 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.767 -0.73 . . . . 61.42 112.445 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -82.25 132.49 35.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.93 0.395 . . . . 75.33 110.942 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 73.03 111.157 -179.988 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 48.5 mtm . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.832 0.349 . . . . 72.11 110.904 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -134.95 103.65 0.48 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.732 -0.747 . . . . 33.14 112.443 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -136.62 128.31 28.91 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.84 0.352 . . . . 75.12 110.868 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 2.5 p-80 -71.4 169.5 15.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 62.11 110.907 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 76.9 m-70 -121.8 92.97 3.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.287 -0.415 . . . . 72.04 110.866 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 19.9 m170 -129.33 147.19 51.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 71.31 110.804 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 31.8 p80 -126.06 164.06 21.69 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.226 -0.443 . . . . 74.02 110.904 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 22.6 t60 -122.75 -64.56 1.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 73.02 110.875 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 2.7 m -104.57 121.62 43.89 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.143 -0.481 . . . . 51.53 111.176 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 52.5 mtmt -101.29 92.24 4.86 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.272 -0.422 . . . . 74.23 110.891 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 86.06 117.17 0.95 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.762 -0.732 . . . . 42.34 112.516 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.0 120.19 3.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.771 0.32 . . . . 73.41 110.928 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 39.1 t -105.93 131.64 54.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.23 -0.441 . . . . 73.33 111.126 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 10.9 p -129.37 159.26 36.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.43 111.126 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -84.34 156.95 21.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.2 110.858 -179.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 8.6 tttp -93.96 20.09 8.23 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.079 -0.509 . . . . 60.22 110.966 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.58 HG21 ' OH ' ' A' ' 59' ' ' TYR . 60.1 p -94.52 -58.42 2.2 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.194 -0.457 . . . . 75.14 111.131 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 50.2 m-20 -122.26 -26.36 4.68 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.168 -0.469 . . . . 72.52 110.915 179.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.64 29.27 5.08 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.753 -0.737 . . . . 53.34 112.539 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 49.4 mt-30 -98.99 159.69 29.6 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.552 0.692 . . . . 74.15 110.953 -179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo -69.71 147.72 63.82 Favored 'Trans proline' 0 C--O 1.233 0.226 0 C-N-CA 122.745 2.296 . . . . 61.23 112.399 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.515 HG21 ' CD2' ' A' ' 56' ' ' TYR . 26.5 mm -94.6 114.97 32.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 75.31 111.084 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.472 HD13 ' CD2' ' A' ' 38' ' ' PHE . 40.4 mt -100.22 138.6 24.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.133 -0.485 . . . . 42.2 111.159 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 76.27 46.64 12.23 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.659 -0.781 . . . . 62.52 112.522 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.461 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -94.87 157.82 15.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.829 0.347 . . . . 63.11 111.043 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -106.01 107.14 17.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 52.44 110.855 -179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.785 HG22 HG23 ' A' ' 54' ' ' ILE . 13.3 t -112.15 122.58 66.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.151 -0.477 . . . . 75.44 111.132 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 15.2 m -138.91 151.95 23.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 74.52 111.177 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.402 ' OE1' HG11 ' A' ' 46' ' ' VAL . 2.4 mm-40 -84.31 174.28 10.27 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 74.12 110.912 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.13 -42.29 69.4 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.441 . . . . 52.43 111.185 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.7 p -112.91 -22.16 10.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 64.03 111.143 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -110.26 76.63 1.0 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 63.21 111.2 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 74.2 p -86.95 -34.38 19.34 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 73.01 111.141 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 60.3 m -53.16 -30.48 37.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.246 -0.434 . . . . 74.23 111.096 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -93.16 30.99 1.53 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.26 -0.427 . . . . 74.3 110.852 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -61.95 138.98 46.21 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.78 -0.724 . . . . 61.22 112.455 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.535 ' OG1' HD23 ' A' ' 44' ' ' LEU . 3.5 m -116.97 160.45 20.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.761 0.315 . . . . 73.43 111.162 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.461 HG22 ' O ' ' A' ' 22' ' ' ALA . 1.0 OUTLIER -114.51 162.2 12.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 72.12 111.165 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.455 HG22 ' HD2' ' A' ' 42' ' ' PHE . 5.6 p -83.87 150.61 25.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.252 -0.431 . . . . 55.34 111.218 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -85.14 -175.89 5.93 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.266 -0.425 . . . . 34.54 110.91 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.472 ' CD2' HD13 ' A' ' 20' ' ' ILE . 8.2 t80 -58.99 -30.18 67.78 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.237 -0.438 . . . . 72.12 110.851 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.56 13.54 13.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.138 -0.483 . . . . 73.22 110.862 -179.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.56 28.0 71.79 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.757 -0.735 . . . . 75.31 112.419 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -126.81 142.59 51.5 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.863 0.363 . . . . 71.23 110.917 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.455 ' HD2' HG22 ' A' ' 36' ' ' THR . 30.9 p90 -132.39 168.01 18.9 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.167 -0.469 . . . . 71.21 110.873 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.7 t -133.43 116.56 16.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 72.34 111.105 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.657 HD13 ' N ' ' A' ' 45' ' ' SER . 1.2 tm? -143.19 132.29 23.06 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.235 -0.439 . . . . 72.23 110.929 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . 0.657 ' N ' HD13 ' A' ' 44' ' ' LEU . 79.2 p -107.35 124.84 50.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.192 -0.458 . . . . 73.42 110.902 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.402 HG11 ' OE1' ' A' ' 26' ' ' GLU . 3.5 m -113.61 155.95 44.2 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.702 0.763 . . . . 71.43 111.111 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -48.5 0.71 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.665 2.243 . . . . 60.01 112.362 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.3 m -112.37 179.68 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 71.24 111.189 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 75.2 m-80 -100.31 36.88 1.77 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 63.41 110.862 -179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.3 t -61.98 -172.59 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 64.13 110.844 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -89.0 154.95 19.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.057 -0.52 . . . . 72.33 111.186 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.723 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.3 mp -127.41 130.96 50.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.26 -0.427 . . . . 62.04 110.91 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -99.82 121.25 41.01 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.14 -0.482 . . . . 74.21 110.917 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.785 HG23 HG22 ' A' ' 24' ' ' VAL . 2.4 mp -117.92 119.14 60.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.295 -0.411 . . . . 73.4 111.14 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 44.5 p -116.08 144.32 44.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.187 -0.46 . . . . 62.11 111.149 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.8 ' CD1' HD11 ' A' ' 74' ' ' LEU . 26.3 m-85 -126.63 152.35 46.8 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.266 -0.425 . . . . 65.43 110.918 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.493 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.4 tt -89.71 107.73 18.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.109 -0.496 . . . . 74.23 111.142 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 122.5 -50.47 0.84 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.745 -0.74 . . . . 45.03 112.49 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.58 ' OH ' HG21 ' A' ' 14' ' ' THR . 12.8 m-85 -103.62 170.69 7.79 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.921 0.391 . . . . 61.23 110.925 -179.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -67.95 145.17 97.71 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.58 0.705 . . . . 75.3 110.867 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 172.34 12.84 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.682 2.254 . . . . 71.32 112.382 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.539 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.5 m -150.08 143.66 17.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 74.11 111.128 179.94 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -122.49 134.76 54.56 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.246 -0.434 . . . . 60.11 111.168 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 70' ' ' VAL . 6.1 m -152.94 158.82 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.227 -0.442 . . . . 74.21 111.127 179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.5 ptpt -82.47 157.28 23.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 70.32 110.882 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.723 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -71.18 138.14 49.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 72.41 111.113 179.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.72 -177.59 4.85 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.201 -0.454 . . . . 63.13 111.093 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -64.37 -58.0 7.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 73.13 111.085 179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 54.6 mt -124.25 137.71 56.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.2 -0.454 . . . . 72.31 111.149 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.441 HG21 HG21 ' A' ' 64' ' ' VAL . 6.1 p -143.61 120.92 5.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 74.42 111.142 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -119.98 110.55 16.83 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 74.11 110.831 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.446 HG11 HG21 ' A' ' 62' ' ' VAL . 22.2 t -116.37 146.32 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 61.34 111.128 179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.1 mp -102.14 135.33 43.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.185 -0.461 . . . . 72.02 110.932 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.8 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.53 120.87 29.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.211 -0.45 . . . . 65.54 110.919 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.2 mm-40 -95.69 142.9 27.44 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 73.42 110.905 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -55.02 141.25 34.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.166 -0.47 . . . . 75.12 110.938 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -124.44 120.2 31.38 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.264 -0.426 . . . . 44.35 110.946 179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -134.65 141.06 46.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.236 -0.438 . . . . 74.43 111.164 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 24.4 mt-30 -106.67 152.75 23.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.232 -0.44 . . . . 74.23 110.89 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -113.29 85.2 2.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 74.23 110.876 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 12.2 p -175.36 134.37 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.237 -0.438 . . . . 72.15 111.113 179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -55.31 131.81 46.47 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.189 -0.46 . . . . 62.52 110.855 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.3 tp10 -106.75 86.21 2.29 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.168 -0.469 . . . . 64.43 110.926 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.9 m -59.67 157.22 2.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.173 -0.467 . . . . 53.25 111.152 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.2 p -52.92 135.74 14.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.139 -0.482 . . . . 62.05 111.129 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 17.4 m -111.87 175.94 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.133 -0.485 . . . . 73.01 111.154 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.5 p -64.02 -179.54 0.43 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.22 -0.445 . . . . 65.24 111.165 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -79.88 151.03 33.23 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.774 -0.727 . . . . 61.42 112.489 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -90.8 156.11 18.28 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.902 0.382 . . . . 75.33 110.966 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.4 p . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.149 -0.478 . . . . 73.03 111.151 -179.937 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.0 mmt . . . . . 0 N--CA 1.457 -0.097 0 CA-C-O 120.852 0.358 . . . . 72.11 110.886 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -88.52 -166.91 42.74 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.745 -0.74 . . . . 33.14 112.496 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 36.3 m170 -118.45 -44.22 2.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.837 0.351 . . . . 75.12 110.855 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -70.34 169.16 14.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 62.11 110.786 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 60.8 m170 -110.36 112.29 24.13 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 72.04 110.874 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 24.7 m170 -72.73 122.2 21.1 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.206 -0.452 . . . . 71.31 110.888 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -115.32 -42.22 3.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.02 110.877 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 40.2 p-80 -62.42 156.56 22.29 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.267 -0.424 . . . . 73.02 110.849 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 5.1 m -94.42 154.02 17.66 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.205 -0.452 . . . . 51.53 111.179 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -126.34 133.65 51.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 74.23 110.865 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 82.53 124.79 0.86 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.705 -0.759 . . . . 42.34 112.529 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -152.74 119.95 5.87 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.855 0.36 . . . . 73.41 110.857 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.638 ' CG2' HD13 ' A' ' 54' ' ' ILE . 22.4 t -107.26 132.11 55.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.174 -0.467 . . . . 73.33 111.153 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.407 HG22 ' C ' ' A' ' 17' ' ' GLN . 0.9 OUTLIER -136.22 160.38 38.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 73.43 111.072 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.16 154.1 35.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 72.2 110.851 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 47.6 tttp -96.46 12.91 29.72 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.139 -0.482 . . . . 60.22 110.845 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 74.3 p -93.86 -58.72 2.17 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.261 -0.427 . . . . 75.14 111.144 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -119.04 -26.57 5.93 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.229 -0.442 . . . . 72.52 110.935 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.32 29.25 5.18 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.728 -0.748 . . . . 53.34 112.445 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . 0.407 ' C ' HG22 ' A' ' 11' ' ' THR . 47.0 mt-30 -90.45 160.46 39.26 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.598 0.713 . . . . 74.15 110.902 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 136.27 32.64 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.673 2.248 . . . . 61.23 112.368 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 44.4 mm -87.4 123.07 39.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.096 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.5 mt -107.92 128.23 63.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 42.2 111.118 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 86.53 32.87 14.68 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.686 -0.768 . . . . 62.52 112.501 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.42 127.76 36.3 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.792 0.329 . . . . 63.11 111.04 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 1.4 t -72.8 107.63 5.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.216 -0.447 . . . . 52.44 110.829 -179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.548 HG22 HG12 ' A' ' 54' ' ' ILE . 21.8 t -111.64 106.68 21.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.114 -0.494 . . . . 75.44 111.065 179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.03 150.49 16.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 74.52 111.121 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.514 ' O ' HG23 ' A' ' 30' ' ' THR . 2.4 mp0 -92.57 137.77 32.08 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 74.12 110.851 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 5.9 p -56.14 -34.85 66.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.066 -0.515 . . . . 52.43 111.204 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 66.5 p -98.16 -22.09 16.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.24 -0.436 . . . . 64.03 111.208 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -133.48 65.81 1.57 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 63.21 111.065 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 26' ' ' GLU . 1.2 p -67.03 -35.32 79.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 73.01 111.17 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 88.8 m -64.1 -30.63 71.68 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.208 -0.451 . . . . 74.23 111.084 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 59.3 t30 -93.51 30.55 1.72 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 74.3 110.86 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -70.9 155.95 53.04 Favored Glycine 0 N--CA 1.453 -0.215 0 C-N-CA 120.749 -0.739 . . . . 61.22 112.422 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 11.5 t -132.76 168.8 17.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.756 0.312 . . . . 73.43 111.199 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 1.9 pp -107.89 150.83 10.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.231 -0.44 . . . . 72.12 111.191 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.488 HG22 ' HD2' ' A' ' 42' ' ' PHE . 19.2 p -70.38 150.14 46.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.19 -0.459 . . . . 55.34 111.186 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -91.3 -179.23 5.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.243 -0.435 . . . . 34.54 110.821 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 15.1 m-85 -58.25 -30.64 66.71 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 72.12 110.846 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -73.84 -19.48 60.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.853 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.03 28.16 12.42 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.689 -0.767 . . . . 75.31 112.501 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -137.68 164.59 28.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.859 0.361 . . . . 71.23 110.925 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.524 ' CZ ' HG11 ' A' ' 24' ' ' VAL . 27.6 p90 -138.78 167.46 21.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.193 -0.458 . . . . 71.21 110.835 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.402 ' O ' HG23 ' A' ' 43' ' ' THR . 5.0 t -119.86 120.38 36.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.114 -0.493 . . . . 72.34 111.187 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 1.3 mt -148.11 108.18 4.06 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.265 -0.425 . . . . 72.23 110.899 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 4.4 t -82.4 108.08 15.55 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 73.42 110.851 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.414 ' O ' HG23 ' A' ' 46' ' ' VAL . 6.7 m -139.98 106.77 6.83 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.653 0.74 . . . . 71.43 111.129 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -32.54 18.45 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.762 2.308 . . . . 60.01 112.365 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.4 m -55.57 -30.61 26.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.455 . . . . 71.24 111.138 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 15.0 m-20 67.32 40.11 2.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.124 -0.489 . . . . 63.41 110.866 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.0 m -74.73 -176.01 2.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 64.13 110.91 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.725 HG23 ' HG3' ' A' ' 65' ' ' LYS . 0.2 OUTLIER -86.95 150.05 24.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.474 . . . . 72.33 111.186 -179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.861 HD11 ' HB2' ' A' ' 66' ' ' ALA . 6.1 mp -117.85 131.57 56.54 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.264 -0.425 . . . . 62.04 110.933 179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.805 ' HA ' HG22 ' A' ' 63' ' ' THR . 0.2 OUTLIER -99.83 128.48 45.92 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 74.21 110.87 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.638 HD13 ' CG2' ' A' ' 10' ' ' VAL . 45.0 mt -123.79 124.93 70.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.233 -0.44 . . . . 73.4 111.097 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . 0.584 HG23 ' HD3' ' A' ' 53' ' ' LYS . 71.8 p -140.88 143.33 34.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.104 -0.498 . . . . 62.11 111.131 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.423 ' HB3' HD21 ' A' ' 74' ' ' LEU . 9.3 t80 -139.29 121.02 15.34 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.216 -0.447 . . . . 65.43 110.856 -179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.452 HG23 ' O ' ' A' ' 57' ' ' ILE . 5.1 tt -50.91 107.68 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.083 -0.508 . . . . 74.23 111.141 179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 138.94 -43.86 1.14 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 45.03 112.46 179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -114.94 170.96 7.95 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.981 0.42 . . . . 61.23 110.902 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 8.1 mmtt -66.29 153.64 92.09 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.596 0.712 . . . . 75.3 110.905 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -69.77 157.68 59.54 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.711 2.274 . . . . 71.32 112.331 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.529 ' CG2' HG11 ' A' ' 72' ' ' VAL . 26.8 m -150.93 137.93 13.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.436 . . . . 74.11 111.141 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.805 HG22 ' HA ' ' A' ' 53' ' ' LYS . 21.2 p -131.96 142.24 49.55 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 60.11 111.107 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.605 HG11 HG22 ' A' ' 72' ' ' VAL . 15.5 m -149.55 156.32 7.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 74.21 111.141 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.725 ' HG3' HG23 ' A' ' 51' ' ' THR . 0.1 OUTLIER -80.51 157.29 26.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.139 -0.482 . . . . 70.32 110.934 179.892 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.861 ' HB2' HD11 ' A' ' 52' ' ' LEU . . . -77.4 137.59 38.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.276 -0.42 . . . . 72.41 111.147 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -164.59 178.65 7.18 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.235 -0.439 . . . . 63.13 111.112 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.569 ' CB ' HD12 ' A' ' 69' ' ' ILE . . . -51.71 -49.61 62.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 73.13 111.087 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 ' CB ' ' A' ' 68' ' ' ALA . 5.4 mp -143.71 111.79 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.233 -0.44 . . . . 72.31 111.144 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 38.4 t -116.12 128.1 73.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.184 -0.462 . . . . 74.42 111.079 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 23.1 m120 -115.39 125.98 53.83 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 74.11 110.887 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.605 HG22 HG11 ' A' ' 64' ' ' VAL . 21.2 t -120.05 149.01 22.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 61.34 111.132 179.908 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 3.5 mp -121.35 120.46 35.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 72.02 110.968 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.423 HD21 ' HB3' ' A' ' 56' ' ' TYR . 3.4 tp -88.06 116.55 26.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.207 -0.451 . . . . 65.54 110.873 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 17.0 pm0 -95.9 146.47 24.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 73.42 110.82 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -56.58 143.89 33.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.131 -0.486 . . . . 75.12 110.932 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -97.7 -34.44 10.92 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.126 -0.488 . . . . 44.35 110.862 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.3 p -139.56 169.01 18.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.19 -0.459 . . . . 74.43 111.168 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 2.3 pp0? -133.39 158.56 42.73 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.207 -0.451 . . . . 74.23 110.916 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -145.73 148.11 32.65 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.286 -0.416 . . . . 74.23 110.908 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 22.4 t -99.84 -44.14 11.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.259 -0.428 . . . . 72.15 111.117 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 13.2 p-10 -127.47 172.4 10.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.101 -0.499 . . . . 62.52 110.933 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -80.52 82.4 6.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 64.43 110.86 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 68.9 t -89.29 117.37 32.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 53.25 111.147 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.5 p -80.03 138.02 20.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 62.05 111.085 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 41.7 t -138.97 121.73 18.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.187 -0.46 . . . . 73.01 111.117 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -64.05 128.26 35.02 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.141 -0.481 . . . . 65.24 111.128 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 132.27 119.87 2.1 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.782 -0.723 . . . . 61.42 112.54 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 4.2 t80 -142.7 164.1 31.03 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.95 0.405 . . . . 75.33 110.86 -179.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.051 -0.522 . . . . 73.03 111.136 -179.97 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.1 mmt . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.845 0.355 . . . . 72.11 110.855 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 131.07 141.99 4.95 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.755 -0.736 . . . . 33.14 112.465 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 24.0 m80 -144.29 150.16 37.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.854 0.359 . . . . 75.12 110.901 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 11.8 t-80 -144.75 144.04 30.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.265 -0.425 . . . . 62.11 110.921 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 3.3 m80 -74.99 163.38 27.68 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.233 -0.44 . . . . 72.04 110.882 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 18.7 m170 -66.18 172.34 3.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.253 -0.43 . . . . 71.31 110.901 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -99.83 109.16 21.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 74.02 110.872 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.0 t-80 -139.32 -55.18 0.58 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 73.02 110.835 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.589 ' O ' HG23 ' A' ' 69' ' ' ILE . 3.5 m -106.13 127.81 53.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.22 -0.445 . . . . 51.53 111.121 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 37.2 ttmt -74.43 102.25 4.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 74.23 110.87 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.38 105.4 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.769 -0.729 . . . . 42.34 112.433 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -156.83 125.76 5.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.829 0.347 . . . . 73.41 110.881 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.654 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 93.1 t -112.35 130.17 66.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.191 -0.459 . . . . 73.33 111.075 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.511 HG22 ' HA ' ' A' ' 18' ' ' PRO . 2.0 p -128.84 164.31 23.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 73.43 111.11 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.2 t -85.32 149.95 25.1 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 72.2 110.801 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.35 18.17 8.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.111 -0.495 . . . . 60.22 110.918 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.93 2.1 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.249 -0.432 . . . . 75.14 111.157 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -119.95 -26.77 5.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.471 . . . . 72.52 110.88 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.11 29.39 5.19 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.773 -0.727 . . . . 53.34 112.507 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 1.2 mm100 -96.9 160.3 29.5 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.672 0.749 . . . . 74.15 110.918 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.511 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.1 Cg_endo -69.73 138.54 38.15 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.649 2.233 . . . . 61.23 112.381 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.602 HG21 ' CD2' ' A' ' 56' ' ' TYR . 49.9 mm -83.79 123.09 38.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.207 -0.451 . . . . 75.31 111.133 179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 19.3 mt -108.24 140.75 25.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 42.2 111.161 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 70.63 51.99 17.95 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.81 -0.71 . . . . 62.52 112.48 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.595 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.05 155.75 16.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.805 0.336 . . . . 63.11 111.078 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 12.5 m -106.14 107.42 18.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.175 -0.466 . . . . 52.44 110.843 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.63 HG13 HG12 ' A' ' 54' ' ' ILE . 94.8 t -113.31 116.8 53.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.163 -0.471 . . . . 75.44 111.158 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.674 ' HB ' HG23 ' A' ' 30' ' ' THR . 13.2 m -138.65 144.01 30.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 74.52 111.049 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.601 ' HG3' HD22 ' A' ' 52' ' ' LEU . 1.7 mp0 -78.94 173.65 12.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.467 . . . . 74.12 110.866 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 66.1 p -75.41 -36.26 60.86 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 52.43 111.143 -179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 38.9 p -112.37 -22.08 11.06 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 64.03 111.111 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB3' ' OE2' ' A' ' 26' ' ' GLU . . . -114.97 75.56 0.94 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 63.21 111.073 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.674 HG23 ' HB ' ' A' ' 25' ' ' VAL . 15.1 m -84.36 -35.9 22.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.456 . . . . 73.01 111.18 -179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -57.38 -28.93 63.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.247 -0.433 . . . . 74.23 111.128 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 43.4 t30 -94.54 31.23 1.81 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.91 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -69.67 149.28 47.97 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.799 -0.715 . . . . 61.22 112.48 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.648 HG22 HD12 ' A' ' 44' ' ' LEU . 13.2 t -123.1 169.12 11.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.716 0.293 . . . . 73.43 111.139 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.595 HG22 ' O ' ' A' ' 22' ' ' ALA . 12.1 pt -124.42 156.64 32.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 72.12 111.148 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.57 HG22 ' HD2' ' A' ' 42' ' ' PHE . 35.6 p -81.79 149.05 28.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 55.34 111.115 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -91.62 -176.24 4.43 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.228 -0.442 . . . . 34.54 110.858 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -56.93 -30.62 64.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.236 -0.438 . . . . 72.12 110.892 -179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -73.8 -18.85 60.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 73.22 110.86 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.37 28.22 20.46 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.725 -0.75 . . . . 75.31 112.457 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.97 162.38 29.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.826 0.346 . . . . 71.23 110.901 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.57 ' HD2' HG22 ' A' ' 36' ' ' THR . 28.2 p90 -146.02 164.14 33.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.235 -0.439 . . . . 71.21 110.921 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.7 t -128.5 116.28 19.44 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 72.34 111.14 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.648 HD12 HG22 ' A' ' 34' ' ' THR . 0.5 OUTLIER -148.5 107.46 3.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.253 -0.43 . . . . 72.23 110.877 179.917 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.6 m -68.82 107.93 3.24 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.23 -0.441 . . . . 73.42 110.83 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.773 HG11 HD21 ' A' ' 52' ' ' LEU . 58.2 t -139.97 133.41 15.31 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.62 0.724 . . . . 71.43 111.126 179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.498 ' O ' ' HB3' ' A' ' 66' ' ' ALA . 53.9 Cg_endo -69.81 173.86 10.4 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.652 2.234 . . . . 60.01 112.384 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' O ' ' A' ' 48' ' ' VAL . 9.8 p -95.48 31.99 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.213 -0.449 . . . . 71.24 111.178 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -92.19 -36.04 13.49 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.145 -0.48 . . . . 63.41 110.912 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 6.3 p -123.47 176.98 5.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 64.13 110.84 -179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.509 ' O ' HD23 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -97.72 176.88 5.66 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.075 -0.511 . . . . 72.33 111.164 -179.977 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.773 HD21 HG11 ' A' ' 46' ' ' VAL . 71.6 mt -131.17 126.78 36.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.241 -0.436 . . . . 62.04 110.951 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.0 tttm -102.44 122.04 43.52 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.445 . . . . 74.21 110.865 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.63 HG12 HG13 ' A' ' 24' ' ' VAL . 61.2 mt -123.79 117.73 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 73.4 111.145 179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 65.0 p -113.19 148.58 35.15 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.167 -0.47 . . . . 62.11 111.122 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 21.9 m-85 -127.37 154.97 44.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.16 -0.473 . . . . 65.43 110.951 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.491 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -91.02 107.77 19.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.141 -0.481 . . . . 74.23 111.072 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 124.09 -51.23 0.82 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.707 -0.759 . . . . 45.03 112.429 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.5 m-85 -105.93 170.66 7.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.995 0.426 . . . . 61.23 110.856 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 35.2 mttt -64.54 148.53 96.48 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.59 0.71 . . . . 75.3 110.878 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -178.75 2.51 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.701 2.268 . . . . 71.32 112.324 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.128 HG21 HG11 ' A' ' 72' ' ' VAL . 4.7 p -152.02 146.02 15.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.449 . . . . 74.11 111.169 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 14.9 p -132.17 130.58 41.27 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 60.11 111.119 -179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 70' ' ' VAL . 8.1 m -152.62 155.15 6.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.28 -0.418 . . . . 74.21 111.069 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 12.3 ptpt -74.68 152.46 39.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.172 -0.467 . . . . 70.32 110.892 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 47' ' ' PRO . . . -58.26 120.74 9.23 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 72.41 111.098 179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -148.49 150.76 33.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 63.13 111.089 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -51.81 -53.73 36.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.097 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.589 HG23 ' O ' ' A' ' 6' ' ' THR . 4.6 mp -117.17 133.28 64.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.235 -0.439 . . . . 72.31 111.204 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.542 HG21 HG21 ' A' ' 64' ' ' VAL . 5.4 p -146.39 118.05 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.145 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 32.9 m120 -120.11 109.46 15.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.158 -0.473 . . . . 74.11 110.904 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 1.128 HG11 HG21 ' A' ' 62' ' ' VAL . 22.0 t -126.79 144.14 37.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.232 -0.44 . . . . 61.34 111.15 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 5.0 mp -96.92 145.19 26.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 72.02 111.008 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.3 tp -87.77 121.49 30.25 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.281 -0.418 . . . . 65.54 110.931 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -98.71 136.11 39.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.247 -0.433 . . . . 73.42 110.888 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -55.05 140.46 37.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 75.12 110.88 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 43.0 t0 -106.4 86.84 2.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 44.35 110.861 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.0 p -127.02 -178.6 4.48 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.237 -0.438 . . . . 74.43 111.144 -179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -54.91 121.05 7.81 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.434 . . . . 74.23 110.904 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 77.3 mmm -118.8 176.6 5.2 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.466 . . . . 74.23 110.904 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.4 t -140.04 113.69 6.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 72.15 111.108 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -97.14 170.05 9.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.135 -0.484 . . . . 62.52 110.887 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 53.52 53.17 11.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.221 -0.445 . . . . 64.43 110.862 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 57.8 t -92.69 140.13 16.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.153 -0.476 . . . . 53.25 111.153 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 11.9 p -92.7 138.11 20.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 62.05 111.134 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.5 p -135.38 141.43 42.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 73.01 111.103 179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 15.0 t -106.56 150.77 25.82 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.188 -0.46 . . . . 65.24 111.134 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -142.58 -104.28 0.51 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.705 -0.759 . . . . 61.42 112.497 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 33.6 t80 -93.32 150.74 20.25 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.918 0.39 . . . . 75.33 110.943 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.124 -0.489 . . . . 73.03 111.165 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 16.6 ptm . . . . . 0 N--CA 1.458 -0.042 0 CA-C-O 120.844 0.354 . . . . 72.11 110.866 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . 160.18 161.27 11.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.752 -0.737 . . . . 33.14 112.508 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 12.4 t60 -152.05 121.45 6.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.833 0.349 . . . . 75.12 110.843 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 32.8 m170 -105.53 167.34 9.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.22 -0.445 . . . . 62.11 110.879 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -117.37 137.92 52.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.189 -0.46 . . . . 72.04 110.849 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.5 p80 -58.32 154.23 13.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 71.31 110.841 179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 34.2 p-80 -120.1 140.67 50.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 74.02 110.917 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.2 t-160 -118.43 61.2 0.78 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.196 -0.456 . . . . 73.02 110.845 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.414 ' HB ' HD13 ' A' ' 69' ' ' ILE . 0.3 OUTLIER -87.68 149.49 24.22 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 51.53 111.061 -179.878 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -152.35 -176.07 5.54 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.479 . . . . 74.23 110.879 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -52.17 127.29 32.34 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.729 -0.748 . . . . 42.34 112.481 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -151.23 127.64 10.68 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.834 0.349 . . . . 73.41 110.896 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.544 HG21 ' OH ' ' A' ' 56' ' ' TYR . 90.7 t -118.29 130.61 72.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.177 -0.465 . . . . 73.33 111.136 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.602 HG22 ' HA ' ' A' ' 18' ' ' PRO . 20.3 p -127.14 169.39 13.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 73.43 111.163 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.21 155.1 19.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 72.2 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 34.0 tttt -92.63 18.64 8.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.104 -0.498 . . . . 60.22 110.848 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.95 -58.64 2.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.229 -0.441 . . . . 75.14 111.165 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -120.85 -26.42 5.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.3 -0.409 . . . . 72.52 110.832 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 105.79 29.05 5.12 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 53.34 112.491 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -100.63 154.19 37.31 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 121.566 0.698 . . . . 74.15 110.93 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.602 ' HA ' HG22 ' A' ' 11' ' ' THR . 53.8 Cg_endo -69.7 147.2 62.75 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.756 2.304 . . . . 61.23 112.335 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.486 HG21 ' CD2' ' A' ' 56' ' ' TYR . 15.5 mm -93.5 120.38 42.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.205 -0.452 . . . . 75.31 111.066 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 30.3 mt -103.07 150.81 6.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.096 -0.502 . . . . 42.2 111.103 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.61 48.33 82.49 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.744 -0.741 . . . . 62.52 112.474 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.45 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -95.28 167.65 11.22 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.813 0.34 . . . . 63.11 111.028 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.0 m -106.34 106.62 17.23 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.163 -0.471 . . . . 52.44 110.856 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.697 HG13 HG13 ' A' ' 54' ' ' ILE . 5.9 t -110.42 128.86 66.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.089 -0.505 . . . . 75.44 111.122 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 14.8 m -148.44 137.99 16.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 74.52 111.143 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.674 ' OE2' HG11 ' A' ' 46' ' ' VAL . 15.7 tt0 -82.87 129.27 34.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.249 -0.432 . . . . 74.12 110.878 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.44 HG22 ' O ' ' A' ' 51' ' ' THR . 1.2 t -51.4 -33.21 29.19 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 52.43 111.168 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 42.1 p -89.45 -22.24 22.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 64.03 111.1 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -148.61 98.66 2.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.209 -0.451 . . . . 63.21 111.115 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 66.3 p -86.69 -32.83 20.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.215 -0.448 . . . . 73.01 111.189 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 85.3 m -52.78 -29.69 28.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.169 -0.469 . . . . 74.23 111.135 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -93.25 31.08 1.53 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.247 -0.433 . . . . 74.3 110.841 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -66.44 150.53 51.93 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.71 -0.757 . . . . 61.22 112.474 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.526 ' CG2' HD11 ' A' ' 44' ' ' LEU . 13.5 t -135.76 169.43 17.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.806 0.336 . . . . 73.43 111.151 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.45 HG22 ' O ' ' A' ' 22' ' ' ALA . 17.9 pt -113.16 152.08 14.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.175 -0.466 . . . . 72.12 111.146 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.436 HG22 ' HD2' ' A' ' 42' ' ' PHE . 10.0 p -69.98 150.72 46.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.241 -0.436 . . . . 55.34 111.119 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -81.26 -177.43 6.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.216 -0.447 . . . . 34.54 110.84 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -60.32 -30.61 69.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 72.12 110.867 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -97.42 20.38 11.75 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.21 -0.45 . . . . 73.22 110.867 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 63.27 27.94 71.46 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.719 -0.753 . . . . 75.31 112.474 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -108.5 139.38 43.33 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.882 0.372 . . . . 71.23 110.919 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.472 ' HE2' HG23 ' A' ' 10' ' ' VAL . 13.2 p90 -133.49 168.13 19.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.159 -0.473 . . . . 71.21 110.928 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.508 ' C ' HD12 ' A' ' 44' ' ' LEU . 25.6 p -145.1 117.69 8.6 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 72.34 111.092 -179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.577 HD22 HD22 ' A' ' 52' ' ' LEU . 7.4 mp -126.59 109.58 12.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 72.23 110.889 179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 2.0 m -99.89 117.91 35.2 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 73.42 110.845 -179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.674 HG11 ' OE2' ' A' ' 26' ' ' GLU . 3.6 m -138.34 155.9 73.79 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 71.43 111.124 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.67 -48.34 0.76 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.634 2.223 . . . . 60.01 112.381 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 21.2 t -86.18 150.72 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.199 -0.455 . . . . 71.24 111.111 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 52.7 p-10 -91.3 46.07 1.28 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.091 -0.504 . . . . 63.41 110.91 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 84.0 p -66.4 -169.83 0.08 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.183 -0.462 . . . . 64.13 110.819 -179.814 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.44 ' O ' HG22 ' A' ' 27' ' ' THR . 0.2 OUTLIER -94.64 160.74 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.503 . . . . 72.33 111.165 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.667 HD23 ' HG3' ' A' ' 26' ' ' GLU . 19.1 mt -121.15 117.62 27.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 62.04 110.931 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 8.7 ttpt -97.82 114.58 26.66 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.867 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.697 HG13 HG13 ' A' ' 24' ' ' VAL . 4.0 mp -115.62 121.2 66.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 73.4 111.168 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 43.8 p -117.14 145.26 43.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.15 -0.477 . . . . 62.11 111.04 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.544 ' OH ' HG21 ' A' ' 10' ' ' VAL . 18.7 m-85 -125.81 155.29 41.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.141 -0.481 . . . . 65.43 110.903 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.498 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.5 107.38 18.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.11 -0.496 . . . . 74.23 111.158 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 127.07 -46.16 1.1 Allowed Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.759 -0.734 . . . . 45.03 112.467 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -111.82 170.89 7.83 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.026 0.441 . . . . 61.23 110.828 -179.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -63.6 150.75 89.74 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.568 0.699 . . . . 75.3 110.927 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 178.2 4.83 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 122.645 2.23 . . . . 71.32 112.371 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.666 HG21 HG11 ' A' ' 72' ' ' VAL . 3.7 p -152.03 147.9 14.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.254 -0.43 . . . . 74.11 111.088 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 4.6 p -132.14 130.82 41.63 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 60.11 111.174 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.65 HG11 HG21 ' A' ' 70' ' ' VAL . 19.5 m -141.66 145.97 23.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.263 -0.426 . . . . 74.21 111.125 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.97 157.18 37.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.129 -0.487 . . . . 70.32 110.965 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.18 98.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 72.41 111.155 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -131.15 178.2 6.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.221 -0.445 . . . . 63.13 111.071 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -86.36 -42.37 13.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.13 111.16 179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.414 HD13 ' HB ' ' A' ' 6' ' ' THR . 54.6 mt -129.87 125.48 60.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.239 -0.437 . . . . 72.31 111.137 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.65 HG21 HG11 ' A' ' 64' ' ' VAL . 6.3 p -146.44 122.14 3.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.135 -0.484 . . . . 74.42 111.133 179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -120.12 119.74 34.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.17 -0.468 . . . . 74.11 110.856 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.666 HG11 HG21 ' A' ' 62' ' ' VAL . 27.8 t -133.03 147.02 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.455 . . . . 61.34 111.173 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . . . . . . . . . 24.8 mt -98.17 135.19 40.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 72.02 110.912 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.485 HD21 ' HB2' ' A' ' 56' ' ' TYR . 4.4 tp -89.32 117.89 28.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.131 -0.486 . . . . 65.54 110.89 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -94.07 132.53 38.48 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.42 110.867 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -56.65 145.84 27.38 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.097 -0.501 . . . . 75.12 110.936 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -111.88 97.87 6.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.464 . . . . 44.35 110.861 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 7.0 p -107.06 100.65 10.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 74.43 111.129 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -66.37 117.05 8.07 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.409 . . . . 74.23 110.979 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 20.2 mtt -52.39 128.94 27.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 74.23 110.83 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.5 m -113.86 67.62 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.15 111.113 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -70.57 164.39 24.96 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.169 -0.469 . . . . 62.52 110.815 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 -153.98 43.74 0.56 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 64.43 110.962 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 70.4 t 50.78 87.33 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.097 -0.501 . . . . 53.25 111.166 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.8 p -163.55 143.36 2.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.208 -0.451 . . . . 62.05 111.163 179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 30.6 m -77.32 146.85 7.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.219 -0.446 . . . . 73.01 111.125 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -138.82 151.49 47.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 65.24 111.124 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -110.13 148.1 17.39 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.793 -0.717 . . . . 61.42 112.489 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 53.6 t80 -91.59 144.87 25.1 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.931 0.396 . . . . 75.33 110.924 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 23.3 p . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.132 -0.486 . . . . 73.03 111.172 179.99 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -2' ' ' MET . . . . . . . . . . . . . 4.0 ptp . . . . . 0 N--CA 1.457 -0.091 0 CA-C-O 120.828 0.346 . . . . 72.11 110.877 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -1' ' ' GLY . . . . . . . . . . . . . . . -140.92 163.4 26.62 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.784 -0.722 . . . . 33.14 112.547 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 0' ' ' HIS . . . . . . . . . . . . . 43.9 p-80 -118.02 164.73 14.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.887 0.375 . . . . 75.12 110.837 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -154.69 162.22 41.22 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 62.11 110.841 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' HIS . . . . . . . . . . . . . 14.4 m80 -69.75 140.42 53.43 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.226 -0.443 . . . . 72.04 110.855 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.5 m-70 -89.09 -63.09 1.34 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.22 -0.445 . . . . 71.31 110.864 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' HIS . . . . . . . . . . . . . 9.5 t-80 -92.7 161.58 14.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 74.02 110.913 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 33.8 m170 -115.45 154.06 29.97 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.288 -0.414 . . . . 73.02 110.793 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -96.48 145.28 25.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.135 -0.484 . . . . 51.53 111.175 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 4.3 mtpm? -72.41 102.22 3.12 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.22 -0.445 . . . . 74.23 110.91 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 80.84 117.72 0.38 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.691 -0.766 . . . . 42.34 112.464 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -158.13 119.85 3.6 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.843 0.354 . . . . 73.41 110.909 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.643 HG11 ' CZ ' ' A' ' 56' ' ' TYR . 87.1 t -108.84 130.91 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 73.33 111.143 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 18' ' ' PRO . 3.7 p -127.31 169.5 13.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.108 -0.497 . . . . 73.43 111.113 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.512 ' N ' HD11 ' A' ' 19' ' ' ILE . 1.4 t -89.16 150.09 22.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.196 -0.457 . . . . 72.2 110.832 -179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.5 ' CG ' HD13 ' A' ' 73' ' ' LEU . 14.9 tttm -90.83 15.0 12.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 60.22 110.882 179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.74 -58.47 2.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.248 -0.433 . . . . 75.14 111.178 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -118.86 -26.66 5.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.231 -0.441 . . . . 72.52 110.828 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 102.28 29.29 6.08 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.738 -0.744 . . . . 53.34 112.503 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -96.93 160.16 29.81 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.533 0.682 . . . . 74.15 110.916 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 11' ' ' THR . 54.0 Cg_endo -69.78 132.96 24.38 Favored 'Trans proline' 0 N--CA 1.465 -0.162 0 C-N-CA 122.664 2.242 . . . . 61.23 112.337 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.551 HG21 ' CD2' ' A' ' 56' ' ' TYR . 25.4 mm -77.67 118.11 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.212 -0.449 . . . . 75.31 111.164 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.493 HD13 ' CD2' ' A' ' 38' ' ' PHE . 23.8 mt -108.7 132.62 56.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.454 . . . . 42.2 111.142 179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 85.9 31.98 19.21 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.736 -0.745 . . . . 62.52 112.462 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.404 ' O ' HG22 ' A' ' 35' ' ' ILE . . . -86.39 153.94 21.55 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.777 0.322 . . . . 63.11 111.114 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 19.9 m -106.86 107.04 17.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.257 -0.429 . . . . 52.44 110.865 -179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.763 HG23 HG12 ' A' ' 54' ' ' ILE . 4.1 p -118.81 130.13 74.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 75.44 111.106 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.524 HG12 ' HA3' ' A' ' 33' ' ' GLY . 15.9 m -146.01 163.8 10.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.173 -0.467 . . . . 74.52 111.108 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . 0.685 ' OE1' HG21 ' A' ' 46' ' ' VAL . 4.1 mm-40 -85.24 172.82 10.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 74.12 110.931 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -72.58 -42.03 65.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 52.43 111.162 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.3 p -112.55 -21.98 11.02 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.198 -0.455 . . . . 64.03 111.155 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -103.16 64.55 0.84 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 63.21 111.109 179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 21.8 p -78.52 -35.24 46.52 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.224 -0.444 . . . . 73.01 111.176 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.1 p -53.23 -30.93 40.77 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.097 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -93.78 31.33 1.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 74.3 110.968 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.524 ' HA3' HG12 ' A' ' 25' ' ' VAL . . . -63.81 148.37 50.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.794 -0.717 . . . . 61.22 112.434 -179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . 0.582 HG22 HD11 ' A' ' 44' ' ' LEU . 13.2 t -135.49 170.57 15.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.76 0.314 . . . . 73.43 111.194 -179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 22' ' ' ALA . 11.6 pt -122.94 152.38 27.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.227 -0.442 . . . . 72.12 111.119 179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.549 HG22 ' HD2' ' A' ' 42' ' ' PHE . 18.1 p -70.85 150.94 45.29 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 55.34 111.145 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -91.0 -177.02 4.81 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.238 -0.437 . . . . 34.54 110.896 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.493 ' CD2' HD13 ' A' ' 20' ' ' ILE . 0.4 OUTLIER -60.2 -30.01 69.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 72.12 110.883 -179.876 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -73.17 -18.52 61.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.855 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 89.46 28.04 20.74 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.723 -0.751 . . . . 75.31 112.452 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -129.65 166.88 18.88 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.887 0.375 . . . . 71.23 110.922 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PHE . . . . . 0.549 ' HD2' HG22 ' A' ' 36' ' ' THR . 26.8 p90 -151.35 167.92 26.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.205 -0.452 . . . . 71.21 110.865 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 4.5 t -134.66 125.61 27.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.141 -0.481 . . . . 72.34 111.1 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.697 HD22 HD21 ' A' ' 52' ' ' LEU . 0.2 OUTLIER -130.73 128.84 41.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 72.23 110.898 179.969 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 9.9 t -105.04 119.97 40.34 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.14 -0.482 . . . . 73.42 110.801 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.685 HG21 ' OE1' ' A' ' 26' ' ' GLU . 58.0 t -139.0 133.23 16.27 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-O 121.614 0.721 . . . . 71.43 111.157 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.441 ' HD2' HG13 ' A' ' 46' ' ' VAL . 53.6 Cg_endo -69.77 -48.35 0.73 Allowed 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.725 2.283 . . . . 60.01 112.325 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 24.0 m -86.65 171.64 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.259 -0.428 . . . . 71.24 111.12 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 34.7 m-80 -111.08 81.75 1.48 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.108 -0.496 . . . . 63.41 110.829 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.7 t -109.39 -169.41 1.47 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.185 -0.461 . . . . 64.13 110.924 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -87.54 161.93 17.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.187 -0.461 . . . . 72.33 111.133 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LEU . . . . . 0.697 HD21 HD22 ' A' ' 44' ' ' LEU . 0.4 OUTLIER -128.42 130.18 47.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 62.04 110.91 179.933 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 1.4 ttpm? -101.98 124.45 47.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.858 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.763 HG12 HG23 ' A' ' 24' ' ' VAL . 10.3 mt -123.64 119.57 57.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.448 . . . . 73.4 111.115 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' THR . . . . . . . . . . . . . 51.2 p -117.78 144.32 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.221 -0.445 . . . . 62.11 111.152 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.832 ' CD1' HD11 ' A' ' 74' ' ' LEU . 25.0 m-85 -126.22 155.06 42.43 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.21 -0.45 . . . . 65.43 110.94 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.492 HG23 ' O ' ' A' ' 57' ' ' ILE . 9.2 tt -92.24 107.72 19.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 74.23 111.144 179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 121.17 -51.1 0.8 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 45.03 112.513 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 11.0 m-85 -101.5 170.75 8.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.897 0.379 . . . . 61.23 110.906 -179.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LYS . . . . . . . . . . . . . 57.0 mttt -68.6 143.61 95.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.551 0.691 . . . . 75.3 110.963 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.73 174.22 9.8 Favored 'Trans proline' 0 N--CA 1.465 -0.155 0 C-N-CA 122.713 2.275 . . . . 71.32 112.391 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.555 HG22 ' HE1' ' A' ' 56' ' ' TYR . 16.8 m -150.24 140.37 16.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.243 -0.435 . . . . 74.11 111.168 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 41.7 p -125.76 130.25 51.09 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.225 -0.443 . . . . 60.11 111.148 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 4.9 m -153.41 159.23 3.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.283 -0.417 . . . . 74.21 111.143 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -73.07 157.23 37.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.32 110.9 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.691 ' HB2' HD12 ' A' ' 52' ' ' LEU . . . -71.89 138.31 48.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.245 -0.434 . . . . 72.41 111.078 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . -159.91 167.54 27.82 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 63.13 111.096 179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -56.37 -57.14 13.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.165 -0.47 . . . . 73.13 111.064 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 57.1 mt -120.5 135.28 61.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.236 -0.438 . . . . 72.31 111.143 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.419 ' O ' HG13 ' A' ' 70' ' ' VAL . 6.1 p -146.48 120.72 2.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 74.42 111.185 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 31.2 m120 -120.01 109.81 15.94 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.449 . . . . 74.11 110.848 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.454 ' O ' HG13 ' A' ' 10' ' ' VAL . 36.7 t -123.65 135.18 64.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.163 -0.471 . . . . 61.34 111.148 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.5 HD13 ' CG ' ' A' ' 13' ' ' LYS . 4.5 pp -92.71 145.49 24.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 72.02 110.955 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.832 HD11 ' CD1' ' A' ' 56' ' ' TYR . 1.2 tp -87.61 121.33 29.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.44 . . . . 65.54 110.878 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 59.5 mt-10 -97.69 136.76 37.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 73.42 110.941 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -55.13 139.74 40.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 75.12 110.88 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -107.75 127.91 54.11 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.079 -0.51 . . . . 44.35 110.818 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 69.9 p -137.61 172.26 13.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.145 -0.48 . . . . 74.43 111.105 -179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 14.8 tt0 -90.2 47.89 1.5 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 74.23 110.962 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' MET . . . . . . . . . . . . . 1.8 mpt? 58.4 52.27 7.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 74.23 110.894 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.6 m -133.23 69.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.238 -0.437 . . . . 72.15 111.144 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -108.58 163.37 13.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.155 -0.475 . . . . 62.52 110.936 179.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -103.09 68.66 0.99 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 64.43 110.895 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 49.0 t -66.24 145.1 14.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 53.25 111.124 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.0 p -54.88 131.99 17.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.19 -0.459 . . . . 62.05 111.152 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 39.2 t -80.56 111.17 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.287 -0.415 . . . . 73.01 111.179 179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 70.9 p -87.81 -39.58 14.75 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.138 -0.483 . . . . 65.24 111.202 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 74.77 -102.6 1.43 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.745 -0.74 . . . . 61.42 112.481 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.19 134.48 48.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.008 0.432 . . . . 75.33 110.884 -179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 1.2 p . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.122 -0.49 . . . . 73.03 111.157 -179.976 . . . . . . . . 0 0 . 1 stop_ save_